Conformationally constrained, fully synthetic macrocyclic compounds

ABSTRACT

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT 2B  (5-HT 2B  receptor), and on the prostaglandin F2•receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.

Macrocyclic natural and synthetic products have played a crucial role inthe development of new drugs, especially as anti-infectives (see Review:F. von Nussbaum, M. Brands, B. Hinzen, S. Weigand, D. Häbich, Angew.Chem. Int. Ed. Engl. 2006, 45, 5072-5129; D. Obrecht, J. A. Robinson, F.Bernardini, C. Bisang, S. J. DeMarco, K. Moehle, F. O. Gombert, Curr.Med. Chem. 2009, 16, 42-65), as anti-cancer drugs and in othertherapeutic areas (C. E. Ballard, H. Yu, B. Wang, Curr. Med. Chem. 2002,9, 471-498; F. Sarabia, S. Chammaa, A. S. Ruiz, L. M. Ortiz, F. J.Herrera, Curr. Med. Chem. 2004, 11, 1309-1332). They often displayremarkable biological activities, and many macrocycles or theirderivatives have been successfully developed into drugs (L. A.Wessjohann, E. Ruijter, D. Garcia-Rivera, W. Brandt, Mol. Divers. 2005,9, 171-186; D. J. Newman, G. M. Gragg, K. M. Snader, J. Nat. Prod. 2003,66, 1022-1037). The chemical diversity of macrocyclic natural productsis immense and provides a tremendous source of inspiration for drugdesign.

Macrocyclic natural and synthetic products generally exhibit semi-rigidbackbone conformations placing appended substituents in well-definedpositions in space. Certain ring sizes are preferred (L. A. Wessjohann,E. Ruijter, D. Garcia-Rivera, W. Brandt, Mol. Divers. 2005, 9, 171-186),e.g. 16-membered rings are frequently found in oxygen-containingmacrocycles, such as polyketides (M. Q. Zhang, B. Wilkinson, Curr. Opin.Biotechnol. 2007, 18, 478-488). It is hypothesized that the semi-rigidscaffolds may possess some of the favorable binding properties of rigidmolecules (entropy), yet still retaining enough flexibility to adaptsuitable conformations in the binding event (induced fit).

Macrocyclic natural and synthetic products are generally classifiedaccording to the chemical nature of the backbone, e.g. cyclic peptides(Y. Hamady, T. Shioiri, Chem. Rev. 2005, 105, 4441-4482; N.-H. Tan, J.Zhou, Chem. Rev. 2006, 106, 840-895); cyclic depsipeptides (F. Sarabia,S. Chammaa, A. S. Ruiz, L. M. Ortiz, F. J. Herrera, Curr. Med. Chem.2004, 11, 1309-1332); macrocyclic lactones (macrolactones) andmacrolides; macrocyclic lactams, macrocyclic amines, macrocyclic ethers,macrocyclic ureas and urethanes, and others. The conformational,physico-chemical, pharmacological and pharmacodynamic properties ofmacrocyclic natural and synthetic compounds depend largely on the ringsize, the chemical nature of the backbone, and of appended groups (L. A.Wessjohann, E. Ruijter, D. Garcia-Rivera, W. Brandt, Mol. Divers. 2005,9, 171-186). By modifying these three parameters nature has generated avirtually unlimited repertoire of molecular diversity. Despite theirundisputed interesting biological properties, natural products show somelimitations for drug development, such as:

-   -   High structural complexity    -   Metabolic instability    -   Low oral bioavailability    -   Low membrane permeability; intracellular targets not amenable    -   Low tissue penetration    -   Short half-life    -   Chemical synthesis often very complex and lengthy    -   Often accessible only by fermentation or recombinant methods    -   High production costs    -   Complex QC and development processes.

Broadly speeking, the present invention describes novel, fullysynthetic, macrocyclic natural product-like molecules of type I, whichcan be synthesized e.g. by connecting suitably protected building blocksA, B, and C in a modular fashion to a linear precursor followed bysubsequent cyclization (Scheme 1).

Building blocks A serve as conformation-inducing templates and are basedon appropriately substituted (R¹) and protected phenolic or thiophenolicaromatic carboxylic acids.

Building blocks B are appropriately substituted (R², R³) and protectedtertiary amino alcohols, preferably derived from an amino acid such assubstituted proline, substituted pipecolic acid or substitutedpiperazine-2-carboxylic acid. Building blocks B are linked to buildingblock A via an ether (X═O) or thioether (X═S) bond and to building blockC via a secondary or tertiary amide bond. The sulfur atom of a thioetherlinkage can easily and selectively be oxidized to the correspondingsulfoxide (S═O) or sulfone (S(═O)₂) which forms part of the invention.Importantly, the amide bond between modulator B and spacer C can also bepart of an extended connector moiety U. For example in the case of astandard amide bond, U corresponds to a carbonyl group (—C(═O)—). If Uis defined as a carbamoyl moiety (—NR⁴—C(═O)—) the functional connectionbetween B and C corresponds to a urea moiety. Similarly a carboxyl group(—O—C(═O)—) as U describes a carbamate linkage between B and C. Inaddition, U can represent an oxalyl group (—C(═O)—C(═O)—) or thecorresponding acetal) (—C(—OR²⁰)₂—C(═O)—).

Importantly, in the case that R² of building block B constitutes anamine substituent, an alternative incorporation into the macrocyclicring via the exocyclic amine functionality is possible:

This alternative binding mode is also part of the invention.

Building blocks B serve as a conformational modulator by influencing theconformation of the macrocycle through cis/trans-isomerization of theamide bond.

In molecules of type I the building blocks A and B are connected via thebridges C; the structural element C is linked to A by a secondary ortertiary amide bond. The bridge C can be constituted by one to threeappropriately and independently substituted (R⁴-R¹⁰; R¹⁴⁻¹⁷) subunitsc1-c3 derived from suitably substituted and protected precursors, mostoften from, but not limited to, appropriately substituted and protectedamino acid derivatives or suitably substituted and protected aminederivatives.

These subunits c1-c3 are in turn independently connected to each otherby an amide bond (—C(═O)NR⁴—), a methylene-heteroatom linkage(—CHR³—Z—), an alkene[1,2]diyl moiety (—CHR¹²═CHR¹³—), introduced byolefin metathesis, an alkane[1,2]diyl spacer (—CHR¹²—CHR¹³—), accessiblefrom the metathesis product by hydrogenation, an oxalyl group(—C(═O)—C(═O)—) or a disulfide bridge (—S—S—).

The spatial orientation of the substituents R¹-R¹³ in compounds of typeI is modulated by the ring size and the stereochemical connectivitywithin building blocks A, B and C. Both, the macrocyclic backbone andthe substituents R¹-R¹³ can contribute to the biological activity ofcompounds of type I.

The backbone of the compounds of type I is composed of an aromaticether/thioether linkage and one or more tertiary amide bonds; in somecases an aliphatic ether linkage, an ethylidene or an ethylene moietymay also be part of the backbone as defined above. Ether linkages inmacrocyclic molecules have been shown to be beneficial by favorablyinfluencing physico-chemical and pharmacological properties, such ase.g. solubility in water, metabolic stability towards proteolyticdegradation, cell permeability and oral absorption (K. X. Chen et al.,J. Med. Chem. 2006, 49, 995-1005). In addition, tertiary amidecontaining macrocycles show increased proteolytic stability, cellpermeability and oral bioavailability compared to the parent moleculeswith secondary amide bonds (E. Biron, J. Chatterjee, O. Ovadia, D.Langenegger, J. Brueggen, D. Hoyer, H. A. Schmid, R. Jelinek, C. Gilon,A. Hoffmann, H. Kessler, Angew. Chem. Int. Ed. 2008, 47, 1-6; J.Chatterjee, O. Ovadia, G. Zahn, L. Marinelli, A. Hoffmann, C. Gilon, H.Kessler, J. Med. Chem. 2007, 50, 5878-5881). For example, the cyclicundecapeptide cyclosporin A (INN: Ciclosporin), which is used asimmunosuppressant in organ transplants, contains seven N-methylatedamino acids and possesses good oral bioavailability when formulatedappropriately (P. R. Beauchesne, N. S. C. Chung, K. M. Wasan, DrugDevelop. Ind. Pharm. 2007, 33, 211-220). Peptidyl cis/transisomerization of proline and pipecolic acid containing polypeptides andproteins is a well known process in protein folding events. In vivo,this process can be mediated by peptidyl prolyl cis/trans isomerasessuch as the cyclophilins, the FK506-binding proteins and the parvulins(A. Bell, P. Monaghan, A. P. Page, Int. J. Parasitol. 2006, 36,261-276). Besides their role in protein folding and in the immunesystem, peptidyl prolyl cis/trans isomerases have been implicated incell cycle control (P. E. Shaw, EMBO Reports 2002, 3, 521-526) andtherefore constitute interesting pharmaceutical targets. FK506 andcyclosporin A which bind to the FK506-binding protein and cyclophilins,respectively, are both macrocyclic natural products, with the former onecontaining a pipecolic acid residue.

For many existing and emerging biological targets it is difficult tofind classical small molecule hits as starting points for drugdevelopment (J. A. Robinson, S. DeMarco, F. Gombert, K. Moehle, D.Obrecht, Drug Disc. Today 2008, 13, 944-951). Many of these extra- andintracellular “difficult targets” involve protein-protein interactions,such as receptor tyrosine kinases, growth factor receptors,transcriptional activators/transcription factors, chaperones, andothers. For several of them macrocyclic natural and synthetic compoundshave been described as good starting points for drug discovery programs(e.g. D. Obrecht, J. A. Robinson, F. Bernardini, C. Bisang, S. J.DeMarco, K. Moehle, F. O. Gombert, Curr. Med. Chem. 2009, 16, 42-65).

The novel and fully synthetic macrocyclic compounds of type I describedin this invention combine unique features of macrocyclic naturalproducts with beneficial physico-chemical and pharmacological propertiesof traditional small molecules, like:

-   -   Natural product-like structural complexity    -   Good solubility    -   High metabolic stability    -   Improved oral bioavailability    -   Improved membrane permeability    -   Extra- and intracellular targets amenable    -   Improved tissue penetration    -   Small molecule-like pharmacokinetics    -   Modular chemical synthesis    -   Synthesis process amenable to parallelization    -   Reasonable production costs    -   Small molecule-like QC and development processes

More particularly, the present invention provides macrocyclic compoundsof the general formula I (Figure 2), which are comprised of buildingblocks of general formulae A, B and C as depicted in Scheme 2 below.

With respect to the building blocks A, B and C, the encircled moieties,i.e. a in A, b in B and c1-c3 in C, shall represent their most basicskeletons appropriately and independently substituted as is detailedlater on. The basic skeletons of a and b correspond to the ring systemsdepicted in Table 1 and Table 2.

TABLE 1 Ring Systems a1-a25 of Building Blocks A

a1

a2

a3

a4

a5

a6

a7

a8

a9

a10

a11

a12

a13

a14

a15

a16

a17

a18

a19

a20

a21

a22

a23

a24

a25

TABLE 2 Ring Systems b1-b11 of Building Blocks B

b1

b2

b3

b4

b5

b6

b7

b8

b9

b10

b11

Depending on the substitution pattern of skeletons b alternative bindingmodes are feasible. For skeletons b3 and b4 such incorporation via theexocyclic nitrogen atom is represented by the following two structures,which form part of the invention:

The encircled parts of the bridge subunits c1-c3 represent optionallysubstituted groups. Definitions of c1-c3 are exemplified in Table 3,each reading from the N-terminus to the C-terminus of the linker C. Inthe simplest case the linker C is constituted by one subunit c1, i.e.c1-1 to c1-6. For the embodiments consisting of two or three subunitsall possible combinations of the subunits c1-c3 and the connectivitiesU, V and W are part of the invention.

TABLE 3 Scope of Subunits c1-c3 of the Linker Group C C

U =

V, W =

The substituents directly attached to the basic skeletons containingbuilding block A, B and C, i.e. R¹-R¹⁷, are defined as follows:

-   -   R¹: H; F; Cl; Br; I; CF₃; OCF₃; OCHF₂; NO₂; CN; alkyl; alkenyl;        alkynyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;        arylalkyl; heteroarylalkyl;

-   —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)SR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)OCONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)OCOOR²¹;    —(CR¹⁸R¹⁹)_(q)NR⁴COOR²¹;

-   —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³;

-   —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹;    —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)OPO(OR²¹)₂;    —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂;

-   —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)OSO₃R²¹;    —(CR¹⁸R¹⁹)_(q)R²⁴;

-   —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R²: H; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; —(CR¹⁸R¹⁹)_(q)OR²⁰;

-   —(CR¹⁸R¹⁹)_(q)SR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)OCONR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)OCOOR²¹; —(CR¹⁸R¹⁹)_(q)NR⁴COOR²¹;    —(CR¹⁸R¹⁹)_(q)NR⁴COR²²;

-   —(CR¹⁸R¹⁹)_(q) NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³;    —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³;    —(CR¹⁸R¹⁹)_(q)R²⁴;

-   —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R³: H; CF₃; alkyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl.    -   R⁴: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; or a suitable        N-protecting group.    -   R⁵, R⁷ and R⁹ are independently defined as: H; F; CF₃; alkyl;        alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;        arylalkyl; heteroarylalkyl; —(CR¹⁸R¹⁹)_(s)OR²⁰;        —(CR¹⁸R¹⁹)_(s)SR²⁰;

-   —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)OCONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(s)OCOOR²¹;

-   —(CR¹⁸R¹⁹)_(s)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²;    —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂NR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)COOR²¹;

-   —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂;

-   —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴;    —(CR¹⁸R¹⁹)_(q)R²⁵; or

-   —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R⁶, R⁸ and R¹⁰ are independently defined as: H; F; CF₃; alkyl;        alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;        arylalkyl; or heteroarylalkyl.    -   R¹¹: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; a suitable protecting        group; —(CR¹⁸R¹⁹)_(r)OR²⁰; —(CR¹⁸R¹⁹)_(r)SR²⁰;        —(CR¹⁸R¹⁹)_(r)NR⁴R²⁷;

-   —(CR¹⁸R¹⁹)_(r)OCONR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)OR²¹;    —(CR¹⁸R¹⁹)_(r)NR⁴COOR²¹;

-   —(CR¹⁸R¹⁹)_(r)NR⁴CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)NR⁴SO₂R²³;    —(CR¹⁸R¹⁹)_(r)NR⁴SO₂NR⁴R²⁷;

-   —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)COR²²;

-   —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)R²⁴;    —(CR¹⁸R¹⁹)_(s)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R¹² and R¹³ are independently defined as H; or alkyl.    -   R¹⁴ and R¹⁶ are independently defined as: H; F; CF₃; alkyl;        alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;        arylalkyl; heteroarylalkyl;

-   —(CR¹⁸R¹⁹)_(s)OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COOR²¹;

-   —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³;

-   —(CR¹⁸R¹⁹)_(s)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹;    —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COR²².    -   R¹⁵ and R¹⁷ are independently defined as: H; F; CF₃; alkyl;        alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;        arylalkyl; or heteroarylalkyl.

Substituents introduced in the sub-definitions of the radical R¹-R¹⁷are:

-   -   R¹⁸: H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl;        aryl; heteroaryl; arylalkyl; heteroarylalkyl;

-   —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)SR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(s)OCONR²⁸R³¹; —(CR²⁹R³⁰)_(s)OCOOR²¹;    —(CR²⁹R³⁰)_(s)NR²⁸COOR²¹;

-   —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹;    —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³;

-   —(CR²⁹R³⁰)_(s)NR²⁸SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹;    —(CR²⁹R³⁰)_(q)CONR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)PO(OR²¹)₂;    —(CR²⁹R³⁰)_(q)COR³¹;

-   —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or    —(CR²⁹R³⁰)_(q)R²⁶.    -   R¹⁹: H; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl.    -   R²⁰: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl;

-   —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)SR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(r)OCONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹;    —(CR²⁹R³⁰)_(r)NR²⁸COR³¹;

-   —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³;    —(CR²⁹R³⁰)_(r)NR²⁸SO₂NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹;    —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴;    —(CR²⁹R³⁰)_(q)R²⁵; or

-   —(CR²⁹R³⁰)_(q)R²⁶.    -   R²¹: alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; or a suitable        O-protecting group.    -   R²²: alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl;

-   —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)SR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(s)OCONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COOR²¹;    —(CR²⁹R³⁰)_(s)NR²⁸COR³¹;

-   —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³;    —(CR²⁹R³⁰)_(s)NR²⁸SO₂NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(s)COOR²¹; —(CR²⁹R³⁰)_(s)CONR²⁸R³¹;    —(CR²⁹R³⁰)_(s)SO₂NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(t)COR³¹; —(CR²⁹R³⁰)_(s)SO₂R²³; —(CR²⁹R³⁰)_(t)R²⁴;    —(CR²⁹R³⁰)_(t)R²⁵; or

-   —(CR²⁹R³⁰)_(t)R²⁶.    -   R²³: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; —(CR³²R³³)_(t)R²⁴.    -   R²⁴: aryl, preferably an optionally substituted phenyl group of        type C₆H₂R³⁴R³⁵R³¹; or a heteroaryl group, preferably one of the        groups of formulae H1-H34 (Table 4).

TABLE 4 Groups of Formulae H1-H34

H1

H2

H3

H4

H5

H6

H7

H8

H9

H10

H11

H12

H13

H14

H15

H16

H17

H18

H19

H20

H21

H22

H23

H24

H25

H26

H27

H28

H29

H30

H31

H32

H33

H34

-   -   R²⁵: One of the groups of formulae H35-H41 as shown in Table 5        below.

TABLE 5 Radicals of formulae H35-H41

H35

H36

H37

H38

H39

H40

H41

-   -   R²⁶: One of the groups of formulae H42-H50 as shown in Table 6        below.

TABLE 6 Groups of Formulae H42-H50

H42

H43

H44

H45

H46

H47

H48

H49

H50

-   -   R²⁷: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; a suitable protecting        group; —(CR²⁹R³⁰)_(q)R²⁴.    -   R²⁸: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; a suitable N-protecting        group; —(CR³²R³³)_(s)OR²¹;

-   —(CR³²R³³)_(s)NR⁴³R⁴²; —(CR³²R³³)_(s)NR⁴²CONR⁴³R⁴²;

-   —(CR³²R³³)_(s)NR⁴²COR²¹; —(CR³²R³³)_(s)NR⁴²SO₂NR²¹;    —(CR³²R³³)_(q)COOR²¹;

-   —(CR³²R³³)_(q)COR²³; —(CR³²R³³)_(q)SO₂R²¹.    -   R²⁹: H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl;        aryl; heteroaryl; arylalkyl; heteroarylalkyl;

-   —(CR³²R³³)_(s)OR³¹; —(CR³²R³³)_(s)SR⁻; —(CR³²R³³)_(s)NR²⁸R³¹;

-   —(CR³²R³³)_(s)OCONR²⁸R³¹; —(CR³²R³³)_(s)OCOOR²¹;    —(CR³²R³³)_(s)NR²⁸COOR²¹;

-   —(CR³²R³³)_(s)NR²⁸COR³¹; —(CR³²R³³)_(s)NR²⁸CONR²⁸R³¹;    —(CR³²R³³)_(s)NR²⁸SO₂R²³;

-   —(CR³²R³³)_(s)NR²⁸SO₂NR²⁸R³¹; —(CR³²R³³)_(q)COOR²¹;    —(CR³²R³³)_(q)CONR²⁸R³¹;

-   —(CR³²R³³)_(q)SO₂NR²⁸R³¹; —(CR³²R³³)_(q)PO(OR²¹)₂;    —(CR³²R³³)_(q)COR³¹;

-   —(CR³²R³³)_(q)SO₂R²³; —(CR³²R³³)_(q)R³¹.    -   R³⁰: H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl;        aryl; heteroaryl; arylalkyl; heteroarylalkyl.    -   R³¹: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; or one of the groups of        formulae H51-H55 as shown in Table 7 below.

TABLE 7 Groups of Formulae H51-H55

H51

H52

H53

H54

H55

-   -   R³² and R³³ are independently defined as H; F; CF₃; alkyl;        alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;        arylalkyl; heteroarylalkyl.    -   R³⁴ and R³⁵ are independently defined as H; F; Cl; CF₃; OCF₃;        OCHF₂; NO₂; CN; alkyl; alkenyl; alkynyl; cycloalkyl;        heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl;

-   —(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)SR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)OCONR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹;    —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)NR²⁸SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COOR²¹;

-   —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COR³¹;

-   —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁶: H; alkyl; alkenyl; alkynyl; cycloalkyl; heterocycloalkyl;        aryl; heteroaryl; arylalkyl; heteroarylalkyl; or —NR²⁸R³¹.    -   R³⁷: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; a suitable N-protecting        group; —(CR²⁹R³⁰)_(r)OR³¹;

-   —(CR²⁹R³⁰)_(r)SR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)_(r)OCONR²⁸R³¹;

-   —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹;    —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹;

-   —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(r)NR²⁸SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COOR²¹;

-   —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COR³¹;

-   —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁸: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; —(CR²⁹R³⁰)_(q)OR³¹;

-   —(CR²⁹R³⁰)_(q)SR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹;    —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹;    or

-   —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁹: H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl;        aryl; heteroaryl; arylalkyl; heteroarylalkyl;

-   —(CR³²R³³)_(u)OR²¹; —(CR³²R³³)_(u)NR²⁸R⁴³; —(CR³²R³³)_(t)COOR²¹; or

-   —(CR³²R³³)_(t)CONR²⁸R⁴³.    -   R⁴⁰: H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl;        aryl; heteroaryl; arylalkyl; heteroarylalkyl;

-   —(CR³²R³³)_(u)OR²¹; —(CR³²R³³)_(u)NR²⁸R⁴³; —(CR³²R³³)_(t)COOR²¹; or

-   —(CR³²R³³)_(t)CONR²⁸R⁴³.    -   R⁴¹: H; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; —OR²¹; —NR²⁸R⁴³;

-   —NR²⁸COR²³; —NR²⁸COOR²¹;

-   —NR²⁸SO₂R²³; —NR²⁸CONR²⁸R⁴³; —COOR²¹; —CONR²⁸R⁴³; —C(═NR⁴³)NR²⁸N⁴³;

-   —NR²⁸C(═NR⁴³)NR²⁸N⁴³; or one of the groups of formulae H56-H110 as    shown in Table 8 below.

TABLE 8 Groups of Formulae H56-H110

H56

H57

H58

H59

H60

H61

H62

H63

H64

H65

H66

H67

H68

H69

H70

H71

H72

H73

H74

H75

H76

H77

H78

H79

H80

H81

H82

H83

H84

H85

H86

H87

H88

H89

H90

H91

H92

H93

H94

H95

H96

H97

H98

H99

H100

H101

H102

H103

H104

H105

H106

H106

H108

H109

H110

-   -   R⁴²: H; alkyl; alkenyl; cycloalkyl; cycloheteroalkyl; aryl;        heteroaryl; —

-   (CR²³R³³)_(s)OR²¹; —(CR²³R³³)_(s)NR²⁸R⁴³; —(CR²³R³³)_(q)COOR²¹; or

-   —(CR²³R³³)_(q)CONR²¹R⁴³.    -   R⁴³: H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl;        heteroaryl; arylalkyl; heteroarylalkyl; or a suitable        N-protecting group.    -   R⁴⁴, R⁴⁵ and R⁴⁶ are independently defined as H; F; CF₃; OCF₃;        OCHF₂; NO₂; CN; alkyl; alkenyl; alkynyl; cycloalkyl;        heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl;        —OR²³; —NR²⁸R⁴³; —NR²⁸COR²³; —NR²⁸SO₂R²³; —NR²⁸CONR²⁸R⁴³;        —COR²³; —SO₂R²³;    -   R⁴⁷: H; CF₃; alkyl; alkenyl; alkynyl; cycloalkyl;        heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl;        —COOR²¹; or —CONR²⁸R⁴³.    -   R⁴⁸: H; F; CF₃; alkyl; alkenyl; cycloalkyl; cycloheteroalkyl;        aryl; heteroaryl;

-   (CR²³R³³)_(t)OR²¹; —(CR²³R³³)_(t)NR²⁸R⁴³; —(CR²³R³³)_(t)COOR²¹;

-   —(CR²³R³³)_(t)CONR²¹R⁴³    -   R⁴⁹ and R⁵⁰ are independently defined as H; F; CF₃; alkyl;        alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;        arylalkyl; heteroarylalkyl; —(CR³²R³³)_(q)OR²¹;        —(CR³²R³³)_(q)NR²⁸R⁴³; —(CR³²R³³)_(q)COOR²¹; or        —(CR³²R³³)_(q)CONR²⁸R⁴³.

Taken together the following pairs of said substituents can definecyclic structural elements:

Taken together (R⁴ and R¹¹); (R⁴ and R²⁷); (R⁵ and R⁶); (R⁵ and R⁷); (R⁵and R⁹); (R⁵ and R¹⁴); (R⁵ and R¹⁶); (R⁷ and R⁸); (R⁷ and R⁹); (R⁷ andR¹⁶); (R⁹ and R¹⁰); (R¹⁴ and R¹⁵); (R¹⁶ and R¹⁷); (R¹⁸ and R¹⁹); (R²⁷and R²⁸); (R²⁸ and R³¹); (R²⁸ and R⁴³); (R²⁹ and R³⁰); (R³² and R³³);(R³⁴ and R³⁵); (R³⁷ and R³⁸); (R³⁹ and R⁴⁰); (R³⁹ and R⁴¹); (R³⁹ andR⁴⁹); (R⁴² and R⁴³); (R⁴⁴ and R⁴⁵); or (R⁴⁴ and R⁴⁶) can form optionallysubstituted cycloalkyl or heterocycloalkyl moieties.

In addition, the structural elements —NR⁴R¹¹; —NR²⁷R²⁸; —NR²⁸R³¹ or—NR²⁸R⁴³ can form one of the groups of formulae H111-H118 as shown inTable 9 below.

TABLE 9 Heterocyclic Groups Defined by Linking the Residues of theDisubstituted Amino Groups —NR⁴R¹¹; —NR²⁷R²⁸; —NR²⁸R³¹ or —NR²⁸R⁴³.

H111

H112

H113

H114

H115

H116

H117

H118

Variable heteroatoms and connector groups in the aforementionedstructures are

-   -   Z: O; S; S(═O); S(═O)₂; or NR²⁸.    -   Y: O; S; or NR³⁷.    -   X: O; S; S(═O); or S(═O)₂.    -   Q: O; S; or NR²⁸.    -   U, V and W: As defined in Table 3.    -   T: CR⁴⁶ or N. In case T occurs several times in the same ring        structure each T is defined independently of the other.

And indices are defined as: q=0-4; r=2-4; s=1-4; t=0-2; and u=1-2.

Salts are especially the pharmaceutically acceptable salts of compoundsof formula I.

Such salts are formed, for example, as acid addition salts, preferablywith organic or inorganic acids, from compounds of type I with a basicnitrogen atom, especially the pharmaceutically acceptable salts.Suitable inorganic acids are, for example, halogen acids, such ashydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organicacids are, for example, carboxylic, phosphonic, sulfonic or sulfamicacids, for example acetic acid, propionic acid, octanoic acid, decanoicacid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid,succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid,malic acid, tartaric acid, citric acid, amino acids, such as glutamicacid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleicacid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoicacid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylaceticacid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid,2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid,benzenesulfonic acid, 2-naphthalenesulfonic acid,1,5-naphthalene-disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid,methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid,N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamicacid, or other organic protonic acids, such as ascorbic acid.

As used in this description, the term “alkyl”, taken alone or incombinations (i.a. as part of another group, such as “arylalkyl”)designates saturated, straight-chain or branched hydrocarbon radicalshaving up to 24, preferably up to 12, carbon atoms. In accordance with apreferred embodiment of the present invention “alkyl” is “lower alkyl”which designated alkyl groups having up to 6 carbon atoms.

The term “alkenyl”, taken alone or in combinations, designates straightchain or branched hydrocarbon radicals having up to 24, preferably up to12, carbon atoms and containing at least one or, depending on the chainlength, up to four olefinic double bonds. Such alkenyl moieties canexist as E or Z configurations, both of which are part of the invention.

The term “alkynyl”, taken alone or in combinations, refers to analiphatic hydrocarbon chain and includes, but is not limited to,straight and branched chains having 2 to 10 carbon atoms (unlessexplicitly specified otherwise) and containing at least one triple bond.

The term “cycloalkyl”, taken alone or in combinations, refers to asaturated alicyclic moiety having from three to ten carbon atoms.

The term “heterocycloalkyl”, taken alone or in combinations, describes asaturated or partially unsaturated heterocyclic moiety having from threeto seven ring carbon atoms and one or more ring heteroatoms selectedfrom nitrogen, oxygen and sulphur. This term includes, for example,azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl and the like.

The term “aryl”, taken alone or in combinations, designates aromaticcarbocyclic hydrocarbon radicals containing one or two six-memberedrings, such as phenyl or naphthyl, which may be substituted by up tothree substituents such as Br, Cl, F, CF₃, NO₂, lower alkyl or loweralkenyl.

The term “heteroaryl”, taken alone or in combinations, designatesaromatic heterocyclic radicals containing one or two five- and/orsix-membered rings, at least one of them containing up to threeheteroatoms selected from the group consisting of O, S and N and wherebythe heteroaryl radicals or tautomeric forms thereof may be attached viaany suitable atom. Said heteroaryl ring(s) are optionally substituted,e.g. as indicated above for “aryl”.

The term “arylalkyl”, as used herein, whether used alone or as part ofanother group, refers to the group —R^(a)-R^(b), where R^(a) is an alkylgroup as defined above, substituted by R^(b), an aryl group, as definedabove. Examples of arylalkyl moieties include, but are not limited to,benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl andthe like. Similarly, the term “lower arylalkyl”, refers to the abovemoiety —R^(a)-R^(b) but wherein R^(a) is a “lower alkyl” group.

The term “heteroarylalkyl”, whether used alone or as part of anothergroup, refers to the group —R^(a)-R^(c), where R^(a) is an alkyl groupas defined above, substituted by R^(c), a heteroaryl group, as definedabove. Analogously the term “lower heteroarylalkyl”, refers to the abovemoiety —R^(a)-R^(c) but wherein R^(a) is a “lower alkyl” group.

The terms “alkoxy” and “aryloxy”, taken alone or in combinations, referto the group —O—R^(a), wherein R^(a), is an alkyl group or an aryl groupas defined above.

“Amino” designates primary (i.e. —NH₂), secondary (i.e. —NRH) andtertiary (i.e. —NRR′) amines. Particular secondary and tertiary aminesare alkylamines, dialkylamines, arylamines, diarylamines,arylalkylamines and diarylamines wherein the alkyl is as herein definedand optionally substituted.

The term “optionally substituted” is intended to mean that a group, suchas but not limited to alkyl, alkenyl, alkynyl, cycloalkyl, aryl,heteroaryl, heterocycloalkyl, alkoxy and aryloxy may be substituted withone or more substituents independently selected from, e.g., halogen (F,Cl, Br, I), cyano (—CN), nitro (—NO₂), —SR^(a), —S(O)R^(a), —S(O)₂R^(a),—R^(a), —C(O)R^(a), —C(O)OR^(a), —C(O)NR^(b)R^(c),—C(═NR^(a))N^(R)R^(c), —OR^(a), —OC(O)R^(a), —OC(O)OR^(a),—OC(O)NR^(b)R^(c), —OS(O)R^(a), —OS(O)₂R^(a), —OS(O)NR^(b)R^(c),—OS(O)₂NR^(b)R^(c), —NR^(b)R^(c), —NR^(a)C(O)R^(b), —NR^(a)C(O)OR^(b),—NR^(a)C(O)NR^(b)R^(c), —NR^(a) C(═NR^(d))NR^(b)R^(c), —NR^(a)S(O)R^(b),—NR^(a)S(O)₂R^(b), wherein R^(a), R^(b), R^(c), and R^(d) are eachindependently, e.g., hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,aryl, heteroaryl, or heterocycloalkyl as described herein; or R^(b) andR^(c) may be taken together with the N atom to which they are attachedforming heterocycloalkyl or heteroaryl. These groups in turn can besubstituted with any described moiety, including, but not limited to,one or more moieties selected from the group consisting of halogen(fluoro, chloro, bromo, or iodo), hydroxyl, amino, alkylamino (e.g.,monoalkylamino, dialkylamino, or trialkylamino), arylamino (e.g.,monoarylamino, diarylamino, or triarylamino), hydroxy, carboxy, alkoxy,aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid,phosphate, or phosphonate.

Said groups, especially but not limited to hydroxy, amino and carboxyl,may be either unprotected or protected, if necessary, as well-known tothose skilled in the art. Examples of suitable protecting groups are asdetailed in Peter G. M. Wuts, Theodora W. Greene, Greene's ProtectiveGroups in Organic Synthesis, John Wiley and Sons, 4th Edition, 2006.

As used herein, all groups that can be substituted in one embodiment areindicated to be “optionally substituted,” unless otherwise specified.

As mentioned earlier herein, the term “lower” designates radicals andcompounds having up to 6 carbon atoms. Thus, for example, the term“lower alkyl” designates saturated, straight-chain, or branchedhydrocarbon radicals having up to 6 carbon atoms, such as methyl, ethyl,n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, and the like.Similarly, the term “lower cycloalkyl” designates saturated cyclichydrocarbon radicals having up to 6 carbon atoms, such as cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl and the like.

The present invention includes within its scope so-called “prodrugs” ofthe compounds of this invention. In general, such prodrugs will befunctional derivatives of the compounds, which in vivo are readilyconvertible into the required compound. Conventional procedures for theselection and preparation of suitable prodrug derivatives are described,for example, in Hans Bundgaard, Design of Prodrugs, Elsevier, 1985; andin Valentino J. Stella et al., Prodrugs: Challenges and Rewards,Springer, 1st ed., 2007.

Some of the aforementioned substituents can occur several times withinthe same molecular entity, for example, but not limited to R¹⁴, R¹⁵,R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁸, R¹⁹, R³⁰, R³¹, R³², R³³, R³⁹, R⁴⁰, R⁴¹, R⁴²,R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, and R⁵⁰. Each of such multiply occurringsubstituents shall be selected independently from the other radicals ofthe same type and within the scope of the definition of the respectivegroup.

All possible stereoisomers, explicitly also including rotamers andatropisomers, of macrocycles of type I are part of this invention.

The general scope of the current invention is defined by groups ofselected building blocks A, B and C and the appending substituents asoutlined in this section.

Building blocks A1-A626 (Table 10) constitute a subset of possiblebuilding blocks based on the ring systems a1-a25 (Table 1). Asstructural characteristic, groups of type A carry one nucleophilicmoiety XH (where X is O or S) and one carboxylic acid C(O)OHfunctionality. The underlying divalent radicals of type —X-a-CO— are anintegral part of macrocyclic backbones of type I, into which they areincorporated by appropriate reactions of the XH and COOH groups of therespective starting materials with suitable reactants.

As mentioned earlier hereinabove, building blocks of type A act astemplates and exert an important conformational constraint on productsof type I. The structural effects of building blocks of type A dependlargely on the relative orientation of the attachment vectors of —X— and—C(O)— and on the spatial distance between these groups. Molecularmodeling revealed that the distances (typically between 2.5 and 7.5 Å)and vector arrangements for —X— and —C(O)— in A1-A626 (Table 10) varyconsiderably, thus strongly influencing the conformations of macrocyclesof type I.

The general scope of the current invention is defined by groups ofselected building blocks A, B and C and the appending substituents asoutlined in this section.

Building blocks A1-A626 (Table 10) constitute a subset of possiblebuilding blocks based on the ring systems a1-a25 (Table 1). Asstructural characteristic, groups of type A carry one nucleophilicmoiety XH (where X is O or S) and one carboxylic acid C(O)OHfunctionality. The underlying divalent radicals of type —X-a-CO— are anintegral part of macrocyclic backbones of type I, into which they areincorporated by appropriate reactions of the XH and COOH with suitablereactants.

As mentioned earlier hereinabove, building blocks of type A act astemplates and exert an important conformational constraint on productsof type I. The structural effects of building blocks of type A dependslargely on the relative orientation of the attachment vectors of —X— and—C(O)— and on the spatial distance between these groups. Molecularmodeling revealed that the distances (typically between 2.5 and 7.5 Å)and vector arrangements for —X— and —C(O)— in A1-A626 (Table 10) varyconsiderably, thus strongly influencing the conformations of macrocyclesof type I.

TABLE 10 Radicals A1 (a1)-A626 (a25)

A1 (a1)

A2 (a1)

A3 (a1)

A4 (a1)

A5 (a1)

A6 (a1)

A7 (a1)

A8 (a1)

A9 (a1)

A10 (a1)

A11 (a1)

A12 (a1)

A13 (a1)

A14 (a1)

A15 (a1)

A16 (a1)

A17 (a1)

A18 (a1)

A19 (a1)

A20 (a1)

A21 (a1)

A22 (a1)

A23 (a1)

A24 (a1)

A25 (a1)

A26 (a1)

A27 (a1)

A28 (a1)

A29 (a1)

A30 (a1)

A31 (a1)

A32 (a1)

A33 (a1)

A34 (a1)

A35 (a1)

A36 (a1)

A37 (a1)

A38 (a1)

A39 (a1)

A40 (a1)

A41 (a1)

A42 (a1)

A43 (a1)

A44 (a1)

A45 (a1)

A46 (a1)

A47 (a1)

A48 (a1)

A49 (a1)

A50 (a1)

A51 (a1)

A52 (a1)

A53 (a1)

A54 (a1)

A55 (a1)

A56 (a1)

A57 (a1)

A58 (a1)

A59 (a1)

A60 (a2)

A61 (a2)

A62 (a2)

A63 (a2)

A64 (a2)

A65 (a2)

A66 (a2)

A67 (a2)

A68 (a2)

A69 (a2)

A70 (a2)

A71 (a2)

A72 (a2)

A73 (a2)

A74 (a2)

A75 (a2)

A76 (a2)

A77 (a2)

A78 (a2)

A79 (a2)

A80 (a2)

A81 (a2)

A82 (a2)

A83 (a2)

A84 (a2)

A85 (a2)

A86 (a2)

A87 (a2)

A88 (a2)

A89 (a2)

A90 (a2)

A91 (a2)

A92 (a2)

A93 (a2)

A94 (a2)

A95 (a2)

A96 (a2)

A97 (a2)

A98 (a2)

A99 (a2)

A100 (a2)

A101 (a2)

A102 (a2)

A103 (a2)

A104 (a2)

A105 (a2)

A106 (a2)

A107 (a2)

A108 (a2)

A109 (a2)

A110 (a2)

A111 (a2)

A112 (a2)

A113 (a2)

A114 (a2)

A115 (a2)

A116 (a2)

A117 (a2)

A118 (a2)

A119 (a2)

A120 (a2)

A121 (a2)

A122 (a2)

A123 (a2)

A124 (a2)

A125 (a2)

A126 (a2)

A127 (a2)

A128 (a2)

A129 (a2)

A130 (a2)

A131 (a2)

A132 (a2)

A133 (a2)

A134 (a2)

A135 (a2)

A136 (a2)

A137 (a2)

A138 (a2)

A139 (a2)

A140 (a2)

A141 (a2)

A142 (a2)

A143 (a2)

A144 (a3)

A145 (a3)

A146 (a3)

A147 (a3)

A148 (a3)

A149 (a3)

A150 (a3)

A151 (a3)

A152 (a3)

A153 (a3)

A154 (a3)

A155 (a3)

A156 (a3)

A157 (a3)

A158 (a3)

A159 (a3)

A160 (a3)

A161 (a3)

A162 (a3)

A163 (a3)

A164 (a3)

A165 (a3)

A166 (a4)

A167 (a4)

A168 (a4)

A169 (a4)

A170 (a4)

A171 (a4)

A172 (a4)

A173 (a4)

A174 (a4)

A175 (a4)

A176 (a4)

A177 (a4)

A178 (a4)

A179 (a4)

A180 (a4)

A181 (a4)

A182 (a4)

A183 (a4)

A184 (a4)

A185 (a4)

A186 (a4)

A187 (a4)

A188 (a4)

A189 (a5)

A190 (a5)

A191 (a5)

A192 (a5)

A193 (a5)

A194 (a5)

A195 (a5)

A196 (a5)

A197 (a5)

A198 (a5)

A199 (a5)

A200 (a5)

A201 (a6)

A202 (a6)

A203 (a6)

A204 (a6)

A205 (a6)

A206 (a6)

A207 (a7)

A208 (a7)

A209 (a7)

A210 (a7)

A211 (a7)

A212 (a7)

A213 (a7)

A214 (a7)

A215 (a7)

A216 (a7)

A217 (a7)

A218 (a7)

A219 (a7)

A220 (a7)

A221 (a7)

A222 (a7)

A223 (a7)

A224 (a7)

A225 (a7)

A226 (a7)

A227 (a7)

A228 (a7)

A229 (a8)

A230 (a8)

A231 (a8)

A232 (a8)

A233 (a8)

A234 (a8)

A235 (a9)

A236 (a9)

A237 (a9)

A238 (a9)

A239 (a9)

A240 (a10)

A241 (a10)

A242 (a10)

A243 (a10)

A244 (a10)

A245 (a10)

A246 (a10)

A247 (a10)

A248 (a10)

A249 (a10)

A250 (a10)

A251 (a10)

A252 (a10)

A253 (a10)

A254 (a10)

A255 (a10)

A256 (a10)

A257 (a10)

A258 (a10)

A259 (a10)

A260 (a10)

A261 (a10)

A262 (a10)

A263 (a10)

A264 (a10)

A265 (a10)

A266 (a10)

A267 (a10)

A268 (a10)

A269 (a10)

A270 (a10)

A271 (a10)

A272 (a10)

A273 (a10)

A274 (a10)

A275 (a10)

A276 (a10)

A277 (a10)

A278 (a10)

A279 (a10)

A280 (a10)

A281 (a10)

A282 (a10)

A283 (a10)

A284 (a10)

A285 (a10)

A286 (a10)

A287 (a10)

A288 (a10)

A280 (a10)

A290 (a10)

A291 (a10)

A292 (a10)

A293 (a10)

A294 (a10)

A295 (a10)

A296 (a10)

A297 (a10)

A298 (a10)

A299 (a10)

A300 (a10)

A301 (a10)

A302 (a10)

A303 (a10)

A304 (a10)

A305 (a10)

A306 (a10)

A307 (a10)

A308 (a10)

A309 (a10)

A310 (a10)

A311 (a10)

A312 (a10)

A313 (a10)

A314 (a10)

A315 (a10)

A316 (a10)

A317 (a10)

A318 (a10)

A319 (a10)

A320 (a10)

A321 (a10)

A322 (a10)

A323 (a10)

A324 (a10)

A325 (a10)

A326 (a10)

A327 (a10)

A328 (a10)

A329 (a10)

A330 (a10)

A331 (a10)

A332 (a10)

A333 (a10)

A334 (a10)

A335 (a10)

A336 (a10)

A337 (a10)

A338 (a10)

A339 (a10)

A340 (a10)

A341 (a10)

A342 (a10)

A343 (a10)

A344 (a10)

A345 (a10)

A346 (a10)

A347 (a10)

A348 (a10)

A349 (a10)

A350 (a10)

A351 (a10)

A352 (a10)

A353 (a10)

A354 (a10)

A355 (a10)

A356 (a10)

A357 (a10)

A358 (a11)

A359 (a11)

A360 (a11)

A361 (a11)

A362 (a11)

A363 (a11)

A364 (a11)

A365 (a11)

A366 (a11)

A367 (a11)

A368 (a11)

A369 (a11)

A370 (a11)

A371 (a11)

A372 (a11)

A373 (a12)

A374 (a12)

A375 (a12)

A376 (a12)

A377 (a12)

A378 (a12)

A379 (a12)

A380 (a12)

A381 (a12)

A382 (a12)

A383 (a12)

A384 (a12)

A385 (a12)

A386 (a13)

A387 (a13)

A388 (a13)

A389 (a13)

A390 (a13)

A391 (a13)

A392 (a13)

A393 (a13)

A394 (a13)

A395 (a13)

A396 (a13)

A397 (a13)

A398 (a13)

A399 (a14)

A400 (a14)

A401 (a14)

A402 (a14)

A403 (a14)

A404 (a14)

A405 (a14)

A406 (a14)

A407 (a14)

A408 (a14)

A409 (a14)

A410 (a14)

A411 (a14)

A412 (a14)

A413 (a14)

A414 (a15)

A415 (a15)

A416 (a15)

A417 (a15)

A418 (a15)

A419 (a15)

A420 (a15)

A421 (a15)

A422 (a15)

A423 (a15)

A424 (a15)

A425 (a15)

A426 (a15)

A427 (a15)

A428 (a15)

A429 (a15)

A430 (a15)

A431 (a15)

A432 (a15)

A433 (a15)

A434 (a15)

A435 (a15)

A436 (a15)

A437 (a15)

A438 (a15)

A439 (a15)

A440 (a15)

A441 (a15)

A442 (a15)

A443 (a15)

A444 (a15)

A445 (a15)

A446 (a15)

A447 (a15)

A448 (a15)

A449 (a15)

A450 (a16)

A451 (a16)

A452 (a16)

A453 (a16)

A454 (a16)

A455 (a16)

A456 (a16)

A457 (a16)

A458 (a16)

A459 (a16)

A460 (a17)

A461 (a17)

A462 (a17)

A463 (a17)

A464 (a17)

A465 (a17)

A466 (a17)

A467 (a17)

A468 (a17)

A469 (a17)

A470 (a17)

A471 (a17)

A472 (a17)

A473 (a17)

A474 (a17)

A475 (a17)

A476 (a17)

A477 (a17)

A478 (a17)

A479 (a17)

A480 (a17)

A481 (a17)

A482 (a17)

A483 (a17)

A484 (a17)

A485 (a17)

A486 (a17)

A487 (a17)

A488 (a17)

A489 (a17)

A490 (a17)

A491 (a17)

A492 (a17)

A493 (a17)

A494 (a17)

A495 (a17)

A496 (a17)

A497 (a17)

A498 (a17)

A499 (a17)

A500 (a17)

A501 (a17)

A502 (a17)

A503 (a17)

A504 (a17)

A505 (a17)

A506 (a17)

A507 (a17)

A508 (a17)

A509 (a17)

A510 (a17)

A511 (a17)

A512 (a17)

A513 (a17)

A514 (a17)

A515 (a17)

A516 (a18)

A517 (a18)

A518 (a18)

A519 (a18)

A520 (a18)

A521 (a18)

A522 (a18)

A523 (a18)

A524 (a18)

A525 (a18)

A526 (a18)

A527 (a18)

A528 (a18)

A529 (a18)

A530 (a18)

A531 (a18)

A532 (a18)

A533 (a18)

A534 (a18)

A535 (a18)

A536 (a18)

A537 (a18)

A538 (a18)

A539 (a18)

A540 (a18)

A541 (a18)

A542 (a18)

A543 (a18)

A544 (a18)

A545 (a18)

A546 (a18)

A547 (a18)

A548 (a18)

A549 (a19)

A550 (a19)

A551 (a19)

A552 (a19)

A553 (a19)

A554 (a19)

A555 (a19)

A556 (a19)

A557 (a19)

A558 (a19)

A559 (a19)

A560 (a19)

A561 (a19)

A562 (a19)

A563 (a19)

A564 (a19)

A565 (a20)

A566 (a20)

A567 (a20)

A568 (a20)

A569 (a20)

A570 (a20)

A571 (a20)

A572 (a20)

A573 (a20)

A574 (a20)

A575 (a20)

A576 (a20)

A577 (a20)

A578 (a21)

A579 (a21)

A580 (a21)

A581 (a21)

A582 (a21)

A583 (a21)

A584 (a21)

A585 (a21)

A586 (a21)

A587 (a21)

A588 (a22)

A589 (a22)

A590 (a22)

A591 (a22)

A592 (a22)

A593 (a22)

A594 (a22)

A595 (a22)

A596 (a22)

A597 (a22)

A598 (a22)

A599 (a22)

A600 (a22)

A601 (a22)

A602 (a23)

A603 (a23)

A604 (a23)

A605 (a23)

A606 (a23)

A607 (a23)

A608 (a23)

A609 (a24)

A610 (a24)

A611 (a24)

A612 (a24)

A613 (a24)

A614 (a24)

A615 (a24)

A616 (a24)

A617 (a24)

A618 (a24)

A619 (a25)

A620 (a25)

A621 (a25)

A622 (a25)

A623 (a25)

A624 (a25)

A625 (a25)

A626 (a25)

Divalent building blocks B1-B21 (Table 11, hereinbelow) constitute asubset of possible building blocks based on the ring systems b1-b11(Table 2, above). They are based on optionally substituted cyclicsecondary amines carrying a moiety of type —CHR³-LG, wherein LG is asuitable leaving group (e.g., but not limited to, —OH forming a suitableLG in situ during Mitsunobu reactions, or halogens like —Br or —Iamenable to S_(N) reactions) that can be replaced by the nucleophilicgroups of building blocks A thus forming an ether (—O—) or a thioether(—S—) linkage between building blocks of type A and B. In most productsof type I, the secondary amine nitrogen of building block B forms atertiary amide linkage with the carboxyl group of building blocks oftype C. In case a suitable exocyclic amine functionality is present, itcan be, instead of the ring-nitrogen, involved in the formation of asecondary or preferably tertiary amide bond to C. Such an alternativebinding mode is realized with, but not limited to B10.

By virtue of inducing peptidyl cis-trans isomerization or stabilizingcis amide bonds, building blocks of type B can function asconformational modulators in products of type I.

TABLE 11 Radicals B1-B21

B1 (b1)

B2 (b2)

B3 (b2)

B4 (b3)

B5 (b3)

B6 (b3)

B7 (b3)

B8 (b3)

B9 (b3)

B10 (b3)

B11 (b4)

B12 (b4)

B13 (b4)

B14 (b4)

B15 (b4)

B16 (b4)

B17 (b5)

B18 (b8)

B19 (b10)

B20 (b11)

B21 (b11)

The divalent moiety C may consist of an ensemble of one to threesubunits c1-c3, each derived from suitably protected and functionalizedamine or amino acid derivatives. As a consequence the C moiety directlyinfluences the ring size of the resulting macrocycle and can be regardedas spacer or linker. This linker ensemble C is joined to building blockA via its N-terminus and to building block B via its C-terminus to forma macrocyclic ring of type I. According to its definition theconnections within the linker ensemble, i.e. V or W, can be accomplishedby amide bonds (—NR⁴—C(═O)—), an alkene[1,2]diyl (—CHR¹²═CHR¹³—), analkane[1,2]diyl (—CHR¹²—CHR¹³—), or methylene-heteroatom moiety(—CHR³—Z—), an oxalyl unit (—C(═O)—C(═O)—) or a disulfide bridge(—S—S—). With respect to the macrocyclic backbone of I it follows thatthe linker C contributes at least one amide bonds.

Suitable linker C can be represented by, but are not limited to, themoieties shown in Table 12. For example C1 represents a linker moietyconstituted of one to three α-amino acid derivatives connected alongtheir main chains, while C₇-C₁₀ are equivalent to dipeptide moieties ofβ-amino acids. The simplest embodiments in which at least one connectionbetween the subunits is realized by a non-amidic group are C2-C5.Finally C58-C101 shall depict situations in which a longer (>3 C-atoms)side chain connection of a suitable diamine or diacid is involved in anamide bond.

TABLE 12 Representative Embodiments of Linker C

C1

C2

C3

C4

C5

C6

C7

C8

C9

C10

C11

C12

C13

C14

C15

C16

C17

C18

C19

C20

C21

C22

C23

C24

C25

C26

C27

C28

C29

C30

C31

C32

C33

C34

C35

C36

C37

C38

C39

C40

C41

C42

C43

C44

C45

C46

C47

C48

C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C59

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

C71

C72

C73

C74

C75

C76

C77

C78

C79

C80

C81

C82

C83

C84

C85

C86

C87

C88

C89

C90

C91

C92

C93

C94

C95

C96

C97

C98

C99

C100

C101

According to the preceding explanations, products of type I contain atleast two amide bonds. As mentioned in the introduction, tertiary amidecontaining products generally show various ratios of cis and trans amidebond conformations in solution; this preference is in contrast tosecondary amides that generally adopt trans conformations only. Theoccurrence of cis and/or trans conformations in macrocyclic naturalproducts containing tertiary amides is well documented. In some cases arapid equilibration between the cis and trans amide bonds, the so-called“peptidyl cis/trans isomerization”, is observed; whereas in other casesdiscrete cis and trans tertiary amide bonds are detected as two stableconformers in solution at room temperature.

All possible stereoisomers, including atropisomers, and distinctconformers or rotamers of macrocycles of type I are part of thisinvention.

Within the general scope of building blocks A preferred radicals are:

Within the general scope of building blocks A preferred radicals areA1(a1); A2(a1); A3(a1); A4(a1); A5(a1); A6(a1); A7(a1); A9(a1); A10(a1);A73(a2); A170(a4); A209(a7); A240(a10); A272(a10); A532(a18); A609(a24);A612(a24) and A614(a24) (Table 13).

TABLE 13 Preferred Building Blocks of Type A

A1 (a1)

A2 (a1)

A3 (a1)

A4 (a1)

A5 (a1)

A6 (a1)

A7 (a1)

A9 (a1)

A10 (a1)

A73 (a2)

A170 (a4)

A209 (a7)

A240 (a10)

A272 (a10)

A532 (a18)

A609 (a24)

A612 (a24)

A614 (a24)

Preferred building blocks of type B are B4 (b3); B5 (b3); B6 (b3); B7(b3); B8 (b3); B9 (b3); B10 (b3); B12 (b4); B13 (b4); B14 (b4); B15(b4); B16 (b4) and B17 (b5) (Table 14).

TABLE 14 Preferred Building Blocks of Type B

B4 (b3)

B5 (b3)

B6 (b3)

B7 (b3)

B8 (b3)

B9 (b3)

B10 (b3)

B12 (b4)

B13 (b4)

B14 (b4)

B15 (b4)

B16 (b4)

B17 (b5)

Preferred embodiments of linker C are shown in Table 15.

TABLE 15 Preferred Linker of type C

C1

C2

C3

C4

C5

C6

C7

C8

C9

C10

C11

C12

C13

C14

C15

C16

C17

C18

C19

C20

C21

C25

C26

C27

C28

C29

C30

C34

C35

C36

C37

C38

C39

C43

C44

C45

C46

C47

C48

C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C59

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

C71

C72

C73

C74

C75

C76

C77

C78

C79

C80

C81

C86

C87

C88

C89

C90

C91

C92

C93

The preferred substituents of the preferred building blocks A, B and Care defined as:

-   -   R¹: H; F; Cl; Br; I; CF₃; OCF₃; OCHF₂; NO₂; CN; lower alkyl;        lower alkenyl; lower alkynyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;

-   —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴COOR²¹;

-   —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³;

-   —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹;    —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂;    —(CR¹⁸R¹⁹)_(q)COR²²;

-   —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)OSO₃R²¹; —(CR¹⁸R¹⁹)_(q)R²⁴;    —(CR¹⁸R¹⁹)_(q)R²⁵; or)

-   —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R²: H; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;

-   —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴COOR²¹;

-   —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³;

-   —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³;

-   —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R³: Defined as above.    -   R⁴: H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; or a suitable N-protecting group.    -   R⁵, R⁷ and R⁹ are independently defined as: H; F; CF₃; lower        alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl;        aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl;

-   (CR¹⁸R¹⁹)₃OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COOR²¹;

-   —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³;

-   —(CR¹⁸R¹⁹)_(s)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹;    —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂;    (CR¹⁸R¹⁹)_(q)COR²²;

-   —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or    —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R⁶, R⁸ and R¹⁰ are independently defined as: H; CF₃; or lower        alkyl.    -   R¹¹: H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; a suitable protecting group;        —(CR¹⁸R¹⁹)_(r)OR²⁰; —(CR¹⁸R¹⁹)_(r)NR⁴R²⁷;        —(CR¹⁸R¹⁹)_(r)NR⁴COOR²¹;

-   —(CR¹⁸R¹⁹)_(r)NR⁴CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)NR⁴SO₂R²³;    —(CR¹⁸R¹⁹)_(r)NR⁴SO₂NR⁴R²⁷;

-   —(CR¹⁸R¹⁹)_(q)COOR²¹;

-   —(CR¹⁸R¹⁹)_(q)CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³;

-   —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(s)R²⁵; or    —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R¹² and R¹³ are independently defined as H; or lower alkyl.

R¹⁴ and R¹⁶ are independently defined as: H; F; CF₃; lower alkyl; loweralkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl;lower arylalkyl; lower heteroarylalkyl;

-   —(CR¹⁸R¹⁹)_(s)OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COOR²¹;-   —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³;-   —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COR²².    -   R¹⁵ and R¹⁷ are independently defined as: H; CF₃; lower alkyl.    -   R¹⁸: H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl;        lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;-   —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COOR²¹;-   —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹;    —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³;-   —(CR²⁹R³⁰)_(s)NR²⁸SO₂NR²⁸R³¹;-   —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹;    —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹;-   —(CR²⁹R³⁰)_(q)PO(OR²¹)₂; (CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³;-   —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or —(CR²⁹R³⁰)_(q)R²⁶.    -   R¹⁹: H; CF₃; or lower alkyl.    -   R²⁰: H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;-   —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹;-   —(CR²⁹R³⁰)_(r)NR²⁸COR³¹; —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹;    —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³;-   —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹;    —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹;-   —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴;    —(CR²⁹R³⁰)_(q)R²⁵; or-   —(CR²⁹R³⁰)_(q)R²⁶.    -   R²¹ and R²³: Defined as above.    -   R²²: lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;-   —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COOR²¹;-   —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹;    —(CR²⁹R³⁰)_(s)NR²⁸SO₂—R²³;-   —(CR²⁹R³⁰)_(s)COOR²¹; —(CR²⁹R³⁰)_(s)CONR²⁸R³¹;    —(CR²⁹R³⁰)_(s)SO₂NR²⁸R³¹;-   —(CR²⁹R³⁰)_(t)COR³¹; —(CR²⁹R³⁰)_(s)SO₂R²³; —(CR²⁹R³⁰)_(t)R²⁴;    —(CR²⁹R³⁰)_(t)R²⁵; or-   —(CR¹⁸R¹⁹)_(t)R²⁶.    -   R²⁴, R²⁵ and R²⁶: Defined as above.    -   R²⁷ and R²⁸: Defined as above.    -   R²⁹: H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl;        lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; —-   (CR³²R³³)_(s)OR³¹; —(CR³²R³³)_(s)NR²⁸R³¹; —(CR³²R³³)_(s)NR²⁸COOR²¹;-   —(CR³²R³³)_(s)NR²⁸COR³¹; —(CR³²R³³)_(s)NR²⁸CONR²⁸R³¹;    —(CR³²R³³)_(s)NR²⁸SO₂R²³;-   —(CR³²R³³)_(q)COOR²¹; —(CR³²R³³)_(q)CONR²⁸R³¹;    —(CR³²R³³)_(q)SO₂NR²⁸R³¹;-   —(CR³²R³³)_(q)PO(OR²¹)₂; —(CR³²R³³)_(q)COR³¹; —(CR³²R³³)_(q)SO₂R²³;    —(CR³²R³³)_(q)R³¹.    -   R³⁰ and R³³: H; CF₃; lower alkyl.    -   R³¹ and R³²: Defined as above.    -   R³⁴ and R³⁵ are independently defined as H; F; Cl; CF₃; OCF₃;        OCHF₂; NO₂; CN; lower alkyl; lower alkenyl; lower alkynyl; lower        cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower        arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(q)OR³¹;        —(CR²⁹R³⁰)_(q)NR²⁸R³¹;-   —(CR²⁹R³⁰)_(q)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹;    —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹;-   —(CR²⁹R³⁰)_(q)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)COOR²¹;-   —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COR³¹;-   —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁶: Defined as above.    -   R³⁷: H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; a suitable N-protecting group;        —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹;-   —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹;    —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹;-   —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)COOR²¹;-   —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COR³¹;-   —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁸: H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; —-   —(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸COOR²¹;-   —(CR²⁹R³⁰)_(q)NR²⁸COR³¹; —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COOR²¹;-   —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; or —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁹; R¹⁰; R⁴¹; R⁴²; R⁴³; R⁴⁴; R⁴⁵; R⁴⁶; R⁴⁷; R⁴⁸; R⁴⁹ and R⁵⁰:        Defined as above.

In the aforementioned preferred structures the variable heteroatom Z andthe connector U are defined as:

-   -   Z: O; S(═O); or S(═O)₂.    -   U: —C(═O)—; —NR⁴—C(═O)—; —C(═O)—C(═O)—;    -   or —C(—OR²⁰)₂—C(═O)—.

Defined as above are:

-   -   Substituents that can be pairwise taken together and form        optionally substituted cycloalkyl or heterocycloalkyl moieties.    -   Structural elements that can form one of the groups of formulae        H111-H118 (Table 9).    -   Variable heteroatoms Q, T, X and Y.    -   Indices q-u.

The above preferred structures include all possible stereoisomers,explicitly also including rotamers and atropisomers, of macrocycles oftype I.

Particularly preferred among the building blocks of type A are A1(a1);A2(a1); A3(a1); A4(a1); A5(a1); A6(a1); A7(a1); A9(a1); A10(a1);A73(a2); A170(a4); A209(a7); A240(a10); A272(a10); A532(a18); A614(a24).For most of these building blocks, oxygen is the preferred nucleophilicmoiety. However in the case of A170 it consists of a sulfur atom; and inthe case of the three building blocks A5-A7, both oxygen and sulfurderivatives are part of the invention (Table 16).

TABLE 16 Particularly Preferred Building Blocks of Type A

A1 (a1)

A2 (a1)

A3 (a1)

A4 (a1)

A5 (a1)

A6 (a1)

A7 (a1)

A9 (a1)

A10 (a1)

A73 (a2)

A170 (a4)

A209 (a7)

A272 (a10)

A532 (a18)

A614 (a24)

Among the building blocks of type B particularly preferred are B7, B8,B9 and B-17 as shown in Table 17.

TABLE 17 Particularly Preferred Building Blocks of Type B

B7-1

B7-2

B7-3

B7-4

B8-1

B8-2

B8-3

B8-4

B9-1

B9-2

B9-3

B9-4

B17-1

B17-2

Particularly preferred embodiments of the linker C are listed in Table18.

TABLE 18 Particularly Preferred Embodiments of Linker C

C1

C2

C3

C4

C5

C6

C7

C8

C9

C10

C11

C12

C13

C14

C15

C16

C17

C18

C19

C20

C21

C25

C26

C27

C28

C29

C30

C34

C35

C36

C37

C38

C39

C43

C44

C45

C46

C47

C48

C49

C54

C55

C56

C57

C58

C59

C60

C61

C62

C63

C64

C65

C70

C71

C72

C73

C74

C75

C76

C77

C90

C91

C92

C93

The particularly preferred substituents on the particularly preferredbuilding blocks A, B and C are defined as:

-   -   R¹: H; F; Cl; CF₃; OCF₃; OCHF₂; NO₂; CN; lower alkyl; lower        alkenyl; lower alkynyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;

-   —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴COR²²;

-   —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³;    —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴;    —(CR¹⁸R¹⁹)_(q)R²⁵; or

-   —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R²: H; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; —

-   (CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴COR²²;

-   —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³;    —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;    —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴;    —(CR¹⁸R¹⁹)_(q)R²⁵; or

-   —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R³: Defined as earlier hereinabove.    -   R⁴: H; lower alkyl; lower alkenyl; or a suitable N-protecting        group.    -   R⁵, R⁷ and R⁹ are independently defined as: H; CF₃; lower alkyl;        lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl;        heteroaryl; lower arylalkyl; lower heteroarylalkyl;

-   —(CR¹⁸R¹⁹)_(s)OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²;

-   —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³;    —(CR¹⁸R¹⁹)_(q)COOR²¹;

-   —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹;

-   —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³;

-   —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R⁶, R⁸ and R¹⁰ are independently defined as: H; CF₃; or CH₃.    -   R¹¹; H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; a suitable protecting group;        —(CR¹⁸R¹⁹)_(r)OR²⁰; —(CR¹⁸R¹⁹)_(r)NR⁴R²⁷;        —(CR¹⁸R¹⁹)_(r)NR⁴CONR⁴R²⁷;

-   —(CR¹⁸R¹⁹)_(r)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)COOR²¹;

-   —(CR¹⁸R¹⁹)_(c)—CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)R²⁴;    —(CR¹⁸R¹⁹)₃R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶.    -   R¹² and R¹³ are independently defined as H; or lower alkyl.    -   R¹⁴ and R¹⁶ are independently defined as: H; F; CF₃; lower        alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl;        aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl;

-   —(CR¹⁸R¹⁹)₃OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²;

-   —(CR¹⁸⁻¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹.    -   R¹⁵ and R¹⁷ are independently defined as: H; CF₃; or CH₃.    -   R¹⁸: H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl;        lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;

-   —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹;    —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³;

-   —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹;    —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴;    —(CR²⁹R³⁰)_(q)R²⁵; or

-   —(CR²⁹R³⁰)_(q)R²⁶.    -   R¹⁹: H; CF₃; or CH₃.    -   R²⁰: H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; —

-   (CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹;

-   —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³;    —(CR²⁹R³⁰)_(q)COOR²¹;

-   —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COR³¹;

-   —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or    —(CR²⁹R³⁰)_(q)R²⁶.    -   R²¹ and R²³: Defined as above    -   R²²: lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; —

-   (CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —

-   (CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³;    —(CR²⁹R³⁰)_(s)COOR²¹;

-   —(CR²⁹R³⁰)_(s)CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(t)COR³¹;

-   —(CR²⁹R³⁰)_(s)SO₂R²³; —(CR²⁹R³⁰)_(t)R²⁴; —(CR²⁹R³⁰)_(t)R²⁵; or    —(CR²⁹R³⁰)_(t)R²⁶.

R²⁴, R²⁵ and R²⁶: Defined as above.

-   -   R²⁷ and R²⁸: Defined as above.    -   R²⁹: H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl;        lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;

-   —(CR³²R³³)_(s)OR³¹; —(CR³²R³³)_(s)NR²⁸R³¹;

-   —(CR³²R³³)_(s)NR²⁸COR³¹; —(CR³²R³³)_(s)NR²⁸CONR²⁸R³¹;

-   —(CR³²R³³)_(q)COOR²¹; —(CR³²R³³)_(q)CONR²⁸R³¹; —(CR³²R³³)_(q)COR³¹;    —(CR³²R³³)_(q)R³¹.    -   R³⁰ and R³³: H; CF₃; or CH₃.    -   R³¹ and R³²: Defined as above    -   R³⁴ and R³⁵ are independently defined as H; F; Cl; CF₃; OCF₃;        OCHF₂; lower alkyl; lower alkenyl; lower alkynyl; lower        cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower        arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(q)OR³¹;        —(CR²⁹R³⁰)_(q)NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)NR²⁸COR³¹; —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹;    —(CR²⁹R³⁰)_(q)NR²⁸SO₂R²³;

-   —(CR²⁹R³⁰)_(q)COOR²¹;

-   —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹;    —(CR²⁹R³⁰)_(q)COR³¹;

-   —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁶: Defined as in Part 3 “General Scope of the Invention”.    -   R³⁷: H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl; a suitable N-protecting group;        —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹;

-   —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹;    —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹;

-   or —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁸: H; lower alkyl; lower alkenyl; lower cycloalkyl; lower        heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower        heteroarylalkyl;

-   —(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹;

-   —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹;

-   —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹;

-   or —(CR²⁹R³⁰)_(q)R³¹.    -   R³⁹; R⁴⁰; R⁴¹; R⁴²; R⁴³; R⁴⁴; R⁴⁵; R⁴⁶; R⁴⁷; R⁴⁸; R⁴⁹ and R⁵⁰:        Defined as above.

In the aforementioned structures the variable heteroatom Z and theconnector U are defined as:

-   -   Z: O; or S(═O)₂.    -   U: —C(═O)—; —NR⁴—C(═O)—; or —C(═O)—C(═O)—.

Defined as above are:

-   -   Substituents that can be pairwise taken together and form        optionally substituted cycloalkyl or heterocycloalkyl moieties.    -   Structural elements that can form one of the groups of formulae        H111-H118 (Table 9).    -   Variable heteroatoms Q, T, X and Y.    -   Indices q-u.

The above particularly preferred structures include all possiblestereoisomers, exlicity also rotamers and atropisomers, of macrocyclesof type I.

Examples of, but not limited to, readily accessible substances thatdefine possible subunits of the linker C are listed in Table 19.

TABLE 19 Substances Representing Subunits of Particularly PreferredLinkers C Code Chemical Name Ala L-Alanine ^(D)Ala D-Alanine ArgL-Arginine ^(D)Arg D-Arginine Asn L-Asparagine ^(D)Asn D-Asparagine AspL-Aspartic acid ^(D)Asp D-Aspartic acid Cys L-Cysteine ^(D)CysD-Cysteine Glu L-Glutamic acid ^(D)Glu D-Glutamic acid Gln L-Glutamine^(D)Gln D-Glutamine Gly Glycine His L-Histidine ^(D)His D-Histidine IleL-Isoleucine ^(D)Ile D-Isoleucine Leu L-Leucine ^(D)Leu D-Leucine LysL-Lysine ^(D)Lys D-Lysine Met L-Methionine ^(D)Met D-Methionine PheL-Phenylalanine ^(D)Phe D-Phenylalanine Pro L-Proline ^(D)Pro D-ProlineSer L-Serine ^(D)Ser D-Serine Thr L-Threonine ^(D)Thr D-Threonine TrpL-Tryptophan ^(D)Trp D-Tryptophan Tyr L-Tyrosine ^(D)Tyr D-Tyrosine ValL-Valine ^(D)Val D-Valine Apa 3-Amino-propanoic acid H-β³-HAla-OH(3S)-3-Amino-butyric acid H-β³-HVal-OH (3R)-3-Amino-4-methyl-valericacid H-β³-HIle-OH (3R,4S)-3-Amino-4-methyl-hexanoic acid H-β³-HLeu-OH(3S)-3-Amino-5-methyl-hexanoic acid H-β³-HMet-OH(3S)-3-Amino-5-methylthio pentanoic acid H-β³-HTyr-OH(3S)-3-Amino-4-(4′-hydroxyphenyl)-butyric acid H-β³-HHis-OH(3S)-3-Amino-4-(imidazole-4′-yl)-butyric acid H-β³-HPhe-OH(3S)-3-Amino-4-phenyl butyric acid H-β³-HTrp-OH(3S)-3-Amino-4-(indol-3′-yl)-butyric acid H-β³-HSer-OH(3R)-3-Amino-4-hydroxy-butyric acid H-β³-HAsp-OH 3-Amino-pentanedioicacid H-β³-HGlu-OH (3S)-3-Amino-hexanedioic acid H-β³-HLys-OH(3S)-3,7-Diamino-heptanoic acid H-β³-HArg-OH(3S)-3-Amino-6-guanidino-hexanoic-acid H-β³-HCys-OH(3R)-3-Amino-4-mercapto-butyric acid H-β³-HAsn-OH(3S)-3-Amino-4-carbamoyl-butyric acid H-β³-HGln-OH(3S)-3-Amino-5-carbamoyl-pentanoic acid H-β³-HThr-OH(3R,4R)-3-Amino-4-hydroxy-pentanoic acid Gaba 4-Amino-butyric acidH-γ⁴-DiHAla-OH (4S)-4-Amino-pentanoic acid H-γ⁴-DiHVal-OH(4R)-4-Amino-5-methyl-hexanoic acid H-γ⁴-DiHIle-OH(4R,5S)-4-Amino-5-methyl-heptanoic acid H-γ⁴-DiHLeu-OH(4R)-4-Amino-6-methyl-heptanoic acid H-γ⁴-DiHMet-OH(4R)-4-Amino-6-methylthio-hexanoic acid H-γ⁴-DiHTyr-OH(4R)-4-Amino-5-(4′-hydroxyphenyl)- pentanoic acid H-γ⁴-DiHHis-OH(4R)-4-Amino-5-(imidazole-4′-yl)- pentanoic acid H-γ⁴-DiHPhe-OH(4R)-4-Amino-5-phenyl-pentanoic acid H-γ⁴-DiHTrp-OH(4R)-4-Amino-5-(indol-3′-yl)-pentanoic acid H-γ⁴-DiHSer-OH(4R)-4-Amino-5-hydroxy-pentanoic acid H-γ⁴-DiHAsp-OH(4R)-4-Amino-hexanedioic acid H-γ⁴-DiHGlu-OH 4-Amino-heptanedioic acidH-γ⁴-DiHLys-OH (4S)-4,8-Diamino-octanoic acid H-γ⁴-DiHArg-OH(4S)-4-Amino-7-guanidino-heptanoic-acid H-γ⁴-DiHCys-OH(4R)-4-Amino-5-mercapto-pentanoic acid H-γ⁴-DiHAsn-OH(4R)-4-Amino-5-carbamoyl-pentanoic acid H-γ⁴-DiHGln-OH(3S)-3-Amino-5-carbamoyl-hexanoic acid H-γ⁴-DiHThr-OH(4R,5R)-4-Amino-5-hydroxy-hexanoic acid Cit L-Citrulline ^(D)CitD-Citrulline Orn L-Ornithine ^(D)Orn D-Ornithine tBuA L-t-Butylalanine^(D)tBuA D-t-Butylalanine Sar Sarcosine Pen L-Penicillamine ^(D)PenD-Penicillamine tBuG L-tert.-Butylglycine ^(D)tBuG D-tert.-Butylglycine4AmPhe L-para-Aminophenylalanine ^(D)4AmPhe D-para-Aminophenylalanine3AmPhe L-meta-Aminophenylalanine ^(D)3AmPne D-meta-Aminophenylalanine2AmPhe L-ortho-Aminophenylalanine ^(D)2AmPhe D-ortho-AminophenylalaninePhe(mC(NH₂)═NH) L-meta-Amidinophenylalanine ^(D)Phe(mC(NH₂)═NH)D-meta-Amidinophenylalanine Phe(pC(NH₂)═NH) L-para-Amidinophenylalanine^(D)Phe(pC(NH₂)═NH) D-para-Amidinophenylalanine Phe(mNHC(NH₂)═NH)L-meta-Guanidinophenylalanine ^(D)Phe(mNHC(NH₂)═NH)D-meta-Guanidinophenylalanine Phe(pNHC(NH₂)═NH)L-para-Guanidinophenylalanine ^(D)Phe(pNHC(NH₂)═NH)D-para-Guanidinophenylalanine 2Pal(2S)-2-Amino-3-(pyridine-2′-yl)-propionic acid ^(D)2Pal(2R)-2-Amino-3-(pyridine-2′-yl)-propionic acid 4Pal(2S)-2-Amino-3-(pyridine-4′-yl)-propionic acid ^(D)4Pal(2R)-2-Amino-3-(pyridine-4′-yl)-propionic acid Phg L-Phenylglycine^(D)Phg D-Phenylglycine Cha L-Cyclohexylalanine ^(D)ChaD-Cyclohexylalanine C₄al L-3-Cyclobutylalanine ^(D)C₄alD-3-Cyclobutylalanine C₅al L-3-Cyclopentylalanine ^(D)C₅alD-3-Cyclopentylalanine Nle L-Norleucine ^(D)Nle D-Norleucine 2-NalL-2-Naphthylalanine ^(D)2Nal D-2-Naphthylalanine 1-NalL-1-Naphthylalanine ^(D)1Nal D-1-Naphthylalanine 4ClPheL-4-Chlorophenylalanine ^(D)4ClPhe D-4-Chlorophenylalanine 3ClPheL-3-Chlorophenylalanine ^(D)3ClPhe D-3-Chlorophenylalanine 2ClPheL-2-Chlorophenylalanine ^(D)2ClPhe D-2-Chlorophenylalanine 3,4Cl₂PheL-3,4-Dichlorophenylalanine ^(D)3,4Cl₂Phe D-3,4-Dichlorophenylalanine4FPhe L-4-Fluorophenylalanine ^(D)4FPhe D-4-Fluorophenylalanine 3FPheL-3-Fluorophenylalanine ^(D)3FPhe D-3-Fluorophenylalanine 2FPheL-2-Fluorophenylalanine ^(D)2FPhe D-2-Fluorophenylalanine ThiL-β-2-Thienylalanine ^(D)Thi D-β-2-Thienylalanine TzaL-2-Thiazolylalanine ^(D)Tza D-2-Thiazolylalanine Mso L-Methioninesulfoxide ^(D)Mso D-Methionine sulfoxide AcLys N-Acetyllysine ^(D)AcLysN-Acetyl-D-lysine Dap 2,3-Diaminopropionic acid ^(D)DapD-2,3-Diaminopropionic acid Dab 2,4-Diaminobutyric acid ^(D)Dab(2R)-2,4-Diaminobutyric acid Dbu (2S)-2,3-Diamino-butyric acid ^(D)Dbu(2R)-2,3-Diamino-butyric acid Abu γ-Aminobutyric acid (GABA) Ahaε-Aminohexanoic acid Aib α-Aminoisobutyric acid Cyp 1-Amino cyclopentanecarboxylic acid Y(Bzl) L-O-Benzyltyrosine ^(D)Y(Bzl) D-O-BenzyltyrosineH(Bzl) (3S)-2-Amino-3-(1′-benzylimidazole-4′- yl)-propionic acid^(D)H(Bzl) (3R)-2-Amino-3-(1′-benzylimidazole-4′- yl)-propionic acid BipL-(4-phenyl)phenylalanine ^(D)Bip D-(4-phenyl)phenylalanine S(Bzl)L-O-Benzylserine ^(D)S(Bzl) D-O-Benzylserine T(Bzl) L-O-Benzylthreonine^(D)T(Bzl) D-O-Benzylthreonine alloT (2S,3S)-2-Amino-3-hydroxy-butyricacid ^(D)alloT (2R,3S)-2-Amino-3-hydroxy-butyric acid Leu3OH(2S,3R)-2-Amino-3-hydroxy-4-methyl- pentanoic acid ^(D)Leu3OH(2R,3R)-2-Amino-3-hydroxy-4-methyl- pentanoic acid hAla L-Homo-alanine^(D)hAla D-Homo-alanine hArg L-Homo-arginine ^(D)hArg D-Homo-argininehCys L-Homo-cysteine ^(D)hCys D-Homo-cysteine hGlu L-Homo-glutamic acid^(D)hGlu D-glutamic acid hGln L-Homo-glutamine ^(D)hGln D-Homo-glutaminehHis L-Homo-histidine ^(D)hHis D-Homo-histidine hIle L-Homo-isoleucine^(D)hIle D-Homo-isoleucine hLeu L-Homo-leucine ^(D)hLeu D-Homo-leucinehNle L-Homo-norleucine ^(D)hNle D-Homo-norleucine hLys L-Homo-lysine^(D)hLys D-Homo-lysine hMet L-Homo-Methionine ^(D)hMet D-Homo-MethioninehPhe L-Homo-phenylalanine ^(D)hPhe D-Homo-phenylalanine hSerL-Homo-serine ^(D)hSer D-Homo-serine hThr L-Homo-threonine ^(D)hThrD-Homo-threonine hTrp L-Homo-tryptophan ^(D)hTrp D-Homo-tryptophan hTyrL-Homo-tyrosine ^(D)hTyr D-Homo-tyrosine hVal L-Homo-valine ^(D)hValD-Homo-valine hCha L-Homo-cyclohexylalanine ^(D)hChaD-Homo-cyclohexylalanine Bpa L-4-Benzoylphenylalanine ^(D)BpaD-4-Benzoylphenylalanine OctG L-Octylglycine ^(D)OctG D-Octylglycine Tic(3S)-1,2,3,4-Tetrahydroisoquinoline-3- carboxylic acid ^(D)Tic(3R)-1,2,3,4-Tetrahydroisoquinoline-3- carboxylic acid Tiq(1S)-1,2,3,4-Tetrahydroisoquinoline-1- carboxylic acid ^(D)Tiq(1R)-1,2,3,4-Tetrahydroisoquinoline-1- carboxylic acid Oic(2S,3aS,7aS)-1-Octahydro-1H-indole-2- carboxylic acid ^(D)Oic(2R,3aS,7aS)-1-Octahydro-1H-indole-2- carboxylic acid 4AmPyrr1(2S,4S)-4-Amino-pyrrolidine-2-carboxylic acid ^(D)4AmPyrr1(2R,4S)-4-Amino-pyrrolidine-2-carboxylic acid 4AmPyrr2(2S,4R)-4-Amino-pyrrolidine-2-carboxylic acid ^(D)4AmPyrr2(2R,4R)-4-Amino-pyrrolidine-2-carboxylic acid 4PhePyrr1(2S,4R)-4-Phenyl-pyrrolidine-2- carboxylic acid ^(D)4PhePyrr1(2R,4R)-4-Phenyl-pyrrolidine-2- carboxylic acid 4PhePyrr2(2S,4S)-4-Phenyl-pyrrolidine-2- carboxylic acid ^(D)4PhePyrr2(2R,4S)-4-Phenyl-pyrrolidine-2- carboxylic acid 5PhePyrr1(2S,5R)-5-Phenyl-pyrrolidine-2- carboxylic acid ^(D)5PhePyrr1(2R,5R)-5-Phenyl-pyrrolidine-2- carboxylic acid 5PhePyrr2(2S,5S)-5-Phenyl-pyrrolidine-2- carboxylic acid ^(D)5PhePyrr2(2R,5S)-5-Phenyl-pyrrolidine-2- carboxylic acid 4Hyp1(4S)-L-Hydroxyproline ^(D)4Hyp1 (4S)-D-Hydroxyproline 4Hyp2(4R)-L-Hydroxyproline ^(D)4Hyp2 (4R)-D-Hydroxyproline 4Mp1(4S)-L-Mercaptoproline ^(D)4Mp1 (4S)-D-Mercaptoproline 4Mp2(4R)-L-Mercaptoproline ^(D)4Mp2 (4R)-D-Mercaptoproline Pip L-Pipecolicacid ^(D)Pip D-Pipecolic acid H-β³-HCit-OH(3S)-3-Amino-6-carbamidyl-hexanoic acid H-β³-HOrn-OH(3S)-3,6-Diamino-hexanoic acid H-β³-HtBuA-OH(3S)-3-Amino-5,5-dimethyl-hexanoic acid H-β³-HSar-OHN-Methyl-3-amino-propionic acid H-β³-HPen-OH(3R)-3-Amino-4-methyl-4-mercapto- pentanoic acid H-β³-HtBuG-OH(3R)-3-Amino-4,4-dimethyl-pentanoic acid H-β³-H4AmPhe-OH(3S)-3-Amino-4-(4′-aminophenyl)-butyric acid H-β³-H3AmPhe-OH(3S)-3-Amino-4-(3′-aminophenyl)-butyric acid H-β³-H2AmPhe-OH(3S)-3-Amino-4-(2′-aminophenyl)-butyric acid H-β³-(3S)-3-Amino-4-(3′-amidinophenyl)-butyric HPhe(mC(NH₂)═NH)—OH acid H-β³-(3S)-3-Amino-4-(4′-amidinophenyl)-butyric HPhe(pC(NH₂)═NH)—OH acid H-β³-(3S)-3-Amino-4-(3′-guanidinophenyl)- HPhe(mNHC(NH₂)═NH)—OH butyric acidH-β³- (3S)-3-Amino-4-(4′-guanidino-phenyl)- HPhe(pNHC(NH₂)═NH)—OHbutyric acid H-β³-H2Pal-OH (3S)-3-Amino-4-(pyridine-2′-yl)-butyric acidH-β³-H4Pal-OH (3S)-3-Amino-4-(pyridine-4′-yl)-butyric acid H-β³-HPhg-OH(3R)-3-Amino-3-phenyl-propionic acid H-β³-HCha-OH(3S)-3-Amino-4-cyclohexyl-butyric acid H-β³-HC₄al-OH(3S)-3-Amino-4-cyclobutyl-butyric acid H-β³-HC₅al-OH(3S)-3-Amino-4-cyclopentyl-butyric acid H-β³-HNle-OH(3S)-3-Amino-heptanoic acid H-β³-H2Nal-OH(3S)-3-Amino-4-(2′-naphthyl)-butyric acid H-β³-H1Nal-OH(3S)-3-Amino-4-(1′-naphthyl)-butyric acid H-β³-H4ClPhe-OH(3S)-3-Amino-4-(4′-chlorophenyl)-butyric acid H-β³-H3ClPhe-OH(3S)-3-Amino-4-(3′-chlorophenyl)-butyric acid H-β³-H2ClPhe-OH(3S)-3-Amino-4-(2′-chlorophenyl)-butyric acid H-β³-H3,4Cl₂Phe-OH(3S)-3-Amino-4-(3′,4′-dichlorophenyl)- butyric acid H-β³-H4FPhe-OH(3S)-3-Amino-4-(4′-fluorophenyl)-butyric acid H-β³-H3FPhe-OH(3S)-3-Amino-4-(3′-fluorophenyl)-butyric acid H-β³-H2FPhe-OH(3S)-3-Amino-4-(2′-fluorophenyl)-butyric acid H-β³-HThi-OH(3R)-3-Amino-4-(2′-thienyl)-butyric acid H-β³-HTza-OH(3R)-3-Amino-4-(2′-thiazolyl)-butyric acid H-β³-HMso-OH(3R)-3-Amino-4-methylsulfoxyl-butyric acid H-β³-HAcLys-OH(3S)-7-Acetylamino-3-amino-heptanoic acid H-β³-HDpr-OH(3R)-3,4-diamino-butyric acid H-β³-HA₂Bu—OH (3S)-3,5-Diamino-pentanoicacid H-β³-HDbu-OH (3R)-3,4-Diamino-pentanoic acid H-β³-HAib-OHAmino-dimethyl acetic acid H-β³-HCyp-OH 1-Amino-cyclopentane-1-yl-aceticacid H-β³-HY(Bzl)-OH (3S)-3-Amino-4-(4′-benzyloxyphenyl)- butyric acidH-β³-HH(Bzl)-OH (3S)-3-Amino-4-(1′-benzylimidazole-4′- yl)-butyric acidH-β³-HBip-OH (3S)-3-Amino-4-biphenylyl-butyric acid H-β³-HS(Bzl)-OH(3S)-3-Amino-4-(benzyloxy)-butyric acid H-β³-HT(Bzl)-OH(3R,4R)-3-Amino-4-benzyloxy-pentanoic acid H-β³-HalloT-OH(3R,4S)-3-Amino-4-hydroxy-pentanoic acid H-β³-HLeu3OH—OH(3R,4R)-3-Amino-4-hydroxy-5-methyl- hexanoic acid H-β³-HhAla-OH(3S)-3-Amino-pentanoic acid H-β³-HhArg-OH(3S)-3-Amino-7-guanidino-heptanoic acid H-β³-HhCys-OH(3R)-Amino-5-mercapto-pentanoic acid H-β³-HhGlu-OH(3S)-3-Amino-heptanedioic acid H-β³-HhGln-OH (3S)-3-Amino-6-carbamoylhexanoic acid H-β³-HhHis-OH (3S)-3-Amino-5-(imidazole-4′-yl)- pentanoicacid H-β³-HhIle-OH (3S,5S)-3-Amino-5-methyl-heptanoic acid H-β³-HhLeu-OH(3S)-3-Amino-6-methyl-heptanoic acid H-β³-HhNle-OH (3S)-3-Amino-octanoicacid H-β³-DiAoc-OH (3S)-3,8-Diamino-octanoic acid H-β³-HhMet-OH(3S)-3-Amino-6-methylthio-hexanoic acid H-β³-HhPe-OH(3S)-3-Amino-5-phenyl-pentanoic acid H-β³-HhSer-OH(3S)-3-Amino-5-hydroxy-pentanoic acid H-β³-HhThr-OH(3S,5R)-3-Amino-5-hydroxy-hexanoic acid H-β³-HhTrp-OH(3S)-3-Amino-5-(indol-3′-yl)-pentanoic acid H-β³-HhThr-OH(3S)-3-Amino-5-(4′-hydroxyphenyl)- pentanoic acid H-β³-HhCha-OH(3S)-3-Amino-5-cyclohexyl-pentanoic acid H-β³-HBpa-OH(3S)-3-Amino-4-(4′-benzoylphenyl)-butyric acid H-β³-HOctG-OH(3S)-3-Amino-undecanoic acid H-β³-HNle-OH (3S)-3-Amino-heptanoic acidH-β³-HTic-OH (3S)-1,2,3,4-Tetrahydroisoquinoline-3-yl- acetic acidH-β³-HTiq-OH (1S)-1,2,3,4-Tetrahydroisoquinoline-1- acetic acidH-β³-HOic-OH (2S,3aS,7aS)-1-Octahydro-1H-indole-2- yl-acetic acidH-β³-H4AmPyrr1-OH (2S,4S)-4-Amino-pyrrolidine-2-acetic acidH-β³-H4AmPyrr2-OH (2S,4R)-4-Amino-pyrrolidine-2-acetic acidH-β³-H4PhePyrr1-OH (2S,4R)-4-Phenyl-pyrrolidine-2-acetic acidH-β³-H4PhePyrr2-OH (2S,4S)-4-Phenyl-pyrrolidine-2-acetic acidH-β³-H5PhePyrr1-OH (2S,5R)-5-Phenyl-pyrrolidine-2-acetic acidH-β³-H5PhePyrr2-OH (2S,5S)-5-Phenyl-pyrrolidine-2-acetic acidH-β³-H4Hyp1-OH (2S,4S)-4-Hydroxy-pyrrolidine-2-acetic acidH-β³-H4Hyp2-OH (2S,4R)-4-Hydroxy-pyrrolidine-2-acetic acid H-β³-H4Mp1-OH(2R,4S)-4-Mercapto-pyrrolidine-2-acetic acid H-β³-H4Mp2-OH(2R,4R)-4-Mercapto-pyrrolidine-2-acetic acid H-β³-HPip-OH(2S)-piperidine-2-acetic acid H-β³-HPro-OH (2S)-pyrrolidine-2-aceticacid H-β³-H^(D)Pro-OH (2R)-pyrrolidine-2-acetic acid Ahb4-Amino-2-hydroxy butyric acid H-γ⁴-DiHCit-OH(4S)-4-Amino-7-carbamidyl-heptanoic acid H-γ⁴-DiHOrn-OH(4S)-4,7-Diamino-heptanoic acid H-γ⁴-DiHtBuA-OH(4R)-4-Amino-6,6-dimethyl-heptanoic acid H-γ⁴-DiHSar-OHN-Methyl-4-amino-butyric acid H-γ⁴-DiHPen-OH(4R)-4-Amino-5-methyl-5-mercapto-hexanoic acid H-γ⁴-DiHtBuG-OH(4R)-4-Amino-5,5-dimethyl-hexanoic acid H-γ⁴-DiH4AmPhe-OH(4R)-4-Amino-5-(4′-aminophenyl)-pentanoic acid H-γ⁴-DiH3AmPhe-OH(4R)-4-Amino-5-(3′-aminophenyl)-pentanoic acid H-γ⁴-DiH2AmPhe-OH(4R)-4-Amino-5-(2′-aminophenyl)-pentanoic acid H-γ⁴-(4R)-4-Amino-5-(3′-amidinophenyl)- DiHPhe(mC(NH₂)═NH)—OH pentanoic acidH-γ⁴- (4R)-4-Amino-5-(4′-amidinophenyl)- DiHPhe(pC(NH₂)═NH)—OH pentanoicacid H-γ⁴- (4R)-4-Amino-5-(3′-guanidino-phenyl)- DiHPhe(mNHC(NH₂)═NH)—OHpentanoic acid H-γ⁴⁻ (4R)-4-Amino-5-(4′-guanidino-phenyl)-DiHPhe(pNHC(NH₂)═NH)—OH pentanoic acid H-γ⁴-DiH2Pal-OH(4R)-4-Amino-5-(pyridine-4′-yl)-pentanoic acid H-γ⁴-DiH4Pal-OH(4R)-4-Amino-5-(pyridine-4′-yl)-pentanoic acid H-γ⁴-DiHPhg-OH(4R)-4-Amino-4-phenyl-butyric acid H-γ⁴-DiHCha-OH(4R)-4-Amino-5-cyclohexyl-pentanoic acid H-γ⁴-DiHC₄al-OH(4R)-4-Amino-5-cyclobutyl-pentanoic acid H-γ⁴-DiHC₅al-OH(4R)-4-Amino-5-cyclopentyl-pentanoic acid H-γ⁴-DiHNle-OH(4S)-4-Amino-octanoic acid H-γ⁴-DiH2Nal-OH(4S)-4-Amino-5-(2′-naphthyl)-pentanoic acid H-γ⁴-DiH1Nal-OH(4S)-4-Amino-5-(1′-naphthyl)-pentanoic acid H-γ⁴-DiH4ClPhe-OH(4R)-4-Amino-5-(4′-chlorophenyl)- pentanoic acid H-γ⁴-DiH3ClPhe-OH(4R)-4-Amino-5-(3′-chlorophenyl)- pentanoic acid H-γ⁴-DiH2ClPhe-OH(4R)-4-Amino-5-(2′-chlorophenyl)- pentanoic acid H-γ⁴-DiH3,4Cl₂Phe-OH(4R)-4-Amino-5-(3′,4′-dichloro-phenyl)- pentanoic acid H-γ⁴-DiH4FPhe-OH(4R)-4-Amino-5-(4′-fluorophenyl)- pentanoic acid H-γ⁴-DiH3FPhe-OH(4R)-4-Amino-5-(3′-fluorophenyl)- pentanoic acid H-γ⁴-DiH2FPhe-OH(4R)-4-Amino-5-(2′-fluorophenyl)- pentanoic acid H-γ⁴-DiHThi-OH(4R)-4-Amino-5-(2′-thienyl)-pentanoic acid H-γ⁴-DiHTza-OH(4R)-4-Amino-5-(2′- thiazolyl)-pentanoic acid H-γ⁴-DiHMso-OH(4R)-4-Amino-5-methylsulfoxyl-pentanoic acid H-γ⁴-DiHAcLys-OH(4S)-8-Acetylamino-4-amino-ocatanoic acid H-γ⁴-DiHDpr-OH(4R)-4,5-diamino-pentanoic acid H-γ⁴-DiHA₂Bu—OH(4R)-4,5-Diamino-hexanoic acid H-γ⁴-DiHDbu-OH (4R)-4,5-Diamion-hexanoicacid H-γ⁴-DiHAib-OH 3-Amino-3,3-dimethyl propionic acid H-γ⁴-DiHCyp-OH(1′-Amino-cyclopentane-1′-yl)-3-propionic acid H-γ⁴-DiHY(Bzl)-OH(4R)-4-Amino-5-(4′-benzyloxyphenyl)- pentanoic acid H-γ⁴-DiHH(Bzl)-OH(4R)-4-Amino-5-(1′-benzylimidazole-4′- yl)-pentanoic acid H-γ⁴-DiHBip-OH(4R)-4-Amino-5-biphenylyl-pentanoic acid H-γ⁴-DiHS(Bzl)-OH(4S)-4-Amino-5-(benzyloxy)-pentanoic acid H-γ⁴-DiHT(Bzl)-OH(4R,5R)-4-Amino-5-benzyloxy-hexanoic acid H-γ⁴-DiHalloT-OH(4R,5S)-4-Amino-5-hydroxy-hexanoic acid H-γ⁴-DiHLeu3OH—OH(4R,5R)-4-Amino-5-hydroxy-6-methyl- heptanoic acid H-γ⁴-DiHhAla-OH(4S)-4-Amino-hexanoic acid H-γ⁴-DiHhArg-OH(4S)-4-Amino-8-guanidino-octanoic acid H-γ⁴-DiHhCys-OH(4R)-Amino-6-mercapto-hexanoic acid H-γ⁴-DiHhGlu-OH(4S)-4-Amino-ocatanedioic acid H-γ⁴-DiHhGln-OH(4S)-4-Amino-7-carbamoyl-heptanoic acid H-γ⁴-DiHhHis-OH(4S)-4-Amino-6-(imidazole-4′-yl)-hexanoic acid H-γ⁴-DiHhIle-OH(4S,6S)-4-Amino-6-methyl-octanoic acid H-γ⁴-DiHhLeu-OH(4S)-4-Amino-7-methyl-ocatanoic acid H-γ⁴-DiHhNle-OH(4S)-4-Amino-nonanoic acid H-γ⁴-DiHhLys-OH (4S)-4,9-Diamino-nonanoicacid H-γ⁴-DiHhMet-OH (4R)-4-Amino-7-methylthioheptanoic acidH-γ⁴-DiHhPhe-OH (4S)-4-Amino-6-phenyl-hexanoic acid H-γ⁴-DiHhSer-OH(4R)-4-Amino-6-hydroxy-hexanoic acid H-γ⁴-DiHhThr-OH(4R,6R)-4-Amino-6-hydroxy-heptanoic acid H-γ⁴-DiHhTrp-OH(4S)-4-Amino-6-(indol-3′-yl)-hexanoicacid H-γ⁴-DiHhTyr-OH(4S)-4-Amino-6-(4′-hydroxyphenyl)- hexanoic acid H-γ⁴-DiHhCha-OH(4R)-4-Amino-5-cyclohexyl-pentanoic acid H-γ⁴-DihBpa-OH(4R)-4-Amino-5-(4′-benzoylphenyl)- pentanoic acid H-γ⁴-DiHOctG-OH(4S)-4-Amino-dodecanoic acid H-γ⁴-DiHNle-OH (4S)-4-Amino-octanoic acidH-γ⁴-DiHTic-OH (3R)-1′,2′,3′,4′-Tetrahydroisoquinoline-3′-yl-3-propionic acid H-γ⁴-DiHTiq-OH(1′R)-1′,2′,3′,4′-Tetrahydroisoquinoline- 1′-yl-3-propionic acidH-γ⁴-DiHOic-OH (2′S,3′aS,7′aS)-1′-Octahydro-1H-indole- 2′-yl-3-propionicacid H-γ⁴-DiH4AmPyrr1-OH (2′R,4′S)-4′-Amino-pyrrolidine-2′-yl-3-propionic acid H-γ⁴-DiH4AmPyrr2-OH(2′R,4′R)-4′-Amino-pyrrolidine-2′-yl-3- propionic acidH-γ⁴-DiH4PhePyrr1-OH (2′R,4′R)-4′-Phenyl-pyrrolidine-2′-yl-3- propionicacid H-γ⁴-DiH4PhePyrr2-OH (2′R,4′S)-4′-Phenyl-pyrrolidine-2′-yl-3-propionic acid H-γ⁴-DiH5PhePyrr1-OH(2′S,5′R)-5′-Phenyl-pyrrolidine-2′-yl-3- propionic acidH-γ⁴-DiH5PhePyrr2-OH (2′S,5′S)-5′-Phenyl-pyrrolidine-2′-yl-3- propionicacid H-γ⁴-DiH4Hyp1-OH (2′R,4′S)-4′-Hydroxy-pyrrolidine-2′-yl-2-propionic acid H-γ⁴-DiH4Hyp2-OH(2′R,4′R)-4′-Hydroxy-pyrrolidine-2′-yl- 3-propionic acid H-γ⁴-DiH4Mp1-OH(2′R,4′S)-4′-Mercapto-pyrrolidine-2′-yl- 3-propionic acidH-γ⁴-DiH4Mp2-OH (2′R,4′R)-4′-Mercapto-pyrrolidine-2′-yl- 3-propionicacid H-γ⁴-DiHPip-OH (2′S)-Piperidine-2′-yl-3-propionic acidH-γ⁴-DiHPro-OH (2′S)-Pyrrolidine-2′-yl-3-propionic acid (AEt)GN-(2-Aminoethyl)glycine (APr)G N-(3-Amino-n-propyl)glycine (ABu)GN-(4-Amino-n-butyl)glycine (APe)G N-(5-Amino-n-pentyl)glycine (GuEt)GN-(2-Guanidinoethyl)glycine (GuPr)G N-(3-Guanidino-n-propyl)glycine(GuBu)G N-(4-Guanidino-n-butyl)glycine (GuPe)GN-(5-Guanidino-n-pentyl)glycine (PEG₃-NH₂)GN—[H₂N—(CH₂)₃—(OCH₂—CH₂)₂—O(CH₂)₃] glycine (Me)G N-Methylglycine (Et)GN-Ethylglycine (Bu)G N-Butylglycine (Pe)G N-Pentylglycine (Ip)GN-Isopropylglycine (2MePr)G N-(2-Methylpropyl)glycine (3MeBu)GN-(3-Methylbutyl)glycine (1MePr)G (1S)-N-(1-Methylpropyl)glycine(2MeBu)G (2S)-N-(2-Methylbutyl)glycine (MthEt)GN-(Methylthioethyl)glycine (MthPr)G N-(Methylthiopropyl)glycine (Ben)GN-(Benzyl)glycine (PhEt)G N-(2-Phenylethyl)glycine (HphMe)GN-([4′-hydroxyphenyl]methyl)glycine (HphEt)GN-(2-[4′-hydroxyphenyl]ethyl)glycine (ImMe)GN-(Imidazol-5-yl-methyl)glycine (ImEt)GN-(2-(Imidazol-5′-yl)ethyl)glycine (InMe)G N-(Indol-2-yl-methyl)glycine(InEt)G N-(2-(Indol-2′-yl)ethyl)glycine (CboMe)GN-(Carboxymethyl)glycine (CboEt)G N-(2-Carboxyethyl)glycine (CboPr)GN-(3-Carboxypropyl)glycine (CbaMe)G N-(Carbamoylmethyl)glycine (CbaEt)GN-(2-Carbamoylethyl)glycine (CbaPr)G N-(3-Carbamoylpropyl)glycine(HyEt)G N-(2-Hydroxyethyl)glycine (HyPr)G(2R)-N-(2-Hydroxypropyl)glycine (Mcet)G N-(2-Mercaptoethyl)glycineNMeAla L-N-Methylalanine NMe^(D)Ala D-N-Methylalanine NMeValL-N-Methylvaline NMe^(D)Val D-N-Methylvaline NMeIle L-N-MethylisoleucineNMe^(D)Ile D-N-Methylisoleucine NMeLeu L-N-Methylleucine NMe^(D)LeuD-N-Methylleucine NMeNle L-N-Methylnorleucine NMe^(D)NleD-N-Methylnorleucine NMeMet L-N-Methylmethionine NMe^(D)MetD-N-Methylmethionine NMeTyr L-N-Methyltyrosine NMe^(D)TyrD-N-Methyltyrosine NMeHis L-N-Methylhistidine NMe^(D)HisD-N-Methylhistidine NMePhe L-N-Methylphenylalanine NMe^(D)PheD-N-Methylphenylalanine NMeTrp L-N-Methyltryptophane NMe^(D)TrpD-N-Methyltryptophane NMeSer L-N-Methylserine NMe^(D)SerD-N-Methylserine NMeAsp L-N-Methylaspartic acid NMe^(D)AspD-N-Methylaspartic acid NMeGlu L-N-Methylglutamic acid NMe^(D)GluD-N-Methylglutamic acid NMeLys L-N-Methyllysine NMe^(D)LysD-N-Methyllysine NMeArg L-N-Methylarginine NMe^(D)Arg D-N-MethylarginineNMeDab L-N-Methyl-2,4-diamino butyric acid NMe^(D)DabD-N-Methyl-2,4-diamino butyric acid NMeCys L-N-Methylcysteine NMe^(D)CysD-N-Methylcysteine NMeAsn L-N-Methylasparagine NMe^(D)AsnD-N-Methylasparagine NMeGln L-N-Methylglutamine NMe^(D)GlnD-N-Methylglutamine NMeThr L-N-Methylthreonine NMe^(D)ThrD-N-Methylthreonine

Particularly preferred macrocyclic compounds of formula I are theexamples: Ex.9, Ex.11, Ex.12, Ex.16, Ex.30, Ex.49, Ex.184, Ex.200, andEx.213.

Synthesis of the Building Blocks

Building blocks C used in the synthesis of the macrocyclic compounds ofthe invention are detailed to the level of fully-defined structuresshown in Table 19, above and are easily available. Possible syntheticapproaches to the modulator building blocks B and, especially, theproduction of the template building blocks A are described in somedetail hereinbelow.

Synthesis of the Template Building Blocks A

General Transformations

Building blocks of type A are based on readily available substancescarrying a carboxylic acid group and either a phenolic (Ar/Hetar-OH) ora thiophenolic moiety (Ar/Hetar-SH). The —COOH group may be attached tothe same ring as the —OH/—SH group or to an annelated ring which in turnmay be aromatic or partially unsaturated.

In general phenol derivatives are more abundantly described in theliterature than the corresponding thiophenols. However, transformationsof phenols into thiophenols are well established. Therefore the phenolicsystems can be regarded as precursors towards their thio-analogs.Alternatively thiophenols might be derived from the corresponding arylhalides or diazonium salts.

Selected examples of general scope for the transformationsAr/Hetar-X→Ar/Hetar-SH(X═OH, F, Cl, Br, I, N₂ ⁺) are introduced below:

T-I) A sequence of broad applicability is the transformation of a phenolinto a thiocarbamate with N,N-dimethylthiocarbamoyl chloride, followedby Newman-Kwart rearrangement and subsequent hydrolysis (A.Gallardo-Godoy et al., J. Med. Chem. 2005, 48, 2407-2419; P. Beaulieu etal., Biorg. Med. Chem. Lett. 2006, 16, 4987-4993; H. Sugiyama et al.,Chem. Pharm. Bull. 2007, 55, 613-624; S. Lin et al., Org. Prep. Proced.Int. 2000; 547-556).

T-II) The direct transformation of an —OH adjacent to a pyridinicnitrogen (equivalent to the pyridone tautomer) can be accomplished byheating with P₂S₅ (K. Hirai et al., Heterocycles 1994, 38, 277-280).

T-III) As an alternative to phenols, halogen-substituted (esp. with F orCl) aromatic ring systems might serve as precursors. In case the halogenis in a position activated by an electron withdrawing group in ortho- orpara-position the —SH moiety or a protected analog can be introducedunder mild conditions by nucleophilic aromatic substitution reactions(S_(N)Ar) (G. J. Atwell et al., J. Med. Chem. 1994, 37, 371-380).Especially in the field of heterocyclic compounds, where the electronwithdrawing effect is exerted by pyridine-like nitrogen atoms, this typeof substitution is often utilized (S. McCombie et al., Heterocycles,1993, 35, 93-97).

T-IV) Similarly, in Sandmeyer-type reactions a diazonium group (—N₂ ⁺)is replaced (C. Mukherjee, E. Biehl, Heterocycles 2004, 63, 2309-2318).

T-V) In non-activated positions the substitution of halogen atoms (esp.Br or I) can be accomplished via the corresponding organolithium orGrignard reagents (J. L. Kice, A. G. Kutateladze, J. Org. Chem. 1993,58, 917-923; P. C. Kearney et al., J. Am. Chem. Soc. 1993, 115,9907-9919; K.-Y. Jen, M. P. Cava, Tetrahedron Lett. 1982, 23,2001-2004). Alternatively, transition metal-catalyzed transformationsare feasible for this type of reaction, e.g. Cu-catalyzed substitutionwith benzothioic S-acid (N. Sawada et al., Tetrahedron Lett. 2006, 47,6595-6597), or Pd-catalyzed substitution with KS-Si(i-Pr)₃ followed bydesilylation of the thus introduced —SSi(i-Pr)₃ group (A. M. Rane etal., Tetrahedron Lett. 1994, 35, 3225-3226).

The hydroxyl group attached to the aromatic ring (Ar—OH or Hetar-OH) inturn, if not part of a commercially available substance, can beintroduced by various methods:

H-I) Analogously to T-III) the hydroxy group or a surrogate can beintroduced by an S_(N)Ar reaction of halogen atoms, esp. Cl or F, orthoor para to an electron withdrawing substituent (W. Cantrell, TetrahedronLett. 2006, 47, 4249-4251) or to a pyridinic nitrogen atom (S. D. Tayloret al., J. Org. Chem. 2006, 71, 9420-9430).

H-II) Sandmeyer-type hydroxylations of aromatic amines via intermediatediazonium salts (P. Madsen et al., J. Med. Chem. 2002, 45, 5755-5775).

H-III) The substitution of halogen atoms (esp. Br and I), not activatedfor an S_(N)Ar, can be achieved by transition metal-catalyzedC—O-couplings; predominant are Pd-catalysts (K. W. Anderson et al., J.Am. Chem. Soc. 2006, 128, 10694-10695; B. J. Gallon et al., Angew.Chem., Int. Ed. 2007, 46, 7251-7254), but also others, like Cu-catalysts(J. E. Ellis, S. R. Lenger, Synth. Commun. 1998, 28, 1517-1524), findapplication.

H-IV) Of broad scope is also a two-step process which first transformshalogen atoms (Cl, Br and I) into a boronate and then oxidativelycleaves the carbon-boron bond to the phenol (J. R. Vyvyan et al., J.Org. Chem. 2004, 69, 2461-2468).

The carboxylic acid groups of template building blocks A, if not alreadypresent in a commercial available building block, can be introduced bystandard procedures:

C-I) The oxidation of functional groups like hydroxymethyl (—CH₂—OH) oraldehyde (—C(═O)H) can be achieved under mild conditions (G. V. M.Sharma et al., Synth. Commun. 2000, 30, 397-406; C. Wiles et al.,Tetrahedron Lett. 2006, 47, 5261-5264). Also methyl groups on benzenerings can be oxidized; however, as harsh reaction conditions are usuallyrequired, its applicability is limited. In contrast, the relative acidicmethyl groups ortho or para to a pyridine nitrogen can be oxidized undermilder conditions; making this the method of choice for many pyridinering analogs (T. R. Kelly, F. Lang, J. Org. Chem. 1996, 61, 4623-4633).

C-II) Halogen atoms can easily be replaced by a carboxyl group orsurrogates thereof, e.g. by halogen metal exchange and subsequentcarboxylation of the intermediate Grignard or organolithium species (C.G. Screttas, B. R. Steele, J. Org. Chem. 1989, 54, 1013-1017), or byutilizing Mander's reagent (methyl cyanoformate) (A. Lepretre et al.,Tetrahedron 2000, 56, 265-274).

C-III) In the case that acidified ring positions are to be carboxylated,a viable method is deprotonation with a strong base (usually tert-butyllithium) followed by carboxylation of the intermediate organolithiumspecies in analogy to C-II).

C-IV) Hydrolysis of ester, amide or nitrile groups. The CN group in turncan easily be introduced by treating organic halides with CuCN(Rosenmund-von Braun reaction: C. F. Koelsch, A. G. Whitney, J. Org.Chem., 1941, 6, 795-803).

Applied to commercially available starting materials these generaltransformations offer a tool box for accessing templates A. Furtherliterature example are cited within the category of each embodimentbelow.

A1-A59 Phenyl Derivatives

A plethora of hydroxy benzoic acids with diverse substitution patternsare commercially available and can be directly incorporated as templateA into the macrocyclic backbone. In several other cases the presence ofan optional substituent provides a suitable functionality that can befurther extended into more complex high variation substituents bystandard methods of organic synthesis and parallel/combinatorialchemistry.

Even not so common tetrasubstituted hydroxy benzoic acids (A53-A59) canbe built up by procedures in accordance with the general methodsmentioned above, for example by carboxylation of pentasubstituted phenolderivatives (K. Sung, R. J. Lagow, J. Mater. Chem. 1996, 6, 917-918; E.Marzi, M. Schlosser, Tetrahedron 2005, 61, 3393-3402; K. C. Nicolaou etal., Angew. Chem., Int. Ed. 1999, 38, 3334-3339). Alternative approachesto tetrasubstituted hydroxy benzoic acids involve, for example, theoxidation of benzaldehydes followed by the introduction of substituentsinto remaining free positions, also feasible to build up polysubstitutedbenzoic acids from less substituted ones (K. C. Nicolaou et al., Chem.Eur. J. 2000, 6, 3095-3115).

A60-A143 Pyridine Derivatives

As in the case of the above class of compounds also for pyridinederivatives a very large number of substances are commercially availablewhich can be incorporated into the macrocycle directly, or can easily betransformed into suitable hydroxyl pyridine carboxylic acids by thegeneral methods mentioned above: selected literature examples can becited for transformations of type C-III (M. Shimano et al. TetrahedronLett. 1998, 39; 4363-4366; ibid., Tetrahedron 1998, 54, 12745-12774);for H-II (L. Carpino et al., J. Org. Chem. 2004, 69; 54-61); and for C-I(T. R. Kelly, F. Lang, Tetrahedron Lett. 1995, 36, 5319-5322), or forC-IV (J. L. LaMattina, R. L. Taylor, J. Org. Chem. 1981, 46, 4179-4182).

A144-A165 Pyridazine Derivatives

In analogy to general transformations which are readily available,suitably substituted methylpyridazines can be oxidized to thecorresponding 3- or 4-carboxylic acids with dichromate (M. Morishita etal., Chem. Pharm. Bull. 1994, 42, 371-372; M. Winn et al., J. Med. Chem.1993, 36, 2676-2688). Of similarly broad scope is the hydrolysis of thecorresponding nitriles under chemical conditions (hydroxide; G.Heinisch, D. Lassnigg, Arch. Pharm. (Weinheim, Ger.) 1987, 320,1222-1226) or under enzymatic conditions (nitrilase from Rhodococcussp.; N. Klempier et al., Tetrahedron Lett. 1991, 32, 341-344). Onepossibility to construct the heterocyclic pyridazine core fromnon-cyclic precursors starts with β-ketoesters which can be subjected toa Staudinger reaction followed by a aza-Wittig-cyclization of theintermediate azides (S. V. Galiullina et al., Russ. J. Org. Chem. 2007,43, 607-614; M. Guillaume et al., Synthesis 1995, 8, 920-922) ordirectly cyclocondensed with monohydrazone (E. E. Schweizer, K.-J. Lee,J. Org. Chem. 1982, 47, 2768-2773).

A166-A189 Pyrimidine Derivatives

Similarly as with the pyridine derivatives, a large number of suitablebuilding blocks are commercially available and can be directlyincorporated into the macrocycle, or they can easily be transformed intothe target compounds by the standard procedures mentioned above,including selected examples for transformations of type C-I (Y. Honma etal., Chem. Pharm. Bull. 1982, 30, 4314-4324); and C-IV (I. V. Oleinik,O. A. Zagulyaeva, Chem. Heterocycl. Compd. 1993, 29, 427-431). Inaddition, the pyrimidine core can easily be constructed bycyclocondensation of oxalylic compounds with malonamidine derivative (G.A. Howard et al., J. Chem. Soc. 1944, 476-477) or of malonates withamidine derivatives (M. Otsuka et al., Chem. Pharm. Bull. 1985, 33,515-519).

A190-A200 Pyrazine Derivatives

Pyrazine carboxylic acids are easily obtained by cyclocondensation ofα,β-diaminopropionic acid with α,β-dicarbonyl derivatives (J. Bostroemet al., Bioorg. Med. Chem. 2007, 15, 4077-4084). Standard protocolexamples are for C-I (J. R. Young et al., Bioorg. Med. Chem. Lett. 2000,10, 1723-1728); for C-111 (N. Ple et al., Tetrahedron 1998, 54,9701-9710); and for H-II (A. P. Krapcho et al., J. Heterocycl. Chem.1997, 34, 27-32). Highly chemosoelective oxidations of type C-I can beachived by biotransformations with Pseudomonas putida (A. Kiener, Ang.Chem. 1992, 104, 748-749).

A201-A206 Triazine Derivatives

A possible route to suitably substituted precursors of difunctionaltriazines is the cyclocondensation of amidrazones with α,β-diketones orα,β-diketoesters (M. Sagi et al., Heterocycles 1990, 30, 1009-1021).Also α,γ-diketoesters are described as suitable starting materials, inthis case, however, a multi step reaction sequence being required thatproceeds via intermediate 4-nitrosopyrazoles (R. Fusco, S. Rossi,Tetrahedron 1958, 3, 209-224).

A207-A228 Furan, Thiophene and Pyrrole Derivatives

The furans A207 and A208 can be synthesized from suitably substituted2-formyl- or 2-acetyl-3-oxo-butanoates by bromination followed bycyclization (A. Becker, Helv. Chim. Acta 1949, 32, 1114-1122; R.Richter, Helv. Chim. Acta 1949, 32, 1123-1136). The thiophenes A207 andA208 can be prepared from (substituted)3-methoxycarbonyl-tetrahydrothiophene-4-one by oxidation (M. R. Banks etal., J. Chem. Res. (M) 1984, 369-389) or by condensation with aldehydesfollowed by isomerization (R. Jaunin, Helv. Chim. Acta 1980, 63,1542-1553). The pyrroles A207 and A208 (X═O) can be obtained fromN-protected, suitably substituted 3-amino-acrylates by reaction with(substituted) 2-chloroacetyl chlorides followed by base-inducedcyclization (E. Benary, R. Konrad, Chem. Ber. 1923, 56, 44-52). Thethioanalogues (X═S) can be synthesized from 3-methoxycarbonyl-furan bydibromination/methanolysis, subsequent reaction with3-mercapto-propionate and amines, followed by acid-induced cyclizationand S-deprotection (F. Eiden, U. Grusdt, Arch. Pharm. 1989, 322,807-810).

The furans A209 and A210 (X═O) are accessible from (substituted)acetyl(methoxycarbonyl)methylene]-triphenylphosphorane by reaction withaldehydes followed by ozonolysis and acid-induced isomerization (H. H.Wasserman, G. M. Lee, Tetrahedron Lett. 1994, 35, 9783-9786). Thethiophenes A209 and A210 can be prepared from 2-mercaptoacetate and(substituted) acetylene carboxylates (H. Fiesselmann, G. Pfeiffer, Chem.Ber. 1954, 87, 848-856) or from acetyl acetates and 2-mercaptoacetatefollowed by base-induced cyclization (H. Fiesselmann, F. Thoma, Chem.Ber. 1956, 89, 1907-1912).

The pyrroles A209 and A210 can be obtained by condensation ofbeta-alanine ethyl ester and (substituted) 2,3-dioxo-pent-4-enoic esters(H. H. Wasserman et al., Tetrahedron Lett. 1989, 30, 1721-1724) or byreaction of suitably substituted 3-oxo-propanoates with glycine esters(A. Treibs, A. Ohorodnik, Liebigs Ann. Chem. 1958, 611, 139-149). Thethioanalogues (X═S) can be synthesized from (substituted)pyrrolidine-2-carboxylates by subsequent reaction with bistosylsulfurdiimide and trimethylphosphite followed by demethylation (J. Häusler,Monatsh. Chem. 1986, 117, 269-274).

The furans of type A211 and A212 can be synthesized from diazomalonatesand suitably substituted alkynes in a two-step-procedure catalyzed byrhodium(II)-acetate (P. Müller, C. Gränicher, Helv. Chim. Acta 1993, 76,521-534). The thioanalogues (X═S) can be obtained from suitablysubstituted oxazoles by deprotonation and reaction with dimethyldisulfide, then bromination, lithiation and carboxylation followed bydemethylation (S. M. Nolan, T. Cohen, J. Org. Chem. 1981, 46,2473-2476). The thiophenes A211 and A212 are accessible from(substituted) thiophenes by 5-alkylation and/or 3-carboxylation bydeprotonation or lithiation (J. Sicé, J. Am. Chem. Soc. 1953, 75,3697-3700). The thioanalogues (X═S) can be obtained from (substituted)2-trimethylsilyloxy-cyclopropanecarboxylates by reaction with carbondisulfide (C. Brückner, H.-U. Reissig, Liebigs Ann. Chem. 1988,465-470).

The pyrroles A211 and A212 can be prepared from suitably substituted2-chloroethylidene-malonates by substitution with sodium azide followedby cyclization in the presence of triphenylphosphine (F.-P. Montforts etal., Liebigs Ann. Chem. 1990, 1037-1043). The thioanalogues (X═S) can beobtained from suitably substituted 2-oxoethyl-malonates by reaction withisothiocyanates followed by acid-induced cyclization and decarboxylation(J. Fuentes et al., Tetrahedron: Asymm. 1998, 9, 2517-2532).

Furans of type A213 and A214 are accessible either by5-lithiation/carboxylation of (substituted) O-protected 2-hydroxy-furansor by 5-bromination of furan-2-carboxylates followed by substitutionwith methylate and demethylation (D. G. Manly, E. D. Amstutz, J. Org.Chem. 1956, 21, 516-519). The thioanalogues (X═S) can be obtained from(substituted) 1,1-bis(methylthio)prop-1-en-3-one and bromoacetatefollowed by demethylation (A. Datta et al., Tetrahedron 1989, 45,7631-7641). The thiophenes A213 and A214 can be prepared analogously asfor the compounds A211 and A212 (J. Sicé, J. Am. Chem. Soc. 1953, 75,3697-3700). The thioanalogues of thiophenes A213 and A214 (X═S) can besynthesized from suitably substituted 2-chloro-thiophenes by5-carboxylation and subsequent substitution with sodium hydrogensulfide(K. Clarke et al., J. Chem. Soc., Perkin Trans. 11980, 1029-1037). Thepyrrols A213 and A214 can be obtained from suitably substituted,N-protected glutamate, which is transformed into the didehydroderivative and cyclized in the presence of LiCuMe₂ (M. M. Paz., F. J.Sardina, J. Org. Chem. 1993, 58, 6990-6995). The thiophenes A215 andA216 (X═S) can be synthesized from (substituted) 3-bromo-thiophenes by asequence of 3-lithiation/sulfanylation, 2-bromination,4-lithiation/carboxylation, 2-debromination and 3-demethylation (E. C.Taylor, D. E. Vogel, J. Org. Chem. 1985, 50, 1002-1004). The pyrrolesA215 and A216 can be prepared from aminooxoacetate and oxalyl chloride,alcoholysis of the isocyanate, reaction with(3-bromoacetonyl)triphenylphosphonium bromide and N-deprotection (J. P.Bazureau et al., Tetrahedron Lett. 1988, 29, 1921-1922), or from(substituted) N-Pfp-protected 3-oxo-prolinates by subsequent reactionwith base and acid (F.-A. Marcotte, W. D. Lubell, Org. Lett. 2002, 4,2601-2603). The thioanalogues (X═S) can be obtained from suitablysubstituted pyrrole-2-carboxylates by subsequent reaction withdicyanodisulfane and zinc/acetic acid (A. Berlin et al., J. Chem. Soc,Perkin Trans. 2 1990, 5, 699-704).

The furans A217 and A218 may be obtained from (substituted) acetylenecarboxylates by reaction with suitably substitutedethoxyvinylidene-tetracarbonyl-ferrocene complexes followed byO-deprotection (Atiq-ur-Rehman et al., J. Am. Chem. Soc. 1993, 115,9848-9849). The thioanalogues (X═S) can be synthesized from suitablysubstituted furan-3-carboxylates by subsequent 5-bromination, reactionwith dimethyl disulfide and S-deprotection (G. Majetich et al.,Tetrahedron Lett. 1994, 35, 4887-4890). The thiophenes A217 and A218should be accessible from (substituted) formylsuccinates by cyclizationin the presence of methanol, hydrogen chloride and hydrogen sulfide,followed by demethylation (S. Mitra et al., J. Chem. Soc. 1939,1116-1117); or from (substituted) 2,4-dibromothiophene by subsequentreaction with methanol, butyllithium and carbon dioxide followed bydemethylation (D. Spinelli et al., J. Chem. Res. (M) 1993, 8,1873-1890). The pyrroles A217 and A218 (keto-tautomer) can be obtainedfrom suitably substituted aminomethylene succinates by base-inducedcyclization (C. A. Grob, P. Ankli, Helv. Chim. Acta 1949, 32,2023-2038). The thioanalogues (X═S) can be synthesized from(substituted) dimethyl(trimethylsilyl)methyl-carbonimidodithioate and(substituted) acetylene carboxylates in the presence of silver fluoride(A. Padwa et al., J. Org. Chem. 1987, 52, 1027-1035).

A229-A234 Oxazole, Thiazole and Imidazole Derivatives

The oxazoles of type A229 can be obtained by reaction of acetylisocyanates and diazoacetate followed by cyclization (O. Tsuge et al.,Tetrahedron 1973, 29, 1983-1990), whereas the thiazoles A229 can besynthesized from bromomalonates and thioamides (F. A. J. Kerdesky etal., J. Med. Chem. 1991, 34, 2158-2165). The imidazoles A229 areaccessible by reaction of aminomalonate with substituted acetimidates(M. S. Poonian, E. F. Nowoswiat, J. Org. Chem. 1980, 45, 203-208).

The oxazoles and thiazoles of type A230 are accessible by cyclizingmonoethyl acetamidomalonate in the presence of trifluoroacetic anhydride(to the oxazoles; J. Morgan et al., J. Chem. Soc., Perkin Trans. 1 1997,5, 613-620), or in the presence of phosphorus pentasulfide (to thethiazoles; A. G. Long, A. Tulley, J. Chem. Soc. 1964, 1190-1192). Thethiazoles A230 (with X═S) can be synthesized either fromN-thioacetyl-glycine by PCl₃-mediated cyclization followed by subsequentreaction with the Vilsmeyer reagent and hydrosulfide and oxidation ofthe intermediate aldehyde (to give 2-substituted 5-mercapto-thiazoles;I. Y. Kvitko et al., Chem. Heterocycl. Comp. 1980, 16, 28-31) or from(substituted) 3-bromo-2-oxo-propionic acid by reaction with thiourea,2-deamination via diazotation, 5-bromination, substitution anddeprotection (to give 2-unsubstituted 5-mercapto-thiazoles; B. Blank etal., J. Med. Chem. 1977, 20, 572-576). The imidazoles A230 (X═O) can beobtained from aminomalonate by reaction with trimethylorthoformiatefollowed by cyclization in the presence of ammonia or amines (R. S.Hosmane, B. B. Lim, Tetrahedron Lett. 1985, 26, 1915-1918) or, for (X═S)by subsequent reaction of 2-amino-2-cyano-acetate with (substituted)trimethylorthoformiate and hydrogen sulfide A. K. Sen, A. K.Mukhopadhyay, Indian J. Chem. B. 1981, 20, 275-278).

The oxazoles A231 (X═S) should be obtainable starting fromhydroxyacetaldehyde dimer and potassium thiocyanate followed byS-methylation, lithiation/acylation with chloroformiate anddemethylation (C. M. Shafer, T. F. Molinski, J. Org. Chem. 1998, 63,551-555). The corresponding thiazoles A231 (X═S) may be synthesized fromsuitably substituted beta-ketoesters by subsequent reaction with[hydroxy(tosyloxy)iodo]benzene and ammonium dithiocarbamate (P.-F.Zhang, Z.-C. Chen, Synth. Comm. 2001, 31, 415-420). The imidazoles A231(X═S) can be prepared from N-protected glycine by subsequent reactionwith formic acid, methyl formiate and potassium thiocyanate (G. vanLommen et al., Bioorg. Med. Chem. Lett. 2005, 15, 497-500), or byC-alkylation of N-protected glycine with suitably substitutedchloroacetates followed by reaction with potassium thiocyanate (J. Singhet al., Tetrahedron Lett. 1993, 34, 211-214). Oxazoles of type A232 canbe prepared from suitably substituted diazoacetates by rhodium-catalyzedreaction with cyanoformiate (G. Shi et al., J. Fluorine Chem. 1991, 52,149-157). Oxazoles of type A233 can be obtained by heating suitablysubstituted acetylene carboxylates with diazoacetate followed bydemethylation (R. Huisgen, H. Blaschke, Chem. Ber. 1965, 98, 2985-2997).The S-analogues of oxazoles A233 (X═S) are accessible fromN-(bismethylthio)glycine esters by reaction with DMF-acetals followed byacid-induced cyclization and demethylation (R. Gompper, U. Heinemann,Angew. Chem. 1981, 93, 297-298). The thiazoles A233 (X═O) can beprepared from suitably substituted cysteine ethyl ester by reaction withdiphosgene followed by bromination/elimination (G. Serra et al.,Heterocycles 1995, 41, 2701-2711).

The oxazoles A234 (X═O) can be prepared from suitably substitutedhydroxyacetonitriles and oxalyl chloride followed by methanolysis of theintermediate and demethylation (K. van Aken, G. Hoornaert, J. Chem.Soc., Chem. Comm. 1992, 12, 895-896). The thiazoles A234 (X═O) areaccessible from suitably substituted 2-mercaptoacetate and cyanoformiate(G. Satzinger, Liebigs Ann. Chem. 1978, 473-511). The correspondingthioanalogues (X═S) can be prepared from (substituted) S-methyl3-oxopropanedithioates and glycine esters followed by cyclizationinduced by thionyl chloride and demethylation (A. Rahman et al.,Synthesis 1984, 250-252).

A235-A239 Isoxazole, Isothiazole and Pyrazole Derivatives

Isoxazoles A235 can be synthesized from (2-methoxymethylene)-malonatesubstituted in 2-position by reaction with hydroxylamine followed byaqueous HCl (K. Bowden et al., J. Chem. Soc. C 1968, 172-185). Thecorresponding pyrazoles A235 can be prepared similarly but withhydrazine instead of hydroxylamine (T. M. Willson et al., Bioorg. Med.Chem. Lett. 1996, 6, 1047-1050).

The isothiazoles A236 can be obtained from suitably substitutedO-toluenesulfonyloxyiminoacetates by reaction with thioglycolates (B.Rezessy et al., Tetrahedron Lett. 1992, 33, 6523-6526). Thecorresponding pyrazoles A236 can be prepared either from suitablysubstituted 2-oxopropionates by reaction with ethyl hydrazinoacetatefollowed by methoxide-mediated cyclization (R. N. Comber et al.,Carbohyd. Res. 1992, 216, 441-452) or from substituted 3-oxopropionatesby 2-diazotation followed by cyclization in the presence of sodiumhydride (F. J. L. Herrera, C. U. Baelo, Carbohyd. Res. 1985, 143,161-174). The isoxazoles A237 are accessible by reaction of4-chloro-3-oxo-butanoates substituted in 4-position withisopentylnitrite (G. Hesse, G. Krehbiel, Chem. Ber. 1955, 88, 130-133).The pyrazoles A237 can be obtained from suitably substituted malonatesby reaction with diazoacetate (A. Bertho, H. Nüssel, Liebigs Ann. Chem.1927, 457, 278-307). The pyrazoles of type A238 (keto-isomers) can besynthesized from suitably substituted ketosuccinic acids by reactionwith hydrazines in the presence of acetic acid (K. J. Duffy et al., J.Med. Chem. 2001, 44, 3730-3745).

Isoxazoles of type A239 can be obtained from 3-substituted 2-bromomaleicacids by esterification followed by reaction with hydroxyurea (C.Bennouna et al., Bull. Soc. Chim. Fr. 1980, 2, 478-480). Theisothiazoles A239 can be prepared from 3-substituted 2-aminofurmaramidesby subsequent reaction with hydrogen sulfide and bromine followed byhydrolysis of the formed amides (J. Lykkeberg, P. Krogsgaard-Larsen,Acta Chem. Scand. B 1976, 30, 781-785). The corresponding pyrazoles areaccessible from (substituted) maleates by reaction with hydrazinesfollowed by oxidation to give the pyrazole ring (G. P. Lahm et al.,Bioorg. Med. Chem. Lett. 2007, 17, 6274-6279).

A240-A357 Benzofurane, Benzothiophene and Indole Derivatives

The benzothiophenes A240 can be prepared in a multistep sequencestarting from suitably substituted 2-hydroxy-benzaldehydes, which aretransformed into the 3-isopropoxy-2,3-dihydrobenzothiophen-2-ones andthen further on functionalized in 2-position and carboxylated in3-position (A. V. Kalinin et al., J. Org. Chem. 2003, 68, 5992-5999).

A possible route to benzofuranes of type A241-A243 involves condensationof suitably substituted cyclohexane-1,3-diones and3-bromo-2-oxo-propionic acid followed by Pd-catalyzed dehydrogenation(G. Kneen, P. J. Maddocks, Synth. Comm. 1986, 16, 1635-1640). Theindoles A244-A247 can be obtained from suitably substituted2-bromo-3-nitro-benzoates by a Stille coupling to the corresponding1-ethoxy-styrene followed by a Pd-catalyzed reductive cyclization in thepresence of CO and subsequent deprotection of the alcohol and acid (R.W. Clawson et al., Tetrahedron 2006, 62, 10829-10834).

The benzofuranes of type A248-A251 can be synthesized from suitablysubstituted 2,6-dihydroxy-benzoates by reaction with 2-chloroketones (F.H. Curd, A. Robertson, J. Chem. Soc. 1933, 714-720) or withchloroacetonitrile in the presence of Lewis acids and HCl followed byacetylation and reductive deoxygenation in 3-position (W. Gruber, K.Horvath, Mh. Chem. 1950, 81, 828-836). The corresponding indoles A250and A251 should accessible from 6-hydroxy-3-methyl-2-nitro-benzoic acid,which is reacted with dimethylformamide followed by hydrogenation of thenitro group, cyclization, diazotation of the amine and hydroxylation (H.D. Hollis Showalter et al., J. Org. Chem. 1996, 61, 1155-1158). Thebenzothiophenes A250 and A251 could be obtained from suitablysubstituted 2-(thiophen-3-yl-)acetaldehydes by reaction with propargylalcohol followed by iodo-cyclization, oxidation of the alcohol to theacid and transformation of the 6-iodo-compound into the alcohol (J. P.Waldo et al., J. Org. Chem. 2008, 73, 6679-6685).

The benzothiophenes of type A252-A255 are accessible from suitablysubstituted methyl 3-methyl-thiophene-2-carboxylate, which is firsttransformed into the 3-toluenesulfinylmethyl compound and then furtherreacted with suitably substituted acrylates in the presence of base togive the methyl esters of A252-A255 (J. W. Terpstra, A. M. van Leusen,J. Org. Chem. 1986, 51, 230-238). Indoles A252-A255 can be synthesizedfrom methyl 2-methoxy-4-methyl-benzoates, which are subsequentlybrominated in 5-position, nitrated in 3-position, then reacted withdimethylformamide and reduced with Ra/Ni and hydrazine, which triggers acyclization to the 7-methoxy-6-methoxycarbonyl-indoles. Theseintermediates can then be deprotected to the indoles A252-A255 (P. L.Beaulieu et al., Bioorg. Med. Chem. Lett. 2006, 16, 4987-4993).

Possible precursors for benzofuranes A256-A259 and A264-A267 aresuitably substituted 2,4-dihydroxy-benzoates which are subjected toalkylation in 4-position with bromoacetaldehyde diethyl acetal followedby cyclization mediated by Amberlyst A15 (M. Dixit et al., Synlett 2006,10, 1497-1502). Indoles of type A256-A259 (TMS-protected in 4-position,if there is no other substituent) and A264-A267 can be obtained fromsuitably substituted 5-hydroxy-indoles by formation of the diethylcarbamate followed by anionic Fries rearrangement to the diethyl amide,which is subsequently hydrolyzed with aqueous sodium hydroxide orperchloric acid (E. J. Griffen et al., J. Org. Chem. 1995, 60,1484-1485). The benzothiophenes of type A260 and A263 should accessiblefrom 4,6-dibromo-benzene-1,3-carbaldehyde (substituted in 2- or5-position) by subsequent substitution of the bromides with methoxideand with 2-mercaptoacetate followed by cyclization, decarboxylation,demethylation and oxidation of the aldehyde to the acid (A. E. Jakobs etal., Tetrahedron 1994, 50, 9315-9324).

Benzofuranes of type A268-A271 can be synthesized from the corresponding4-hydroxy-benzofuranes by carboxylation with carbon dioxide in thepresence of methoxide (T. Reichstein, R. Hirt, Helv. Chim. Acta 1933,16, 121-129) or from suitably substituted5-carbomethoxy-6-hydroxy-salicylaldehydes by reaction with bromoacetatesfollowed by saponification and cyclization in the presence of aceticanhydride (R. T. Foster, A. Robertson, J. Chem. Soc. 1948, 115-116). Thepreparation of the corresponding benzothiophenes A268-A271 should bepossible from suitably substituted 4-oxo-tetrahydrobenzothiophene byacylation with dimethyl carbonate followed by aromatization with DDQ (P.P. Yadav et al., Bioorg. Med. Chem. 2005, 13, 1497-1505). The indolesA268-A271 can be prepared similarly from the 4-oxo-tetrahydroindoles, oralternatively from suitably substituted N-protected 4-amino-salicylicacid via Claisen rearrangement of the O-allyl ether followed by cleavageof the double bond and cyclization (T. Kakigami et al., Chem. Pharm.Bull. 1988, 46, 42-52). Benzofuranes of type A273-A275 can be obtainedfrom 4-O-protected 4-hydroxy-salicylaldehydes by reaction with ethyldiazoacetate in the presence of tetrafluoroboric acid followed bydehydration and deprotection (M. E. Dudley et al., Synthesis 2006,1711-1714). The benzothiophenes A272-A275 are accessible from5-bromo-benzothiophene (which, in turn, can be prepared from suitablysubstituted 4-bromo-thiophenols and bromoacetaldehyde diethyl acetal) byFriedel-Crafts acylation, conversion of the methyl ketone into thecarboxylate, substitution of the bromide with methoxide anddemethylation (S. Mitsumori et al., J. Med. Chem. 2003, 46, 2446-2455).The synthesis of corresponding indoles A272-A275 should be possible bythe reaction of suitably substituted para-benzoquinones with substituted2-aminoacrylates in a Nenitzescu reaction (E. A. Steck et al., J. Org.Chem. 1959, 24, 1750-1752) Benzofuranes of type A276-A279 can beobtained from the 3-acetyl-4-hydroxy-benzoates by bromination of themethyl ketone followed by base-induced cyclization to the keto-tautomerof A276-A279 (G. Doria et al., Farmaco 1980, 35, 674-680). The synthesisof 2-substituted benzofuranes A278 can be achieved by alkylation oracylation. The corresponding benzothiophenes A276-A279 may be preparedfrom suitably substituted 4-fluorobenzoates and thioglycolate byAlCl₃-induced intramolecular Fridel-Crafts acylation of the intermediate4-alkoxycarbonyl-phenylsulfanyl acetates (D. L. Gernert et al., Bioorg.Med. Chem. Lett. 2004, 14, 2759-2764).

The benzofuranes and benzothiophenes of type A284-A287 can besynthesized from suitably substituted 3-furaldehydes or3-formyl-thiophenes by condensation with diethyl succinate followed bycyclization in the presence of acetic anhydride and then base (D. Simoniet al., J. Med. Chem. 2006, 49, 3143-3152). The indoles of type A284 andA287 are accessible from 3-methoxy-4-amino-benzoates by subsequent5-iodination, Sonogashira coupling with TMS-acetylene and CuI-mediatedcyclization followed by demethylation (J. Ezquerra et al., J. Org. Chem.1996, 61, 5804-5812). Benzofuranes and benzothiophenes of type A288-A291can be obtained from suitably substituted 2-furaldehydes similarly asdescribed for A284-A287 (D. Simoni et al., J. Med. Chem. 2006, 49,3143-3152). The indoles A288-A291 can be synthesized similarly frompyrrole-2-carbaldehydes and diethyl succinate followed by base-inducedcyclization (C. Fuganti, S. Serra, J. Chem. Res. (M) 1998, 10,2769-2782).

The indoles of type A292-A295 can be prepared from N-protected ethylfuro[3,2-b]pyrrole-5-carboxylates by decarboxylation with copperchromite in quinoline followed by Diels-Alder reaction with ethylpropiolate and subsequent deprotection (A. Krutosikova, M. Hanes,Collect. Czech. Chem. Comm. 1992, 57, 1487-1494).

Benzofuranes of type A296-A299 can be obtained from suitably substituted(p-acetoxyphenoxy)acetyl chlorides by reaction with cyanide followed bycyclization with 1,3-dihydroxy-benzene mediated by zinc(II)-chloride andhydrogen chloride (L. Crombie et al., J. Chem. Soc., Perkin Trans. 11987, 2783-2786). The corresponding benzothiophenes A296-A299 can besynthesized from suitably substituted 3-bromothiophenols similarly tothe synthesis of A272-A275 (S. Mitsumori et al., J. Med. Chem. 2003, 46,2446-2455). The access of the indoles A296-A299 can be achieved eitherfrom O-protected 6-hydroxyindoles by acylation in 3-position withtrichloroacetyl chloride and methanolysis followed by deprotection (M.Fedouloff et al., Bioorg. Med. Chem. 2001, 9, 2119-2128) or by acylationof suitably substituted indoles in 3-position followed by6-hydroxylation via a Friedel-Crafts acylation/Baeyer-Villiger oxidationsequence (S, Nakatsuka et al., Heterocycles 1987, 26, 1471-1474).

The benzofuranes A300-A303 can be obtained from suitably substituted3-acetyl-furanes by transformation into the silylenol ether followed byDiels-Alder reaction, elimination and dehydrogenation (A. Benitez etal., J. Org. Chem. 1996, 61, 1487-1492).

The benzofuranes A304-A307 can be synthesized either from substituted2-allyl-3-allyloxy-4-methoxy-benzaldehydes by isomerization/metathesisfollowed by oxidation of the aldehyde and demethylation (W. A. L. vanOtterlo et al., Tetrahedron 2005, 61, 7746-7755) or from substituted2-hydroxy-3-methoxy-6-bromo-benzaldehydes by reduction of the alcohol,formation of the phosphonium salt and cyclization in the presence of anacid chloride followed by lithiation/carboxylation and demethylation (K.Hagihara et al., Bioorg. Med. Chem. Lett. 2007, 17, 1616-1621). Thecorresponding benzothiophenes A304-A307 are accessible from suitablysubstituted methyl thiophene-2-carboxylates by transformation into the1-(2′-thienyl)-1,4-dioxobutanes followed by BF₃-mediated cyclization,4-carbonylation by Vilsmeyer-Haack reaction, oxidation of the aldehydeand demethylation (S. S. Samanta et al., J. Chem. Soc., Perkin Trans. 11997, 3673-3678).

The indoles A304-A307 can be obtained either by Diels-Alder reaction ofthe silylenolate of N-protected 2-acetylpyrrole with propiolate followedby air oxidation (M. Ohno et al., Heterocycles 1991, 32, 1199-1202) orfrom suitably substituted 4-benzyloxy-2-methyl-3-nitro-benzoates(prepared from the 3-methylphenols in a multistep sequence) bysubsequent reaction with dimethylformamide and zinc/acetic acid followedby deprotection (M. Tanaka et al., Eur. J. Med. Chem. 1996, 31,187-198).

A358-A372 Pyrrolo[2,3-b]Pyridine Derivatives

The pyrrolopyridines A365 and A366 can be synthesized from 7-azaindole,which is first transformed into N-protected 4-chloro-7-azaindole via thepyridyl-N-oxide (X. Wang et al., J. Org. Chem. 2006, 71, 4021-4023),followed by 5-lithiation and carboxylation, hydrolysis of the chlorideand of the ester and N-deprotection (A. L'Heureux et al., TetrahedronLett. 2004, 45, 2317-2320). The pyrrolopyridines of type A367 and A368can be obtained from suitably substituted 4-chloro-3-formyl-pyridines byreaction with azidoacetate followed by a Hemetsberger-Knittel reaction(P. J. Roy et al., Synthesis 2005, 2751-2757). The pyrrolopyridines oftype A369 and A370 may be accessible from the corresponding substituted5-chloro-pyrrolopyridine by formylation in a Duff reaction, oxidation tothe acid and hydrolysis of the chloride (R. H. Bahekar et al., Bioorg.Med. Chem. 2007, 15, 6782-6795) The synthesis of pyrrolopyridines A371and A372 may be possible from 4-chloro-7-azaindole bypyridyl-N-oxidation and -methylation followed by substitution withcyanide and hydrolysis of the nitrile and chloride (T. Storz et al.,Synthesis 2008, 201-214).

A373-A385 Pyrrolo[2,3-c]pyridine Derivatives

The pyrrolopyridine A379 might be obtained from suitably substituted4-iodo-3-nitro-pyridines by a Sonogashira coupling, ethanolysis of thealkyne, reduction of the nitro group and TiCl₄-mediated cyclization (T.Sakamoto et al., Chem. Pharm. Bull. 1986, 34, 2362-2368). Thepyrrolopyridines of type A382 and A383 can be prepared from2-methoxy-4-iodo-5-aminopyridines by Sonogashira coupling withTMS-acetylene, CuI-mediated cyclization, formylation (and oxidation) in3-position and demethylation (D. Mazeas et al., Heterocycles 1999, 50,1065-1080).

Pyrrolopyridines of type A384 and A385 are accessible from suitablysubstituted 4-methoxy-pyrrole-2-carbaldehyde by reductive amination with3,3-diethoxy-2-amino-propionate, TiCl₄-mediated cyclization anddemethylation (S. K. Singh et al., Heterocycles 1997, 44, 379-392).

A386-A398 Pyrrolo[3,2-c]pyridine Derivatives

The pyrrolopyridines A387 and A388 could be accessible starting fromsuitably substituted N-alkylated 2-formyl-pyrroles via the 2-pyrrylacrylazides, which are then cyclized to the pyrrolopyridinones. Theseintermediates are then transformed into the 3-carboxy compounds via thecorresponding aldehydes (J. S. New et al., J. Med. Chem. 1989, 32,1147-1156). The pyrrolopyridines of type A389 and A390 can be obtainedfrom suitably substituted 2-methoxy-3-formyl-pyridines by reaction withazidoacetate followed by a Hemetsberger-Knittel reaction, similarly tothe synthesis of A367 and A368 (P. J. Roy et al., Synthesis 2005,2751-2757).

A399-A413 Pyrrolo[3,2-b]pyridine Derivatives

Pyrrolopyridines of type A406 and A407 can be obtained from substituted2-(6-methoxy-3-nitro-2-pyridyl)-acetates by Knoevenagel reaction withformaldehyde followed by Pd-catalyzed cyclization in the presence ofhydrogen and CO (B. C. G. Soederberg et al., Synthesis 2008, 6,903-912).

Pyrrolopyridines A410 and A413 can be synthesized from suitablysubstituted 2-chloro-3-nicotinonitriles by Sonogashira coupling withTMS-acetylene followed by ethanolysis of the alkyne and degradation ofthe nitrile and finally acid-induced cyclization (T. Sakamoto et al.,Chem. Pharm. Bull. 1986, 34, 2362-2368). Alternatively, the synthesis ofA410 and A413 can be achieved by reaction of suitably substituted3-nitro-pyridines with vinylmagnesium bromide (Z. Zhang et al., J. Org.Chem. 2002, 67, 2345-2347). The pyrrolopyridines A408 and A412 can beobtained from 2-alkynyl-3-amino-pyridines by CuI-catalyzed cyclization(A. M. Palmer et al., Bioorg. Med. Chem. 2008, 16, 1511-1530).

A414-A449 Benzoxazole, Benzothiazole and Benzoimidazole Derivatives

Benzoxazoles A415 and A416 can be prepared starting from N-acylated3-chloro-4-anisidines via benzyne-formation and carboxylation (D. R.Reavill, S. K. Richardson, Synth. Comm. 1990, 20, 1423-1436). Thecorresponding benzimidazoles A415 and A416 are accessible from of2-amino-3-halo-benzoates by acylation of the amine, nitration in6-position, alkylation of the amide and cyclization under reductiveconditions (K. Kubo et al., J. Med. Chem. 1993, 36, 1772-1784).

Benzimidazoles of type A417-A419 can be obtained from4-acetamido-2-methoxy-benzoates by subsequent chlorination in 5-positionand nitration in 3-position, followed by reductive cyclization of theobtained 3-nitro-4-amino-benzoates in the presence of carboxylic acidsor formic acid (S. Bolgunas et al., J. Med. Chem. 2006, 49, 4762-4766).This reductive cyclization procedure might also be applicable to thesynthesis of other benzimidazoles. Benzimidazoles A420-A422 areaccessible from the corresponding 5-methoxy-6-methyl-benzimidazoles bydemethylation and oxidation of the methyl group to the carboxylate (B.D. Palmer et al., J. Med. Chem. 1999, 42, 2373-2382). Benzoxazoles oftype A423-A425 can be obtained by condensation of substituted4-methylene-2-oxazolin-5-ones and4-triphenylphosphoranylidene-3-oxobutanoates followed by iodine-mediatedaromatization (F. Clericl et al., Tetrahedron 1991, 47, 8907-8916). Thesynthesis of the corresponding benzimidazoles A423-A425 should bepossible starting from 4-amino-2-hydroxy-5-nitrobenzoates via acylation,then reduction of the nitro group and cyclization, as is described forthe 2-chloro-benzoates (A. Tanaka et al., Chem. Pharm. Bull. 1994, 42,560-569). Benzoxazoles of type A426-A428 can be synthesized startingfrom 2,5-dihydroxybenzoate, which is aminated in 6-position in amultistep sequence, then acylated and cyclized (D. Diez-Martin et al.,Tetrahedron 1992, 48, 7899-7939).

The benzimidazoles A429-A431 should be accessible from O-protected3,4-diamino-2-hydroxy-benzoates, which are mono-acylated and thencyclized under acidic conditions (Y. Hirokawa et al., Chem. Pharm. Bull.2002, 50, 941-959; A. Viger, P. B. Dervan, Bioorg. Med. Chem. 2006, 14,8539-8549). Benzothiazoles of type A438-A440 can be synthesized byheating suitably substituted 4-amino-3-methoxy-benzoates with potassiumthiocyanate in the presence of copper(II)-sulfate and subsequent2-desamination and 3-demethylation (I. A. Ismail et al., J. Org. Chem.1980, 45, 2243-2246). Benzimidazoles A441-A443 can be prepared by amulti-step sequence from 8-aminoquinolines via the corresponding5,6-dihydro-4H-imidazoquinolines (R. C. Elderfield, F. J. Kreysa, J. Am.Chem. Soc. 1948, 70, 44-48). Benzimidazoles A444 and A447 can beobtained by reaction of suitably substituted 3-amino-4-methoxy-benzoateswith nitriles followed by NaOCl-induced cyclization and subsequentdeprotection (J. Reagn et al., Bioorg. Med. Chem. Lett. 1998, 8,2737-2742).

A450-A459 Benzoisoxazole, Benzoisothiazole and Indazole Derivatives

Benzoisoxazoles of type A456 and A459 can be synthesized starting from2,6-dihydroxy-3-formyl-4-methyl-benzoates by reaction with hydroxylaminefollowed by thermal cyclization (D. H. R. Barton et al., J. Chem. Soc. C1971, 2166-2174). The application of this method to the synthesis of theother benzisoxazoles (A450-A455, A457 and A458) should be possible. Thepreparation of indazoles A457 has been described by reaction of3-amino-2-methoxy-4-methylbenzoate with isoamylnitrite followed bydemethylation (S. Bolgunas et al., J. Med. Chem. 2006, 49, 4762-4766);the application to other indazoles (A450-A456 and A458) appearsfeasible.

A460-A515 Naphthalene Derivatives

A relatively large number of suitably substituted naphthalenederivatives is commercially available. In addition, naphthalenes of typeA460-A465 and A496-A499 can be obtained from the corresponding2-hydroxy-naphthalenes via lithiation and carboxylation (K. Takahashi etal., Tetrahedron 1994, 50, 1327-1340). Alternatively, the demethylationof 2-methoxynaphthalene carboxylic acids has been described (Y. Gao etal., J. Med. Chem. 2001, 44, 2869-2878). Higher substituted compoundscan be prepared in a multistep sequence from suitably substituted2-bromotoluenes via 2-tetralone-1-carboxylates analogously to the methoddescribed by F. C. Goerth et al., Eur. J. Org. Chem. 2000, 2605-2612.

Naphthalenes of type A478-A483 and A508-A511 can be prepared either bydemethylation of the 3-methoxynaphthalene-1-carboxylates (R. E. Royer etal., J. Med. Chem. 1995, 38, 2427-2432) or by diazotation and subsequenthydrolysis of the corresponding 3-aminonaphthalene-1-carboxylates (K. J.Duffy et al., J. Med. Chem. 2001, 44, 3730-3745).

The naphthalenes of type A484-A489 and A504-A507 can be easily built upby a condensation reaction with succinic esters, starting either fromsuitably substituted benzaldehydes (A. M. El-Abbady et al., J. Org.Chem. 1961, 26, 4871-4873; M. Kitamura et al., Angew. Chem. Int. Ed.1999, 38, 1229-1232) or from benzophenones (F. G. Baddar et al., J.Chem. Soc. 1955, 1714-1718), depending on the substitution pattern inthe desired product.

Naphthalene derivatives of type A490-A495 and A512-A515 can be obtainedfrom 2-methoxynaphthalenes by bromination in 4-position, lithiation ofthe bromide followed by carboxylation and demethylation (J. A. O'Mearaet al., J. Med. Chem. 2005, 48, 5580-5588) or from 2-chloro-naphthaleneby reaction with phthalic anhydride followed by KOH-induced cleavage (G.Heller, Chem. Ber. 1912, 45, 674-679).

A516-A548 Quinoline Derivatives

The synthesis of quinolines of type A516-A518 can be accomplished byreaction of suitably substituted isatins with substitutedphenacylbromides (H. John, J. Prakt. Chem. 1932, 133, 259-272; E. J.Cragoe et al., J. Org. Chem. 1953, 18, 552-560).

Quinolines of type A522-A524 are easily accessible from suitablysubstituted 2-amino-benzaldehydes via a modified Friedländer synthesis(D. L. Boger, J.-H. Chen, J. Org. Chem. 1995, 60, 7369-7371). Similarly,quinoline derivatives A527-A529 can be obtained from2-aminobenzaldehydes by condensation with malonic acid (J. Troeger, C.Cohaus, J. Prakt. Chem. 1927, 117, 97-116).

Quinolines A525 can be synthesized from the corresponding2-cyanoquinoline-1-oxides by rearrangement (C. Kaneko, S. Yamada, Chem.Pharm. Bull. 1967, 15, 663-669). The quinolines A526 (with asubstitution in 4-position) are in principle accessible from substituted2-aminoacetophenones (with the substitution on the acetyl moiety) byreaction with 3-chloro-3-oxopropionate and subsequent base-inducedcyclization (A. Capelli et al., Bioorg. Med. Chem. 2002, 10, 779-802).

Quinolines of type A530-A533 can be built up starting from 2-anisidinesby reaction with 2-oxosuccinic esters followed by thermal cyclization,demethylation and removal of the 4-hydroxy group via hydrogenation ofthe corresponding chloride (L. Musajo, M. Minchilli, Chem. Ber. 1941,74, 1839-1843). For the synthesis of quinolines of type A543-A545 thecondensation of suitably substituted isatins with malonic acid has beendescribed (e.g. W. Borsche, W. Jacobs, Chem. Ber. 1914, 47, 354-363; J.A. Aeschlimann, J. Chem. Soc. 1926, 2902-2911).

A549-A564 Isoquinoline Derivatives

Isoquinolines of type A549-A553 with the carboxylate in the 1-positioncan be prepared from suitably substituted benzaldehydes, which aretransformed into the aminoethanes followed by reaction with oxalic esteraldehyde or acid chloride, cyclization, oxidative aromatization andfinally saponification (M. Keizo et al., Chem. Pharm. Bull. 1982, 30,4170-4174; S, Naoki et al., Chem. Pharm. Bull. 1989, 37, 1493-1499).

Isoquinoline-3-carboxylates (A554-A556) are accessible from hydroxylatedphenylalanines via a Bischler-Napieralski reaction followed by oxidativearomatization, or alternatively from suitably substituted 2-methylbenzaldehydes, which are reacted with methyl azidoacetate and thencyclized under thermal conditions followed by aromatization (Y. Fukudaet al., J. Med. Chem. 1999, 42, 1448-1458; T. R. Burke et al.,Heterocycles 1992, 34, 757-764).

Compounds of type A557 and A558 can be built up by reaction betweensuitably substituted 2-aminobenzoic acids and5-chloro-3-carboxy-1,2,4-pyrazines in the presence of amylnitritefollowed by hydrolysis (A. M. d'A. Rocha Gonsalves, T. M. V. D. Pinho eMelo, Tetrahedron 1992, 48, 6821-6826), whereas isoquinolines A559 andA560 can be prepared by reaction of 2-formylbenzoic acids with2-thioxothiazolidin-4-one followed by cyclization and transformation ofthe isothiochromenone into the isoquinoline with ethanolic ammonia (D.J. Dijksman, G. T. Newbold, J. Chem. Soc. 1951, 1213-1217).

The access to isoquinolines A561 and A562 might be possible bytransformation of suitably substituted isquinolines into thecorresponding Reissert compounds, nitration in 4-position and hydrolysisof the nitrile (M. Sugiura et al., Chem. Pharm. Bull. 1992, 40,2262-2266) followed by hydrogenation of the nitro group, diazotation ofthe amine and transformation into the hydroxyl group.

Isoquinolines of type A563 and A564 are accessible from suitablysubstituted (2-methoxycarbonyl-phenyl-)acetic acids via reaction withmethyl formiate followed by cyclization of the formed enol and aminationof the isochromenone (H. E. Ungnade et al., J. Org. Chem. 1945, 10,533-536).

A565-A577 Quinazoline Derivatives

The most general routes to quinazolines use appropriately substitutedphenyl derivatives onto which the pyrimido ring is cyclized, e.g. thecyclocondensation of 2-amino benzamides with oxalates (M. Suesse et al.,Helv. Chim. Acta 1986, 69, 1017-1024), of ortho-carbonyl substitutedphenyl oxalamic acid esters with ammonium formate (S. Ferrini et al.,Org. Lett. 2007, 9, 69-72), or of 2-amino benzonitriles withcarbonylformimidate or chloroformamidine (A. McKillop et al.,Tetrahedron Lett. 1982, 23, 3357-3360; N. Harris et al., J. Med. Chem.1990, 33, 434-444), or of ortho-oxalyl anilides with ammonia (M. T.Bogert, F. P. Nabenhauer, J. Am. Chem. Soc. 1924, 46, 1702-1707).

A578-A587 Quinoxaline Derivatives

The synthesis of quinoxalines of types A578-581 via their2-carbaldehydes is well-described (E. Lippmann et al., Zeitschr. Chem.1990, 30, 251-252). The other representatives of these groups A582-587are available by cyclocondensation of β-dicarbonyl derivatives orβ-keto-esters with appropriately substituted ortho-phenylendiamines (S.Grivas et al., Acta Chem. Scand. 1993, 47, 521-528; A. Zychilinski, I.Ugi, Heterocycles 1998, 49, 29-32; D. Zhou et al., Bioorg. Med. Chem.2008, 16, 6707-6723). Unique to the quinoxaline is the possibility tointroduce a carboxyl group in the 2-position by enzyme catalystbiotransformation applying Arthrobacter nicotianae (T. Yoshida et al.,Biosci. Biotech. Biochem. 2002, 66, 2388-2394).

A588-A601 Pyrido[5,4-d]pyrimidine Derivatives

The bicyclic core can be accessed by annelating suitably substitutedpyridines by cyclocondensation reactions. Feasible starting materialsinclude pyridine-2,3-dicarboxylic acids (A. Tikad et al., Synlett 2006,12, 1938-1942), 3-aminopyridine-2-carboxylates (M. Hayakawa et al.,Bioorg. Med. Chem. 2006, 14, 6847-6858) or 3-aminopyridine-2-nitriles(J. B. Smaill et al., J. Med. Chem. 2000, 43, 1380-1397).

A602-A608 Pyrimido[5,4-d]pyrimidine Derivatives

Access to the pyrimidopyrimidine group of templates might be achievedvia the literature-known 4,6-dichloro derivative (G. Rewcastle et al.,J. Med. Chem. 1997, 40; 12, 1820-1826) or the corresponding2,4,6,8-tetrachloro derivative (J. Northen et al., J. Chem. Soc., PerkinTrans. 1, 2002, 108-115) using the general methods described above andseparation of the expected isomeric mixtures.

A609-A618 Tetraline Derivatives

A large number of reaction sequences that lead to tetraline derivativesinvolve an intramolceular Friedel-Crafts acylation as a key step, andthe prerequisite cyclization precusors can be elaborated fromphenylacetonitriles, 2-phenyl malonates (R. S, Natekar, S. D. Samant,Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 2002, 41, 187-190;L. Gong, H. Parnes, J. Labelled Compd. Radiopharm. 1996, 38, 425-434).Alternatively, the intramolecular cyclization can be achieved by aBuchner Reaction (A. Cheung et al., Bioorg. Med. Chem. Lett. 2003, 13,133-138). Subsequently, the carbonyl groups of the thus obtained 1- or2-tetralones can easily be converted into carboxyl moieties (M. Meyer etal., J. Med. Chem. 1997, 40, 104-1062; F. Berardi et al., J. Med. Chem.2004, 47, 2308-2317).

A619-A626 Indane Derivatives

Indane derivatives of types A619-A623 with a carboxyl group in the1-position are accessible from appropriately substituted and easilyavailable 3-cyano-indenes by hydrogenation to the indane core followedby hydrolysis to the carboxylic acid moiety (T. McLean et al. J. Med.Chem. 2006, 49, 4269-4274). Also indan-1-ones can be transferred intoindane-1-carboxylic acids, for example via oxiranes (D.-I. Kato et al.,J. Org. Chem. 2003, 68, 7234-7242), or in a Corey-Seebach-type reactionvia 1,3-dithianes (Y.-P. Pang et al., J. Org. Chem. 1991, 56,4499-4508).

Indane derivatives of types A624-A626 with a carboxyl group in2-position can be obtained from readily accessible, suitably substitutedindan-1-ones by treatment of the corresponding enolate with a dimethylcarbonate, hydrogenation of the carbonyl group and hydrolysis of theintroduced ester group (T. Tanaka et al., Chem. Pharm. Bull. 1994, 42,1756-1759; U. Hacksell et al. J. Med. Chem. 1981, 24, 429-434).Alternatively the indane ring system can be built up starting fromortho-xylenes by NBS bromination of both methyl residues,alkylation-spirocyclization with the enolate of barbituric acid andfinally decarboxylative ring cleavage to indane-2-carboxylic acids (G.A. Kraus et al., J. Org. Chem. 2002, 67, 5857-5859).

Synthesis of Building Blocks for the Modulators B

The Modulator moieties B of the macrocycle I are derived fromappropriately substituted aminoalcohols, wherein the amino and alcoholgroup, which contribute to the ring connectivity, are separated from by2-4 C-atoms.

If not already present in a commercial building block, the substituentR³ can be introduced by standard nucleophilic addition of organometallic reagents to carbonyl or carboxyl derivatives. For B18-B21,carrying no additional C-substituent on their ring system, suchprecursors are commercially available. Similarly, in the case of B9,B10, B16 and B17 the diversification of the substituent pattern can beeasily achieved by standard transformations of the commercial analogswith free amine functionalities (i.e. —NH₂→NR¹¹R²⁷ in the case of B9 and—NH→—NR¹¹ for B10, B16 and B17).

B1 Aziridine Derivatives

Usually, the access to hydroxymethyl aziridines relies on reactionsequences involving the construction of the aziridine ring. The startingmaterials with the broadest applicability are β-ketoesters:Transformation into the β-hyroxyimino analog, intramolecular cyclisationto the aziridine ring and reduction of the ester to the alcohol groupleads to building blocks of type B1 (e.g. T. Sakai et al., J. Org. Chem.2005, 70, 1369-1375). An alternative approach uses α,β-dihaloester whichare converted into substances of type B1 via aziridination with ammoniaand reduction of the ester group (P. Davoli et al., Tetrahedron 2001,57, 1801-1812).

B2-B3 Azetidine Derivatives

The standard approaches to hydroxymethyl azetidines comprises subjectingeasily accessible O-protected glycidols to, successively, anepoxide-ring opening with azide, transformation of the OH group of thethus obtained alcohol into a suitable leaving group (e.g. tosylate orsulfate), reduction of the azide to an amine and concomitantintramolceular cyclization (F. Hosono et al., Tetrahedron 1994, 50,13335-13346; D.-G. Liu, G.-Q. Lin, Tetrahedron Lett. 1999, 40, 337-340).

B4-B8 Pyrrolidine Derivatives and B11-B15 Piperidine Derivatives

The synthetic approaches to the pyrrolidine and piperidine classes ofbuilding blocks B rely on the same strategies and are thereforediscussed together. Intramolecular cyclization reactions are thepredominant routes applicable to a broad number of diversely substitutedsubstrates: Amines carrying a residue with a leaving group in theω-position lead directly to the desired saturated ring systems by anintramoleular nulceophilic substitution (G. Ceulemans et al.,Tetrahedron 1997, 53, 14957-14974; S. H. Kang, D. H. Ryu, TetrahedronLett. 1997, 38, 607-610; J. L. Ruano et al., Synthesis 2006, 687-691).Also N-haloamines can be directly transformed to the desired compoundsby the Hofmann-Löffler-Freytag reaction (M. E. Wolff, Chem. Rev. 1963,63, 55-64). Alternatively amines carrying two substituents, each with analkene or alkyne bond, can be subjected to a ring closing metathesis(RCM) reaction (Y. Coquerel, J. Rodriguez, Eur. J. Org. Chem. 2008,1125-1132) and subsequent reduction of the thus obtained partiallyunsaturated ring to the saturated heterocycle.

Also the reduction of the corresponding aromatic five- and six-memberedheterocycles to their saturated analogs is described in the literature.However, due to the large number of commercially available pyridinesthis approach is mainly applied to the synthesis of the piperidinesystem (J. Bolos et al., J. Heterocycl. Chem. 1994, 31, 1493-1496; A.Solladie-Cavallo et al., Tetrahedron Lett. 2003, 44, 8501-8504; R. Naefet al., J. Agric. Food Chem. 2005, 53, 9161-9164).

Procedures for the synthesis of libraries of macrocyclic compounds ofgeneral structure I are described below but it will immediately apparentto those skilled in the art how these procedures have to be modified ifit is intended to synthesize one single macrocyclic compound of formulaI.

The macrocyclic compounds of the invention are obtained by cyclizationof suitable linear precursors which are derived from optionallysubstituted hydroxyaryl, hydroxyheteroaryl, mercaptoaryl, ormercaptoheteroaryl carboxylic acids A (“template”, a), substituted aminoalcohols B (“modulator”, b) and one to three building blocks of type Cforming the “bridge”, c.

Variable substituents are introduced by pre- or postcyclativederivatization of one or more orthogonally protected attachment points(e.g. amino groups, carboxyl groups, hydroxyl groups) on building blocksB and C, and optionally A. Variable R-groups may also be introduced asside chain motifs in building blocks C.

The macrocyclic products of the invention can be prepared either insolution or on a solid support.

In accordance with the present invention, the ring closure reaction is,in principle, possible between any of the building blocks.

Macrocycles of general structure I with building block c forming thebridge c are obtained by either

-   a) macrolactamisation between c and B; or-   b) macrolactamisation between A and c; or-   c) aryl- or thioaryl ether formation between A and B; or,    alternatively,-   d) Ring closure metathesis reaction within building blocks of type C    is also possible.

Macrocycles of structure I with orthogonally protected exocyclicfunctional groups (attachment points for derivatization) are prepared insolution by a process which comprises:

-   a¹) condensation of an appropriately protected hydroxy- or    mercapto-aryl/heteroaryl carboxylic acid PG-A-OH and a suitably    C-terminal- and appropriately side-chain-protected building block    H-c1-OPG to form PG-A-c1-OPG;-   b¹) if required release of the aryl/heteroaryl (phenolic) OH group    or mercapto group, respectively;-   c¹) aryl/heteroaryl ether or thioether formation with a suitably    N-protected amino alcohol HO—B-PG leading to the fully protected    linear cyclization precursor PG-B-A-c1-OPG;-   d¹) cleavage of the “main chain” protective groups (PG) affording    the free amino acid H—B-A-c1-OH (still carrying appropriately    protected side chain functional groups); followed by either

e¹) intramolecular amide coupling affording protected macrocycles ofgeneral formula I (yielding cyclo-(B-A-c1) still carrying orthogonallyprotected side chain functional groups); or

-   f¹) N-reprotection of the product obtained in step d¹);-   g¹) coupling of a suitably C-protected amino acid H-c2-OPG;-   h¹) cleavage of the “main chain” protective groups affording the    free amino acid H—B-A-c1-c2-OH (still carrying appropriately    protected side chain functional groups);-   i¹) intramolecular amide coupling affording the protected    macrocycles of general formula I (yielding cyclo-(B-A-c1-c2); still    carrying orthogonally protected side chain functional groups); or-   j¹) N-protection of the product obtained in step d¹);-   k¹) coupling of a suitably C-protected amino acid H-c2-OPG-   l¹) cleavage of the C-terminal protective group or cleavage of N-    and C-terminal main chain protective groups and reprotection of the    N-terminus;-   m¹) coupling of a suitably C-protected amino acid H-c3-OPG;-   n¹) release of the “main chain” protective groups affording the free    amino acid H—B-A-c1-c2-c3-OH (still carrying protected side chain    functional groups); and-   o¹) intramolecular amide coupling affording the protected    macrocycles of general formula I (yielding cyclo-(B-A-c1-c2-c3),    still carrying protected side chain functional groups).

The appropriately protected, preferably acyloxy- or acylmercapto-, mostpreferably acetyloxy- or acetylmercapto-substituted aryl/heteroarylcarboxylic acid (PG¹-A-OH) is converted into the corresponding acidchloride and condensed with a suitably protected amino acid ester

-   H-c1-OPG² in the presence of an auxiliary base (e.g i-Pr₂NEt, Et₃N,    pyridine, collidine) and in solvents like CH₂Cl₂, CHCl₃, THF to    afford after deacylation (preferably by aminolysis) the hydroxyl or    mercapto aryl/heteroaryl amide H-A-c1-OPG².

The aminolysis is advantageously carried out with a dialkylaminoalkylamine in solvents like THF at 0-25° C. Acyl amine side products formedin the course of the reaction can thus be removed by extraction withacidic aqueous solutions.

Alternatively, the acyloxy or acylmercapto aryl/heteroaryl carboxylicacid (PG¹-A-OH) can be coupled in the presence of a coupling reagent(such as benzotriazol derivatives like HBTU, HCTU, PyBOP, or their azaanalogs such as HATU, or carbodiimides such as EDC) to the amino acidester H-c1-OPG² to afford, after deacylation, the phenol or thiophenolH-A-c1-OPG².

The phenol H-A-c1-OPG² can also be directly obtained from thehydroxyaryl/heteroaryl carboxylic acid H-A-OH and the amino acid esterH-c1-OPG² in the presence of a coupling reagent.

Alkylation of the phenol or thiophenol H-A-C₁—OPG² with a suitablyN-protected amino alcohol HO—B-PG³ to give the ether or thioether

-   PG³-B-A-c1-OPG² is achieved using azodicarboxylic acid derivatives    such as DEAD, DIAD or ADDP in the presence of trialkyl or triaryl    phosphines in solvents like benzene, toluene, CH₂Cl₂, CHCl₃ or THF    at 0° C. to room temperature. As a variation, the reaction can be    induced with CMBP in toluene at temperatures ranging from 20-110° C.

As an alternative, the alcohol HO—B-PG³ can be converted into acorresponding sulfonates (such as for example the mesylate, tosylate,triflate) or a corresponding halide (such as chloride, bromide andiodide) and subsequently be treated with the phenol or thiophenol

-   H-A-c1-OPG² in the presence of an auxiliary base such as for example    NaH or K₂CO₃ in solvents like DMF, DMSO, NMP, HMPA, THF, to give the    ether or thioether PG³-B-A-c1-OPG².

Simultaneous or stepwise cleavage of the main chain protective groupsprovides the linear amino acid cyclization precursor H-B-A-c1-OH. Alloc(for PG³) and allylester groups (for PG²) are preferred as protectinggroups and best cleaved simultaneously mediated by palladium catalysts,e.g. Pd(PPh₃)₄, in the presence of 1,3-dimethyl barbituric acid insolvents like CH₂Cl₂ or EtOAc or mixtures thereof.

Macrolactamization occurs upon treatment of the cyclization precursor

-   H—B-A-c1-OH—if required in the presence of an auxiliary base such as    i-Pr₂NEt—with coupling reagents like T3P or FDPP in solvents like    CH₂Cl₂ or DMF under high dilution conditions and at temperatures    ranging from 20 to 100° C. to yield cyclo-(B-A-c1).

For examples of macrolactamizations mediated by FDPP see J. Dudash, J.Jiang, S. C. Mayer, M. M. Joullié, Synth. Commun. 1993, 23 (3), 349-356;R. Samy, H. Y. Kim, M. Brady, and P. L. Toogood, J. Org. Chem. 1999, 64,2711-2728.

It is well known that many other coupling reagents have been used insuch head to tail cyclizations to prepare macrolactams, and such othercoupling reagents might, alternatively, be engaged in the abovementioned reactions. Examples include benzotriazole derivatives such asHBTU, HCTU, PyBOP and their aza analogs such as HATU, as well as DPPA,and carbodiimides like EDC, DIPCDI; for examples see P. Li, P. P.Roller, Current Topics in Mecicinal Chemistry 2002, 2, 325-341; D. L.Boger, S. Miyazaki, S. H. Kim, J. H. Wu, S. L. Castle, O. Loiseleur, andQ. Jin, J. Am. Chem. Soc. 1999, 121, 10004-10011).

Another option to obtain macrolactams comprises the intramolecularreaction of an active ester with an in situ released amino group(carbamate deprotection, azide reduction) as demonstrated for example inthe synthesis of peptide alkaloids and vancomycin model systems (U.Schmidt, A. Lieberknecht, H. Griesser, J. Talbiersky, J. Org. Chem.1982, 47, 3261-3264; K. C. Nicolaou, J. M. Ramanjulu, S, Natarajan, S.Bräse, H. Li, C. N. C. Boddy, F. Rubsam, Chem. Commun. 1997, 1899-1900.)

N-reprotection of H—B-A-c1-OH can be achieved applying standard aminoacid protection protocols. Chloroformates or N-hydroxy-succinimidylcarbonates in solvents like dioxane, if required in the presence of abase such as aqueous K₂CO₃ solution, react to give the N-protected aminoacid PG³-B-A-c1-OH.

Coupling of an additional amino acid can be effected applying classicalpeptide coupling conditions.

Building blocks c1-c3 can be derived from tri-functionalized aminoacids(e.g. derivatives of Dap, Dab, Orn, Lys, Asp, Glu), main chain- or sidechain-functional groups of which may be part of the macrocyclicscaffold.

Non proteinogenic tri-functionalized amino acid building blocks can beobtained by various synthetic methods, among others formal alkylation ofthe side chain hydroxyl group of Ser, HomoSer, Thr or derivation of themercapto group of Cys, HomoCys with Ω-haloalkyl carboxylic esters.

An alternative route for synthesizing macrocyclic compounds of theinvention comprises

-   a²) synthesis of the H-A-c1-OPG² fragment as described above;-   b²) N-acylation of the aminoalcohol HO—B—H with a suitably    N-terminal protected amino acid PG⁴-c2-OH to afford the amidoalcohol    PG⁴-c2-B—OH;-   c²) aryl or thioaryl ether synthesis starting from H-A-c1-OPG² and    PG⁴-c2-B—OH, applying conditions as described above;-   d²) release of the “main chain” protective groups to give the    cyclization precursor H-c2-B-A-c1-OH; and-   e²) macrolactamization as described above, affording the protected    macrocycles of general formula I (cyclo-(c2-B-A-c1), side chain    functional groups still carrying orthogonal protective groups).

The fragment PG⁴-c3-B—OH can be prepared by N-Acylation of the aminoalcohol HO—B—H with suitable N-terminal protected amino acid PG4-C3-OH.N-deprotection and coupling to an appropriately N-terminal protectedamino acid PG⁵-c2-OH affords the alcohol PG⁵-c2-c3-B—OH which can thenbe converted—by effecting steps corresponding to c²), d²) and e²)—intothe protected macrocycles of general formula I (cyclo(c2-c3-B-1′-c1),side chain functional groups still carrying orthogonal protectivegroups).

As a further alternative, cyclization can be obtained by ring closingmetathesis. The orthogonally protected macrocycles of general structureI are synthesized applying a process which comprises

-   a³) coupling of an optionally substituted alkenyl amine containing    building block c1(alkenyl) of type C to the acyloxy or hydroxy or    acylmercapto aryl/heteroaryl carboxylic acid PG¹-A-OH;-   b³) if required release of the aryl/heteroaryl (phenolic) OH group    or mercapto group, respectively;-   c³) N-acylation of the aminoalcohol HO—B—H with an optionally    suitably substituted alkenyl carboxylic acid PG⁶-c2(alkenyl)-OH to    afford the amido alcohol PG⁶-c2(alkenyl)-B—OH;-   d³) aryl or thioaryl ether formation as described above to yield the    cyclization precursor PG⁶-c2(alkenyl)-B-A-c1(alkenyl);-   e³) ring closure metathesis; and-   f³) optional hydrogenation of the newly generated olefinic double    bond of the metathesis product of step e³).

Ring closure metathesis to form macrocyclic compounds from olefinicprecursors is well known (for examples see A. Fürstner, O. Guth, A.Duffels, G. Seidel, M. Liebl, B. Gabor, and R. Mynott, Chem. Eur. J.2001, 7 (22), 4811-4820).

Ring closure metathesis of PG⁶-c2(alkenyl)-B-A-c1(alkenyl) isconveniently performed in suitable solvents, like CH₂Cl₂ or toluene, at20 to 100° C. in the presence of indenylidene-ruthenium complexesincludingdichloro-(3-phenyl-1H-inden-1-ylidene)bis(tricyclohexylphosphine)-ruthenium(II),[1,3-Bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]-dichloro-(3-phenyl-1H-inden-1-ylidene(tricyclohexylphosphine)-ruthenium(II),[1,3-Bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]-dichloro-(3-phenyl-1H-inden-1-ylidene)(pyridyl)ruthenium(II) (see S. Monsaert, R. Drozdzak, V. Dragutan, I.Dragutan, and F. Verpoort, Eur. J. Inorg. Chem. 2008, 432-440 andreferences therein).

Derivatization of the macrocyclic core structures with variable R-groupscan be effected as described hereinbelow.

Orthogonally protected attachment points (e.g. exocyclic amino groups,carboxyl groups, hydroxyl groups) allow stepwise deprotection andderivatization.

The reactions can be carried out in a parallel fashion to generatelibraries of final products. The following general process can beapplied:

-   a⁴) Cleavage of the first protective group;-   b⁴) derivatization of the free functional group;-   c⁴) cleavage of the second protective group, and-   d⁴) derivatiszation or the free functional group.

Amine protecting groups such as preferably Boc, Cbz, Teoc, Alloc, Fmocare removed applying standard conditions, cf. T. W. Greene, P. G. M.Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley &Sons, 1999; P. J. Koncienski, Protecting Groups, 3rd edition, GeorgThieme Verlag, 2005. Carboxylic acid protecting groups such astert.butyl, benzyl, allyl, methyl are removed applying standardconditions.

Alcohol protecting groups such as tert.butyl, benzyl, allyl, acetyl,benzoyl, pivaloyl are removed applying standard conditions.

Attachment point amino groups can be converted into amides by reactionwith carbonyl chlorides, carboxylic acid anhydrides active esters or bytreatment with carboxylic acids in the presence of soluble orpolymer-supported coupling reagents such as for example HATU, T3P orpolymer-supported carbodiimides.

Reductive alkylation of the attachment point amino groups or theirreaction with alkyl halides, alkylsulfonates or Michael acceptorsaffords higher alkylated amines.

The reaction of attachment point amino groups with isocyanates orequivalents like carbamoyl chlorides or hydroxysuccinimidyl estersaffords ureas.

The reaction of attachment point amino groups with isothiocyanatesprovides thioureas.

The reaction of attachment point amino groups with chloroformates orequivalents such as hydroxysuccinimidyl carbonates affords carbamates.

The reaction of attachment point amino groups with sulfonyl chloridesyields sulfonamides.

The reaction of attachment point amino groups with suitably activatedaromatic or heteroaromatic halides or sulfonates—in the presence ofauxiliary base and if required a Pd catalyst (e.g. Buchwaldcouplings)—affords the corresponding N-aryl or N-heteroaryl derivatives.

Attachment point carboxyl groups are converted into amides using aminesand coupling reagents.

Attachment point alcoholic hydroxyl groups can be alkylated with alkylhalides or alkylsulfonates to give alkylethers. Their reaction withphenols in the presence of azodicarboxylic acid derivatives and triarylor trialkyl phosphines as well as their reaction with suitably activatedaryl or heteroaryl halides or sulfonates affords aryl or heteroarylethers.

Attachment point secondary alcoholic hydroxyl groups can be oxidized tothe corresponding ketones which in turn may be submitted to a reductiveamination using amines and a suitable reducing agent.

Attachment point alcoholic hydroxyl groups can be converted into esters.

Appropriate macrocyclic compounds of general formula I with one or more(orthogonally) protected exocyclic functional groups and a free primaryamino group can be converted into fully derivatized products on solidsupport.

A process, which allows an efficient parallel array derivatization,comprises

-   a⁵) attachment of the macrocyclic amine to an appropriately    functionalized solid support in a reductive amination step;-   b⁵) acylation, carbamoylation, oxycarbonylation or sulfonylation of    the secondary amine thus obtained in step a⁵);-   c⁵) Removal of the protective group of the next attachment point;-   d⁵) Derivatisation of the second free functional group whereby amino    groups can be converted into amides, ureas, thioureas carbamates, or    sulfonamides, or can be alkylated; and carboxylic acids can be    converted into amides;-   e⁵) repetition of steps c⁵) and d⁵) if an additional derivatisation    site is available; and-   f⁵) Release of the final product from solid support.

In principle a macrocyclic carbocylic acid can be coupled topolymer-supported amines and be converted into final products byeffecting steps corresponding c⁵) to f⁵).

The functionalized solid support is a derivative of polystyrenecross-linked with preferably 1-5% divinylbenzene, of polystyrene coatedwith polyethyleneglycol (Tentagel®), and of polyacrylamid resins (see D.Obrecht, J.-M. Villalgordo, “Solid-Supported zombinatorial and ParallelSynthesis of Small-Molecular-Weight Compound Libraries”, TetrahedronOrganic Chemistry Series, Vol. 17, Pergamon, Elsevier Science, 1998).

The solid support is functionalized by means of a linker, i.e. abifunctional spacer molecule which contains on one end an anchoringgroup for attachment to the solid support and on the other end aselectively cleavable functional group used for the subsequent chemicaltransformations and cleavage procedures. For the purposes of the presentinvention, linkers are used which are designed to release an N-acylderivative (amide, urea, carbamate) or a sulfonamide under acidicconditions. Such linkers have been applied in the backbone amide linker(BAL) strategy for solid-phase synthesis of C-terminal modified andcyclic peptides (K. J. Jensen, J. Alsina, M. F. Songster, J. Vagner, F.Albericio, and G. Barnay, J. Am. Chem. Soc. 1998, 120, 5441-5452; J.Alsina, K. J. Jensen, F. Albericio, and G. Barany, Chem. Eur. J. 1999, 5(10), 2787-2795) as well as for the synthesis of heterocyclic compounds(T. F. Herpin, K. G. Van Kirk, J. M. Savino, S. T. Yu, and R. F.Labaudinière, J. Comb. Chem. 2000, 2, 513-521, M. del Fresno, J. Alsina,M. Royo, G. Barany, and F. Albericio, Tetrahedron Lett. 1998, 39,2639-2642; N. S. Gray, S. Kwon, P. G. Schultz, Tetrahedron Lett. 1997,38 (7), 1161-1164).

Examples of resins functionalized by such linker structures include DFPEpolystyrene (2-(3,5-dimethoxy-4-formylphenoxy)ethyl polystyrene), DFPEMpolystyrene (2-(3,5-dimethoxy-4-formylphenoxy)ethoxymethyl polystyrene),FMPB resins (4-(4-formyl-3-methoxyphenoxy)butyryl AM resin), FMPEpolystyrene HL (2-(4-formyl-3-methoxyphenoxy)ethyl polystyrene HL), FMPBNovaGel™ (4-(4-formyl-3-methoxyphenoxy)butyryl NovaGel™; a PEG PSresin).

The macrocyclic primary amine is attached to such solid support by meansof reductive amination preferably using NaBH(OAc)₃ in 1,2 dichloroethanein the presence of trimethyl orthoformate.

The use of reductive amination to couple amines to resins with the abovementioned linker is well documented; for example NaBH₃CN in DMF or inmethanol, or NaBH(OAc)₃ in DMF/acetic acid or in dichloromethane/aceticacid have been used (see K. J. Jensen, J. Alsina, M. F. Songster, J.Vagner, F. Albericio, and G. Barany, J. Am. Chem. Soc. 1998, 120,5441-5452; J. Alsina, K. J. Jensen, F. Albericio, and G. Barnay, Chem.Eur. J. 1999, 5 (10), 2787-2795; T. F. Herpin, K. G. Van Kirk, J. M.Savino, S. T. Yu, and R. F. Labaudinière, J. Comb. Chem. 2000, 2,513-521; A. L. Vergnon, R. S. Pottorf, M. R. Player, J. Comb. Chem.2004, 6, 91-98.). These authors also describe a variety of conditionsfor the acylation of the resulting secondary amine, using carboxylicacid and coupling reagents including PyBOP, PyBroP, HATU as well ascarboxylic acid fluorides or carboxylic acid anhydrides.

The second functional group is an Alloc or Fmoc protected amino group ora carboxyl group protected as allyl ester. Standard conditions areapplied to deprotect and derivatize these functional groups.

The final products are detached from the solid support by means of acidin organic solvents or in H₂O. The use of TFA in dichloromethane, TFA indichloromethane in the presence of a scavenger such as H₂O or dimethylsulfide, or of TFA/H₂O and TFA/H₂O/dimethylsulfide has been described,references see above.

Macrocyclic compounds of general formula I with highly variable aminoacid side chain motifs in bridge c can advantageously be prepared in aparallel array synthesis on solid support. This synthesis comprisesimmobilization of an appropriately protected and functionalizedprecursor comprising building blocks A, B and subsequent coupling of oneto three amino acids c1, c2 and c3, followed by cyclization and releaseof the product thus obtained.

The corresponding process comprises:

-   a⁶) condensation of a suitable hydroxy or mercapto aryl/heteroaryl    carboxylic acid ester H-A-OPG⁷ with an appropriately N-protected    amino alcohol HO—B-PG⁸, substituted with an orthogonally protected    primary amino group, applying the methods discussed above;-   b⁶) removal of the protective group of the primary amine;-   c⁶) attachment of the product obtained in step b⁶) to the solid    support in a reductive alkylation step in analogy to the previously    described process providing a polymer-supported fragment    PG⁸-B-A-O-PG⁷ with free secondary side chain amino group;-   d⁶) acylation, carbamoylation, oxycarbonylation or sulfonylation of    the secondary amine obtained in step c⁶);-   e⁶) cleavage of the “main chain” amine protective group (PG⁸);-   f⁶) coupling of a appropriately N-terminal protected amino acid    PG9-c3-OH;-   g⁶) removal of the N-terminal protective group (PG⁹) of the product    obtained in step f⁶);-   h⁶) next coupling to introduce amino acid PG⁹-c1-OH (for target    compounds with bridges comprising two amino acid building blocks),    or coupling/deprotection cycle to introduce amino PG⁹-c2-OH followed    by coupling of amino acid PG⁹-c1-OH (for target compounds with    bridges comprising three amino acid building blocks) by effecting    steps corresponding to f⁶) and g⁶);-   i⁶) cleavage of the aryl/heteroaryl ester group (PG⁷);-   j⁶) cleavage of the N-terminal protective group (PG⁹);-   k⁶) macrolactamization of the linear cyclization precursor on solid    support (for an example of cyclization on solid support see the    synthesis of cyclic peptides attached to the solid support with the    side chain as described by C. Cabrele, M. Langer, and A. G.    Beck-Sickinger, J. Org. Chem. 1999, 64, 4353-4361.); and-   l⁶) detachment of the final product.

As an alternative, the linear cyclization precursor obtained in step j⁶)can be released from the solid support and cyclized in solution by

-   k⁶′) detachment of the linear cyclization precursor; and-   l⁶′) macrolactamization in solution.

In a parallel array synthesis soluble coupling reagents as describedabove as well as polymer supported coupling reagents such asN-cyclohexyl-carbodiimide-N′-methylpolystyrene or N-alkyl-2-chloropyridinium triflate resin (S. Crosignani, J. Gonzales, D. Swinnen, Org.Lett. 2004, 6 (24), 4579-4582) may be used.

Further alternatives include ring closure in other positions, forexample between amino acids c1 and c2.

Thus a precursor with two amino acids coupled to the immobilizedprecursor would be prepared (polymer supported PG⁹-c2-c3-B-A-OPG⁷) byeffecting steps corresponding to steps a⁶) to h⁶) described in the aboveparagraph. The subsequent steps then comprise

-   i⁶′) cleavage of the aryl/heteroaryl ester group (PG⁷);-   j⁶′) coupling of an appropriately C-terminal protected amino acid-   H-c1-OGP⁷;-   k⁶′) cleavage of the c-terminal protective group (PG⁷);-   l⁶′) cleavage of the N-terminal protective group (PG⁹) and-   m⁶′) macrolactamization either on solid support or in solution after    detachment of the linear precursor from the solid support.

The macrocycles of formula I of the present invention interact withspecific biological targets. In particular, they show agonistic orantagonistic activity on the motilin receptor (MR receptor), on theserotonin receptor of subtype 5-HT_(2B) (5-HT_(2B) receptor), and on theprostaglandin F2α receptor (FP receptor). Accordingly, these compoundsare useful for the treatment of hypomotility disorders of thegastrointestinal tract such as diabetic gastroparesis and constipationtype irritable bowl syndrome; for the treatment of CNS related diseaseslike migraine, schizophrenia, psychosis or depression; for the treatmentof ocular hypertension such as associated with glaucoma and for pretermlabour.

The macrocycles, as such or after further optimization, may beadministered per se or may be applied as an appropriate formulationtogether with carriers, diluents or excipients well-known in the art.

When used to treat or prevent the diseases mentioned above themacrocycles can be administered singly, as mixtures of severalmacrocycles, or in combination with other pharmaceutically activeagents. The macrocycles can be administered per se or as pharmaceuticalcompositions.

Pharmaceutical compositions comprising macrocycles of the invention maybe manufactured by means of conventional mixing, dissolving,granulating, coated tablet-making, levigating, emulsifying,encapsulating, entrapping or lyophilizing processes. Pharmaceuticalcompositions may be formulated in conventional manner using one or morephysiologically acceptable carriers, diluents, excipients or auxiliarieswhich facilitate processing of the active macrocycles into preparationswhich can be used pharmaceutically. Proper formulation depends upon themethod of administration chosen.

For topical administration the macrocycles of the invention may beformulated as solutions, gels, ointments, creams, suspensions, etc. asare well-known in the art.

Systemic formulations include those designed for administration byinjection, e.g. subcutaneous, intravenous, intramuscular, intrathecal orintraperitoneal injection, as well as those designed for transdermal,transmucosal, oral or pulmonary administration.

For injections, the macrocycles of type I may be formulated in adequatesolutions, preferably in physiologically compatible buffers such asHank's solution, Ringer's solution, or physiological saline buffer. Thesolutions may contain formulatory agents such as suspending, stabilizingand/or dispersing agents. Alternatively, the macrocycles of theinvention may be in powder form for combination with a suitable vehicle,e.g., sterile pyrogen-free water, before use.

For transmucosal administration, penetrants appropriate to the barrierto be permeated are used in the formulation as known in the art.

For oral administration, the compounds can be readily formulated per seor by combining the active macrocycle of the invention withpharmaceutically acceptable carriers well known in the art. Suchcarriers enable the macrocycles of type I to be formulated as tablets,pills, dragees, capsules, liquids, gels, syrups, slurries, suspensionsetc., for oral ingestion by a patient to be treated. For oralformulations such as, for example, powders, capsules and tablets,suitable excipients include fillers such as sugars, (e.g. lactose,sucrose, mannitol or sorbitol) or such as cellulose preparations (e.g.maize starch, wheat starch, rice starch, potato starch, gelatin, gumtragacanth, methyl cellulose, hydroxypropylmethyl cellulose, sodiumcarboxymethylcellulose); and/or granulating agents; and/or bindingagents such as polyvinylpyrrolidone (PVP). If desired, desintegratingagents may be added, such as cross-linked polyvinylpyrrolidones, agar,or alginic acid or a salt thereof, such as sodium alginate. If desired,solid dosage forms may be sugar-coated or enteric-coated using standardtechniques.

For oral liquid preparations such as, for example, suspensions, elixirsand solutions, suitable carriers, excipients or diluents include water,glycols, oils, alcohols, etc. In addition, flavoring agents,preservatives, coloring agents and the like may be added.

For buccal administration, the composition may take the form of tablets,lozenges, etc. formulated as usual.

For administration by inhalation, the macrocycles of the invention areconveniently delivered in form of an aerosol spray from pressurizedpacks or a nebulizer, with the use of a suitable propellant, e.g.hydrofluoroalkanes (HFA) such as HFA 134a (1,1,1,2,-tetrafluoroethane);carbon dioxide or another suitable gas. In the case of a pressurizedaerosol the dose unit may be determined by providing a valve to delivera metered amount. Capsules and cartridges of e.g. gelatin for use in aninhaler or insufflator may be formulated containing a powder mix of themacrocycles of the invention and a suitable powder base such as lactoseor starch.

The compounds may also be formulated in rectal or vaginal compositionssuch as suppositories together with appropriate suppository bases likecocoa butter or other glycerides.

In addition to the formulations described afore, the macrocycles of theinvention may also be formulated as depot preparations. Such slowrelease, long acting formulations may be administered by implantation(e.g. subcutaneously or intramuscularly) or by intramuscular injection.For the manufacture of such depot preparations the macrocycles of theinvention may be formulated with suitable polymeric or hydrophobicmaterials (e.g. as an emulsion in an acceptable oil) or ion exchangeresins, or as sparingly soluble salts.

In addition, other pharmaceutical delivery systems may be employed suchas liposomes and emulsions well known in the art. Certain organicsolvents such as dimethylsulfoxide may also be employed. Additionally,the macrocycles of type I may be delivered using a sustained-releasesystem, such as semi-permeable matrices of solid polymers containing thetherapeutic agent. Various sustained-release materials have beenestablished and are well-known by those skilled in the art.Sustained-release capsules may, depending on their chemical nature,release the compounds over a period of a few days up to several months.Depending on the chemical nature and the biological stability of thetherapeutic agent, additional strategies for stabilization may beemployed.

As the macrocycles of the invention may contain charged residues, theymay be included in any of the above-described formulations as such or aspharmaceutically acceptable salts. Pharmaceutically acceptable saltstend to be more soluble in aqueous and other protic solvents than thecorresponding free base or acid forms.

The macrocycles of the invention, or compositions thereof, willgenerally be used in an amount effective to achieve the intendedpurpose. It is to be understood that the amount used will depend on aparticular application.

For example, the therapeutically effective dose for an systemicadministration can be estimated initially from in vitro assays: A dosecan be formulated in animal models to achieve a circulating macrocycleconcentration range that includes the IC₅₀ or EC₅₀ as determined in thecell culture (i.e. the concentration of a test compound that shows halfmaximal inhibitory concentration in case of antagonists or half maximaleffective concentration in case agonists). Such information can be usedto more accurately determine useful doses in humans. Initial dosages canalso be determined from in vivo data, e.g. animal models, usingtechniques that are well known in the art. One having ordinary skill inthe art could readily optimize administration to humans based on animaldata.

Dosage amounts for applications such as gastroparesis or schizophreniaetc. may be adjusted individually to provide plasma levels of the activecompound that are sufficient to maintain the therapeutic effect.Therapeutically effective serum levels may be achieved by administeringmultiple doses each day.

In cases of local administration or selective uptake, the effectivelocal concentration of the macrocycles of the invention may not berelated to plasma concentration. Those having the ordinary skill in theart will be able to optimize therapeutically effective local dosageswithout undue experimentation.

The amount of macrocycle administered will, of course, be dependent onthe subject being treated, on the subject's weight, the severity of theaffliction, the manner of administration and the judgment of theprescribing physician.

Normally, a therapeutically effective dose of the macrocycles describedherein will provide therapeutic benefit without causing substantialtoxicity.

Toxicity of the macrocycles of the invention can be determined bystandard pharmaceutical procedures in cell cultures or experimentalanimals, e.g., by determining the LD₅₀ (the dose lethal to 50% of thepopulation) or the LD₁₀₀ (the dose lethal to 100% of the population).The dose ratio between toxic and therapeutic effect is the therapeuticindex. Compounds which exhibit high therapeutic indices are preferred.The data obtained from cell culture assays and animal studies can beused in formulating a dosage range that is not toxic for use in humans.The dosage of the macrocycles of the invention lies preferably within arange of circulating concentrations that include the effective dose withlittle or no toxicity. The dosage may vary within the range dependingupon the dosage form employed and the route of administration utilized.The exact formulation, route of administration and dose can be chosen bythe individual physician in view of the patient's condition (cf. E.Fingl et al., The Pharmacological Basis of Therapeutics, 5^(th) ed. 1975(Ed. L. Goodman and A. Gilman), Ch.1, p. 1).

A further embodiment of the present invention may also includecompounds, which are identical to the compounds of formula I, exceptthat one or more atoms are replaced by an atom having an atomic massnumber or mass different from the atomic mass number or mass usuallyfound in nature, e.g. compounds enriched in ²H (D), ³H, ¹¹C, ¹⁴C, ¹²⁵Ietc. These isotopic analogs and their pharmaceutical salts andformulations are considered useful agents in the therapy and/ordiagnostic, for example, but not limited to, where a fine-tuning of invivo half-life time could let to an optimized dosage regimen.

EXAMPLES

The following Examples illustrate the invention in more detail but arenot intended to limit its scope in any way. The following abbreviationsare used in these Examples:

-   ADDP: azodicarboxylic dipiperidide-   All: allyl-   Alloc: allyloxycarbonyl-   AllocCl: allyl chloroformate-   AllocOSu: allyloxycarbonyl-N-hydroxysuccinimide-   AM-resin: aminomethyl resin-   aq.: aqueous-   arom.: aromatic-   BnBr: benzyl bromide-   Boc: tert-butoxycarbonyl-   br.: broad-   Cbz: benzyloxycarbonyl-   CbzOSu: N-(benzyloxycarbonyloxy)succinimide-   Cl-HOBt: 6-chloro-1-hydroxybenzotriazole-   CMBP: cyanomethylenetributyl-phosphorane-   m-CPBA: 3-chloroperbenzoic acid-   d: day(s) or doublet (spectral)-   DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene-   DCE: 1,2-dichloroethane-   DEAD: diethyl azodicarboxylate-   DFPE polystyrene: 2-(3,5-dimethoxy-4-formylphenoxy)ethyl polystyrene-   DIAD: diisopropyl azodicarboxylate-   DIC: N,N′-diisopropylcarbodiimide-   DMF: dimethylformamide-   DMSO: dimethyl sulfoxide-   DPPA: diphenyl phosphoryl azide-   DVB: divinylbenzene-   EDC: 1-[3-(dimethylamino)propyl-3-ethylcarbodiimide-   equiv.: equivalent-   Et₃N: triethylamine-   EtOAc: ethyl acetate-   FC: flash chromatography-   FDPP: pentafluorophenyl diphenylphosphinate-   Fmoc: 9-fluorenylmethoxycarbonyl-   h: hour(s)-   HATU: O-(7-azobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium    hexafluorophosphate-   HBTU: O-(benortriazol-1-yl)-N,N,N′,N′-tetramethyluronium    hexafluorophosphate-   HCTU: O-(1H-6-chlorobenortriazol-1-yl)-N,N,N′,N′-tetramethyluronium    hexafluorophosphate-   HOAt: 1-hydroxy-7-azabenzotriazole-   HOBt.H₂O: 1-hydroxybenzotriazole hydrate-   HMPA: hexamethylphosphoramide-   i.v.: in vacuo-   m: multiplet (spectral)-   MeOH: methanol-   NMP: 1-methyl-2-pyrrolidinone-   Pd(PPh₃)₄: Tetrakis(triphenylphosphine)palladium(0)-   PEG PS resin: polyethyleneglycol coated polystyrene resin-   PG: protective group-   PPh₃: triphenylphosphine-   prep.: preparative-   i-Pr₂NEt: N-ethyl-N,N-diisopropylamine-   PyBOP: (Benzotriazol-1-yloxy)tripyrrolidinophosphonium    hexafluorophosphate-   PyBroP: Bromotripyrrolidinophosphonium hexafluorophosphate-   q: quartet (spectral)-   quant.: quantitative-   sat.: saturated-   soln: solution-   t: triplet (spectral)-   TBAF: tetrabutylammonium fluoride-   Teoc: 2-(trimethylsilyl)ethoxycarbonyl-   TeocONp: 2-(trimethylsilyl)ethyl 4-nitrophenyl carbonate-   TFA: trifluoroacetic acid-   THF: tetrahydrofuran-   tlc: thin layer chromatography-   T3P™: propanphosphonic acid cyclic anhydride-   p-TsOH: p-toluenesulfonic acid    General Methods

TLC: Merck (silica gel 60 F254, 0.25 mm).

Flash chromatography (FC): Fluka silica gel 60 (0.04-0.063 mm) andInterchim Puriflash IR 60 silica gel (0.04-0.063 mm).

I. Analytical HPLC-MS Methods:

R_(t) in min (purity at 220 nm in %), m/z [M+H]⁺

Volume of injection: 5 μL for all methods

Method 1a and 1b

Column: XBridge C18 2.5 μm, 2.1 × 50 mm (186003085 - Waters) MobilePhases A: 0.1% TFA in Water B: 0.085% TFA in Acetonitrile Column oventemp. 45° C. Time Flow (min.) (μl/min) % A % B Gradient 0 500 97  3 0.1500 97  3 3 500  3 97 3.6 500  3 97 3.7 500 97  3 4.3 500 97  3 Method1, cont. UV Wavelenght: 220 nm 254 nm MS scan Range: Method 1a 100-800Da Method 1b Centroid 300-2000 Da mode Scan Time: 1 sec. Ionizationtype: ElectrosprayMethod 2

Column: Gemini NX C18 3 μm, 2.1 × 50 mm (00B-4453-B0 - Phenomenex)Mobile Phases A: 0.1% TFA in Water B: 0.085% TFA in Acetonitrile Columnoven temp. 45° C. Time Flow (min.) (μl/min) % A % B Gradient 0  800 97 3 0.1  800 97  3 2.2  800  3 97 2.5  800  3 97 2.55 1000 97  3 2.751000 97  3 2.8  800 97  3 UV Wavelenght: 220 nm 254 nm MS scan Range:100-2000 Da Centroid mode Scan Time: 1 sec. Ionization type:ElectrosprayMethod 3

Column: Gemini NX C18 3 μm, 2.1 × 50 mm (00B-4453-B0 - Phenomenex) 1 mMammonium Mobile Phases A: bicarbonate pH 10 B: Acetonitrile Column oventemp. 45° C. Time Flow (min.) (μl/min) % A % B Gradient 0  800 97  3 0.1 800 97  3 2.2  800  3 97 2.5  800  3 97 2.55 1000 97  3 2.75 1000 97  32.8  800 97  3 Method 3, cont. UV Wavelenght: 220 nm 254 nm MS scanRange: 100-2000 Da Centroid mode Scan Time: 1 sec. Ionization type:ElectrosprayMethod 4a-4-b

Column: Gemini NX C18 3 μm, 2.1 × 50 mm (00B-4453-B0 - Phenomenex)Mobile Phases A: 0.1% TFA in Water B: 0.085% TFA in Acetonitrile Columnoven temp. 45° C. Time Flow (min.) (μl/min) % A % B Gradient 0  800 97 3 0.1  800 97  3 2.7  800  3 97 3  800  3 97 3.05 1000 97  3 3.25 100097  3 3.3  800 97  3 UV Wavelenght: 220 nm 254 nm MS scan Range: Method4a Centroid 100-2000 Da mode Method 4b Profile 350-2000 Da mode ScanTime: 1 sec. Ionization type: ElectrosprayMethod 5a-5b

Column: Gemini NX C18 3 μm, 2.1 × 50 mm (00B-4453-B0 - Phenomenex) 1 mMammonium Mobile Phases A: bicarbonate pH 10 B: Acetonitrile Column oventemp. 45° C. Time Flow (min.) (μl/min) % A % B Gradient 0  800 97  3 0.1 800 97  3 2.7  800  3 97 3  800  3 97 3.05 1000 97  3 3.25 1000 97  33.3  800 97  3 Method 5, cont. UV Wavelenght: 220 nm 254 nm MS scanRange: Method 5a Centroid 100-2000 Da mode Method 5b Profile 350-2000 Damode Scan Time: 1 sec. Ionization type: ElectrosprayMethod 6

Column: Acquity UPLC BEH C18 1.7 μm, 2.1 × 50 mm (cod. 186002350 -Waters) Mobile Phases A: 0.1% TFA in Water B: 0.085% TFA in AcetonitrileColumn oven temp. 55° C. Time Flow (min.) (μl/min) % A % B Gradient 01250 97  3 0.05 1250 97  3 1.65 1250  3 97 1.95 1250  3 97 2.00 1250 97 3 2.30 1250 97  3 UV Wavelenght: 220 nm 254 nm MS scan Range: 100-1650Da Centroid mode Scan Time: 0.5 sec. Ionization type: ElectrosprayMethod 7

Column: Acquity UPLC BEH C18 1.7 μm, 2.1 × 50 mm (cod. 186002350 -Waters) Mobile Phases A: 0.1% TFA in Water B: 0.085% TFA in AcetonitrileColumn oven temp. 55° C. Time Flow (min.) (μl/min) % A % B Gradient 01250 97  3 0.05 1250 97  3 1.65 1250  3 97 1.95 1250  3 97 2.00 1250 97 3 2.30 1250 97  3 Method 7, cont. UV Wavelenght: 220 nm 254 nm MS scanRange: 100-1650 Da Profile mode Scan Time: 0.5 sec. Ionization type:ElectrosprayMethod 8

Column: Acquity UPLC BEH C18 1.7 μm, 2.1 × 50 mm (cod. 186002350 -Waters) 1 mM ammonium Mobile Phases A: bicarbonate pH 10 B: AcetonitrileColumn oven temp. 55° C. Volume of 5 μl injection: Time Flow (min.)(μl/min) % A % B Gradient 0 1250 97  3 0.05 1250 97  3 1.65 1250  3 971.95 1250  3 97 2.00 1250 97  3 2.30 1250 97  3 UV Wavelenght: 220 nm254 nm MS scan Range: 100-1650 Da Profile mode Scan Time: 0.5 sec.Ionization type: ElectrosprayMethod 9a-9c

Column: Acquity UPLC BEH C18 1.7 μm, 2.1 × 100 mm (cod. 186002352 -Waters) Mobile Phases A: 0.1% TFA in Water/ Acetonitrile B: 95/5 v/v0.085% TFA in Acetonitrile Column oven temp. 55° C. Method 9, cont. TimeFlow (min.) (μl/min) % A % B Gradient 0 700 99  1 0.2 700 99  1 2.5 700 3 97 2.85 700  3 97 2.86 700 99  1 3.20 700 99  1 UV Wavelenght: 220 nmMS scan Range: Method 9a: 100-800 Da; Method 9b: 100-1200 Da; Method 9c:200-1400 Da Profile mode Scan Time: 1 sec. Ionization type: Electrospray

Analytical HPLC (x % CH₃CN): R_(t) in min (purity at 220 nm in %)

-   Column: Develosil RPAq 5 μm, 4.6×50 mm;-   Flow rate: 1.5 ml/min-   0.0-0.5 min (x % CH₃CN, 100-x % H₂O containing 0.1% TFA);-   0.5-5.0 min (x % CH₃CN, 100-x % H₂O containing 0.1% TFA to 100%    CH₃CN) 5.0-6.2 min (100% CH₃CN)    II. Preparative HPLC Methods:    1. Reverse Phase—Acidic Conditions-   Column: XBridge C18 5 μm, 30×150 mm (Waters)    Mobile Phases:-   A: 0.1% TFA in Water/Acetonitrile 95/5 v/v-   1B: 0.1% TFA in Water/Acetonitrile 5/95 v/v    2. Reverse Phase—Basic Conditions-   Column: XBridge C18 5 μm, 30×150 mm (Waters)-   Mobile Phases:-   A: 10 mM Ammonium Bicarbonate pH 10/Acetonitrile 95/5 v/v-   B: Acetonitrile    3. Normal Phase

Column: VP 100/21 NUCLEOSIL 50-10, 21 × 100 mm (Macherey-Nagel) Mobilephases: A: Hexane B: Ethylacetate C: Methanol

NMR Spectroscopy: Bruker Avance 300, ¹H-NMR (300 MHz) in the indicatedsolvent at ambient temperature. Chemical shifts δ in ppm, couplingconstants J in Hz.

The term “isomers” comprises in the present invention species ofidentical chemical formula, constitution and thus molecular mass, suchas but not limited to amide cis/trans isomers, rotamers, conformers,diastereomers.

Examples Starting Materials Building Blocks of Type A (Scheme 1)

2-Acetoxy-5-fluoro benzoic acid (2) was prepared according to the methodof C. M. Suter and A. W. Weston, J. Am. Chem. Soc. 1939, 61, 2317-2318.

3-Acetoxybenzoic acid (3) is commercially available.

4-Acetoxybenzoic acid (4) is commercially available.

5-Hydroxy nicotinic acid (5) is commercially available.

8-Acetoxyquinoline-2-carboxylic acid (8) was prepared according to themethod of R. W. Hay, C. R. Clark, J. Chem. Soc. Dalton 1977, 1993-1998.

(S)-2-tert-Butoxycarbonylamino-8-hydroxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylicacid (10) was prepared according to the method of M. M. Altorfer,Dissertation Universität Zürich, 1996.

3-Mercaptobenzoic acid (11) is commercially available

Building Blocks of Type B (Scheme 2)

tert-Butyl (3S,5S)-5-(hydroxymethyl)pyrrolidin-3-ylcarbamate (13) aswell as the corresponding HCl salt (13.HCl) are commercially available.

tert-Butyl (3R,5S)-5-(hydroxymethyl)pyrrolidin-3-ylcarbamate (17) aswell as the corresponding HCl salt (17.HCl) are commercially available.

(S)-tert-Butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride(21.HCl) is commercially available.

(R)-tert-Butyl 3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride(83.HCl) (Scheme 5) is commercially available.

(2S,4S)-Allyl2-(hydroxymethyl)-4-((2-(trimethylsilyl)ethoxy)carbonylamino)pyrrolidine-1-carboxylate(16) was prepared in three steps (1. Alloc protection of the secondaryamino group with allyloxycarbonyl-N-hydroxysuccinimide (AllocOSu) inCH₂Cl₂, 2. cleavage of the Boc group with dioxane-HCl;

3. Teoc protection of the primary amino group with2-(trimethylsilyl)ethyl 4-nitrophenyl carbonate (Teoc-ONp) in CH₂Cl₂ inthe presence of Et₃N) from amino alcohol 13, applying standardconditions; as leading references cf. T. W. Greene, P. G. M. Wuts,Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons,1999; P. J. Kocienski, Protecting Groups, 3rd edition, Georg ThiemeVerlag, 2005.

Data of 16: C₁₅H₂₈N₂O₅Si (344.5): Flow injection MS (APCI): 689([2M+H]⁺), 345 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 7.28 (d, J=6.1, 1 H), 5.90(m, 1 H), 5.25 (qd, J=1.7, 17.2, 1 H), 5.16 (qd, J=1.5, 10.5, 1 H), 4.90(br. t, 1 H), 4.54-4.42 (m, 2 H), 4.04-3.97 (m, 2 H), 3.90 (q, J=6.8, 1H), 3.80-3.66 (br. m and dd, 2 H), 3.57-3.43 (br. m, 2 H), 2.96 (br. m,1 H), 2.19 (br. m, 1 H), 1.78 (br. m, 1 H), 0.89 (t, J ca 8.3, 2 H),0.00 (s, 9 H)

(2S,4R)-Allyl2-(hydroxymethyl)-4-((2-(trimethylsilyl)ethoxy)carbonylamino)pyrrolidine-1-carboxylate(20) was prepared from amino alcohol hydrochloride 17.HCl, applying thesame transformations as described for the synthesis of diastereomer 16with the exception of the Alloc protection step which was performedusing allyl chloroformate in CH₂Cl₂ in the presence of aqueous NaHCO₃solution.

Data of 20: C₁₅H₂₈N₂O₅Si (344.5): LC-MS (method 9a): R_(t)=1.98, 345([M+H]⁺); 317; 259. ¹H-NMR (DMSO-d₆): 7.26 (d, J=6.6, 1 H), 5.89 (m, 1H), 5.25 (br. d, J=17.0, 1 H), 5.15 (br. d, J=10.2, 1 H), 4.75 (m, 1 H),4.48 (m, 2 H), 4.16-3.98 (m, 3 H), 3.82 (br. m, 1 H), 3.48-3.30 (m, 3H), 3.21 (m, 1 H), 2.01 (m, 1 H), 1.80 (m, 1 H), 0.89 (t, J=8.3, 2H),0.00 (s, 9 H).

(S)-1-Allyl 4-tert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate(22) was prepared from amino alcohol hydrochloride 21.HCl, applyingallyl chloroformate in CH₂Cl₂ in the presence of aqueous NaHCO₃solution; as leading references cf. T. W. Greene, P. G. M. Wuts,Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons,1999; P. J. Kocienski, Protecting Groups, 3rd edition, Georg ThiemeVerlag, 2005.

Data of 22: C₁₄H₂₄N₂O₅ (300.4): LC-MS (method 9a): R_(t)=1.70, 201([M+H]⁺). ¹H-NMR (DMSO-d₆): 5.90 (m, 1 H), 5.29 (qd, J=1.7, 17.3, 1 H),5.18 (qd, J=1.5, 10.5, 1 H), 4.81 (t, J=4.9, 1 H), 4.53 (d-like m, J ca.5.1, 2 H), 4.04-3.75 (br. m, 4 H), 3.39 (m, 2 H), 2.95-2.70 (br. m, 3H), 1.40 (s, 9 H).

Building Blocks of Type C (Scheme 3) (S)-5-Allyl 1-benzyl2-(methylamino)pentanedioate hydrochloride (27.HCl)

A mixture of Boc-L-Glu(OAll)OH (23; 33 g, 115 mmol) and NaHCO₃ (27 g,322 mmol) in DMF (500 mL) was stirred for 1 h at room temperaturefollowed by the slow addition of benzyl bromide (35 mL, 299 mmol) in DMF(15 mL). Stirring was continued for 16 h followed by aqueous workup(diethyl ether, sat. aq. NaHCO₃ soln, sat aq. NaCl soln) andpurification by FC(CH₂Cl₂/MeOH 100:0 to 98:2) to give the correspondingbenzyl ester (34.4 g, 79%), which was dissolved in dioxane (40 mL) andtreated with 4 M HCl-dioxane (400 mL) for 1 h. The volatiles wereevaporated. The residue was crystallized from diethyl ether to afford24.HCl (23.8 g, 83%).

4-Nitrobenzenesulfonyl chloride (39 g, 178 mmol) was added at 0° C. to asolution of 24.HCl (46.5 g, 148 mmol) and pyridine (42 mL, 519 mmol) inCH₂Cl₂ (700 mL). The mixture was stirred for 15 h followed by aqueousworkup (CH₂Cl₂, 1 M aq. HCl soln) and purification of the crude by FC(hexane/EtOAc 80:20 to 75:25) to yield 25 (55.54 g, 81%).

A solution of 25 (41.3 g, 89 mmol) in dry DMF (200 mL) was cooled to 0°C. Methyliodide (5.8 mL, 94 mmol) in DMF (100 mL) was slowly added,followed by a solution of DBU (14 mL, 94 mmol) in DMF (100 mL). Themixture was stirred for 4 h at room temperature followed by aqueousworkup (EtOAc, 1 M aq. HCl soln., H₂O, sat. aq. NaHCO₃ soln, sat. aq.NaCl soln) to afford 26 (42.8 g, 99%).

A solution of 26 (17.4 g, 37 mmol) in dry, degassed CH₃CN (270 mL) wastreated with thiophenol (6.7 mL, 66 mmol) and Cs₂CO₃ (39 g, 121 mmol) atroom temperature for 16 h. The mixture was filtered and the residue waswashed with diethyl ether. The filtrate was carefully concentrated (bathtemperature 20° C.) and immediately purified by FC (hexane/EtOAc 80:20to 50:50). The combined product fractions were carefully concentrated,immediately treated with 4 M HCl-dioxane (20 mL) for 5 min andconcentrated to give 27.HCl (8.62 g, 72%).

Data of 27.HCl: C₁₆H₂₁NO₄.HCl (291.3, free base). LC-MS (method 9b):R_(t)=1.44, 292 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 9.57 (br. s, NH₂ ⁺),7.45-7.34 (m, 5 arom. H), 5.88 (M, 1 H), 5.32-5.19 (m, 4 H), 4.53 (td,J=1.3, 5.4, 1 H), 4.13 (br. t, J ca. 6.0, 1 H), 2.69-2.40 (m, 2 H), 2.56(s, 3 H), 2.30-2.05 (m, 2 H).

(R)-5-Allyl 1-benzyl 2-(methylamino)pentanedioate hydrochlorided(29.HCl) was prepared from Boc-D-Glu(OAll)OH (28) applying the methodsdescribed above for the synthesis of the enantiomer (27.HCl).

Data of 29.HCl: C₁₆H₂₁NO₄.HCl (291.3, free base). LC-MS (method 9b):R_(t)=1.44, 292 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 9.92 (br. s, NH⁺), 9.54 (br.s, NH⁺), 7.45-7.34 (m, 5 arom. H), 5.88 (M, 1 H), 5.32-5.19 (m, 4 H),4.53 (td, J=1.3, 5.4, 1 H), 4.13 (br. t, J ca. 6.0, 1 H), 2.69-2.40 (m,2 H), 2.56 (s, 3 H), 2.30-2.05 (m, 2 H).

(S)-Allyl 2-(benzyloxycarbonylamino)-3-(methylamino)propanoatehydrochloride (32.HCl)

Cbz-L-SerOH (30) was converted into amino acid 31 by β-lactone formationand opening with HNCH₃Si(CH₃)₃ (see J. Kim, S. G. Bott, D. M. HoffmanInorg. Chem. 1998, 37, 3835-3841), following the procedures of J. K.Kretsinger and J. P. Schneider, J. Am. Chem. Soc. 2003, 125, 7907-7913and E. S. Ratemi and J. C. Vederas, Tetrahedron Lett. 1994, 35,7605-7608.

A solution of 31.HCl (2.2 g, 7.6 mmol) in allyl alcohol (55 mL) wastreated with thionyl chloride (1.7 mL, 23 mmol) for 15 min at roomtemperature and for 1.5 h at 70° C. The volatiles were evaporated. Thecrude product was dissolved in CH₂Cl₂ and washed with aq. NaHCO₃solution. The aqueous layers were extracted with CH₂Cl₂ and with EtOAc.The combined organic phase was dried (Na₂SO₄), filtered, andconcentrated. The resulting oil (2.18 g) was dissolved in CH₂Cl₂ (80mL), treated with 4 M HCl-dioxane (20 mL), stirred for 5 min andconcentrated to afford 32.HCl (2.5 g, quantitative).

Data of 32.HCl: C₁₅H₂₀N₂O₄.HCl (292.3, free base). LC-MS (method 9a):R_(t)=1.26, 293 ([M+H]⁺). ¹H-NMR (DMSO-d₆):

9.20 (br. s, NH⁺), 9.03 (br. s, NH⁺), 8.02 (d, J=8.2, NH), 7.38-7.30 (m,5 arom. H), 5.89 (m, 1 H), 5.33 (d, J=17.3, 1 H), 5.23 (d, J=10.5, 1 H),5.08 (s, 2 H), 4.63 (d, J=5.3, 2 H), 4.56 (m, 1 H), 3.35 (br. m, 1 H),3.25 (br. m, 1 H), 2.56 (br. s, 3 H).

As an alternative, 32.HCl was prepared from Cbz-L-DapOH applying themethod described below for the synthesis of the enantiomer 36.HCl.

(R)-Allyl 2-(benzyloxycarbonylamino)-3-(methylamino)propanoatehydrochloride (36.HCl)

Cbz-D-DapOH was converted into the allylester-pTsOH salt 33 pTsOHaccording to the procedure of T. M. Kamenecka and S. J. Danishefsky,Chem. Eur. J. 2001, 7, 41-63, describing the synthesis of D-threonineallyl ester.

The amino ester 33 pTsOH was converted into the free base by extraction(CH₂Cl₂, sat. aq. NaHCO₃ soln) and treated with 4-nitrobenzenesulfonylchloride (1.05 equiv.) in CH₂Cl₂ in the presence of pyridine (3.0equiv.) to give the p-nitrophenyl sulfonamide 34.

At 0° C., a solution of methyl iodide (2.3 mL, 37 mmol) in DMF (80 mL)was added to a solution of 34 (16.4 g, 35 mmol) in DMF (80 mL). Asolution of DBU (5.6 mL, 37 mmol) in DMF (80 mL) was slowly added over 2h. The mixture was stirred at room temperature for 1.5 h, followed by anaqueous workup (EtOAC, 1 M HCl soln, H₂O, sat. aq. NaHCO₃ soln, sat. aq.NaCl soln) to afford 35 (17.07 g, quant.).

At 0° C., thiophenol (3.02 mL, 29.6 mmol) was added (dropwise, rapidly)to a mixture of 35 (7.85 g, 16.5 mmol) and K₂CO₃ (7.95 g, 57.5 mmol) inDMF (78 mL). The mixture was stirred for 2.5 h at 0-10° C. The mixturewas diluted with EtOAc and washed with H₂O and sat. aq. NaCl soln. Theorganic layer was extracted with ice-cold 1 M aqueous HCl soln. Theaqueous phase (base extract) was poured onto aqueous Na₂CO₃ soln toreach pH ca 7; 2 M aq. NaOH soln. was added to reach pH ca 10, followedby extraction with EtOAc. The organic phase was dried (Na₂SO₄) andconcentrated. The remaining oil (2.72 g) was dissolved in CH₂Cl₂ (30 mL)and treated with 4 M HCl-dioxane (10 mL) to afford after evaporation ofthe volatiles 36.HCl (3.34 g, 62%).

Data of 36.HCl: C₂₅H₂₀N₂O₄.HCl (292.3, free base). LC-MS (method 7):R_(t)=0.88, 293 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 9.06 (br. s, NH⁺), 8.94 (br.s, NH⁺), 8.00 (d, J=8.3, NH), 7.38-7.30 (m, 5 arom. H), 5.88 (m, 1 H),5.33 (d, J=17.3, 1 H), 5.23 (d, J=10.5, 1 H), 5.08 (s, 2 H), 4.63 (d,J=5.3, 2 H), 4.56 (m, 1 H), 3.35 (br. m, 1 H), 3.20 (br. m, 1 H), 2.57(br. s, 3 H).

(S)-Allyl 2-(benzyloxycarbonylamino)-4-(methylamino)butanoatehydrochloride (40.HCl)

Cbz-L-DabOH (37) was converted into the allylester-pTsOH salt 38.pTsOHaccording to the procedure of T. M. Kamenecka and S. J. Danishefsky,Chem. Eur. J. 2001, 7, 41-63, describing the synthesis of D-threonineallyl ester.

A mixture of 38.pTsOH (45 g, 97 mmol) in CH₂Cl₂ (600 mL) was cooled to0° C. MeOH (60 mL) was added, followed by ethyl trifluoroacetate (23 mL,194 mmol). Et₃N (53 mL, 387 mmol) was added dropwise. The mixture wasstirred at 0° C. for 15 min, then at room temperature for 4 h. Thevolatiles were evaporated. The residue was dissolved in EtOAc, washed (1M aq. HCl soln, sat. aq. Na₂CO₃ soln), dried (Na₂SO₄), filtered andconcentrated to afford the corresponding trifluoroacetamide (32 g, 84%).N-Methylation of the acetamide (21.78 g, 56 mmol; applying CH₃I andK₂CO₃ in DMF) following the procedure described by Chu-Biao Xue et al.J. Med. Chem. 2001, 44, 2636-2660—with the exception that thetransformation was performed at room temperature for 4 h—afforded 39 (25g, ca 90%). Treatment of 39 (8.0 g, ca 18 mmol) in THF (80 mL) withPd(PPh₃)₄ (0.2 g) and morpholine (8.5 mL, 98 mmol) at room temperaturefor 3 h afforded after aqueous workup (EtOAc, 1 M aq HCl soln.) thecorresponding trifluoroacetamido acid (7.3 g) which was treated with NH₃(25% in H₂O; 50 mL) for 2 h and concentrated to give the correspondingaminoacid (8 g). This material was dissolved in allyl alcohol (150 mL)and treated at 0° C. with thionyl chloride (6.6 mL, 91 mmol). Themixture was stirred at 0° C. for 15 min and at room temperature for 3 hand concentrated to give 40.HCl (7.6 g, used in the next step withoutfurther purification)

Data of 40.HCl: C₁₆H₂₂N₂O₄.HCl (306.3, free base). Flow injection MS(ESI, positive modus): 307 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 8.97 (br. s, NH₂⁺), 7.92 (d, J=7.8, NH), 7.40-7.25 (m, 5 arom. H), 5.88 (m, 1 H), 5.32(d, J=17.2, 1 H), 5.22 (d, J=10.5, 1 H), 5.05 (s, 2 H), 4.60 (d, J=5.2,2 H), 4.22 (m, 1 H), 2.94 (m, 2 H), 2.50 (s, 3 H, superimposed by DMSO-dsignal), 2.10 (m, 1 H), 2.00 (m, 1 H).

(S)-Allyl 2-(benzyloxycarbonylamino)-5-(methylamino)pentanoatehydrochloride (44.HCl)

Cbz-L-OrnOH (41) was converted into the allylester-pTsOH salt 42.pTsOHaccording to the procedure of T. M. Kamenecka and S. J. Danishefsky,Chem. Eur. J. 2001, 7, 41-63, describing the synthesis of D-threonineallyl ester.

The ester 42.pTsOH (5.5 g, 11 mmol) was converted into 43 (3.97 g, 83%)applying the conditions described for the synthesis of 39, with theexception that the N-methylation was continued at room temperature for 8h.

The allyl ester group was then cleaved applying the conditions describedfor the treatment of 39. The saponification of the resultingtrifluoroacetamido acid was performed according to the procedure ofChu-Biao Xue et al. J. Med. Chem. 2001, 44, 2636-2660, with theexception that 2 equiv. of LiOH were used. The resulting amino acid(3.80 g, containing LiCl ca. 9 mmol) was treated at room temperaturewith allyl alcohol (100 mL) and thionyl chloride (3.0 mL, 41 mmol). Themixture was heated for 2 h at 70° C. Stirring was continued at roomtemperature for 17 h. The volatiles were evaporated. The resulting solidwas washed with CH₂Cl₂ to afford 44.HCl (3.62 g, ca 75% w/w; yield 83%,used without further purification).

Data of 44.HCl: C₁₇H₂₄N₂O₄.HCl (320.4, free base). LC-MS (method 9b):R_(t)=1.48, 321 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 9.26 (br. s, NH₂ ⁺), 7.86(d, J=7.7, NH), 7.39-7.13 (m, 5 arom. H), 5.89 (m, 1 H), 5.31 (br. d,J=17.3, 1 H), 5.20 (br. d, J=10.4, 1 H), 5.04 (s, 2 H), 4.58 (d, J=5.2,2 H), 4.05 (br. m, 1 H), 2.81 (br. m, 2 H), 2.44 (s, 3 H), 1.80-1.60(br. m, 4 H), Sarcosine allyl ester (46) was prepared as p-TsOH saltapplying the procedure of T. M. Kamenecka and S. J. Danishefsky, Chem.Eur. J. 2001, 7, 41-63, describing the synthesis of D-threonine allylester.

2-((Allyloxycarbonyl) (methyl)amino)acetic acid (47) was preparedaccording to the method of M. Mori, A. Somada, S. Oida, Chem. Pharm.Bull. 2000, 48, 716-728.

3-((Allyloxycarbonyl) (methyl)amino)propanoic acid (49) was preparedapplying the method of M. Mori, A. Somada, S. Oida, Chem. Pharm. Bull.2000, 48, 716-728, describing the synthesis ofN-allyloxycarbonylsarcosine.

(S)-2-(Benzyloxycarbonylamino)pent-4-enoic acid (51) was prepared from(S)-allylglycine by N-protection (CBzOSu, dioxane, aqueous Na₂CO₃) inanalogy to the procedure of D. R. Ijzendoorn, P. N. M. Botman, R. H.Blaauw, Org. Lett 2006, 8, 239-242.

Acid 51 was also described by Z-Y Sun, C—H. Kwon, J. N. D. Wurpel, J.Med. Chem. 1994, 37, 2841-2845.

General Procedures

Synthesis of the A-c1 Fragment

Procedure A

A.1: Acid Chloride Formation

Oxalyl chloride (3.5-5.0 equiv.) was added to a mixture of theacetoxyaryl carboxylic acid (Ac-A-OH) and dry diethyl ether or CH₂Cl₂.The resulting mixture was stirred at room temperature for 15 minfollowed by the addition of a few drops (ca 50-100 μL) of dry DMF.Stirring was continued for 16 h. The mixture was filtered. The filtratewas concentrated and the residue dried i.v. to afford the crudeacetoxyaryl carboxylic acid chloride (Ac-A-Cl), which was immediatelyused in the next step.

A.2: Amide Coupling

A mixture of the amino ester salt (H-c1-OAll.HCl), the crude acetoxyarylcarboxylic acid chloride (Ac-A-Cl, 1.1-1.5 equiv.) and dry CH₂Cl₂ or THFwas cooled to 0° C. An auxiliary base (sym-collidine or i-Pr₂NEt; 3.0equiv.) was added dropwise. The mixture was stirred at room temperaturefor 16 h. The mixture was distributed between EtOAc and 1 M aq. HClsolution. The organic phase was washed (1 M aq. HCl soln., then sat. aq.NaHCO₃ soln. or sat aq. NaCl soln.), dried (Na₂SO₄), filtered andconcentrated. FC (hexane/EtOAc gradients) gave the acetoxyaryl amide(Ac-A-c1-OAll).

A.3: Deacetylation

A solution of acetoxyarylamide (Ac-A-c1-OAll) in dry THF was treated at0° C. with 3-dimethylaminopropylamine (3.0-4.5 equiv.). The solution wasstirred at room temperature for 1-5 h. The mixture was distributedbetween EtOAc and icecold 0.1 M or 1 M aq. HCl solution. The organicphase was washed (0.1 or 1 M aq. HCl soln., sat. aq. NaCl soln.), dried(Na₂SO₄), filtered and concentrated to afford the hydroxyaryl amide(H-A-c1-OAll).

Synthesis of the Linear Cyclization Precursor H—B-A-c1-OH

Procedure B

B.1.1: Mitsunobu Aryl Ether Synthesis Using PPh₃/DEAD

A mixture of the hydroxyaryl amide (H-A-c1-OAll) and PPh₃ (1.5 equiv.)was dried i.v. for 15 min. Under argon a solution of alcohol(HO—B-Alloc, 1.2 equiv.) in dry benzene was added and the resultingsolution was cooled to 0° C. A solution DEAD (40% in toluene, 1.2equiv.) in benzene was slowly added (by syringe pump). The mixture wasstirred at room temperature for 18 h and concentrated. FC (hexane/EtOAcgradients) gave the protected amino acid (Alloc-B-A-c1-OAll, sometimescontaminated with byproducts such as e.g. triphenylphosphine oxide,however acceptable for the use in the next step without furtherpurification).

B.1.2: Mitsunobu Aryl Ether Synthesis Using CMBP

A solution of the hydroxyaryl amide (HO-A-c1-OAll), the alcohol(HO—B-Alloc, 1.2-1.3 equiv) and CMBP (2 equiv) was heated in dry tolueneat reflux for 3-4 h. The solution was concentrated. FC (hexane/EtOAcgradients) afforded the protected amino acid (Alloc-B-A-c1-OAll).

B.2: Cleavage of the Allyl/Alloc Protective Groups

Pd(PPh₃)₄ (0.05-0.1 equiv.) was added to a mixture of the protectedamino acid (Alloc-B-A-c1-OAll) and 1,3-dimethylbarbituric acid (2.5equiv.) in degassed EtOAc/CH₂Cl₂ (ca. 1:1). The resulting solution wasstirred at room temperature for 1-3 h and concentrated. FC (EtOAC,CH₂Cl₂/EtOH, or CH₂Cl₂/MeOH gradients) afforded the free amino acid(H—B-A-c1-OH)

Synthesis of the Linear Cyclization Precursor H—B-a-c1-c2-Oh

Procedure C

C.1: Alloc Carbamate Formation

At 0° C., allylchloroformate (1.1 equiv.) was slowly added to a mixtureof aminoacid (H—B-A-c1-OH) and Na₂CO₃ (1.5-3 equiv.) in dioxane/H₂O 1:1.The mixture was stirred at room temperature for 15 h. The mixture wasdiluted with EtOAc and treated with 1 M aq. HCl solution until pH ca 2was reached. The organic phase was separated, washed (sat. aq. NaClsoln.), dried (Na₂SO₄), filtered, concentrated and dried i.v. to affordthe alloc protected amino acid (Alloc-B-A-c1-OH).

C.2: Amid Coupling

i-Pr₂NEt (5.0 equiv.) was slowly added to a mixture of the allocprotected amino acid (Alloc-B-A-c1-OH), the aminoacid ester salt(H-c2-0All.p-TsOH, 1.2 equiv.), HOAt (1.5 equiv.) and HATU (1.5 equiv.)in DMF. The mixture was stirred at room temperature for 20 h followed bydistribution between EtOAc and ice-cold 0.5 M aq, HCl solution. Theorganic phase was washed (0.5 M aq. HCl soln., H₂O, sat. aq. NaHCO₃soln., sat. aq. NaCl soln.), dried (Na₂SO₄), filtered and concentrated.FC (hexane/EtOAc gradients) afforded the protected amino acid(Alloc-B-A-c1-c2-OAll)

C.3: Cleavage of the Allyl/Alloc Protective Groups

Pd(PPh₃)₄ (0.1 equiv.) was added to a mixture of the protected aminoacid (Alloc-B-A-c1-c2-OAll) and 1,3-dimethylbarbituric acid (2.5 equiv.)in degassed EtOAc/CH₂Cl₂ 1:1. The resulting solution was stirred at roomtemperature for 1-2 h and concentrated. FC (EtOAC, CH₂Cl₂/EtOH, orCH₂Cl₂/MeOH gradients) afforded the free amino acid (H—B-A-c1-c2-OH).

Synthesis of the c2-B Fragment

Procedure D

Synthesis in Two Steps, Via Amidoester and Subsequent Saponification

i-Pr₂NEt (5.0 equiv.) was slowly added to a mixture of the N-protectedamino acid (Alloc-c2-OH, 2.2 equiv.), the aminoalcohol hydrochloride(HO—B—H HCl), Cl-HOBt (0.25 equiv.) and HCTU (2.5 equiv.) in DMF. Theresulting solution was stirred at room temperature for 17 h, followed bydistribution between EtOAc and sat. aq. Na₂CO₃ solution. The organicphase was washed (1 M aq. HCl soln, sat. aq. NaCl soln), dried (Na₂SO₄),filtered and concentrated. FC (hexane/EtOAc or CH₂Cl₂/MeOH gradients)afforded the corresponding amidoester, which was dissolved in THF/H₂O4:1 and treated with lithium hydroxide monohydrate (3.0 equiv.) for 2 hat room temperature. The mixture was concentrated to about 50% of theoriginal volume, diluted with EtOAc and extracted with 1 M aq. NaOHsolution. The organic phase was washed (H₂O, sat. aq. NaCl soln), dried(Na₂SO₄), filtered and concentrated to afford the amidoalcohol(HO—B-c2-Alloc).

Synthesis of the Linear Cyclization Precursor H-c2-B-A-c1-OH

Procedure E

E.1.1: Mitsunobu Aryl Ether Synthesis Using PPh₃/DEAD

A mixture of the hydroxyaryl amide (HO-A-c1-OAll) and PPh₃ (1.5-4.5equiv.) was dissolved in benzene. The solution was concentrated and theresidue was dried i.v. for 15-30 min. Under argon, a solution of thealcohol (HO—B-c2-Alloc, 1.2-2.3 equiv.) in dry and degassed benzene wasadded and the resulting mixture was cooled to 0° C. A solution of DEAD(40% in toluene, 1.2-4.5 equiv.) was slowly added. The mixture wasstirred at room temperature for 18 h. In case of incomplete consumptionof the hydroxyaryl amide, additional triphenylphosphine (1.0-1.3 equiv.)and DEAD (40% in toluene, 1.0 equiv.) and alcohol (1.0 equiv.)—ifconsumed according to tlc—were added and stirring was continued for 18h. The mixture was concentrated.

FC (hexane/EtOAc, CH₂Cl₂/EtOH, or CH₂Cl₂/MeOH gradients) affordedAlloc-c2-B-A-c1-OAll (possibly contaminated with byproducts such as e.g.triphenylphosphine oxide, however acceptable for the use in the nextstep without further purification).

E.1.2: Mitsunobu Aryl Ether Synthesis Using CMBP

CMBP (2-3 equiv.) was added to a mixture of the hydroxyaryl amide(H-A-c1-OAll) and the alcohol (HO—B-c2-Alloc, 1.2-2.2 equiv.) in drytoluene. The mixture was heated at reflux for 16 h and concentrated. FC(hexane/EtOAc gradients) afforded the protected amino acid(Alloc-c2-B-A-c1-OAll).

E.2: Cleavage of the Allyl/Alloc Protective Groups

Pd(PPh₃)₄ (0.05-0.1 equiv.) was added to a mixture of the protectedamino acid (Alloc-c2-B-A-c1-OAll) and 1,3-dimethylbarbituric acid (2.4equiv.) in degassed EtOAc/CH₂Cl₂ 1:1. The resulting solution was stirredat room temperature for 1-3 h and concentrated. FC(EtOAC, CH₂Cl₂/EtOH,or CH₂Cl₂/MeOH gradients) afforded the free amino acid (H-c2-B-A-c1-OH).

Synthesis of the Macrocycles Cyclo-(B-A-c1), and Cyclo-(c2-B-A-c1)

Procedure F

The macrolactamization was typically performed at final concentrationsranging from 0.01 M to 0.001 M

F.1.1: T3P Mediated Lactam Formation

A solution of the precursor (H—B-A-c1-OH or H-c2-B-A-c1-OH orH—B-A-c1-c2-OH, respectively) in dry CH₂Cl₂ was added within 2 h bysyringe pump to a solution of T3P (50% in EtOAc, 2 equiv.) and i-Pr₂NEt(4 equiv.) in dry CH₂Cl₂. The solution was stirred at room temperaturefor 20 h, extracted with sat. aq. Na₂CO₃ solution and with H₂O, dried(Na₂SO₄), filtered and then concentrated. FC (hexane/EtOAc/MeOH orCH₂Cl₂/MeOH gradients) afforded the macrocyclic compound (cyclo-(B-A-c1)or cyclo-(c2-B-A-c1), respectively).

F.1.2: FDPP Mediated Lactam Formation

A solution of the precursor (H—B-A-c1-OH or H-c2-B-A-c1-OH orH—B-A-c1-c2-OH, respectively) in dry DMF was added within 2 h to asolution of FDPP (2.0 equiv.) in dry DMF. The solution was stirred atroom temperature for 20 h. The volatiles were evaporated and the residuetaken up in EtOAc and washed (sat. aq. NaHCO₃ soln, H₂O, sat. aq. NaClsoln). The organic phase was dried (Na₂SO₄), filtered and concentrated.FC (hexane/EtOAc/MeOH or CH₂Cl₂/MeOH gradients gradients) afforded themacrocyclic compound (cyclo-(B-A-c1) or cyclo-(c2-B-A-c1),respectively).

Attachment of Substituents to the Macrocyclic Core Structures: Synthesisof the Final Products

Procedure H

A solution of a macrocyclic benzylester in MeOH or MeOH/THF (ca 100 mLper g of starting material) was hydrogenated for 2 h at room temperatureand at normal pressure in the presence of palladium hydroxide onactivated charcoal (moistened with 50% H₂O; 0.5 g per g of startingmaterial). The mixture was filtered trough a pad of celite. The residuewas washed (MeOH, MeOH/CH₂Cl₂ 1:1, THF). The combined filtrate andwashings were concentrated to obtain a macrocyclic acid.

Procedure I

I.1: Teoc Deprotection with Dioxane-HCl

A solution of a macrocyclic Teoc-amine (1.5 mmol) in dioxane (18 mL) wastreated with 4 M HCl in dioxane (18 mL) and stirred at room temperaturefor 4-16 h. The mixture was treated with diethyl ether and filtered. Thesolid was washed with diethyl ether and dried i.v. to give themacrocyclic amine hydrochloride.

I.2: Teoc Deprotection with TBAF in THF

A solution of TBAF (1 M in THF, 3 equiv.) was added at 0° C. to asolution of a macrocyclic Teoc-amine (1.3 mmol) in THF (34 mL). Stirringat 0° C. to room temperature was continued for 3 h. The solution wasdistributed between CH₂Cl₂ and H₂O. The organic phase was washed (H₂O),dried (Na₂SO₄), filtered and concentrated to provide after FC themacrocyclic amine.

Procedure J

A solution of a macrocyclic Boc-amine in dioxane (10 mL per g ofstarting material) was treated with 4 M HCl in dioxane (20 mL per g ofstarting material) and stirred at room temperature for 2 h. The mixturewas filtered. The solid was washed with diethyl ether and dried i.v. togive the macrocyclic amine hydrochloride.

Procedure K

A solution of a macrocyclic benzylcarbamate (0.9 mmol) in MeCH (52 mL)was hydrogenated for 4 h at room temperature and at normal pressure inthe presence of palladium hydroxide on activated charcoal (moistenedwith 50% H₂O; 0.3 g). The mixture was filtered trough a pad of celite.The residue was washed (MeOH). The combined filtrate and washings wereconcentrated to obtain the macrocyclic amine.

Procedure L

Amide Coupling

L.1.1: with Carboxylic Acid Anhydrides or Acylchlorides

A Solution of an Amino macrocycle (free amine or hydrochloride; 0.09mmol) in CH₂Cl₂ (1 mL) was at 0° C. subsequently treated with pyridine(10 equiv.) and the carboxylic acid anhydride (1.05-5 equiv.) or acarboxylic acid chloride (1.05-2.0 equiv.), respectively. The solutionwas stirred at room temperature for 15 h. After the addition of MeOH(0.1 mL) the solution was stirred for 10 min and concentrated. Theresulting crude product was coevaporated with toluene and purified bychromatography (FC, normal phase or reversed phase prep. HPLC) to givean N-acylamino macrocycle.

L.1.2: with Carboxylic Acid and Polymersupported Carbodiimide

A solution of an amino macrocycle (free amine or hydrochloride; 0.09mmol), a carboxylic acid (1.2 equiv.), HOBt.H₂O (1.2 equiv.) in CH₂Cl₂(1 mL) was treated with N-cyclohexyl-carbodiimide-N′-methylpolystyrene(1.9 mmol/g; 1.5 equiv.) and i-Pr₂NEt (3.0 equiv.). The mixture wasstirred for 15 h at room temperature.(Polystyrylmethyl)trimethylammonium bicarbonate (3.5 mmol/g; 3 equiv.)was added and stirring was continued for 1 h. The mixture was dilutedwith CH₂Cl₂/MeOH 9:1 (2 mL) and filtered. The polymer was washed twicewith CH₂Cl₂/MeOH 8:2 (5 mL). The combined filtrate and washings wereconcentrated. Purification of the crude product by chromatography (FC,normal phase or reversed phase prep. HPLC) afforded an N-acylaminomacrocycle

L.1.3: with a Carboxylic Acid and HATU

A solution of an amino macrocycle (free amine or hydrochloride; 0.145mmol), a carboxylic acid (2.0 equiv.), HATU (2.0 equiv.), HOAt (2.0equiv.) in DMF (2 mL) was treated with i-Pr₂NEt (4.0 equiv.). Themixture was stirred for 15 h at room temperature. The solvent wasremoved. The residue was distributed between CHCl₃ and sat. aq. NaHCO₃solution. The organic phase was washed (H₂O), dried (Na₂SO₄), filteredand concentrated. Purification of the crude product by chromatography(FC, normal phase or reversed phase prep. HPLC) afforded an N-acylaminomacrocycle.

L.2: with an Amine and HATU

A solution of a macrocyclic carboxylic acid (0.78 mmol), an amine (2.0equiv.), HATU (2.0 equiv.), HOAt (2.0 equiv.) in DMF (6 mL) was treatedwith i-Pr₂NEt (4.0 equiv.). The mixture was stirred for 15 h at roomtemperature. The solvent was removed. The residue was distributedbetween CHCl₃ and sat. aq. NaHCO₃ solution. The organic phase was washed(H₂O), dried (Na₂SO₄), filtered and concentrated. Purification of thecrude product by chromatography (FC, normal phase or reversed phaseprep. HPLC) afforded a macrocycle amide.

Procedure M

N,N-Diethylamino macrocycles by Reductive Amination

At 0° C. NaBH(OAc)₃ (5 equiv.) and acetaldehyde (1 mL) were added to asolution of an the amino macrocycle (free amine or hydrochloride; 0.09mmol) in THF (1 mL). The mixture was stirred at 0° C. to roomtemperature for 15 h. The mixture was diluted with CHCl₃ and washed withsat. aq. NaHCO₃ soln. The organic phase was dried (Na₂SO₄), filtered andconcentrated. Purification of the crude product by chromatography (FC,normal phase or reversed phase prep. HPLC) afforded the diethylaminomacocycle.

Procedure N

Methylester Cleavage

A solution of the methylester (57 μmol) in THF (1.5 mL) and MeOH (0.5mL) was treated with H₂O (0.5 mL) and lithium hydroxide monohydrate (3equiv.) for 2 h at room temperature.

The mixture was acidified by addition of aqueous 1 M HCl andconcentrated. The crude product was purified by prep. HPLC.

Synthesis of A-c1 Fragments 1. Synthesis of (S)-5-allyl 1-benzyl2-(5-fluoro-2-hydroxy-N-methylbenzamido)pentanedioate (54) (Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of2-acetoxy-5-fluoro benzoic acid (2, 11.78 g, 59 mmol) and oxalylchloride(18 mL, 206 mmol) in dry CH₂Cl₂ (516 mL) in the presence of DMF (50 μL)afforded 2-acetoxy-5-fluoro benzoyl chloride (52).

Reaction of acid chloride 52 with (S)-5-allyl 1-benzyl2-(methylamino)pentanedioate hydrochloride (27HCl, 15.0 g, 46 mmol) inTHF (260 mL) in the presence of i-Pr₂NEt (23 mL, 137 mmol) yielded theacetate 53 (19.35 g, 90%), which was treated with3-dimethylamino-1-propylamine (23 mL, 185 mmol) in THF (200 mL) toafford after aqueous workup (EtOAc, 0.1 M aq. HCl soln, sat. aq. NaClsoln) and after FC (hexane/EtOAc 8:2 to 7:3) the phenol 54 (14.4 g,81%).

Data of 54: C₂₃H₂₄FNO₆ (429.4). HPLC (30% CH₃CN): R_(t)=3.79 (87%).LC-MS (method 9a): R_(t)=2.09, 430 ([M+H]⁺).

2. Synthesis of (R)-5-allyl 1-benzyl2-(5-fluoro-2-hydroxy-N-methylbenzamido)pentanedioate (56) (Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of2-acetoxy-5-fluoro benzoic acid (2, 13.0 g, 67 mmol) and oxalylchloride(20 mL, 233 mmol) in dry CH₂Cl₂ (585 mL) in the presence of DMF (50 μL)afforded 2-acetoxy-5-fluoro benzoyl chloride (52).

Reaction of acid chloride 52 with (R)-5-allyl 1-benzyl2-(methylamino)pentanedioate hydrochloride (29.HCl, 17.0 g, 52 mmol) inTHF (280 mL) in the presence of i-Pr₂NEt (27 mL, 156 mmol) yielded 55(21.5 g, 88%), which was treated with 3-dimethylamino-1-propylamine (26mL, 205 mmol) in THF (200 mL) to afford after aqueous workup (EtOAc, 0.1M aq. HCl soln, sat. aq. NaCl soln) and after FC (hexane/EtOAc 8:2 to7:3) the phenol 56 (14.8 g, 75%).

Data of 56: C₂₃H₂₄FNO₆ (429.4). HPLC (30% CH₃CN): R_(t)=3.79 (89). LC-MS(method 9c): R_(t)=2.11, 430 ([M+H]⁺).

3. Synthesis of (S)-allyl2-(benzyloxycarbonylamino)-3-(3-hydroxy-N-methylbenzamido)propanoate(59) (Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of 3-acetoxybenzoicacid (3, 6.0 g, 33 mmol) and oxalylchloride (14 mL, 164 mmol) in drydiethyl ether (216 mL) in the presence of DMF (50 μL) afforded3-acetoxybenzoyl chloride (57, 7.0 g, quant.).

Reaction of 57 (7.0 g, 35 mmol) with (S)-allyl2-(benzyloxycarbonylamino)-3-(methylamino)propanoate hydrochloride(32.HCl, 10.5 g, 32 mmol) in CH₂Cl₂ (285 mL) in the presence of2,4,6-collidine (12.8 mL, 96 mmol) yielded 58 (12.34 g, 82%).

The acetate 58 (12.82 g, 28.2 mmol) was treated with3-dimethylamino-1-propylamine (10.6 mL, 84.6 mmol) in THF (114 mL) toafford the phenol 59 (10.45 g, 90%).

Data of 59: C₂₂H₂₄N₂O₆ (412.4). HPLC (10% CH₃CN): R_(t)=3.91 (96). LC-MS(method 9a): R_(t)=1.77, 413 ([M+H]⁺).

4. Synthesis of (R)-allyl2-(benzyloxycarbonylamino)-3-(3-hydroxy-N-methylbenzamido)propanoate(61) (Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of 3-acetoxybenzoicacid (3, 5.82 g, 32.3 mmol) and oxalylchloride (11.1 mL, 129 mmol) indry diethyl ether (210 mL) in the presence of DMF (50 μL) afforded3-acetoxybenzoyl chloride (57, 6.5 g, 100%).

Reaction of 57 (6.5 g, 32.3 mmol) with (R)-allyl2-(benzyloxycarbonylamino)-3-(methylamino)propanoate hydrochloride(36.HCl, 8.5 g, 26 mmol) in CH₂Cl₂ (220 mL) in the presence of2,4,6-collidine (10.3 mL, 77.6 mmol) yielded 60 (10.73 g, 92%).

The acetate 60 (15.46 g, 34 mmol) was treated with3-dimethylamino-1-propylamine (12.8 mL, 102 mmol) in THF (140 mL) toafford the phenol 61 (12.92 g, 92%).

Data of 61: C₂₂H₂₄N₂O₆ (412.4). LC-MS (method 2): R_(t)=1.77 (98), 413([M+H]⁺).

5. Synthesis of (S)-allyl2-(benzyloxycarbonylamino)-4-(3-hydroxy-N-methylbenzamido)butanoate (63)(Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of 3-acetoxybenzoicacid (3, 7.65 g, 43 mmol) and oxalylchloride (18.2 mL, 213 mmol) in dryCH₂Cl₂ (140 mL) in the presence of DMF (300 μL) afforded after 3 h atroom temperature 3-acetoxybenzoyl chloride (57).

Reaction of 57 thus obtained with (S)-allyl2-(benzyloxycarbonylamino)-5-(methylamino)butanoate hydrochloride(40.HCl, 8.7 g, 28 mmol) in THF (140 mL) in the presence of i-Pr₂NEt (15mL, 85 mmol) yielded 62 (8.1 g, 61%).

The acetate 62 (4.85 g, 10 mmol) was treated with3-dimethylamino-1-propylamine (3.8 mL, 31 mmol) in THF (90 mL) to affordthe phenol 63 (4.23 g, 95%).

Data of 63: C₂₃H₂₆N₂O₆ (426.5). LC-MS: (method 6): R_(t)=1.06 (99), 427([M+H]⁺).

6. Synthesis of (S)-allyl2-(benzyloxycarbonylamino)-5-(3-hydroxy-N-methylbenzamido)pentanoate(65) (Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of 3-acetoxybenzoicacid (3, 10 g, 58 mmol) and oxalylchloride (19 mL, 218 mmol) in dryCH₂Cl₂ (450 mL) in the presence of DMF (500 μL) afforded3-acetoxybenzoyl chloride (57).

Reaction of 57 thus obtained with (S)-allyl2-(benzyloxycarbonylamino)-5-(methylamino)pentanoate hydrochloride(44.HCl, 17.3 g, 48 mmol) in THF (200 mL) in the presence of i-Pr₂NEt(25 mL, 145 mmol) yielded 64 (12.08 g, 51%), which was treated with3-dimethylamino-1-propylamine (9.3 mL, 75 mmol) in THF (240 mL) toafford after aqueous workup (EtOAc, 1 M aq. HCl soln, sat. aq. NaHCO₃soln, sat.-aq. NaCl soln) the phenol 65 (10.84 g, 98%).

Data of 65: C₂₄H₂₈N₂O₆ (440.5). LC-MS (method 6): R_(t)=1.15 (91), 441([M+H]⁺).

7. Synthesis of (S)-5-allyl 1-benzyl2-(4-hydroxy-N-methylbenzamido)pentanedioate (68) (Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of 4-acetoxybenzoicacid (4, 10.7 g, 59.5 mmol) and oxalylchloride (17.7 mL, 206 mmol) indry CH₂Cl₂ (350 mL) in the presence of DMF (50 μL) afforded4-acetoxybenzoyl chloride (66).

Reaction of 66 with (S)-5-allyl 1-benzyl 2-(methylamino)pentanedioatehydrochloride (27.HCl, 15.0 g, 46 mmol) in THF (250 mL) in the presenceof i-Pr₂NEt (23.3 mL, 137 mmol) yielded 67 (16.24 g, 78%).

The treatment of 67 (15.2 g, 33.5 mmol) with3-dimethylamino-1-propylamine (12.6 mL, 101 mmol) in THF (140 mL)afforded the phenol 68 (14.86 g, quant.; the product was contaminatedwith 9% EtOAc).

Data of 68: C₂₃H₂₅NO₆ (411.4). LC-MS (method 9b): R_(t)=1.96, 412([M+H]⁺).

8. Synthesis of (S)-allyl2-(benzyloxycarbonylamino)-3-(5-hydroxy-N-methylnicotinamido)propanoate(71) (Scheme 4)

A mixture of 5-hydroxy nicotinic acid (5, 3.5 g, 25.1 mmol) and aceticanhydride (23 mL, 243 mmol) was heated at 95° C. for 45 min and cooledto room temperature. The mixture was filtered. The solid was washed(H₂O, diethyl ether) and dried i.v. to give 5-acetoxynicotinic acid (6;3.76 g, 82%) (Scheme 1) 5-Acetoxynicotinic acid (6; 5.7 g, 31.5 mmol)was suspended in CHCl₃ (stabilized with amylene, 230 mL). Oxalylchloride(9.0 mL, 105 mmol) was added followed by DMF (ca. 50 μl). The mixturewas stirred at room temperature for 15 h, then concentrated,coevaporated with dry CH₂Cl₂ and dried i.v. to afford5-acetoxynicotinoyl chloride (69). (S)-allyl2-(benzyloxycarbonylamino)-3-(methylamino)propanoate hydrochloride (32,8.6 g, 26.2 mmol) and THF (225 mL) were added. The mixture was cooled to0° C. Et₃N (13 mL, 92 mmol) was slowly added. The mixture was stirred at0° C. to room temperature for 18 h. 3-dimethylamino-1-propylamine (9.9mL, 78.6 mmol) was added and stirring at room temperature was continuedfor 2 h. The mixture was distributed between EtOAc and 1 M aq. NaH PO₄solution. The organic layer was separated, washed (sat. aq. NaCl soln),dried (Na₂SO₄), filtered and concentrated. FC(CH₂Cl₂/MeOH 19:1) affordedthe phenol 71 (8.81 g, 81%).

Data of 71: C₂₁H₂₃N₃O₆ (413.4). LC-MS (method 6): R_(t)=0.94 (92), 414([M+H]⁺).

9. Synthesis of allyl(2S)-2-[(benzyloxy)carbonyl]amino-3-[((2S)-2-[(tert-butoxycarbonyl)amino]-8-hydroxy-1,2,3,4-tetrahydro-2-naphthalenylcarbonyl)(methyl)amino]propanoate (72) (Scheme 4)

A mixture of 10 (3.0 g, 9.76 mmol), HATU (5.57 g, 14.6 mmol), HOAt (1.99g, 14.6 mmol) and 32.HCl (6.4 g, 19.5 mmol) were dissolved in DMF (113mL). i-Pr₂NEt (8.36 mL, 48.8 mmol) was added. The mixture was stirred atroom temperature for 3 d. The mixture was distributed between H₂O andEtOAc. The organic phase was dried (Na₂SO₄), filtered, and concentrated.FC (hexane/EtOAc 75:25 to 50:50) afforded 72 (2.58 g, 45%).

Data of 72: C₃₁H₃₉N₃O₈ (581.3). LC-MS (method 7): R_(t)=1.27 (97), 582([M+H]⁺).

10. Synthesis of 5-allyl 1-benzyl(25)-2-[[(8-hydroxy-2-quinolinyl)carbonyl] (methyl)amino]pentanedioate(75) (Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of8-Acetoxyquinoline-2-carboxylic acid (8, 2.22 g 9.6 mmol) andoxalylchloride (2.1 mL, 24 mmol) in dry CH₂Cl₂ (90 mL) (no addition ofDMF) afforded after 2 h at room temperatureacetoxyquinoline-2-carboxylic acid chloride (73).

Reaction of 73 with (S)-5-allyl 1-benzyl 2-(methylamino)pentanedioatehydrochloride (27.HCl, 2.3 g, 8.0 mmol) in CH₂Cl₂ (200 mL) in thepresence of i-Pr₂NEt (5.5 mL, 32 mmol) yielded after 2.5 h at roomtemperature and purification by FC (hexane/EtOAc gradient) 74 (3.03 g,74%), which was treated with 3-dimethylamino-1-propylamine (2.3 mL, 18mmol) in THF (54 mL) to afford after aqueous workup (EtOAc, 1 M aq. HClsoln, sat. aq. NaHCO₃ soln, sat.-aq. NaCl soln) the phenol 75 (2.79 g,99%).

Data of 75: C₂₆H₂₆N₂O₆ (462.5). LC-MS (method 7): R_(t)=1.29 (94), 463([M+H]⁺).

11. Synthesis of N-allyl-3-hydroxy-N-methylbenzamide (77) (Scheme 4)

Following procedure A (steps A.1-A.3), the reaction of 3-acetoxybenzoicacid (3, 23.7 g, 132 mmol) and oxalylchloride (45.3 mL, 527 mmol) in drydiethyl ether (800 mL) in the presence of DMF (100 μL) afforded3-acetoxybenzoyl chloride (57).

Reaction of 57 thus obtained with N-allylmethylamine (10.1 ml, 105 mmol)in CH₂Cl₂ (500 mL) in the presence of 2,4,6-collidine (42 mL, 316 mmol)yielded 76 (24 g, 98%).

The acetate 76 (10.9 g, 46.7 mmol) was treated with3-dimethylamino-1-propylamine (17.5 mL, 140 mmol) in THF (90 mL) toafford after aqueous workup (EtOAc, 1 M aq. HCl soln, sat. aq. NaClsoln) the phenol 77 (9.0 g, 100%).

Data of 77: C₁₁H₁₃NO₂ (191.2). LC-MS (method 2): R_(t)=1.52 (99), 192([M+H]⁺).

12. Synthesis of (S)-5-allyl-1-benzyl2-(3-mercapto-N-methylbenzamido)pentanedioate (80) (Scheme 4)

Acetic anhydride (0.46 mL, 4.86 mmol) was added at 0° C. to a solutionof 3-mercaptobenzoic acid (11, 250 mg, 1.62 mmol) in 1 M aqueous NaOHsolution (5.0 mL, 5.0 mmol). The mixture was stirred at 0° C. for 1 h. Aprecipitate was formed. The mixture was acidified by the addition of 1 Maqueous HCl solution and filtered. The solid was dried i.v. to afford3-(acetylthio)benzoic acid (12; 280 mg, 88%).

Oxalyl chloride (0.34 mL, 3.97 mmol) was added to a mixture of 12 (260mg, 1.33 mmol) and CHCl₃ (stabilized with amylene; 16 mL). DMF (7 μL)was added. The mixture was stirred at room temperature for 2 h. Thevolatiles were evaporated to afford 3-(acetylthio)benzoyl chloride (78).

(S)-5-allyl 1-benzyl 2-(methylamino)pentanedioate hydrochloride (27.HCl,434 mg, 1.33 mmol) and dry THF (5 mL) were added. The mixture was cooledto 0° C., followed by the addition of i-Pr₂NEt (0.79 mL, 4.6 mmol). Themixture was stirred at room temperature for 16 h and distributed betweenEtOAc and 1 M aqueous HCl solution. The organic phase was separated,dried (Na₂SO₄), filtered and concentrated. FC (hexane/EtOAc 2:1)afforded the acetate 79 (420 mg, 67%).

At room temperature, a solution of 79 (246 mg, 0.52 mmol) in degassedTHF (3.6 mL) was treated with 3-dimethylamino-1-propylamine (0.13 mL,1.05 mmol) for 1 h. The mixture was distributed between EtOAc and 1 Maqueous HCl solution. The organic phase was separated, dried (Na₂SO₄),filtered and concentrated. FC (hexane/EtOAc 2:1) afforded 80 (153 mg,68%).

Data of 80: C₂₃H₂₅NO₅S (427.5): LC-MS (method 7): R_(t)=1.39 (84), 428([M+H]⁺).

Synthesis of c2-B Fragments 1. Synthesis of allylN-2-[(2S,4S)-4-[(tert-butoxycarbonyl)amino]-2-(hydroxymethyl)tetrahydro-1H-pyrrol-1-yl]-2-oxoethyl-N-methylcarbamate(81) (Scheme 5)

A solution of (2-((allyloxycarbonyl) (methyl)amino)acetic acid (47, 8.0g, 46 mmol) and aminoalcohol 13 (11.0 g, 51 mmol) in DMF (120 mL) wascooled to 0° C. 2,4,6-Collidine (11 mL, 82 mmol) was added followed byHATU (22 g, 58 mmol). The mixture was stirred for 1 h at 0° C. then for16 h at room temperature followed by distribution between EtOAc and sat.aq. Na₂CO₃ solution. The organic phase was washed (1 M aq. HCl soln,sat. aq. NaCl soln), dried (Na₂SO₄), filtered and concentrated. FC(EtOAc/MeOH 100:0 to 95:5) afforded the amidoalcohol 81 (14.7 g, 86%).

Data of 81: C₁₇H₂₉N₃O₆ (371.4). HPLC (20% CH₃CN): R_(t)=2.94 (97). LC-MS(method 9c): R_(t)=1.55; 743 ([2M+H]⁺), 372 ([M+H]⁺).

2. Synthesis of allylN-2-[(2S,4R)-4-[(tert-butoxycarbonyl)amino]-2-(hydroxymethyl)tetrahydro-1H-pyrrol-1-yl]-2-oxoethyl-N-methylcarbamate(82) (Scheme 5)

Following procedure D, the reaction of the amnioalcohol 17.HCl (10.0 g,39.6 mmol) and 2-((allyloxycarbonyl) (methyl)amino)acetic acid (47, 15.1g, 87 mmol) in DMF (100 mL) in the presence of HCTU (40.9 g, 98.9 mmol),Cl-HOBt (1.68 g, 9.89 mmol) and i-Pr₂NEt (33.6 mL, 198 mmol) affordedafter FC (hexane/EtOAc 20:80 to 0:100) the corresponding amido esterintermediate (13.7 g) which was saponified with lithium hydroxidemonohydrate (3.28 g, 78.1 mmol) in THF (350 mL) and H₂O (90 mL) to yieldthe amidoalcohol 82 (8.89 g, 61%).

Data of 82: C₁₇H₂₉N₃O₆ (371.4). LC-MS (method 9b): R_(t)=1.57; 372([M+H]⁺), 316, 272 ([M+H-Boc]⁺), 156.

3. Synthesis of tert-butyl(3R)-4-{2-[[(allyloxy)carbonyl](methyl)amino]acetyl}-3-(hydroxymethyl)tetrahydro-1(2H)-pyrazinecarboxylate(84) (Scheme 5)

Following procedure D, the reaction of (R)-tert-butyl3-(hydroxymethyl)piperazine-1-carboxylate hydrochloride (83.HCl, 19.7 g,78 mmol) and 3-((allyloxycarbonyl) (methyl)amino)acetic acid (47, 30 g,172 mmol) in DMF (188 mL) in the presence of HCTU (81.0 g, 195 mmol),Cl-HOBt (3.3 g, 19 mmol) and i-Pr₂NEt (67 mL, 390 mmol) afforded afterFC (EtOAc) the corresponding amido ester intermediate (40 g) which wassaponified with lithium hydroxide monohydrate (9.5 g, 228 mmol) in THF(1020 mL) and H₂O (245 mL) to yield after FC (EtOAc) amidoalcohol 84;22.8 g, 79%).

Data of 84: C₁₇H₂₉N₃O₆ (371.4). LC-MS (method 7): R_(t)=0.99 (93), 372([M+H]⁺).

4. Synthesis of benzylN-MS)-1-[(2S,4S)-4-[(tert-butoxycarbonyl)amino]-2-(hydroxymethyl)tetrahydro-1H-pyrrol-1-yl]carbonyl-3-butenyl)carbamate(85) (Scheme 5)

Aminoalcohol-hydrochloride 13.HCl (3.7 g, 14.7 mmol) was added to asolution of acid 51 (5.22 g, 14.7 mmol) in DMF (80 ml). The mixture wascooled to 0° C. HATU (7.0 g, 18.4 mmol) and 2,4,6-collidine (3.51 ml,26.4 mmol) were added. The solution was stirred at 0° C. to roomtemperature for 17 h, followed by distribution between EtOAc and sat.aq. Na₂CO₃ solution. The organic phase was washed (1 M aq. HCl soln,sat. aq. NaHCO₃ soln, sat. aq. NaCl soln), dried (Na₂SO₄), filtered andconcentrated. FC (hexane/EtOAc 30:70 to 20:80) afforded the amidoalcohol(85, 5.78 g, 88%)

Data of 85: C₂₃H₃₃N₃O₆ (447.5). LC-MS (method 2): R_(t)=1.92 (92), 448([M+H]⁺).

5. Synthesis of allylN-3-[(2S,4R)-4-[(tert-butoxycarbonyl)amino]-2-(hydroxymethyl)tetrahydro-1H-pyrrol-1-yl]-3-oxopropyl-N-methylcarbamate(86) (Scheme 5)

Following procedure D, the reaction of aminoalcohol 17.HCl (7.5 g, 30mmol) and 3-((allyloxycarbonyl) (methyl)amino)propanoic acid (49, 12.3g, 66 mmol) in DMF (77 mL) in the presence of HCTU (31.0 g, 75.0 mmol),Cl-HOBt (1.27 g, 7.5 mmol) and i-Pr₂NEt (25.6 mL, 150 mmol) affordedafter FC(CH₂Cl₂/MeOH 100:0 to 97:3) the corresponding amido esterintermediate (17.1 g) which was saponified with lithium hydroxidemonohydrate (3.8 g, 90 mmol) in THF (388 mL) and H₂O (105 mL) to yieldthe amidoalcohol 86 (10.48 g, 86%).

Data of 86: C₁₈H₃₁N₃O₆ (385.4). HPLC (10% CH₃CN): R_(t)=3.49 (88). LC-MS(method 9a): R_(t)=1.62; 386 ([M+H]⁺), 330 ([M+H-tBu]⁺), 286([M+H-Boc]⁺).

Core 01: Synthesis of Ex.1 (Scheme 6)

Synthesis of the Mitsunobu Product 87

To a solution of 54 (350 mg, 0.82 mmol), 16 (590 mg, 1.7 mmol) and PPh₃(1069 mg, 4.08 mmol) in dry degassed CHCl₃ (11 mL) was added ADDP (1028mg, 4.08 mmol) in one portion at 0° C., under a N₂ atmosphere. Theresulting mixture was stirred for 16 h at room temperature. The mixturewas filtered and the slurry washed further with diethyl ether. Thecombined filtrates were concentrated in vacuo. The crude residue waspurified by FC (CH₂Cl₂/EtOH 100:0 to 99:1) to afford 87 (1.05 g,contains triphenylphosphine oxide; used in the next step without furtherpurification).

Synthesis of the Amino Acid 88

Following procedure B.2, the reaction of 87 (441 mg, contaminated withtriphenylphosphine oxide, ca 0.5 mmol), 1,3-dimethylbarbituric acid (219mg, 1.4 mmol) and Pd(PPh₃)₄ (34 mg) in EtOAc/CH₂Cl₂ (55:45, 10 mL)yielded after 1.5 h and subsequent FC(CH₂Cl₂/MeOH 100:0 to 80:20) aminoacid 88 (267 mg, 72%).

Data of 88: C₃₁H₄₂FN₃O₈Si (631.7). LC-MS (method 9a):

R_(t)=2.02, 632 ([M+H]⁺). HPLC (30% CH₃CN): R_(t)=3.41 (96).

Synthesis of the Macrolactam Ex.1

According to procedure F.1.1 the amino acid 88 (75 mg, 0.12 mmol) in dryCH₂Cl₂ (6 mL) was added within 4 h to T3P (50% in EtOAc, 0.21 mL, 0.36mmol) and i-Pr₂NEt (0.1 mL, 0.59 mmol) in dry CH₂Cl₂ (6 mL) to giveafter FC(CH₂Cl₂/MeOH 100:0 to 96:4) the macrolactam Ex.1 (45 mg, 61%).

Data of Ex.1: C₃₄H₄₀FN₃O₇Si (613.7). LC-MS (method 7):

R_(t)=1.45 (41), 614 ([M+H]⁺); 1.47 (44), 614 ([M+H]⁺).

¹H-NMR (DMSO-d₆): complex spectrum, several isomers; 7.45-7.01 (m, 8 H),6.78-6.58 (2 m, 1 H), 5.42-5.06 (m, 3 H), 4.50-3.50 (several m, 7 H),3.30-1.40 (several m, 7 H), 2.84, 2.70, 2.66 (s, 3 H), 0.97-0.82 (m, 2H), 0.03, 0.02, 0.00 (s 9 H).

Core 02: Synthesis of Ex.2 (Scheme 11)

Synthesis of the Protected Macrolactam Ex.2

A solution of T3P (50% in EtOAc, 0.75 mL, 1.27 mmol) and i-Pr₂NEt (0.36mL, 2.2 mmol) in dry CH₂Cl₂ (20 mL) was added within 2 h to a solutionof the amino acid 98 (250 mg, 0.43 mmol) in dry CH₂Cl₂ (730 mL). Thesolution was stirred at room temperature for 20 h, followed byextraction with sat. aq. Na₂CO₃ solution. The organic phase was dried(Na₂SO₄), filtered and concentrated. FC(CH₂Cl₂/MeOH 100:0 to 95:5)afforded Ex.2 (187 mg, 77%).

Data of Ex.2: C₃₀H₃₆FN₃O₇ (569.6) LC-MS (method 7):

R_(t)=1.35 (62), 570 ([M+H]⁺); 1.39 (15), 570 ([M+H]⁺)

¹H-NMR (DMSO-d₆): complex spectrum, several isomers; 7.46-7.30 (m, 5 H),7.27-7.06 (m, 2 H), 6.98-6.67 (4 dd, 1 H), 5.54-5.06 (m, 3 H), 4.68-3.48(m, 6 H), 3.05-1.98 (m 10 H; s at 2.82, 2.69, 2.64), 1.44-1.41 (3s, 9H).

Core 03: Synthesis of Ex.3, Ex.4, and Ex.5 (Scheme 7)

Synthesis of the Mitsunobu Product 89

Following procedure E.1.1, the reaction of phenol 54 (7.8 g, 18 mmol),alcohol 81 (16 g, 43 mmol), DEAD (40% in toluene, 37 mL, 82 mmol), andPPh₃ (21 g, 80 mmol) in dry benzene (250 mL) afforded afterFC(CH₂Cl₂/EtOH 100:0 to 95:5) the protected amino acid 89 (15.9 g,contaminated with ca. 30% triphenylphosphine oxide; used in the nextstep without further purification).

Synthesis of the Amino Acid 90

Following procedure E.2, the reaction of 89 (9.6 g, contaminated withtriphenylphosphine oxide, ca 9 mmol), 1,3-dimethylbarbituric acid (5.0g, 32.0 mmol) and Pd(PPh₃)₄ (0.4 g) in EtOAc/CH₂Cl₂ (55:45, 266 mL)yielded after 1.5 h and after FC(CH₂Cl₂/MeOH 90:10 to 50:50) amino acid90 (4.34 g, 76%).

Data of 90: C₃₃H₄₃FN₄O₉ (658.7). HPLC (10% CH₃CN): R_(t)=3.87 (99).

LC-MS (method 9a): R_(t)=1.77, 659 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.3

According to procedure F.1.2, the amino acid 90 (2.5 g, 3.80 mmol) indry DMF (50 mL) was treated with FDPP (2.51 g, 6.53 mmol) in DMF (400mL) to afford after FC (EtOAc/MeOH 100:0 to 95:5) the macrolactam Ex.3(2.29 g, 94%).

Data of Ex.3: C₃₃H₄₁FN₄O₈ (640.7). HPLC (30% CH₃CN): R_(t)=3.20 (96).LC-MS (method 9c): R_(t)=2.06, 641 ([M+H]⁺). ¹H-NMR (CDCl₃): 7.45-7.32(m, 5 H), 7.06 (m, 1 H), 6.94-6.88 (m, 2 H), 5.57 (dd, J=2.8, 12.6, 1H), 5.42 (br. m, 1 H), 5.26 (d, J=12.2, 1 H), 5.15 (d, J=12.2, 1 H),4.90 (dd, J=2.5, 11.0, 1 H), 4.34 (d, J=17.2, 1 H), 4.35-4.11 (m, 3 H),3.82 (br. t, J ca. 8.5, 1 H), 3.65 (d, J=17.3, 1 H), 3.29 (t, J ca 8.8,1 H), 3.14 (s, 3 H), 2.65 (s, 3 H), 2.51-1.98 (several m, 5 H), 1.76(td, J=8.2, 12.7, 1 H), 1.36 (s, 9 H).

Synthesis of the Acid Ex.4:

According to procedure H, ester Ex.3 (2.0 g, 3.1 mmol) was hydrogenatedin MeOH (120 mL)/THF (40 mL) in the presence of the catalyst (1 g) for 2h to afford Ex.4 (1.68 g, 97%).

Data of Ex.4: C₂₆H₃₅FN₄O₈ (550.6). HPLC (5% CH₃CN): R_(t)=3.60 (86).LC-MS: (method 9c): R_(t)=1.53; 551 ([M+H]⁺), 451 ([M+H-Boc]⁺).

Synthesis of the Amine Ex.5:

According to procedure J, ester Ex.3 (100 mg, 0.16 mmol) in dioxane (3mL) was treated with 4 M HCl-dioxane (3 mL) to afford Ex.5.HCl (100 mg,quant.).

Data of Ex.5.HCl: C₂₈H₃₃FN₄O₆.HCl (540.6, free base). LC-MS: (method9c): R_(t)=1.44, 541 ([M+H]⁺).

Core 04: Synthesis of Ex.56 and Ex.57 (Scheme 8)

Synthesis of the Mitsunobu Product 91

Following procedure E.1.1 the reaction of phenol 54 (8.0 g, 19 mmol),alcohol 82 (16.0 g, 43 mmol), DEAD (40% in toluene, 38 mL, 84 mmol), andPPh₃ (22 g, 84 mmol) in dry benzene (260 mL) afforded after FC theprotected amino acid 91 (33.5 g, contaminated with triphenylphosphineoxide. The material was used in the next step without furtherpurification).

Synthesis of the Amino Acid 92

Following procedure E.2, the reaction of 91 (33.5 g, impure material),1,3-dimethylbarbituric acid (16 g, 102 mmol) and Pd(PPh₃)₄ (0.2 g) inEtOAc/CH₂Cl₂ (45:55, 340 mL) yielded after 3 h and after FC(CH₂Cl₂/EtOH100:0 to 70:30 then CH₂Cl₂/MeOH 90:10 to 70:30) amino acid 92 (4.8 g,39% over the two steps, based on phenol 54).

Data of 92: C₃₃H₄₃FN₄O₉ (658.7). HPLC (10% CH₃CN): R_(t)=3.80 (95).LC-MS (method 9c): R_(t)=1.81, 659 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.56

According to procedure F.1.1, amino acid 92 (3.8 g, 5.80 mmol) in dryCH₂Cl₂ (40 mL) was treated with T3P (50% in EtOAc, 6.8 mL, 12 mmol) andi-Pr₂NEt (4.0 mL, 23 mmol) in dry CH₂Cl₂ (510 mL) to afford after FC(EtOAc/MeOH 100:0 to 95:5) the macrolactam Ex.56 (3.23 g, 87%).

Data of Ex.56: C₃₃H₄₁FN₄O₈ (640.7). HPLC (30% CH₃CN): R_(t)=3.49 (88).LC-MS (method 9c): R_(t)=2.02, 641 ([M+H]⁺). ¹H-NMR (CDCl₃): 7.41-7.32(m, 5 H), 7.04 (m, 1 H), 6.94-6.83 (m, 2 H), 5.54 (dd, J=3.0, 12.7, 1H), 5.25 (d, J=12.2, 1 H), 5.14 (d, J=12.2, 1 H), 4.89 (dd, J=2.1, 11.0,1 H), 4.63 (br. m, 1 H), 4.39-4.10 (m, 4 H), 3.79-3.64 (m, 2 H), 3.49(br. m, 1 H), 3.12 (s, 3 H), 2.64 (s, 3 H), 2.51-2.36 (m, 2 H),2.23-1.98 (m, 4 H), 1.44 (s, 9 H).

Synthesis of the Acid Ex.57:

According to procedure H, the ester Ex.56 (2.25 g, 3.5 mmol) washydrogenated in MeOH (120 mL)/THF (40 mL) in the presence of thecatalyst (1.1 g) for 2 h to afford—after washing of the filtrationresidue with warm (50° C.) MeOH/THF 3:1—the acid Ex.57 (1.9 g, 98%).

Data of Ex.57: C₂₆H₃₅FN₄O₈ (550.6). HPLC LC-MS: (method 2): R_(t)=1.54(82), 551 ([M+H]⁺).

Core 05: Synthesis of Ex.85 and Ex.86 (Scheme 9)

Synthesis of the Mitsunobu Product 93

Following procedure E.1.1, the reaction of phenol 56 (6.6 g, 15 mmol),alcohol 81 (13 g, 35 mmol), DEAD (40% in toluene, 32 mL, 69 mmol), andPPh₃ (18 g, 69 mmol) in dry benzene (220 mL) afforded afterFC(CH₂Cl₂/MeOH 100:0 to 94:6) the protected amino acid 93 (34.5 g,contaminated with triphenylphosphine oxide and diethylhydrazine-1,2-dicarboxylate; acceptable for the use in the next stepwithout further).

Synthesis of the Amino Acid 94

Following procedure E.2, the reaction of 93 (34.5 g, impure material),1,3-dimethylbarbituric acid (17 g, 106 mmol) and Pd(PPh₃)₄ (0.1 g) inEtOAc/CH₂Cl₂ (55:45, 350 mL) yielded after 3 h and after FC(CH₂Cl₂/EtOH100:0 to 70:30 then CH₂Cl₂/MeOH 90:10 to 70:30) the amino acid 94 (5.6g, 55% over the two steps, based on phenol 56).

Data of 94: C₃₃H₄₃FN₄O₉ (658.7). HPLC (10% CH₃CN): R_(t)=3.79 (96).LC-MS (method 9c): R_(t)=1.77, 659 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.85

According to procedure F.1.1, amino acid 94 (2.75 g, 4.2 mmol) in dryCH₂Cl₂ (35 mL) was treated with T3P (50% in EtOAc, 4.9 mL, 8.3 mmol) andi-Pr₂NEt (2.9 mL, 17 mmol) in dry CH₂Cl₂ (355 mL) to yield after FC(EtOAc/MeOH 100:0 to 95:5) macrolactam Ex.85 (2.47 g, 92%).

Data of Ex.85: C₃₃H₄₁FN₄O₈ (640.7). HPLC (30% CH₃CN): R_(t)=3.52 (96).LC-MS (method 9c): R_(t)=2.06; 641 ([M+H]⁺), 541 ([M+H-Boc]⁺). ¹H-NMR(CDCl₃): two isomers, ratio 85:15, 7.42-7.31 (m, 5 H), 7.08-6.77 (m, 3H), 5.33 (d, J=8.3, 1 H), 5.23 (d, J=12.2, 1 H), 5.17 (d, J=12.1, 1 H),4.84 (dd, J=2.9, 8.9, 1 H), 4.37-4.25 (m, 3 H), 4.11 (dd, J=4.2, 12.0, 1H), 3.89 (t, J=8.3, 1 H), 3.80 (d, J=8.9, 1 H), 3.61 (d, J=17.1, 1 H),3.16 (t, J=9.1, 1 H), 3.13 (s, 2.55 H, NCH₃ of major isomer), 3.03 (s,0.45 H, NCH₃ of minor isomer), 2.98 (s, 2.55 H, NCH₃ of major isomer),2.87 (0.45 H, NCH₃ of minor isomer), 2.64-2.41 (m, 2 H), 2.27-2.09 (m, 1H), 1.98-1.83 (m, 2 H), 1.79-1.66 (m, 2 H), 1.45 (s, 7.65 H, Boc, majorisomer), 1.35 (s, 1.35 H, Boc, minor isomer).

Synthesis of the Acid Ex.86:

According to procedure H, ester Ex.85 (2.0 g, 3.1 mmol) was hydrogenatedin MeOH (120 mL)/THF (40 mL) in the presence of the catalyst (1 g) for 2h to afford—after washing of the filtration residue with warm (50° C.)MeOH/TFH 3:1—the acid Ex.86 (1.67 g, 97%).

Data of Ex.86: C₂₆H₃₅FN₄O₈ (550.6). LC-MS: (method 3): R_(t)=1.10 (83),551 ([M+H]⁺); 1.17 (15), 551 ([M+H]⁺).

Core 06: Synthesis of Ex.104 and Ex.105 (Scheme 10)

Synthesis of the Mitsunobu Product 95

Following procedure E.1.2, the reaction of phenol 56 (13.1 g, 30.5mmol), alcohol 82 (13.6 g, 36.6 mmol), and CMBP (14.7 g, 61 mmol) in drytoluene (500 mL) afforded after FC (hexane/EtOAc 50:50 to 30:70) theprotected amino acid 95 (16 g, 67%).

Synthesis of the Amino Acid 96

Following procedure E.2, the reaction of 95 (16.0 g, 20 mmol),1,3-dimethylbarbituric acid (8 g, 49 mmol) and Pd(PPh₃)₄ (0.1 g) inEtOAc/CH₂Cl₂ (55:45, 220 mL) yielded after 3 h and after FC(CH₂Cl₂/EtOH100:0 to 70:30 then CH₂Cl₂/MeOH 90:10 to 70:30) amino acid 96 (11 g,81%).

Data of 96: C₃₃H₄₃FN₄O₉ (658.7). LC-MS (method 2): R_(t)=1.63 (97), 659([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.104

According to procedure F.1.1, amino acid 96 (4.0 g, 6.1 mmol) in dryCH₂Cl₂ (40 mL) was treated with T3P (50% in EtOAc, 7.2 mL, 12.1 mmol)and i-Pr₂NEt (4.2 mL, 24.3 mmol) in dry CH₂Cl₂ (1160 mL) to give afterFC(CH₂Cl₂/MeOH 100:0 to 95:5) macrolactam Ex.104 (2.32 g, 60%).

Data of Ex.104: C₃₃H₄₁FN₄O₈ (640.7). LC-MS (method 7): R_(t)=1.21 (47),641 ([M+H]⁺); 1.24 (53), 641 ([M+H]). ¹H-NMR (DMSO-d₆): complexspectrum, mixture of isomers, 7.44-6.65 (m, 9 H), 5.32-5.05 (m, 2 H),4.70-3.30 (several m, 9 H), 2.92 (s, NCH₃ of major isomer), 2.84 (s,NCH₃ of major isomer), 2.30-1.70 (several m, 6 H), 1.40, 1.38 (2 s, 9H).

Synthesis of the Acid Ex.105:

According to procedure H, ester Ex.104 (2.15 g, 3.3 mmol) washydrogenated in MeOH (215 mL) in the presence of the catalyst (1.07 g)for 4 h to afford acid Ex.105 (1.72 g, 93%).

Data of Ex.105: C₂₆H₃₅FN₄O₈ (550.6). LC-MS: (method 7): R_(t)=0.91 (45),551 ([M+H]⁺); 0.95 (38), 551 ([M+H]⁺).

Core 07: Synthesis of Ex.115 and Ex.116 (Scheme 11)

Synthesis of the Mitsunobu Product 97

A mixture of the phenol 54 (6.42 g, 14.9 mmol), alcohol 22 (4.04 g, 13.5mmol), and PPh₃ (9.73 g, 37.1 mmol) was dried i.v. for 15 min. anddissolved in dry, degassed chloroform (130 mL). The solution was cooledto 0° C. A solution of ADDP (9.36 g, 37.1 mmol) in chloroform (20 mL)was slowly added. The mixture was stirred at room temperature for 3 hfollowed by the addition of more 22 (4.04 g, 13.5 mmol) and PPh₃ (5.97g, 22.8 mmol) in chloroform (20 mL). The mixture was cooled to 0° C. Asolution of ADDP (5.74 g, 22.7 mmol) in chloroform (20 mL) was slowlyadded. The solution was stirred at room temperature for 16 h andconcentrated. The residue was suspended in diethyl ether and filtered.The solid was washed with diethyl ether. The combined filtrate andwashings were concentrated. FC (CH₂Cl₂/EtOAc 10:1) gave 97 (7.73 g,73%).

Synthesis of the Amino Acid 98

Following procedure B.2, the reaction of 97 (7.72 g, 11 mmol),1,3-dimethylbarbituric acid (4.1 g, 26.0 mmol) and Pd(PPh₃)₄ (0.63 g) inEtOAc/CH₂Cl₂ (53:47, 190 mL) yielded after 2 h and after FC (EtOAc, thenCH₂Cl₂/MeOH 95:5 to 90:10) amino acid 98 (4.31 g, 67%).

Data of 98: C₃₀H₃₈FN₃O₈ (587.6). HPLC (10% CH₃CN): R_(t)=3.86 (84).LC-MS (method 9a): R_(t)=1.76; 588 ([M+H]⁺), 488 ([M+H-Boc]⁺).

Synthesis of the Alloc Protected Amino Acid 99

Following procedure C.1, the reaction of the amino acid 98 (4.3 g, 7.3mmol), allyl choroformate (0.86 mL, 8.0 mmol) and Na₂CO₃ (1.2 g, 11mmol) in dioxane (62 mL) and H₂O (60 mL) gave acid 99 (5.07 g, 100%).

Synthesis of the Protected Diamide 100

Following procedure C.2, the acid 99 (4.9 g, 7.3 mmol) was reacted withsarcosine allylester p-toluenesulfonate (46.p-TsOH, 2.6 g, 8.8 mmol),HOAt (1.5 g, 11 mmol), HATU (4.2 g, 11 mmol) and i-Pr₂NEt (6.2 mL, 36mmol) in DMF (75 mL) to afford the protected amino acid 100 (4.37 g,76%).

Data of 100: C₄₀H₅₁FN₄O₁₁ (782.8). HPLC (50% CH₃CN): R_(t)=3.56 (99).LC-MS (method 9a): R_(t)=2.45; 783 ([M+H]⁺), 683 ([M+H-Boc]⁺).

Synthesis of the Deprotected Amino Acid 101

Following procedure C.3, the reaction of the protected amino acid 100(4.36 g, 5.6 mmol), 1,3-dimethylbarbituric acid (2.1 g, 13 mmol) andPd(PPh₃)₄ (0.32 g) in EtOAc/CH₂Cl₂ (45:55, 106 mL) yielded amino acid101 (3.46 g, 93%).

Data of 101: C₃₃H₄₃FN₄O₉ (658.7). LC-MS (method 9b): R_(t)=1.74; 659([M+H]⁺), 559 ([M+H-Boc]⁺).

Synthesis of the Protected Macrolactam Ex.115

According to procedure F.1.1, amino acid 101 (3.44 g, 5.2 mmol) in dryCH₂Cl₂ (50 mL) was treated with T3P (50% in EtOAc, 6.2 mL, 10 mmol) andi-Pr₂NEt (3.6 mL, 21 mmol) in dry CH₂Cl₂ (470 mL) to give afterFC(CH₂Cl₂/MeOH 95:5) macrolactam Ex.115 (2.95 g, 90%).

Data of Ex.115: C₃₃H₄₁FN₄O₈ (640.7). HPLC (20% CH₃CN): R_(t)=4.05 (93).LC-MS (method 9c): R_(t)=2.08; 641 ([M+H]⁺). ¹H-NMR (DMSO-d₆): complexspectrum, mixture of isomers, 7.38 (s, 5 H), 7.35-6.95 (several m, 2 H),6.81-6.72 (several m, 0.4 H), 6.64 (dd, J=3.1, 8.2, 0.25 H), 6.39 (dd,J=3.2, 7.7, 0.25 H), 6.30 (dd, J=3.3, 8.2, 0.1 H), 5.37-4.99 (m, 3 H),4.60-3.60 (several m, 9 H), 3.20-2.60 (several m and s, 8 H), 2.40-1.70(several m, 4 H), 1.45, 1.43, 1.42, 1.38 (4 s, Boc).

Synthesis of the Acid Ex.116:

According to procedure H, the ester Ex.115 (1.2 g, 1.9 mmol) washydrogenated in MeOH (120 mL) in the presence of the catalyst (0.6 g)for 2 h to afford the acid Ex.116 (1.02 g, 99%).

Data of Ex.116: C₂₆H₃₅FN₄O₈ (550.6). HPLC (10% CH₃CN): R_(t)=3.47 (20),3.55 (75). LC-MS: (method 9c): R_(t)=1.53, 1.58; 551 ([M+H]⁺).

Core 08: Synthesis of Ex.132 and Ex.133 (Scheme 12)

Synthesis of the Mitsunobu Product 102

Following procedure E.1.2, the reaction of phenol 56 (2.0 g, 4.7 mmol),alcohol 84 (2.08 g, 5.6 mmol), and CMBP (2.25 g, 9.3 mmol) in drytoluene (80 mL) afforded after 3 h and after FC (hexane/EtOAc 1:1 to1:2) the protected amino acid 102 (2.06 g, 56%).

Synthesis of the Amino Acid 103

Following procedure E.2, the reaction of 102 (2.05 g, 2.6 mmol),1,3-dimethylbarbituric acid (1.0 g, 6.3 mmol) and Pd(PPh₃)₄ (0.15 g) inEtOAc/CH₂Cl₂ (55:45; 45 mL) yielded after 2 h and after FC (EtOAc, thenCH₂Cl₂/MeOH 95:5 to 70:30) amino acid 103 (1.45 g, 85%).

Data of 103: C₃₃H₄₃FN₄O₉ (658.7). HPLC (5% CH₃CN): R_(t)=4.04 (97).LC-MS (method 9c): R_(t)=1.87, 659 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.132

According to procedure F.1.1, the amino acid 103 (1.44 g, 2.19 mmol) indry CH₂Cl₂ (40 mL) was treated with T3P (50% in EtOAc, 2.6 mL, 4.37mmol) and i-Pr₂NEt (1.5 mL, 8.74 mmol) in dry CH₂Cl₂ (170 mL) to giveafter FC(CH₂Cl₂/MeOH 95:5) the macrolactam Ex.132 (1.36 g, 96%).

Data of Ex.132: C₃₃H₄₁FN₄O₈ (640.7). LC-MS (method 2): R_(t)=1.93 (100),641 ([M+H]⁺); LC-MS (method 9c): R_(t)=2.12, 641 ([M+H]⁺).

¹H-NMR (DMSO-d₆): complex spectrum, mixture of isomers, 7.38 (s, 5 H),7.35-6.99 (several m, 2 H), 6.85-6.73 (several m, 0.4 H), 6.65 (dd,J=3.1, 8.2, 0.25 H), 6.39 (dd, J=3.1, 7.9, 0.25 H), 6.30 (dd, J=3.3,8.1, 0.1 H), 5.37-4.99 (m, 3 H), 4.6-3.6 (several m, 9 H), 3.2-2.6(several m and s, 8 H), 2.4-1.7 (several m, 4 H), 1.45, 1.43, 1.41, 1.38(4 s, Boc).

Synthesis of the Acid Ex.133:

According to procedure H, ester Ex.132 (1.13 g, 1.7 mmol) washydrogenated in MeOH (110 mL) in the presence of the catalyst (0.56 g)for 4 h to afford acid Ex.133 (0.92 g, 94%).

Data of Ex.133: C₂₆H₃₅FN₄O₈ (550.6). HPLC (5% CH₃CN): R_(t)=3.65 (27),3.72 (71). LC-MS: (method 9c): R_(t)=1.53, 551 ([M+H]⁺); 1.57, 551([M+H]⁺).

Core 09: Synthesis of Ex.142 and Ex.143 (Scheme 13)

Synthesis of the Mitsunobu Product 104

Following procedure E.1.2, the reaction of the phenol 54 (3.1 g, 7.2mmol), alcohol 86 (3.34 g, 8.7 mmol), and CMBP (3.49 g, 14.4 mmol) indry toluene (123 mL) afforded after 3 h and after FC (hexane/EtOAc 1:1to 1:2) the protected amino acid 104 (4.11 g, 71%).

Synthesis of the Amino Acid 105

Following procedure E.2, the reaction of 104 (4.07 g, 5.1 mmol),1,3-dimethylbarbituric acid (1.9 g, 12 mmol) and Pd(PPh₃)₄ (0.3 g) inEtOAc/CH₂Cl₂ (45:55, 90 mL) yielded after 2 h and after FC (EtOAc, thenCH₂Cl₂/MeOH 95:5 to 70:30) the amino acid 105 (3.19 g, 93%).

Data of 105: C₃₄H₄₅FN₄O₉ (672.7). HPLC (5% CH₃CN): R_(t)=3.96 (88).LC-MS (method 9c): R_(t)=1.83, 673 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.142

According to procedure F.1.1, amino acid 105 (2.4 g, 3.6 mmol) in dryCH₂Cl₂ (40 mL) was treated with T3P (50% in EtOAc, 4.2 mL, 7.1 mmol) andi-Pr₂NEt (2.4 mL, 14.2 mmol) in dry CH₂Cl₂ (300 mL) to give afterFC(CH₂Cl₂/MeOH 95:5) the macrolactam Ex.142 (1.92 g, 82%).

Data of Ex.142: C₃₄H₄₃FN₄O₈ (654.7). HPLC (30% CH₃CN): R_(t)=3.50 (89).LC-MS (method 9b): R_(t)=2.01; 655 ([M+H]⁺), 599 ([M+H-tBu]⁺), 555([M+H-Boc]⁺). ¹H-NMR (DMSO-d₆): complex spectrum, mixture of isomers,7.41-7.38 (m, 5 H), 7.37-7.14 (m, 3 H), 6.80-6.67 (m, 1 H), 5.45-5.13(m, 3 H), 4.60-3.30 (several m, 8 H), 3.10-2.50 (several m and s, 8 H),2.50-1.80 (several m, 6 H), 1.39, 1.38, 1.36 (3 s, Boc).

Synthesis of the Acid Ex.143:

According to procedure H, ester Ex.142 (1.07 g, 1.6 mmol) washydrogenated in MeOH (100 mL) in the presence of the catalyst (0.53 g)for 4 h to afford acid Ex.143 (0.92 g, 99%).

Data of Ex.143: C₂₇H₃₇FN₄O₈ (564.6). LC-MS: (method 2): R_(t)=1.54 (91),565 ([M+H]⁺).

Core 10: Synthesis of Ex.164 and Ex.165 (Scheme 14)

Synthesis of the Mitsunobu Product 106

Following procedure B.1.2, the reaction of phenol 63 (4.2 g, 9.8 mmol),alcohol 16 (4.4 g, 13 mmol), and CMBP (4.8 g, 20 mmol) in dry toluene(120 mL) afforded after 4 h and FC (hexane/EtOAc 50:50) the protectedamino acid 106 (6.37 g, 86%).

Synthesis of the Amino Acid 107

Following procedure B.2, the reaction of 106 (1.18 g, 1.6 mmol),1,3-dimethylbarbituric acid (0.6 g, 3.8 mmol) and Pd(PPh₃)₄ (90 mg) inEtOAc/CH₂Cl₂ (60:40, 15 mL) yielded after 3 h and after FC(CH₂Cl₂/EtOH100:0 to 80:20) the amino acid 107 (0.86 g, 87%).

Data of 107: C₃₁H₄₄N₄O₈Si (628.8). LC-MS: (method 6): R_(t)=1.08 (88),629 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.164

According to procedure F.1.2, amino acid 107 (310 mg, 0.49 mmol) in dryDMF (5 mL) was treated with FDPP (379 mg, 0.99 mmol) in dry DMF (500 mL)to afford after FC (hexane/EtOAc/MeOH 50:50:0 to 0:95:5) the macrolactamEx.164 (131 mg, 43%).

Data of Ex.164: C₃₁H₄₂N₄O₇Si (610.8). LC-MS: (method 7): R_(t)=1.34(98), 611 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 7.42-7.27 (m, 8 H), 6.98 (dd,J=1.4, 8.2, 1 H), 6.91 (d, J=7.5, 1 H), 6.84 (s, 1 H), 4.98 (s, 2 H),4.50 (d, J=11.9, 1 H), 4.35-4.15 (m, 3 H), 4.06-3.96 (m, 4 H), 3.21 (m,1 H), 3.10-2.95 (m, 2 H), 2.87 (s, 3 H), 2.30-1.80 (m, 4 H), 0.91 (t,J=8.3, 2 H), 0.00 (s, 9 H).

Synthesis of the Amine Ex.165

At 0° C., a solution of TBAF in THF (1 M, 3.9 mL, 3.9 mmol) was added toa solution of Ex.164 (1.2 g, 1.96 mmol) in THF (42 mL). The solution wasallowed to stir at 0° C. to room temperature for 15 h, followed by theaddition of more TBAF in THF (1 M, 1.18 mL, 1.18 mmol). Stirring wascontinued for 2 h. The solution was distributed between CH₂Cl₂ and H₂O.The aqueous phase was repeatedly extracted with CH₂Cl₂. The combinedorganic phase was dried (Na₂SO₄), filtered and concentrated. FC(CH₂Cl₂/MeOH 100:0 to 90:10) afforded Ex.165 (0.76 g, 83%).

Data of Ex.165:C₂₅H₃₀N₄O₅ (466.52). LC-MS: (method 4a): R_(t)=1.49 (99),467 ([M+H]⁺).

Core 11: Synthesis of Ex.181 and Ex.182 (Scheme 15)

Synthesis of the Mitsunobu Product 108

Following procedure B.1.2, the reaction of phenol 65 (10.7 g, 24 mmol),alcohol 16 (10.0 g, 29 mmol), and CMBP (12.0 g, 49 mmol) in dry toluene(362 mL) afforded after FC (hexane/EtOAc 50:50 to 70:30) the protectedamino acid 108 (14.55 g, 78%).

Synthesis of the Amino Acid 109

Following procedure B.2, the reaction of 108 (14.50 g, 19 mmol),1,3-dimethylbarbituric acid (7.0 g, 47.0 mmol) and Pd(PPh₃)₄ (0.1 g) inEtOAc/CH₂Cl₂ (55:45, 203 mL) yielded after 3 h and after FC(CH₂Cl₂/MeOH99:1 to 90:10) the amino acid 109 (11.26 g, 92%).

Data of 109: C₃₂H₄₆N₄O₈Si (642.8). LC-MS: (method 6): R_(t)=1.13 (94),643 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.181

According to procedure F.1.1, the amino acid 109 (4.0 g, 6.2 mmol) indry CH₂Cl₂ (100 mL) was treated with T3P (50% in EtOAc, 7.4 mL, 12.4mmol) and i-Pr₂NEt (4.3 mL, 24.8 mmol) in dry CH₂Cl₂ (560 mL). Prior toaqueous workup, the CH₂Cl₂ was replaced by EtOAc. FC (hexane/EtOAc 50:50to 0:100) afforded the macrolactam Ex.181 (2.11 g, 54%).

Data of Ex.181: C₃₂H₄₄N₄O₇Si (624.8). LC-MS (method 7): R_(t)=1.37 (99),625 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 7.46 (d, J=8.0, 1 H), 7.42 (d, J=7.2, 1H), 7.34-7.23 (m, 6 H), 7.06 (d, J=8.2, 1 H), 6.82 (d, J=7.4, 1 H), 6.78(s, 1 H), 5.02-4.86 (m, 3 H), 4.13 (t, J=8.5, 1 H), 4.06-3.67 (m, 7 H),3.05 (br. m, 1 H), 2.88 (br. m, 1 H), 2.88 (s, 3 H), 2.15 (m, 2 H), 1.51(br. m, 2 H), 1.33 (br. m, 1 H), 1.12 (br. m, 1 H), 0.91 (t-like m, Jca. 8.4, 2 H), 0.00 (s, 9 H).

Synthesis of the Amine Ex.182

According to procedure I.2, carbamate Ex.181 (844 mg, 1.3 mmol) in THF(34 mL) was treated with TBAF solution (4.1 mL) to afford afterFC(CH₂Cl₂/MeOH 90:10) the amine Ex.182 (620 mg, 95%)

Data of Ex.182: C₂₆H₃₂N₄O₅ (480.5). LC-MS: (method 2): R_(t)=1.35 (99),481 ([M+H]⁺).

Core 12: Linear Synthesis of Ex.196 and Ex.197 (Scheme 16)

Synthesis of the Mitsunobu Product 110

Following procedure B.1.1, the reaction of phenol 59 (5.22 g, 12.6mmol), alcohol 16 (5.2 g, 15.2 mmol), PPh₃ (5.0 g, 19 mmol) in drybenzene (124 mL) and DEAD (40% in toluene, 7.0 mL, 15.2 mmol) in drybenzene (36 mL) afforded after FC (hexane/EtOAc 60:40 to 40:60) theprotected amino acid 110 (8.3 g, 88%, contaminated with sometriphenylphosphine oxide; acceptable for the use in the next stopwithout further purification).

Synthesis of the Amino Acid 111

Following procedure B.2, the reaction of 110 (4.15 g, 5.62 mmol),1,3-dimethylbarbituric acid (2.19 g, 14.0 mmol) and Pd(PPh₃)₄ (0.71 g)in EtOAc/CH₂Cl₂ 1:1 (60 mL) yielded after 1 h and after FC(CH₂Cl₂/EtOH95:5 to 90:10 then CH₂Cl₂/MeOH 90:10 to 70:30) amino acid 111 (2.75 g,80%).

Data of 111: C₃₀H₄₂N₄O₈Si (614.8). HPLC (10% CH₃CN): R_(t)=3.82 (99).LC-MS (method 9a): R_(t)=1.81; 615 ([M+H]⁺).

Synthesis of the Alloc Protected Amino Acid 112

Following procedure C.1, the reaction of the amino acid 111 (1.5 g, 2.4mmol), allyl choroformate (0.29 mL, 2.68 mmol) and Na₂CO₃ (0.72 g, 6.83mmol) in dioxane (40 mL) and H₂O (40 mL) gave acid 112 (1.7 g, 100%).

Synthesis of the Protected Amino Acid 113

Following procedure C.2, the acid 112 (1.7 g, 2.4 mmol) was reacted withsarcosine allylester p-toluenesulfonate (46.p-TsOH, 0.88 g, 2.9 mmol),HOAt (0.5 g, 3.6 mmol), HATU (1.4 g, 3.6 mmol) and i-Pr₂NEt (2.1 mL, 12mmol) in DMF (25 mL) to afford the protected amino acid 113 (1.51 g,75%).

Data of 113: C₄₀H₅₅N₅O₂₂Si (809.9). HPLC (40% CH₃CN): R_(t)=4.43 (91).LC-MS (method 9c): R_(t)=2.51, 810 ([M+H]⁺).

Deprotection to Amino Acid 114

Following procedure C.3, the reaction of the protected amino acid 113(1.5 g, 1.85 mmol), 1,3-dimethylbarbituric acid (0.72 g, 4.6 mmol) andPd(PPh₃)₄ (0.23 g) in EtOAc/CH₂Cl₂ (1:1, 25 mL) yielded amino acid 114(1.05 g, 83%).

Data of 114: C₃₃H₄₇N₅O₉Si (685.8). HPLC (10% CH₃CN): R_(t)=3.85 (95).LC-MS (method 9c): R_(t)=1.78, 686 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.196

According to procedure F.1.2, amino acid 114 (1.0 g, 1.46 mmol) in dryDMF (20 mL) was treated with FDPP (1.12 g, 2.92 mmol) in dry DMF (130mL) to yield after FC (EtOAc) the macrolactam Ex.196 (0.61 g, 63%).

Data of Ex.196: C₃₃H₄₅N₅O₈Si (667.8). LC-MS (method 1a): R_(t)=2.66(100), 668 ([M+H]⁺). LC-MS (method 9c): R_(t)=2.12, 668 ([M+H]⁺), 640.¹H-NMR (CDCl₃): 7.34-7.26 (m, 6 H), 7.17 (d, J=7.6, 1 H), 7.02 (s, 1 H),6.91 (d, J=9.5, 1 H), 5.49 (d, J=9.5, 2 H), 5.10 (m, 1 H), 5.06 (s, 2H), 4.39-4.13 (m, 5 H), 4.00-3.95 (m, 2 H), 3.65 (m, 1 H), 3.36 (br. s,2 H), 3.14 (m, 2 H), 3.09 (s, 3 H), 2.74 (s, 3 H), 2.45 (m, 1 H), 2.08(m, 1 H), 0.98 (m, 2 H), 0.00 (s, 9 H). ¹H-NMR (DMSO-d₆): 7.98 (d,J=9.9, 1 H), 7.52 (d, J=7.9, 1 H), 7.36-7.27 (m, 6 H), 7.18 (s, 1 H),7.06 (dd, J=1.8, 8.1, 1 H), 6.83 (d, J=7.5, 1 H), 5.12 (d, J=12.5, 1 H),5.04 (d, J=12.5, 1 H), 4.87 (d, J=8.8, 1 H), 4.25-3.89 (m, 8 H),3.71-3.66 (m, 2 H), 3.20 (m, 1 H), 3.02 (m, 1 H), 2.97 (s, 3 H), 2.65(s, 3 H), 2.20 (m, 1 H), 2.09 (m, 1 H), 0.92 (t, J=8.2, 2 H), 0.00 (s, 9H).

Synthesis of the Amine Ex.197

According to procedure I.1, carbamate Ex.196 (120 mg, 0.18 mmol) indioxane (3 mL) was treated with 4 M HCl-dioxane (3 mL) to affordEx.197.HCl (59 mg, 58%).

Data of Ex.197.HCl: C₂₇R₃₃N₅O₆.HCl (523.5, free base). HPLC (5% CH₃CN):R_(t)=3.05 (83). LC-MS (method 9c): R_(t)=1.12, 524 ([M+H]⁺). ¹H-NMR(DMSO-d₆): 8.53 (br. s, NH₃), 8.03 (d, =9.9, 1 H), 7.41-7.31 (m, 7 H),7.15 (m, 1 H), 6.85 (d, J=7.5, 1 H), 5.14 (d, J=12.5, 1 H), 5.04 (d,J=12.5, 1 H), 4.86 (dd, J ca. 2.2, 11.0, 1 H), 4.42-4.13 (m, 2 H), 4.05(t, J=8.5, 1 H), 3.96 (d, J=17.8, 1 H), 3.85-3.75 (m, 2 H), 3.65 (br. m,1 H), ca. 3.3-3.1 (m, 3 H, partially superimposed by the H₂O signal),2.97 (s, 3 H), 2.67 (s, 3 H), 2.42 (m, 1 H), 2.18 (br. q, J ca. 11.1, 1H).

Core 12: Convergent Synthesis of Ex.197 and Ex.198 (Scheme 17)

Synthesis of the Mitsunobu Product 115

Following procedure E.1.1, phenol 59 (4.6 g, 11 mmol) was treated for 40h with alcohol 81 (5.0 g, 13 mmol), DEAD (40% in toluene, 6.1 mL, 13mmol) and PPh₃ (4.4 g, 17 mmol) in dry benzene (150 mL). After 2 h andafter 18 h, more PPh₃ (1.82 g, 6.9 mmol), alcohol 81 (2.04 g, 5.5 mmol)in benzene (50 mL), and DEAD (40% in toluene, 2.55 mL, 5.6 mmol) inbenzene (13 mL) were added. FC (hexane/EtOAc 50:50 to 90:10) affordedthe protected amino acid 115.1 (2.5 g, 29%).

Following procedure E.1.2, the reaction of phenol 59 (2.9 g, 7.0 mmol),alcohol 81, (5.7 g, 15 mmol) and CMBP (5.1 g, 21 mmol) in dry toluene(121 mL) afforded after FC (hexane/EtOAc 20:80 to 90:10) the protectedamino acid 115.2 (2.92 g, 54%).

Synthesis of the Amino Acid 116

Following procedure E.2, the reaction of 115.1 (3.17 g, 4.14 mmol),1,3-dimethylbarbituric acid (1.62 g, 10.3 mmol) and Pd(PPh₃)₄ (0.53 g)in EtOAc/CH₂Cl₂ (1:1, 46 mL) yielded after 1 h and after FC(CH₂Cl₂/MeOH90:10 to 70:30) the amino acid 116.1 (1.86 g, 70%).

Data of 116.1: C₃₂H₄₃N₅O₉ (641.7). HPLC (5% CH₃CN): R_(t)=3.65 (100).LC-MS (method 9c): R_(t)=1.60, 642 ([M+H]⁺).

Following procedure E.2, the reaction of 115.2 (2.9 g, 3.8 mmol),1,3-dimethylbarbituric acid (1.5 g, 9.5 mmol) and Pd(PPh₃)₄ (0.48 g) inEtOAc/CH₂Cl₂ (1:1, 46 mL) yielded after 1 h and after FC(CH₂Cl₂/MeOH90:10 to 70:30) the amino acid 116.2 (2.0 g, 83%).

Data of 116.2: C₃₂H₄₃N₅O₉ (641.7). HPLC (5% CH₃CN): R_(t)=3.73 (98).LC-MS (method 9c): R_(t)=1.61, 642 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.198

According to procedure F.1.1, the amino acid 116.1 (1.0 g, 1.6 mmol) indry CH₂Cl₂ (200 mL) was treated with T3P (50% in EtOAc, 1.8 mL, 3.1mmol) and i-Pr₂NEt (1.1 mL, 6.2 mmol) in dry CH₂Cl₂ (1400 mL) to affordafter FC (EtOAc/MeOH 95:5 to 80:20) the macrolactam Ex.198 (containing15% of the epimer Ex.231; 0.38 g, 39%).

Data of Ex.198: C₃₂H₄₁N₅O₈ (623.7). LC-MS: (method 2): R_(t)=1.78 (84),624 ([M+H]⁺); 1.82 (15). LC-MS (method 9c): R_(t)=1.87, 624 ([M+H]⁺).

¹H-NMR (CDCl₃): 7.42-7.25 (m, 7 H), 7.07 (s, 1 H), 7.00 (d, J=8.2, 1 H),5.59 (d, J=9.5, 1 H), 5.38 (br. d, J ca 7.9, 1 H), 5.18 (dd, J=2.5,12.2, 1 H), 5.13 (s, 2 H), 4.43-4.01 (m, 5 H), 3.73 (m, 1 H), 3.47 (d,J=17.7, 1 H), 3.33 (d, J=17.7, 1 H), 3.20-3.11 (m, 2 H), 3.17 (s, 3 H),2.81 (s, 3 H), 2.50 (m, 1 H), 2.15 (m, 1 H), 1.51 (s, Boc, majorisomer), 1.45 (s, Boc, minor isomer); ¹H-NMR (DMSO-d₆): 7.97 (d, J=10.3,1 H), 7.41-7.30 (m, 7 H), 7.18 (s, 1 H), 7.09 (d, J=8.2, 1 H), 6.85(J=7.6, 1 H), 5.12 (d, J=12.5, 1 H), 5.05 (d, J=12.6, 1 H), 4.89 (J=9.6,1 H), 4.30-3.55 (m, 6 H), 3.40 (2 H, superimposed by H₂O signal),3.25-3.00 (m, 2 H), 2.99 (s, 3 H), 2.65 (s, 3 H), 2.22 (m, 1 H), 2.05(br. q, 1 H), 1.41, (s, 9 H).

According to procedure F.1.1, amino acid 116.2 (0.85 g, 1.3 mmol) in dryCH₂Cl₂ (170 mL) was treated with T3P (50% in EtOAc, 1.56 mL, 2.6 mmol)and i-Pr₂NEt (0.91 mL, 5.3 mmol) in dry CH₂Cl₂ (1190 mL) to afford afterFC (EtOAc/MeOH 95:5 to 80:20) the macrolactam Ex.198 and its epimerEx.231 (ca 1:1 mixture; 0.61 g, 73%).

Data of the mixture Ex.198/Ex.231: C₃₂H₄₁N₅O₈ (623.7). LC-MS: (method2): R_(t)=1.78 (44), 624 ([M+H]⁺); 1.82 (56), 624 ([M+H]⁺). ¹H-NMR(CDCl₃): complex spectrum, mixture of epimers, 7.41-7.20 (m, 6 H),7.07-6.92 (m, 3 H) 5.8-4.8 (several m, 5 H), 4.3-3.0 (several m, 10 H),3.16 (s, NCH₃), 2.81 (s, NCH₃), 2.58-2.45 (m, 1 H), 2.19-2.03 (m, 1 H),1.51, 1.41 (2 s, 9 H)

Synthesis of the Amine Ex.197

According to procedure J, carbamate Ex.198/Ex.231 (ca. 85:15, 749 mg,1.2 mmol) in dioxane (7.5 mL) was treated with 4 M HCl-dioxane (15 mL)to afford Ex.197.HCl/Ex.232.HCl (607 mg, 90%). Data ofEx.197.HCl/Ex.232.HCl: C₂₇H₃₃N₅O₆.HCl (523.5, free base). LC-MS (method2): R_(t)=1.26 (75), 1.33 (14); 524 ([M+H]⁺).

¹H-NMR (DMSO-d₆), major component Ex.197′HCl: spectrum identical withthe one described above for compound Ex.197′HCl (cf. Scheme 16).

According to procedure J, carbamate Ex.198/Ex.231 (ca. 1:1, 1.32 g, 2.12mmol) in dioxane (13 mL) was treated with 4 M HC1-dioxane (26 mL) toafford after separation of the isomers by preparative RP-HPLC (method 1)Ex.197 TFA (460 mg, 34%) and Ex.232 TFA (470 mg, 35%).

Data of Ex.197 TFA: C₂₇H₃₃N₅O₆.C₂HF₃O₂ (523.5, free base). LC-MS (method2): R_(t)=1.25 (99), 524 ([M+H]⁺). LC-MS (method 7): R_(t)=0.74 (97),524 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 8.34 (br. s, NH₃ ⁺), 8.07 (d, J=9.9, 1H), 7.43-7.33 (m, 6 H), 7.20 (s, 1 H), 7.10 (dd, J=1.5, 8.2, 1 H), 6.87(d, J=7.4, 1 H), 5.17 (d, J=12.5, 1 H), 5.05 (d, J=12.5, 1 H), 4.87 (br.dd, 1 H), 4.27-4.16 (m, 2 H), 4.06 (t, J=8.6, 1 H), 4.01-3.91 (m, 2 H),3.82 (t-like dd, J ca. 8.1, 1 H), 3.70 (br. m, 1 H), 3.35-3.20 (m, 3 H),2.98 (s, 3 H), 2.70 (s, 3 H), 2.49 (m, 1 H), 2.18 (br. q, J ca 11.0, 1H).

Data of Ex.232 TFA: See below; Core 14.

Core 13: Synthesis of Ex.215 and Ex.216 (Scheme 18)

Synthesis of the Mitsunobu Product 117

Following procedure B.1.1, the reaction of phenol 59 (2.1 g, 5.1 mmol),alcohol 20 (2.1 g, 6.1 mmol), PPh₃ (2.0 g, 7.6 mmol) in dry benzene (50mL) and DEAD (40% in toluene, 2.8 mL, 6.1 mmol) in dry benzene (14 mL)afforded, after further addition of PPh₃ (0.84 g, 3.2 mmol), alcohol 20(0.88 g, 2.6 mmol) in benzene (21 mL) and DEAD (40% in toluene, 1.2 mL,2.6 mmol) in benzene (6 mL) and after FC (hexane/EtOAc 50:50) theprotected amino acid 117 (3.8 g, 100%).

Synthesis of the Amino Acid 118

Following procedure B.2, the reaction of 117 (7.63 g, 10.3 mmol),1,3-dimethylbarbituric acid (4.03 g, 25.8 mmol) and Pd(PPh₃)₄ (1.31 g)in EtOAc/CH₂Cl₂ (1:1, 110 mL) yielded after 1 h and after FC(CH₂Cl₂/MeOH95:5 to 70:30) the amino acid 118 (3.48 g, 60%).

Data of 118: C₃₀H₄₂N₄O₈Si (614.8). HPLC (10% CH₃CN): R_(t)=3.88 (100).LC-MS (method 9a): R_(t)=1.80, 615 ([M+H]⁺).

Synthesis of the Alloc Protected Amino Acid 119

Following procedure C.1, the reaction of the amino acid 118 (3.36 g, 5.5mmol), allyl choroformate (0.64 mL, 6.0 mmol) and Na₂CO₃ (0.87 g, 8.2mmol) in dioxane (51 mL) and H₂O (51 mL) gave the acid 119 (3.51 g,92%).

Synthesis of the Protected Amino Acid 120

Following procedure C.2, acid 119 (3.47 g, 5.0 mmol) was reacted withsarcosine allylester p-toluenesulfonate (46.p-TsOH, 1.8 g, 6.0 mmol),HOAt (1.0 g, 7.4 mmol), HATU (2.8 g, 7.4 mmol) and i-Pr₂NEt (4.2 mL, 25mmol) in DMF (108 mL) to afford the protected amino acid 120 (3.52 g,88%).

Data of 120: C₄₀H₅₅N₅O₂₂Si (809.9). LC-MS: (method 4b): R_(t)=2.51 (95),810 ([M+H]⁺)

Deprotection to Amino Acid 121

Following procedure C.3, the reaction of the protected amino acid 120(3.49 g, 4.31 mmol), 1,3-dimethylbarbituric acid (1.68 g, 10.8 mmol) andPd(PPh₃)₄ (0.55 g) in EtOAc/CH₂Cl₂ (1:1; 50 mL) yielded the amino acid121 (2.72 g, 92%).

Data of 121: C₃₃H₄₇N₅O₉Si (685.8). LC-MS: (method 4b): R_(t)=1.84 (94),686 ([M+H]⁺)

Synthesis of the Protected Macrolactam Ex.215

According to procedure F.1.2, amino acid 121 (1.33 g, 1.94 mmol) in dryDMF (27 mL) was treated with FDPP (1.49 g, 3.88 mmol) in dry DMF (164mL) to yield after FC (EtOAc/MeOH 95:5) macrolactam Ex.215 (0.89 g,68%).

Data of Ex.215: C₃₃H₄₅N₅O₈Si (667.8). LC-MS: (method 1b): R_(t)=2.60(99), 668 ([M+H]⁺). LC-MS: (method 9c): R_(t)=2.14, 668 ([M+H]⁺). ¹H-NMR(DMSO-d₆): 7.94 (d, J=9.8, 1 H), 7.39-7.27 (m, 7 H), 7.11 (s, 1 H), 6.97(dd, J=1.5, 8.2, 1 H), 6.82 (d, J=7.5, 1 H), 5.05 (s, 2 H), 4.83 (br. d,1 H), 4.25 (br. m, 1 H), 4.17-3.96 (m, 5 H), 3.73 (br. q, J ca. 16.8, 2H), 3.47 (m, 1 H), 3.33 (m, 1 H), 3.19 (m, 2 H), 2.96 (s, 3 H), 2.67 (s,3 H), 2.20 (m, 1 H), 2.00 (m, 1 H), 0.91 (t, J=8.4, 2 H), 0.00 (s, 9 H).

Synthesis of the Amine Ex.216

According to procedure I.1, carbamate Ex.215 (881 mg, 1.3 mmol) indioxane (16 mL) was treated with 4 M HCl-dioxane (16 mL) to affordEx.216.HCl (666 mg, 90%).

Data of Ex.216.HCl: C₂₇H₃₃N₅O₆.HCl (523.5, free base). HPLC (5% CH₃CN):R_(t)=3.11 (91). LC-MS (method 9c): R_(t)=1.19, 524 ([M+H]⁺).

Core 14: Synthesis of Ex.231 and Ex.232 (Scheme 19)

Synthesis of the Mitsunobu Product 122

A mixture of phenol 61 (4.6 g, 11.2 mmol) and PPh₃ (5.27 g, 20.1 mmol)was dissolved in benzene. The solution was concentrated and the residuewas dried i.v. for 20 min. A solution of the alcohol 81, (7.46 g, 20.1mmol) in dry, degassed benzene (120 mL) was added. The resulting mixturewas cooled to 0° C. DEAD (40% in toluene, 11.5 mL, 25.1 mmol) in benzene(10 mL) was slowly added. The solution was stirred at room temperaturefor 16 h. More PPh₃ (1.46 g, 5.6 mmol), alcohol 81 (1.04 g, 2.8 mmol)and at 0° C., a solution of DEAD (40% in toluene, 2.6 mL, 5.7 mmol) inbenzene (2 mL) were added and stirring at room temperature was continuedfor 7 h. More PPh₃ (1.46 g, 5.6 mmol), alcohol 81 (1.04 g, 2.8 mmol),and at 0° C., a solution of DEAD (40% in toluene, 2.6 mL, 5.7 mmol) inbenzene (2 mL) were added. Stirring at room temperature was continuedfor 16 h. The mixture was concentrated. FC (hexane/EtOAc 30:70 to 0:100)afforded 122 (12.8 g, contaminated with ca 40% triphenylphosphinoxide,yield ca 90%). The material was used for the next step without furtherpurification)

Synthesis of the Amino Acid 123

Following procedure E.2, the reaction of the protected amino acid 122(contaminated with ca 40% of triphenylphosphine oxide, 12.8 g, ca 10mmol), 1,3-dimethylbarbituric acid (3.91 g, 25.1 mmol) and Pd(PPh₃)₄(1.27 g) in EtOAc/CH₂Cl₂ (1:1, 120 mL) yielded after 1 h and afterFC(CH₂Cl₂/MeOH 100:0 to 70:30 then CHCl₃/MeOH 70:30) the amino acid 123(2.80 g, 44%).

Data of 123: C₃₂H₄₃N₅O₉ (641.7). LC-MS: (method 2): R_(t)=1.56 (94), 642([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.231

According to procedure F.1.2, amino acid 123 (3.29 g, 5.13 mmol) in dryDMF (150 mL) was added within 4 h at 60° C. to FDPP (3.94 g, 10.3 mmol)in dry DMF (4980 mL) to afford after 16 h at 60° C. and after FC(EtOAc/MeOH 100:0 to 95:5) the macrolactam Ex.231 (contained ca 15% ofits epimer Ex.198; 2.5 g, 78%).

Data of Ex.231: C₃₂H₄₁N₅O₈ (623.7). LC-MS: (method 2): R_(t)=1.78 (12),1.82 (83), 624 ([M+H]⁺). LC-MS: (method 7): R_(t)=1.16 (18), 624([M+H]⁺); 1.18 (80), 624 ([M+H]⁺). ¹H-NMR (CDCl₃): complex spectrum, twoepimers; 7.38-7.22 (m, 6H), 7.06-6.90 (m, 3 H), 5.80-4.80 (several m, 4H), 5.08, 5.12 (2s, 2 H), 4.43-2.80 (several br. m, 15 H), 2.51 (m, 1H), 2.19-2.03 (m, 1 H), 1.50, 1.42 (2 s, 9 H).

Synthesis of the Amine Ex.232

According to procedure J, carbamate Ex.231 (containing 15% of the epimerEx.198; 1.42 g, 2.3 mmol) in dioxane (30 mL) was treated with 4 MHCl-dioxane (45 mL) to afford after preparative RP-HPLC (method 1)Ex.232 TFA (1.10 g, 71%) and Ex.197 TFA (0.27 g, 17%).

Data of Ex.232 TFA: C₂₇H₃₃N₅O₆.C₂HF₃O₂ (523.5, free base). LC-MS (method2): R_(t)=1.32 (99), 524 ([M+H]⁺). ¹H-NMR (DMSO-d₆): complex spectrum,mixture of isomers; 8.40 (br. s), 8.20 (br. s), 7.84 (d, J=7.1),7.50-6.80 (several m), 5.25-3.40 (several m, partially superimposed bythe H₂O signal), 3.30-2.80 (m), 3.04 (s, NCH₃), 2.98 (s, NCH₃), 2.67 (s,NCH₃), 2.64 (s, NCH₃), 2.6-1.9 (several m).

Data of Ex.197 TFA: See above; Core 12.

Core 15 and Core 16 Synthesis of Ex.238 and Ex.239 (Scheme 20)

Synthesis of the Mitsunobu Product 124

Following procedure E.1.1, phenol 77 (1.63 g, 8.5 mmol), alcohol 85(5.72 g, 12.8 mmol) and PPh₃ (4.02 g, 15.3 mmol) in dry benzene (80 mL)were treated with DEAD (40% in toluene, 8.79 mL, 19.2 mmol) for 20 h.Purification by FC (hexane/EtOAc 20:80 to 100:0) then (hexane/EtOAc50:50 to 20:80) afforded the protected amino acid 124 (1.96 g, 37%).

Synthesis of the Macrocycle Ex.238

Dichloro-[1,3-bis(mesityl)-2-imidazoldinylidene]-(3-phenyl-1H-inden-1-ylidene)(tricyclohexylphosphine)ruthenium (II) (Umicore M2 catalyst; 88 mg) wasadded to a solution of 124 (1160 mg, 1.29 mmol) in dry, degassed CH₂Cl₂(170 mL). The solution was stirred in a sealed tube at 40° C. for 68 h,followed by 45 h at room temperature. During this period further equalportions of catalyst (in total 350 mg) were added after 20 h, 28 h, 44h, and 52 h. The solution was concentrated. FC (hexane/EtOAc 70:30 to0:100) gave Ex.238 (350 mg, 46%, mixture of two isomers, ratio>9:1,acceptable for the use in the next step). An analytical sample (69 mg)was further purified by preparative RP-HPLC (method 2) to afford pureEx.238 (major isomer; 45 mg).

Data of Ex.238 (major isomer): C₃₂H₄₀N₄O₇ (592.6). LC-MS: (method 4a):R_(t)=2.23 (92), 593 ([M+H]⁺). ¹H-NMR (CDCl₃): 7.62-7.31 (m, 6 H), 7.07(d, J=7.6, 1 H), 6.99 (dd, J=2.0, 7.9, 1 H), 6.85 (s, 1 H), 5.69-5.61(m, 2 H), 5.48 (d, J=8.2, 1 H), 5.21 (m, 1 H), 5.10 (s, 2 H), 4.76 (d,J=10.1, 1 H), 4.54 (dt, J=3.5, 7.9, 1 H), 4.41-4.25 (m, 2 H), 4.13 (d,J=10.7, 1 H), 3.97 (m, 1 H), 3.62 (m, 2 H), 3.48 (m, 1 H), 3.10 (s, 3H), 2.73 (m, 1 H), 2.60-2.45 (m, 2 H), 2.02 (m, 1 H), 1.46 (s, 9 H).

Synthesis of Amine Ex.239

A solution of Ex.238 (430 mg, 0.73 mmol) in MeOH/THF 1:3, 36 mL) washydrogenated for 3.5 h at room temperature and at normal pressure in thepresence of palladium hydroxide on activated charcoal (moistened with50% H₂O; 215 mg). The mixture was filtered through a pad of celite. Thefiltrate was concentrated to give Ex.239 (355 mg, quantitative; used inthe next step without further purification).

An analytical sample (68 mg) was purified by preparative RP-HPLC (method2) to afford pure Ex.239 (37 mg).

Data of Ex.239: C₂₄H₃₆N₄O₅ (460.6): LC-MS (method 7): R_(t)=0.88 (97),461 ([M+H]⁺). ¹H-NMR (DMSO-d₆): 7.36 (t, J=7.8, 1 H), 7.25 (d, J=6.1, 1H), 7.03 (dd, J=1.6, 8.2, 1 H), 6.88-6.65 (m, 2 H), 4.51 (d, J=8.3, 1H), 4.18 (t, J=10.3, 2 H), 4.09 (br. s, 1 H), 3.96 (br. m, 2 H),3.19-2.72 (m, 3 H), 2.92 (s, 3 H), 2.34 (m, 2 H), 2.05 (br. q, 1 H),1.82 (m, 1 H), 1.60-0.85 (m, 5 H), 1.40 (s, 9 H), 0.82 (m, 1 H).

Core 17: Synthesis of Ex.248 and Ex.249 (Scheme 21)

Synthesis of the Mitsunobu Product 125

Following procedure E.1.1, phenol 68 (6.0 g, 14.6 mmol), alcohol 82(9.75 g, 26.2 mmol), and PPh₃ (6.88 g, 26.2 mmol) were treated in drybenzene (160 mL) with DEAD (40% in toluene, 15 mL, 32.8 mmol) for 40 h.After 18 h and after 25 h, more PPh₃ (1.27 g, 4.8 mmol) and DEAD (40% intoluene, 2.23 mL, 4.9 mmol) in benzene (2 mL) were added. FC(hexane/EtOAc 30:70 to 20:80) afforded the protected amino acid 125(16.85 g, contaminated with ca 40% triphenylphosphinoxide, yield ca85%). The material was used for the next step without furtherpurification)

Synthesis of the Amino Acid 126

Following procedure E.2, the reaction of 125 (16.8 g, contaminated withca 40% of triphenylphosphine oxide, ca. 12 mmol), 1,3-dimethylbarbituricacid (4.80 g, 30.8 mmol) and Pd(PPh₃)₄ (1.56 g) in EtOAc/CH₂Cl₂ (1:1,170 mL) yielded after 1 h and after FC(CH₂Cl₂/MeOH 0:100 to 70:30, thenCHCl₃/MeOH 70:30) amino acid 126 (4.15 g, ca. 52%).

Data of 126: C₃₃H₄₄N₄O₉ (640.7). HPLC (10% CH₃CN): R_(t)=3.67 (69).LC-MS (method 9c): R_(t)=1.75, 641 ([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.248

According to procedure F.1.1, amino acid 126 (4.55 g, 7.1 mmol) in dryCH₂Cl₂ (120 mL) was added within 3 h to T3P (50% in EtOAc, 8.37 ml, 14.2mmol) and i-Pr₂NEt (4.83 ml, 28.4 mmol) in dry CH₂Cl₂ (6660 mL). Priorto aqueous workup, CH₂Cl₂ was replaced with EtOAc. FC(CH₂Cl₂/MeOH 100:0to 95:5) yielded the macrolactam Ex.248 (2.38 g, 54%).

Data of Ex.248: C₃₃H₄₂N₄O₈ (622.7). LC-MS: (method 2): R_(t)=1.83 (100),623 ([M+H]⁺). LC-MS: (method 9c): R_(t)=1.97, 623 ([M+H]⁺). ¹H-NMR(DMSO-d₆): 7.45-7.34 (m, 5 H), 7.15-6.78 (m, 5 H), 5.25 (s, 2 H), 5.08(d, J=12.8, 1 H), 4.62 (d, J=13.5, 2 H), 4.29 (m, 1 H), 4.09 (d, J=7.3,1 H), 3.89 (d, J=12.4, 1 H), 3.54 (br. t, 1 H), 3.27 (m, 1 H), 3.07 (s,3 H), 2.80 (m, 1 H), 2.71 (s, 3 H), 2.28-2.06 (m, 4 H), 1.94 (m, 1 H),1.71 (m, 1 H), 1.39 (s, 9 H).

Synthesis of the Acid Ex.249:

According to procedure H, the ester Ex.248 (2.16 g, 3.5 mmol) washydrogenated in MeOH (130 mL)/THF (40 mL) in the presence of thecatalyst (1.09 g) for 2.5 h to afford the acid Ex.249 (1.83 g, 99%).

Data of Ex.249: C₂₆H₃₆N₄O₈ (532.6). LC-MS: (method 2): R_(t)=1.42 (95),533 ([M+H]⁺).

Core 18: Synthesis of Ex.272, Ex.273, and Ex.274 (Scheme 22)

Synthesis of the Mitsunobu Product 127

Following procedure E.1.1, the reaction of phenol 71 (6.47 g, 15.7mmol), the alcohol 81 (10.5 g, 28.2 mmol), DEAD (40% in toluene, 26 mL,56.3 mmol), and PPh₃ (14.8 g, 56.3 mmol) in dry benzene (380 mL)afforded after 2 h at room temperature and after aqueous workup (EtOAc,sat. aq. Na₂CO₃ soln, sat. aq. NaCl soln), drying (Na₂SO₄),concentration of the organic layer and FC (hexane/EtOAc 30:70, 0:100,then CH₂Cl₂/MeOH 90:10) the protected amino acid 127 (12.0 g, 99%).

Synthesis of the Amino Acid 128

Following procedure E.2, the reaction of 127 (12.0 g, 16 mmol),1,3-dimethylbarbituric acid (5.9 g, 38.0 mmol) and Pd(PPh₃)₄ (0.9 g) inEtOAc/CH₂Cl₂ (55:45, 275 mL) yielded after 2 h and after FC (EtOAc, thenCH₂Cl₂/MeOH 90:10 to 60:40) the amino acid 128 (9.05 g, 90%).

Data of 128: C₃₁H₄₂N₆O₉ (642.7). LC-MS: (method 7): R_(t)=0.90 (94), 643([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.272

According to procedure F.1.1, the amino acid 128 (5.04 g, 7.8 mmol) indry CH₂Cl₂ (100 mL) was treated with T3P (50% in EtOAc, 9.2 mL, 16 mmol)and i-Pr₂NEt (5.4 mL, 31 mmol) in dry CH₂Cl₂ (700 mL) to afford afterFC(CH₂Cl₂/MeOH 39:1 to 19:1) the epimeric macrolactams Ex.272 (1.90 g,38%).

Data of Ex.272: C₃₄H₄₀N₆O₈ (624.7). LC-MS: (method 2): R_(t)=1.61 (99),625 ([M+H]⁺). LC-MS: (method 7): R_(t)=1.01 (99), 625 ([M+H]⁺). ¹H-NMR(DMSO-d₆): 8.47 (d, J=2.6, 1 H), 8.12 (s, 1 H), 7.95 (d, J=9.6, 1 H),7.61 (s, 1 H), 7.40-7.29 (m, 6 H), 5.10 (d, J=12.6, 1 H), 5.04 (d,J=12.6, 1 H), 4.98 (br. d, J=10.7, 1 H), 4.16 (br. d, J=11.8, 1 H),4.10-3.90 (m, 4 H), 3.71 (br. t, J ca. 8.4, 1 H), 3.65-3.40 (m, 2 H),3.23 (br. dd, J=11.1, 15.2, 1 H), 3.04 (s, 3 H), 2.92 (t, J=9.6, 1 H),2.66 (s, 3 H), 2.12 (m, 1 H), 2.09 (br. q, 1 H), 1.42 (s, 9 H).

Synthesis of the Amine Ex.273

According to procedure J, carbamate Ex.272 (3.12 g, 5 mmol) in dioxane(31 mL) was treated with 4 M HCl-dioxane (62 mL) to afford Ex.273.2HCl(2.9 g, 97%)

Data of Ex.273.2HCl: C₂₆H₃₂N₆O₆.2HCl (524.5, free base). LC-MS (method2): R_(t)=1.31 (92), 525 ([M+H]⁺).

Synthesis of the Amine Ex.274

According to procedure K, carbamate Ex.272 (200 mg, 0.32 mmol) washydrogenated in MeOH (20 mL) in the presence of the catalyst (100 mg) toafford Ex.274 (154 mg, 97%).

Data of Ex.274: C₂₃H₃₄N₆O₆. (490.5). LC-MS (method 2): R_(t)=1.26 (98),(491 ([M+H]⁺).

Core 19: Synthesis of Ex.297 and Ex.298 (Scheme 23)

Synthesis of the Mitsunobu Product 129

Following procedure E.1.2, the reaction of phenol 75 (4.58 g, 9.9 mmol),alcohol 81 (5.5 g, 15 mmol), and CMBP (4.8 g, 20 mmol) in dry toluene(24 mL) afforded after FC (hexane/EtOAc 1:3) the protected amino acid129 (5.54 g, 68%).

Synthesis of the Amino Acid 130

Following procedure E.2, the reaction of 129 (5.53 g, 6.8 mmol),1,3-dimethylbarbituric acid (2.5 g, 16 mmol) and Pd(PPh₃)₄ (0.39 g) inEtOAc/CH₂Cl₂ 55:45 (118 mL) yielded after 2 h and after FC(CH₂Cl₂/MeOH95:5 to 70:30) the amino acid 130 (1.45 g, 85%).

Data of 130: C₃₆H₄₅N₅O₉ (691.7). LC-MS (method 7): R_(t)=1.09 (96), 692([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.297

According to procedure F.1.1, amino acid 130 (2.57 g, 3.7 mmol) in dryCH₂Cl₂ (40 mL) was treated with T3P (50% in EtOAc, 4.4 mL, 7.4 mmol) andi-Pr₂NEt (2.5 mL, 14.9 mmol) in dry CH₂Cl₂ (330 mL) to give afterFC(CH₂Cl₂/MeOH 99:1 to 90:10) the macrolactam Ex.297 (2.5 g,contaminated with ca 20% i-Pr₂NEt; yield 80%).

Data of Ex.297: C₃₆H₄₃N₅O₈ (673.7). LC-MS: (method 7): R_(t)=1.18 (93),674 ([M+H]⁺).

Aqueous workup (EtOAc, 1 M aq. NaH PO₄ soln) of ananalytical sample (100mg) afforded pure Ex.297 (81 mg).

LC-MS: (method 2): R_(t)=2.20 (93), 674 ([M+H]⁺). ¹H-NMR(DMSO-d₆):complex spectrum, several isomers, 8.51 (d, J=8.5, 0.2; H),8.47 (d, J=8.7, 0.1 H), 8.40 (d, J=8.5, 0.55 H), 8.32 (d, J=8.5, 0.15H), 7.68-7.10 (several m, 10 H), 5.96 (br. s, 0.3 H), 5.90 (br. s, 0. 3H), 5.4-5.0 (m, 2.4 H), 4.8-3.8 (several m, 8 H), 3.3-2.5 (several m ands, 8 H), 2.5-1.6 (several m, 4 H), 1.42, 1.41, 1.36, 1.26 (4 s, Boc).

Synthesis of the Acid Ex.298:

According to procedure H, the ester Ex.297 (2.0 g, contaminated with ca20% i-Pr₂NEt 2.4 mmol) was hydrogenated in MeOH (200 mL) in the presenceof the catalyst (1 g) for 3 h.

The crude product was suspended in diethyl ether (20 mL) stirred for 20min, filtered, washed (diethyl ether) and dried to afford Ex.298 (1.63g, contaminated with 15% i-Pr₂NEt, quantitative yield).

Aqueous workup (CH₂Cl₂, 1 M aq. NaH PO₄ soln) of an analytical sample(200 mg) afforded pure Ex.298 (135 mg).

Data of Ex.298: C₂₉H₃₇N₅O₈ (583.6). LC-MS: (method 4a): R_(t)=1.78 (86),584 ([M+H]⁺).

Core 20: Synthesis of Ex.311 (Scheme 24)

Synthesis of the Mitsunobu Product 131

A solution of phenol 72 (200 mg, 0.34 mmol), alcohol 16 (178 mg, 0.52mmol) and PPh₃ (180 mg, 0.69 mmol) in benzene (5 mL) was degassed. At 0°C., DEAD (40% in toluene, 0.32 mL, 0.69 mmol) was added. The mixture wasstirred at room temperature for 15 h. More of alcohol 16 (178 mg, 0.52mmol) and PPh₃ (180 mg, 0.69 mmol) were added. DEAD (40% in toluene,0.32 mL, 0.69 mmol) was added at 0° C. The mixture was stirred for 20 hand concentrated. FC(CH₂Cl₂/EtOAc 100:0 to 80:20) afforded 131(containing ca. 20% of diethyl hydrazine-1,2-dicarboxylate; used withoutany further purification).

Synthesis of the Amino Acid 132

Following procedure B.2, the reaction of 131 (250 mg, ca. 80%, 0.22mmol), 1.3-dimethylbarbituric acid (107 mg, 0.69 mmol) and Pd(PPh₃)₄ (16mg) in EtOAc/CH₂Cl₂ (55:45, 4.8 mL) yielded after 3 h and after FC(EtOAc/MeOH 100:0 to 90:10, then CH₂Cl₂/MeOH 90:10 to 80:20) 132 (177mg, yield over the two steps: 73%).

Data of 132: C₃₉H₅₇N₅O₁₀Si (784.0): LC-MS: (method 7): R_(t)=1.31, 784.2([M+H]⁺).

Synthesis of the Alloc Protected Amino Acid 133

Following procedure C.1, the reaction of 132 (150 mg, 0.19 mmol), allylchloroformate (23 μL, 0.21 mmol) and Na₂CO₃ (61 mg, 0.57 mmol) indioxane (1.5 mL) and H₂O (1.5 mL) gave, after 2 h at 0° C., acid 133(154 mg, 92%).

Synthesis of the Protected Amino Acid 134

Following procedure C.2, acid 133 (140 mg, 0.16 mmol) was reacted withsarcosine allylester p-toluenesulfonate (46 pTsOH, 58 mg, 0.194 mmol),HOAt (33 mg, 0.24 mmol), HATU (92 mg, 0.24 mmol) and i-Pr₂NEt (0.138 mL,0.81 mmol) in DMF (2.4 mL) to afford the protected amino acid 134 (106mg, 67%).

Data of 134: C₄₉H₇₀N₆O₁₃Si (979.2). LC-MS: (method 7): R_(t)=1.68, 979.3([M+H]⁺).

Synthesis of Amino acid 135

Following procedure C.3, the reaction of the protected amino acid 134(100 mg, 0.10 mmol), 1.3-dimethylbarbituric acid (38 mg, 0.25 mmol) andPd(PPh₃)₄ (6 mg) in EtOAc/CH₂Cl₂ (45:55, 1.9 mL) yielded after 16 h andafter FC (EtOAc, then CH₂Cl₂/MeOH 90:10) 135 (70 mg, 80%).

Data of 135: C₄₂H₆₂N₆O₁₁Si (855.1). LC-MS: (method 7): R_(t)=1.30, 855.5([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.311

According to procedure F.1.1, a solution of the amino acid 135 (60 mg,0.07 mmol) in dry CH₂Cl₂ (2 mL), was added within 2 h to T3P (50% inEtOAc; 84 μL, 0.14 mmol) and i-Pr₂NEt (48 μL, 0.28 mmol) in CH₂Cl₂ (5mL). Then sat. aq. NaHCO₃ solution was added and the mixture wasextracted with CH₂Cl₂. The organic phase was dried (Na₂SO₄), filteredand concentrated. FC (EtOAc) afforded Ex.311 (26 mg, 44%).

Data of Ex.311: (C₄₂H₆₀N₆O₁₀Si (837.0). LC-MS: (method 7): R_(t)=1.51(90), 837.4 ([M+H]⁺). ¹H-NMR (CDCl₃): 7.26 (s, 5 H), 7.09 (t, J=8.4, 1H), 6.78 (d-like m, 1 H), 6.61 (d, J=7.4, 1 H), 5.50-4.90 (several br.m, 5 H), 4.90-3.80 (several br. m, 8 H), 3.69 (br. t, J ca. 8.5, 1 H),3.6-2.3 (several br. m, 14 H), 2.12 (m, 1 H), 1.61 (m, 1 H), 1.38 (s, 9H), 1.24 (s, 2 H), 0.93 (br. t, J ca. 8.0, 2 H), 0.00, −0.03 (2 s, 9 H).

Core 21: Synthesis of Ex.312 and Ex.313 (Scheme 25)

Synthesis of the Mitsunobu Product 136

Alcohol 82 (217 mg, 0.58 mmol) and CMBP (212 mg, 0.88 mmol) weredissolved in dry degassed toluene (7 mL) and heated at 100° C. for 30min. A solution of 80 (250 mg, 0.58 mmol) in toluene (2 mL) was addeddropwise. Stirring at 100° C. was continued for 1 h. The volatiles wereevaporated. FC (hexane/EtOAc 2:1 to 1:1) yielded 136 (290 mg, 63%).

Synthesis of Amino Acid 137

Following procedure E.2 the reaction of 136 (250 mg, 0.32 mmol),1,3-dimethylbarbituric acid (120 mg, 0.77 mmol) and Pd(PPh₃)₄ (18 mg) inEtOAc/CH₂Cl₂ (45:55, 5.5 mL) yielded after 0.5 h and afterFC(CH₂Cl₂/MeOH 95:5 to 70:30) the aminoacid 137 (164 mg, 78%).

Data of 137: C₃₃H₄₄N₄O₈S (656.8). LC-MS (method 7): R_(t)=1.15 (95), 657([M+H]⁺).

Synthesis of the Protected Macrolactam Ex.312

According to procedure F.1.1, a solution of the amino acid 137 (100 mg,0.15 mmol) in dry CH₂Cl₂ (2 mL) was added over 2 h to T3P (50% in EtOAc,0.18 mL, 0.31 mmol) and i-Pr₂NEt (0.1 mL, 0.61 mmol) in dry CH₂Cl₂ (13mL). Stirring at room temperature was continued for 1 h, followed byaqueous workup (EtOAc, sat. aq. NaHCO₃ soln, Na₂SO₄) and FC (EtOAc) toafford Ex.312 (56 mg, 57%).

Data of Ex.312: C₃₃H₄₂N₄O₇S (638.7). LC-MS (method 7): R_(t)=1.33 (95),639 ([M+H]⁺). ¹H-NMR (CDCl₃): 7.37-7.23 (m, 8 H), 6.92 (br. s, 1 H),5.25 (m, 2 H), 5.17 (s, 1 H), 4.88 (d, J=16.2, 1 H), 4.62 (br. m, 1 H),4.46 (br. t-like m, 1 H), 4.31 (br. m, 1 H), 4.17 (dd, J=4.1, 14.2, 1H), 3.72 (dd, J=4.8, 10.7, 1 H), 3.50 (m, 1 H), 3.30-2.80 (several m, 2H), 3.14 (s, 3 H), 3.01 (s, 3 H), 2.60-1.90 (several m, 6 H), 1.46 (s, 9H).

Synthesis of Sulfon Ex.313

m-CPBA (70% w/w; 10 mg, 41 μmol) was added at 0° C. to a solution ofEx.312 (20 mg, 31 μmol) in CH₂Cl₂ (0.5 mL). The mixture was stirred for15 min followed by the addition of m-CPBA (9 mg, 37 μmol). The mixturewas allowed to warm to room temperature over 1 h, diluted with CH₂Cl₂and washed with aq. Na₂S₂O₃ soln and with aq. NaHCO₃ soln. The organicphase was dried (Na₂SO₄), filtered and concentrated. FC (EtOAc/MeOH100:0 to 90:10) afforded Ex.313 (8 mg, 38%).

Data of Ex.313: C₃₃H₄₂N₄O₉S (670.7). LC-MS (method 6): R_(t)=1.24 (95),671 ([M+H]⁺). ¹H-NMR (CDCl₃): 7.89 (td, J=1.7, 7.3, 1 H), 7.71 (s, 1 H),7.43-7.28 (m, 7 H), 5.17 (d, J=12.0, 1 H), 5.10 (d, J=12.0, 1 H), 5.01(dd, J=5.9, 9.1, 1 H), 4.96-4.85 (m, 2 H), 4.71 (d, J=15.4, 1 H), 4.57(br. m, 1 H), 4.33 (br. m, 2 H), 3.85 (dd, J=7.8, 12.3, 1 H), 3.25 (s, 3H), 3.20 (m, 1 H), 3.10 (m, 1 H), 2.97 (s, 3 H), 2.73-2.54 (m, 2 H),2.45-2.23 (m, 2 H), 2.17 (m, 1 H), 1.99 (m, 1 H), 1.46 (s, 9 H).

Synthesis of Final Products

Advanced macrocyclic intermediates and final products depicted in Tables21a-36a (Scheme 26) and were prepared starting from the suitableprecursor macrocyclic acid or macrocyclic amine applying the generalprocedures (H—N) described above. Deviations from general procedures areindicated in Tables 21a-36a.

Analytical data of these intermediates and final products are depictedin Tables 21b-36b.

IUPAC names of all examples are listed in Tables 20, 21c-36c, and 37.

Detailed Description of Selected Examples Core 03 Synthesis of SelectedAdvanced Intermediates and Final Products (Scheme 27)

Synthesis of Amide Ex.27

A mixture of Ex.4 (432 mg, 0.79 mmol), HATU (597 mg, 1.57 mmol) and HOAt(214 mg, 1.57 mmol) was dissolved in DMF (6 mL).N,N-dimethylethylenediamine (173 μL, 1.57 mmol) and i-Pr₂NEt (537 μL,3.14 mmol) were added. The solution was stirred at room temperature for15 h and concentrated. The residue was dissolved in CHCl₃ and washedwith sat. aq. NaHCO₃ solution and with H₂O. The organic phase was dried(Na₂SO₄), filtered and concentrated. FC(CH₂Cl₂/MeOH/conc. aq. NH₃ soln100:0:0 to 90:10:0.5) afforded Ex.27 (405 mg, 83%).

Data of Ex.27: Cf. Table 21b

Synthesis of Amine Ex.28

A solution of Ex.27 (400 mg, 0.64 mmol) in dioxane (4 mL) was treated atroom temperature with 4 M HCl-dioxane (8 mL) for 2 h. The volatiles wereevaporated. The residue was dissolved in CH₂Cl₂/MeOH, concentrated anddried i.v. to afford Ex.28.HCl (343 mg, 90%).

Data of Ex.28: Cf. Table 21b

Synthesis of Amide Ex.11

A mixture of Ex.28.HCl (75 mg, 0.126 mmol), ¹H-indole-3-acetic acid (44mg, 0.253 mmol), HATU (96 mg, 0.253 mmol) and HOAt (34 mg, 0.253 mmol)was dissolved in DMF (2 mL). i-Pr₂NEt (87 μL, 0.505 mmol) was added. Thesolution was stirred at room temperature for 15 h and concentrated. Theresidue was dissolved in CHCl₃ and washed with sat. aq. NaHCO₃ solutionand with H₂O. The organic phase was dried (Na₂SO₄), filtered andconcentrated. FC(CH₂Cl₂/MeOH/conc. aq. NH₃ soln 100:0:0 to 90:10:1)afforded Ex.11 (50 mg, 58%).

Data of Ex.11: Cf. Table 21b

¹H-NMR (DMSO-d₆): 10.81 (s, 1 H), 8.26 (d, J=7.4, 1 H), 7.62 (t, J=5.5,1 H), 7.46 (d, J=7.9, 1 H), 7.37-7.15 (m, 4 H), 7.09 (d, J=2.2, 1 H),7.04 (t, J=7.5, 1 H), 6.92 (t, J ca. 7.4, 1 H), 5.08 (d, J ca. 12.5, 1H), 4.74 (d, J=8.9, 1 H), 4.37 (d, J=11.0, 1 H), 4.25 (d, J=17.7, 1 H),4.22-4.13 (m, 2 H), 3.97 (d, J=17.6, 1 H), 3.78 (t, J=8.3, 1 H), 3.41(s, 2 H), 3.24 (m, 1 H), 3.15 (m, 1 H), 2.98 (t, J=9.2, 1 H), 2.88 (s, 3H), 2.53 (s, 3 H), 2.41-2.27 (m, 4 H), 2.17 (s, 6 H), 2.04 (m, 1 H),1.83 (t-like m, 2 H), 1.69 (q-like m, 1 H).

Synthesis of Amide Ex.49

A mixture of Ex.28.HCl (60 mg, 0.101 mmol), 1-naphthylacetic acid (23mg, 0.121 mmol), and HOBt.H₂O (19 mg, 0.121 mmol) was dissolved inCH₂Cl₂ (1 mL). N-Cyclohexyl-carbodiimide-N′-methylpolystyrene (1.9mmol/g; 80 mg, 0.152 mmol) and i-Pr₂NEt (52 μL, 0.303 mmol) were added.The mixture was stirred for 15 h at room temperature.(Polystyrylmethyl)-trimethylammonium bicarbonate (3.5 mmol/g; 87 mg,0.303 mmol) was added and stirring was continued for 1 h. The mixturewas diluted with CH₂Cl₂/MeOH 9:1 (2 mL) and filtered. The polymer waswashed with twice with CH₂Cl₂/MeOH 8:2 (5 mL). The combined filtrate andwashings were concentrated. Purification of the crude product byFC(CH₂Cl₂/MeOH/conc. aq. NH₃ soln. 100:0:0 to 90:10:1) afforded Ex.49(58 mg, 83%).

Data of Ex.49: Cf. Table 21b

¹H-NMR (DMSO-d₆): 8.45 (d, J=7.3, 1 H), 8.00-7.87 (m, 2 H), 7.79 (d,J=8.0, 1 H), 7.62 (t, J=5.5, 1 H), 7.53-7.25 (m, 6 H), 7.19 (dd, J=3.0,8.4, 1 H), 5.10 (d, J=12.3, 1 H), 4.75 (d, J=8.9, 1 H), 4.39 (d, J=10.8,1 H), 4.27 (d, J=17.8, 1 H), 4.28-4.08 (m, 2 H), 3.95 (d, J=17.9, 1 H),3.83 (m, 1 H), 3.81 (s, 2 H), 3.24 (m, 1 H), 3.16 (m, 1 H), 3.03 (t,J=9.2, 1 H), 2.87 (s, 3 H), 2.54 (s, 3 H), 2.42-2.27 (m, 4 H), 2.16 (s,6 H), 2.02 (m, 1 H), 1.84 (t-like m, 2 H), 1.71 (q, J ca. 9.4, 1 H).

Synthesis of Amide Ex.30

A mixture of Ex.4 (400 mg, 0.73 mmol), HATU (552 mg, 1.45 mmol), HOAt(198 mg, 1.45 mmol) and tryptamine (233 mg, 1.45 mmol) was dissolved inDMF (6 mL). i-Pr₂NEt (497 μL, 2.91 mmol) was added. The solution wasstirred at room temperature for 15 h followed by aqueous workup (CHCl₃,sat. aq. NaHCO₃ soln, H₂O). The organic phase was dried (Na₂SO₄),filtered and concentrated. FC(CH₂Cl₂/MeOH 100:0 to 95:5) afforded Ex.30(410 mg, 81%).

Data of Ex.30: Cf. Table 21b

¹H-NMR (DMSO-d₆): 10.80 (s, 1 H), 7.91 (t, J=5.6, 1 H), 7.56 (d, J=7.7,1 H), 7.32 (d, J=8.0, 1 H), 7.27-7.12 (m, 5 H), 7.06 (t, J=7.5, 1 H),6.97 (t, J=7.4, 1 H), 5.08 (d, J=12.4, 1 H), 4.75 (d, J=9.3, 1 H), 4.34(d, J=10.9, 1 H), 4.24 (d, J=17.8, 1 H), 4.10 (t-like m, 1 H), 3.97 (d,J=17.7, 1 H), 3.86 (m, 1 H), 3.77 (m, 1 H), 3.42-3.30 (m, 2 H),2.96-2.83 (m, 3 H), 2.89 (s, 3 H), 2.50 (s, 3 H, superimposed by DMSO-dsignal), 2.27 (m, 2 H), 2.08 (m, 1 H), 1.84 (t-like m, 2 H), 1.65 (q,J=10.8, 1 H), 1.34 (s, 9 H).

Synthesis of Amine Ex.55

A solution of Ex.30 (380 mg, 0.55 mmol) in dioxane (4 mL) was treated atroom temperature with 4 M HCl-dioxane (8 mL) for 4 h. The volatiles wereevaporated. The residue was dissolved in dioxane (4 mL) and treatedagain for 2 h with 4 M HCl-dioxane (8 mL). The volatiles wereevaporated. The residue was washed with diethyl ether and purified byFC(CH₂Cl₂/MeOH/conc. aq. NH₃ soln 90:10:0 to 90:10:1) to afford Ex.55(136 mg, 42%).

Data of Ex.55: Cf. Table 21b

Synthesis of Amide Ex.12

A mixture of Ex.55 (68 mg, 0.092 mmol), 1H-indole-3-acetic acid (32 mg,0.184 mmol), HATU (70 mg, 0.184 mmol) and HOAt (25 mg, 0.184 mmol) wasdissolved in DMF (2 mL). i-Pr₂NEt (63 μL, 0.367 mmol) was added. Thesolution was stirred at room temperature for 15 h and concentrated. Theresidue was dissolved in CHCl₃ and washed with sat. aq. NaHCO₃ solutionand with H₂O. The organic phase was dried (Na₂SO₄), filtered andconcentrated. Purification by prep. HPLC, method 1, afforded Ex.12 (38mg, 55%).

Data of Ex.12: Cf. Table 21b

¹H-NMR (DMSO-d₆): 10.81 (s, 2 H), 8.26 (d, J=7.2, 1 H), 7.93 (t, J=5.7,1 H), 7.57 (d, J=7.8, 1 H), 7.46 (d, J=7.7, 1 H), 7.38-6.90 (m, 11 H);5.10 (d, J=12.1, 1 H), 4.76 (d, J=9.3, 1 H), 4.38 (d, J=10.8, 1 H), 4.26(d, J=17.8, 1 H), 4.23-4.11 (m, 2 H), 3.96 (d, J=18.0, 1 H), 3.78 (t,J=8.3, 1 H), 3.7-3.25 (m, 3 H), 3.60 (s, 2 H), 3.01-2.81 (m, 2 H), 2.88(s, 3 H), ca. 2.5 (s, 3 H, superimposed by DMSO-d signal), 2.33 (m, 2H), 2.06 (m, 1 H), 1.85 (t-like m, 2 H), 1.63 (q, J ca. 10.7, 1 H).

Synthesis of Amide Ex.16

A mixture of Ex.55 (68 mg, 0.092 mmol), N,N-dimethyl glycine (19 mg,0.184 mmol), HATU (70 mg, 0.184 mmol) and HOAt (25 mg, 0.184 mmol) wasdissolved in DMF (2 mL). i-Pr₂NEt (63 μL, 0.367 mmol) was added. Thesolution was stirred at room temperature for 15 h and concentrated. Theresidue was dissolved in CHCl₃ and washed with sat. aq. NaHCO₃ solutionand with H₂O. The organic phase was dried (Na₂SO₄), filtered andconcentrated. Purification by prep. HPLC, method 1, afforded Ex.16 TFA(40 mg, 55%).

Data of Ex.16 TFA: Cf. Table 21b

¹H-NMR (DMSO-d₆): 10.81 (s, 1 H), 9.66 (br. s, NH⁺), 8.75 (d, J=6.9, 1H), 7.90 (t, J=5.6, 1 H), 7.56 (d, J=7.8, 1 H), 7.34-7.14 (m, 5 H), 7.06(t, J ca. 7.5, 1 H), 6.97 (t, J=7.4, 1 H), 5.08 (d, J=12.3, 1 H), 4.78(d, J=9.2, 1 H), 4.39 (d, J=10.7, 1 H), 4.24 (d, J=17.8, 1 H), 4.24-4.14(m, 2 H), 4.00 (d, J=17.8, 1 H), 3.96-3.75 (m, 3 H), 3.45-3.35 (m, 2 H),3.0-2.67 (m, 3 H), 2.90 (s, 3 H), 2.75 (s, 6 H), 2.50 (s, 3 H,superimposed by DMSO-d signal), 2.5-2.27 (m, 2 H), 2.08 (m, 1 H), 1.85(t-like m, 2 H), 1.64 (q, J=10.8, 1 H).

Synthesis of Amide Ex.53

Pyridine (2 mL) and acetic anhydride (0.14 mL, 1.48 mmol) were added toa solution of Ex.5.HCl (95 mg, 0.15 mmol) in dry CH₂Cl₂ (2 mL). Thesolution was stirred at room temperature for 20 h. The solution wasdiluted with EtOAc and washed with 1 M aq. HCl soln, sat. aq. NaCl soln,sat. aq. NaHCO₃ soln, and sat. aq. NaCl soln. The organic phase wasdried (Na₂SO₄), filtered and concentrated. FC of the crude productafforded Ex.53 (60 mg, 70%).

Data of Ex.53: Cf. Table 21b

Synthesis of Acid Ex.54

A solution of Ex.53 (58 mg, 0.01 mmol) in MeOH (5 mL) was hydrogenatedat room temperature and normal pressure for 2 h in the presence ofpalladium hydroxide on activated charcoal (moistened with 50% H₂O; 50mg). The mixture was filtered through a pad of celite. The residue waswashed (MeOH). The combined filtrate and washings were concentrated anddried i.v. to yield Ex.54 (45 mg, 92%).

Data of Ex.54: Cf. Table 21b

Synthesis of Amide Ex.9

A mixture of Ex.54 (45 mg, 0.091 mmol), HATU (52 mg, 0.137 mmol) HOAt(19 mg, 0.137 mmol) and tryptamine (22 mg, 0.137 mmol) was dissolved inDMF (1 mL). i-Pr₂NEt (47 μL, 0.274 mmol) was added. The solution wasstirred at room temperature for 20 h followed by aqueous workup (CHCl₃,sat. aq. NaHCO₃ soln, H₂O). The organic phase was dried (Na₂SO₄),filtered and concentrated. FC(CH₂Cl₂/MeOH 100:0 to 86:14) afforded Ex.9(36 mg, 62%).

Data of Ex.9: Cf. Table 21b

¹H-NMR (DMSO-d₆): 10.81 (s, 1 H), 8.06 (d, J=7.0, 1 H), 7.93 (t, J=5.6,1 H), 7.56 (d, J=7.8, 1 H), 7.34-7.14 (m, 5 H), 7.05 (t, J ca. 7.5, 1H), 6.97 (t, J ca. 7.4, 1 H), 5.09 (d, J=12.4, 1 H), 4.75 (d, J=9.1, 1H), 4.38 (d, J=10.8, 1 H), 4.26 (d, J=17.7, 1 H), 4.19-4.10 (m, 2 H),3.97 (d, J=17.9, 1 H), 3.78 (t, J=8.3, 1 H), 3.43-3.30 (m, 2 H),2.96-2.83 (m, 3 H), 2.89 (s, 3 H), 2.50 (s, 3 H, superimposed by DMSO-dsignal), 2.40-2.27 (m, 2 H), 2.08 (m, 1 H), 1.85 (m, 2 H), 1.71 (s, 3H), 1.62 (q, J ca. 10.6, 1 H).

Core 11 and Core 12 Synthesis of Selected Advanced Intermediates andFinal Products (Scheme 28)

Synthesis of Amide Ex.184

A mixture of Ex 182 (500 mg, 1.04 mmol), 2-naphthylacetic acid (232 mg,1.25 mmol), HATU (791 mg, 2.08 mmol) and HOAt (283 mg, 2.08 mmol) wasdissolved in DMF (15 mL). i-Pr₂NEt (712 μL, 4.16 mmol) was added. Thesolution was stirred at room temperature for 20 h and concentrated. Theresidue was dissolved in CHCl₃ and washed with sat. aq. NaHCO₃ solutionand with H₂O. The organic phase was dried (Na₂SO₄), filtered andconcentrated. FC (EtOAc, then CH₂Cl₂/MeOH 95:5) afforded Ex.184 (637 mg,94%).

Data of Ex.184: Cf. Table 29b

¹H-NMR (DMSO-d₆): 8.41 (d, J=7.0, 1 H), 7.90-7.83 (m, 3 H), 7.77 (s, 1H), 7.53-7.44 (m, 4 H), 7.32-7.22 (m, 6 H), 7.04 (d, J=8.4, 1 H), 6.86(d, J=7.4, 1 H), 6.81 (s, 1 H), 5.02-4.90 (m, 3 H), 4.19 (t, J ca. 8.6,1 H), 4.14-3.96 (m, 2 H), 3.83 (t-like m, 2 H), 3.63 (s, 2 H), ca. 3.3(m, 1 H, superimposed by H₂O signal), 3.05 (m, 1 H), 2.95 (m, 1 H), 2.91(s, 3 H), 2.27 (m, 1 H), 2.16 (br. q, J ca. 11.3, 1 H), 1.54 (m, 2 H),1.31 (m, 1 H), 1.15 (m, 1 H).

Synthesis of Amide Ex.200

A mixture of Ex.197 TFA (60 mg, 0.094 mmol), 1H-indole-3-acetic acid (25mg, 0.14 mmol), HATU (54 mg, 0.14 mmol) and HOAt (19 mg, 0.14 mmol) wasdissolved in DMF (1.5 mL). i-Pr₂NEt (81 μL, 0.471 mmol) was added. Thesolution was stirred for 18 h at room temperature and concentrated. Theresidue was dissolved in CHCl₃ and washed (sat. aq. NaHCO₃ soln, H₂O).The organic phase was dried (Na₂SO₄), filtered and concentrated,followed by FC (EtOAc, then CH₂Cl₂/MeOH 95:5) to afford Ex.200 (50 mg,78%).

Data of Ex.200: Cf. Table 30b

¹H-NMR (DMSO-d₆): 10.86 (s, 1 H), 8.42 (d, J=7.8, 1 H), 8.01 (d, J=10.0,1 H), 7.58 (d, J=7.8, 1 H), 7.36-7.19 (m, 9 H), 7.07-7.02 (m, 2 H), 6.97(t, J=7.1, 1 H), 6.86 (d, J=7.6, 1 H), 5.08 (s, 2 H), 4.88 (d, J=8.7, 1H), 4.30-4.10 (m, 2 H), 4.13 (d, J=10.9, 1 H), 4.01 (t-like m, 1 H),3.95 (d, J=18.0, 1 H), 3.75-3.70 (m, 2 H), 3.56 (s, 2 H), 3.4-3.2 (m, 2H, partially superimposed by H₂O signal), 3.04 (t, J=9.9, 1 H), 2.98 (s,3 H), 2.65 (s, 3 H), 2.27 (m, 1 H), 2.09 (q, J=11.7, 1 H).

Synthesis of Amine Ex.202

A solution of Ex.200 (320 mg, 0.47 mmol) in MeOH (28 mL) washydrogenated at normal pressure and at room temperature for 4 h in thepresence of palladium hydroxide on activated charcoal (moistened with50% H₂O; 158 mg). The mixture was filtered through a pad of celite. Theresidue was washed (MeOH). The combined filtrate and washings wereconcentrated and dried i.v. to yield Ex.202 (250 mg, 97%).

Data of Ex.202: Cf. Table 30b

Synthesis of Amide Ex.213

A solution of Ex.202 (60 mg, 0.11 mmol) in dry CH₂Cl₂ (1 mL) was treatedwith pyridine (89 μL, 1.1 mmol). Decanoyl chloride (46 μL, 0.22 mmol)was slowly added at 0° C. The mixture was stirred at 0° C. to roomtemperature for 18 h followed by the addition of MeOH (0.1 mL). Stirringwas continued for 10 min. The volatiles were evaporated. The residue wasthree times treated with toluene and evaporated. Purification by prep.HPLC, method 1 and subsequent FC (EtOAc/MeOH 90:10 to 80:20) affordedEx.213 (27 mg, 35%).

Data of Ex.213: Cf. Table 30b

¹H-NMR (DMSO-d₆): 10.86 (s, 1 H), 8.53 (d, J=9.8, 1 H), 8.44 (d, J=7.7,1 H), 7.57 (d, J=7.7, 1 H), 7.35-7.30 (m, 3 H), 7.27 (s, 1 H), 7.19-6.95(m, 3 H), 6.84 (d, J=7.5, 1 H), 4.86 (dd, J=2.4, 11.2, 1 H), 4.60 (q,J=8.4, 1 H), 4.25 (q-like m, 1 H), 4.14 (d, J=10.7, 1 H), 4.04-3.82 (m,3 H), 3.73 (t, J ca. 8.5, 1 H), 3.55 (s, 2 H), 3.24 (d, J=7.8, 2 H),3.09 (t, J=9.5, 1 H), 2.99 (s, 3 H), 2.67 (s, 3 H), 2.26 (m, 1 H), 2.15(t, J=7.2, 2 H), 2.09 (m, 1 H), 1.51 (t-like m, 2 H), 1.24 (s, 12 H),0.85 (t, J=6.6, 3 H).

Core 11 Synthesis of Ex.186 on Solid Support (Scheme 29)

Synthesis of Amine 139

A solution of Ex.181 (2.0 g, 3.2 mmol) in MeOH (200 mL) was hydrogenatedfor 3 h at room temperature and at normal pressure in the presence ofpalladium hydroxide on activated charcoal (15-20% Pd, moistened with 50%H₂O; 400 mg). The mixture was filtered through a pad of celite. Theresidue was washed (MeOH). The combined filtrate and washings wereconcentrated and dried i.v. to give the corresponding amine (1.57 g),which was dissolved in CH₂Cl₂ (8 mL) and treated with sat. aqueousNaHCO₃ solution (2.9 mL) and allyl chloroformate (0.36 mL, 3.43 mmol).The mixture was stirred at room temperature for 2 h. The organic phasewas separated and concentrated. Purification of the residue by FC(EtOAc) afforded the allyl carbamate 138 (1.65 g, 92%).

TBAF solution (1 M in THF, 7 mL, 7 mmol) was added at 0° C. to asolution of 138 (1.29 g, 2.24 mmol) in THF (53 mL). The solution wasstirred at 0° C. to room temperature for 3 h and concentrated. Theresidue was distributed between CH₂Cl₂ and sat. aq. NaHCO₃ solution. Theaqueous phase was separated and extracted with CH₂Cl₂. The combinedorganic phase was dried (Na₂SO₄), filtered and concentrated. The residuewas dissolved in CH₂Cl₂ (10 mL) and treated for 20 min with 25% aq. HClsolution (0.29 mL). The volatiles were evaporated and the residue wasdried i.v. to afford 139.HCl (1.14 g; contaminated with ca 15%tetrabutylammonium salt and used without further purification; yield ca90%)

Data of 139.HCl: C₂₂H₃₀N₄O₅.HCl (430.5, free base). LC-MS (method 4a):R_(t)=1.22 (92), 431.3 [M+H]⁺.

Synthesis of the Resin 140

DFPE polystyrene (1% DVB, 100-200 mesh, loading 0.89 mmol/g; 200 mg,0.178 mmol) was swollen in DCE (2 mL) for 1 h. The resin was filtered. Asolution of amine hydrochloride 139.HCl (ca 85% w/w, 166 mg, 0.303 mmol)in DCE (1.33 mL) and trimethyl orthoformate (0.66 mL, 6.02 mmol) wereadded. The resin was shaken for 1 h at room temperature, followed by theaddition of sodium triacetoxyborohydride (75 mg, 0.356 mmol). Themixture was shaken for 15 h and the resin was filtered. The resin wassuccessively washed three times each with DMF, 10% i-Pr₂NEt in DMF, DMF,CH₂Cl₂ and dried i.v. to afford resin 140 (293 mg).

Synthesis of the Resin 141

1st Acid coupling step: The resin 140 (loading 0.77 mmol/g; 50 mg, 0.038mmol) was swollen in DMF (1 mL) for 30 min and filtered. CH₂Cl₂ (0.5mL), DMF (0.5 mL), 2-naphthylacetic acid (65 mg, 0.35 mmol), i-Pr₂NEt(0.13 mL, 0.76 mmol) and HATU (144 mg, 0.38 mmol) were successivelyadded. The resin was shaken for 1 h, filtered and washed with DMF.CH₂Cl₂ (0.5 mL), DMF (0.5 mL) 2-naphthylacetic acid (65 mg, 0.35 mmol),i-Pr₂NEt (0.13 mL, 0.76 mmol) and then HATU (144 mg, 0.38 mmol) wereadded to the resin. The mixture was shaken for 1 h and filtered. Theresin was washed three times with DMF and two times with CH₂Cl₂.

Cleavage of the Alloc group: CH₂Cl₂ (1 mL), phenylsilane (41 mg, 0.375mmol) and Pd(PPh₃)₄ (9 mg) were added to the resin. The mixture wasshaken for 15 min and filtered. The resin was washed with CH₂Cl₂ andtreated again for 15 min with CH₂Cl₂ (1 mL), phenylsilane (41 mg, 0.375mmol) and Pd(PPh₃)₄ (9 mg). The resin was filtered, washed three timeseach with CH₂Cl₂, DMF and twice with MeOH and CH₂Cl₂.

2nd Acid coupling step: DMF (0.5 mL), CH₂Cl₂ (1 mL), 2-naphthylaceticacid (70 mg, 0.375 mmol), i-Pr₂NEt (0.13 mL, 0.75 mmol) and PyBOP (195mg, 0.375 mmol) were added to the resin. The mixture was shaken for 1 hand filtered. The resin was washed three times each with DMF and CH₂Cl₂to afford resin 141, which was immediately used in the next step.

Release of the Amide Ex.186

The resin 141 was treated with 20% TFA in CH₂Cl₂ (1 mL) for 10 min,filtered and washed with CH₂Cl₂. The resin was treated again for 10 minwith 20% TFA in CH₂Cl₂ (1 mL), filtered and washed three times withCH₂Cl₂. The combined filtrates and washings were concentrated. Theresidue was treated with CH₃CN, evaporated and dried i.v. Purificationof the crude product by prep. HPLC, method 3, afforded Ex.186 (11 mg,yield: overall 32% based on 139).

Data of Ex.186: C₄₂H₄₂N₄O₅ (682.8). LC-MS (method 4a): R_(t)=2.26 (98).¹H-NMR (DMSO-d₆): 8.38 (d, J=7.0, 2 H), 7.91-7.69 (m, 8 H), 7.54-7.27(m, 7 H), 7.03 (dd, J=1.5, 8.2, 1 H), 6.86-6.82 (m, 2 H), 4.94 (d,J=12.7, 1 H), 4.19 (t, J=8.6, 1 H), 4.11-3.94 (m, 3 H), 3.71 (dd, J=9.2,16.5, 1 H), 3.62 (s, 2 H), 3.58 (s, 2 H), 3.08 (m, 1 H), 2.89 (m, 1 H),2.89 (s, 3 H), 2.5 (m, 1 H, superimposed by DMSO-d signal), 2.30 (m, 1H), 2.14 (q-like m, 1 H), 1.64-1.49 (m, 2 H), 1.34 (m, 1 H), 1.14 (m, 1H).

The ¹H-NMR spectrum is identical with the spectrum of the sampleprepared in solution, cf. Table 29

TABLE 20 Examples of Core 01 and Core 02 (Ex. 1-Ex. 2) No IUPAC nameCore 01 R2  R50 Ex. 1

OCH₂Ph 8-benzyl 2-[2-(trimethylsilyl)ethyl](2S,8S,16aS)-12-fluoro-9-methyl-5,10-dioxo-2,3,5,6,7,8,9,10,16,16a-decahydro-1H-pyrrolo[2,1-c][1,4,9]benzoxadiazacyclododecine-2,8-dicarboxylate Core 02 R11 R50 Ex.2

OCH₂Ph 9-benzyl 2-(tert-butyl) (9s,17aS)-13-fluoro-10-methyl-6,11-dioxo-3,4,6,7,8,9,10,11,17,17a-decahydropyrazino[2,1-c][1,4,9]benzoxadiazacyclododecine-2,9(1H)-dicarboxylate

TABLE 21a Examples of Core 03 (Ex. 3-Ex. 55,) General Yield, StartingPro- Purification (isolated No R50 R2 material cedure Reagent Methodsalt) Ex. 3-Ex. 5: cf. experimental description Ex. 6 OH

Ex. 52 H H₂, Pd(OH)₂—C^(*)) Crude product 70% Ex. 7

Ex. 25 L.1.1 acetic anhydride (5 equiv.) prep. HPLC, method 1 56% Ex. 8

Ex. 28 L.1.1 acetic anhydride (10 equiv.) prep. HPLC, method 1 26% (TFAsalt) Ex. 9

Ex. 53 L.2 tryptamine (1.5 equiv.) HATU (1.5 equiv.) HOAt (1.5 equiv.)i-Pr₂NEt (3 equiv.) FC (CH₂Cl₂/ MeOH) 62% Ex. 10

Ex. 31 N LiOH•H₂O prep. HPLC, method 1 57% Ex. 11

Ex. 28 L.1.3 3-indoleacetic acid FC (CH₂Cl₂/ MeOH/ aq. NH₃) 58% Ex. 12

Ex. 55 L.1.3 3-indoleacetic acid prep. HPLC, method 1 55% Ex. 13

Ex. 34 N LiOH•H₂O prep. HPLC, method 1 60% Ex. 14

Ex. 25 **) N,N-dimethyl glycine prep. HPLC, method 1 22% (TFA salt) Ex.15

Ex. 28 L.1.3 N,N-dimethyl glycine prep. HPLC, method 1 42% (TFA salt)Ex. 16

Ex. 55 L.1.3 N,N-dimethyl glycine prep. HPLC, method 1 56% (TFA salt)Ex. 17

Ex. 33 N LiOH•H₂O prep. HPLC, method 1 77% (TFA salt) Ex. 18

Ex. 25 L.1.1 succinic anhydride (1.05 equiv) prep. HPLC, method 1 62%Ex. 19

Ex. 28 L.1.1 succinic anhydride (1.05 equiv) pyridine (49 equiv.) prep.HPLC, method 1 67% (TFA salt) Ex. 20

Ex. 32 N LiOH•H₂O prep. HPLC, method 1 72% Ex. 21

Ex. 23 L.1.3 3-indoleacetic acid prep. HPLC, method 1 32% Ex. 22

Ex. 23 L.1.1 acetic anhydride (10 equiv) pyridine (120 equiv.) prep.HPLC, method 1 53% (TFA salt) Ex. 23

NH₂ Ex. 29 J HCl-dioxane prep. HPLC, method 1 52% (TFA salt) Ex. 24

Ex. 4 L.2 methylamine-HCl (10 equiv.), HATU (1.5 equiv.) HOAt (1.5equiv.) i-Pr₂NEt (13 equiv.) FC (CH₂Cl₂/ MeOH) 89% Ex. 25

NH₂ Ex. 24 J HCl-dioxane crude product 84% (HCl salt) Ex. 26

Ex. 4 L.2 β-alaninemethylester hydrochloride FC (CH₂Cl₂/ MeOH) 97% Ex.27

Ex. 4 L.2 N,N-dimethyl- ethylenediamine FC (CH₂Cl₂/ MeOH/ aq. NH₃) 83%Ex. 28

NH₂ Ex. 27 J HCl-dioxane (crude product) 90% (HCl salt) Ex. 29

Ex. 4 L.2 N,N,N′-trimethyl- ethylenediamine FC (CH₂Cl₂/ MeOH/ aq. NH₃)74% Ex. 30

Ex. 4 L.2 tryptamine FC (CH₂Cl₂/ MeOH) 81% Ex. 31

Ex. 51 L.1.1 acetic anhydride (5 equiv) prep. HPLC, method 1 72% Ex. 32

Ex. 51 L.1.1 succinic anhydride (1.05 equiv) prep. HPLC, method 1 68%Ex. 33

Ex. 51 L.1.3 N,N-dimethyl glycine prep. HPLC, method 1 64% (TFA salt)Ex. 34

Ex. 51 L.1.3 3-indoleacetic acid prep. HPLC, method 1 24% Ex. 35

Ex. 23 L.1.1 succinic anhydride (1.05 equiv) prep. HPLC, method 1 63%(TFA salt) Ex. 36

Ex. 23 L.1.3 N,N-dimethyl glycine prep. HPLC, method 1 40% (TFA salt)Ex. 37

Ex. 42 L.1.1 acetic anhydride (5 equiv) prep. HPLC, method 1 61% Ex. 38

Ex. 42 L.1.3 3-indoleacetic acid prep. HPLC, method 1 43% Ex. 39

Ex. 42 L.1.3 N,N-dimethyl glycine prep. HPLC, method 1 56% (TFA salt)Ex. 40

Ex. 42 L.1.1 succinic anhydride (1.05 equiv) prep. HPLC, method 1 37%Ex. 41

Ex. 4 L.2 pyrrolidine FC (CH₂Cl₂/ MeOH) 76% Ex. 42

NH₂ Ex. 41 J HCl-dioxane (crude product) 90% (HCl salt) Ex. 43

Ex. 42 M acetaldehyde prep. HPLC, method 1 67% (TFA salt) Ex. 44

Ex. 25 M acetaldehyde prep. HPLC, method 1 33% (TFA salt) Ex. 45

Ex. 25 L.1.3 2-naphthylacetic acid prep. HPLC, method 1 46% Ex. 46

Ex. 28 L.1.1 2-naphthoyl chloride (3.6 equiv.) FC (CH₂Cl₂/ MeOH/ aq.NH₃) 85% Ex. 47

Ex. 28 L.1.2 1-naphthoic acid FC (CH₂Cl₂/ MeOH/ aq. NH₃) 85% Ex. 48

Ex. 28 L.1.2 2-naphthylacetic acid FC (CH₂Cl₂/ MeOH/ aq. NH₃) 83% Ex. 49

Ex. 28 L.1.2 1-naphthylacetic acid FC (CH₂Cl₂/ MeOH/ aq. NH₃) 83% Ex. 50

Ex. 28 L.1.1 3-(trifluoromethyl)- benzoyl chloride (4 equiv.) FC(CH₂Cl₂/ MeOH/ aq. NH₃) 24% Ex. 51

NH₂ Ex. 26 J HCl-dioxane crude product 93% (HCl salt) Ex. 52 OCH₂Ph

Ex. 5 L.1.3 N,N-dimethylglycine (1.7 equiv.) HATU (1.0 equiv.) HOAt (2.0equiv.) i-Pr₂NEt (4.0 equiv.) prep. HPLC, method 1 88% (TFA salt) Ex. 53OCH₂Ph

Ex. 5 L.1.1 Acetic anhydride (10 equiv.) pyridine/CH₂Cl₂ 1:1 FC 70% Ex.54 OH

Ex. 54 H H₂, Pd(OH)₂—C crude product 92% Ex. 55

NH₂ Ex. 30 J HCl-dioxane FC (CH₂Cl₂/ MeOH/ aq. NH₃) 42% ^(*))Prior todebenzylation, the starting material Ex. 52•TFA was converted into thefree base (CHCl₃, aq. Na₂CO₃ soln.) **)The amide coupling reaction wasperformed at room temperature with N,N-dimethyl glycine (2.2 equiv.) inCH₂Cl₂, in the presence of T3P (50% in EtOAc; 2.2 equiv.) and i-Pr₂NEt(3 equiv.).

TABLE 21b Examples of Core 03 (Ex. 3-Ex. 55,) Monoisotopic Rt (purity[M + H]⁺ LC-MS- No R50 R2 Formula Mass at 220 nm) found Method Ex. 3-Ex.5: cf. experimental description Ex. 6 OH

C25H34FN5O7 535.2 1.05 (99) 536.3 Method 2 Ex. 7

C24H32FN5O6 505.2 1.21 (87) 506.3 Method 2 Ex. 9

C33H39FN6O6 634.3 2.12 (99) 635.4 Method 1a Ex. 10

C26H34FN5O8 563.2 1.20 (91) 564.2 Method 2 Ex. 11

C35H44FN7O6 677.3 1.34 (93) 678.4 Method 2 Ex. 12

C41H44FN7O6 749.3 1.73 (92) 750.4 Method 2 Ex. 13

C34H39FN6O8 678.3 1.45 (87) 679.3 Method 2 Ex. 14

C26H37FN6O6 548.3 1.08 (88) 549.3 Method 2 Ex. 15

C29H44FN7O6 605.3 0.99 (96) 606.4 Method 2 Ex. 16

C35H44FN7O6 677.3 1.41 (97) 678.4 Method 2 Ex. 17

C28H39FN6O8 606.3 1.09 (94) 607.3 Method 2 Ex. 18

C26H34FN5O8 563.2 1.20 (88) 564.3 Method 2 Ex. 19

C29H41FN6O8 620.3 1.08 (100) 621.3 Method 2 Ex. 20

C28H36FN5O10 621.2 1.18 (91) 622.2 Method 2 Ex. 21

C36H46FN7O6 691.4 1.35 (88) 692.4 Method 2 Ex. 22

C28H41FN6O6 576.3 1.12 (96) 577.4 Method 2 Ex. 23

NH₂ C26H39FN6O5 534.3 0.96 (88) 535.4 Method 2 Ex. 24

C27H38FN5O7 563.3 1.54 (93) 564.3 Method 2 Ex. 25

NH₂ C22H30FN5O5 463.2 1.06 (91) 464.2 Method 2 Ex. 26

C30H42FN5O9 635.3 1.61 (87) 636.4 Method 2 Ex. 27

C30H45FN6O7 620.3 1.53 (92) 621.3 Method 4a Ex. 28

NH₂ C25H37FN6O5 520.3 0.93 (94) 521.3 Method 2 Ex. 29

C31H47FN6O7 634.4 1.41 (96) 635.4 Method 2 Ex. 30

C36H45FN6O7 692.3 1.79 (99) 693.4 Method 2 Ex. 31

C27H36FN5O8 577.3 1.32 (90) 578.3 Method 2 Ex. 32

C29H38FN5O10 635.3 1.30 (83) 636.2 Method 2 Ex. 33

C29H41FN6O8 620.3 1.18 (100) 621.3 Method 2 Ex. 34

C35H41FN6O8 692.3 1.56 (90) 693.3 Method 2 Ex. 35

C30H43FN6O8 634.3 1.10 (94) 635.3 Method 2 Ex. 36

C30H46FN7O6 619.4 1.00 (91) 620.3 Method 2 Ex. 37

C27H36FN5O6 545.3 1.36 (93) 546.3 Method 2 Ex. 38

C35H41FN6O6 660.3 1.60 (94) 661.3 Method 2 Ex. 39

C29H41FN6O6 588.3 1.19 (94) 589.3 Method 2 Ex. 40

C29H38FN5O8 603.3 1.33 (94) 604.3 Method 2 Ex. 41

C30H42FN5O7 603.3 1.67 (90) 604.3 Method 2 Ex. 42

NH₂ C25H34FN5O5 503.3 1.17 (92) 504.2 Method 2 Ex. 43

C29H42FN5O5 559.3 1.26 (96) 560.3 Method 2 Ex. 44

C26H38FN5O5 519.3 1.13 (97) 520.3 Method 2 Ex. 45

C34H38FN5O6 631.3 1.65 (97) 632.2 Method 2 Ex. 46

C36H43FN6O6 674.3 1.49 (97) 675.5 Method 2 Ex. 47

C36H43FN6O6 674.3 1.43 (96) 675.5 Method 2 Ex. 48

C37H45FN6O6 688.3 1.50 (95) 689.5 Method 2 Ex. 49

C37H45FN6O6 688.3 1.48 (95) 689.5 Method 2 Ex. 50

C33H40F4N6O6 692.3 1.49 (97) 693.5 Method 2 Ex. 51

NH₂ C25H34FN5O7 535.2 1.05 536.3 Method 9c Ex. 52 OCH₂Ph

C32H40FN5O7 625.3 1.47 626.3 Method 9c Ex. 53 OCH₂Ph

C30H35FN4O7 582.3 1.65 582.9 Method 9c Ex. 54 OH

C23H29FN4O7 492.2 1.04 493.1 Method 9c Ex. 55

NH₂ C31H37FN6O5 592.3 1.38 593.0 Method 9c

TABLE 21c Examples of Core 03 (Ex. 3-Ex.55,) No R50 R2 IUPAC name Ex. 3OCH₂Ph

benzyl (2S,11S,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate Ex. 4 OH

(2S,11S,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylic acid Ex. 5 OCH₂Ph NH₂ benzyl(2S,11S,19aS)-2-amino-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate Ex. 6 OH

(2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylic acid Ex. 7

(2S,11S,19aS)-2-(acetylamino)-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 8

(2S,11S,19aS)-2-(acetylamino)-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 9

(2S,11S,19aS)-2-(acetylamino)-15-fluoro-N-[2-(1H-indol-3-yl)ethyl]-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 10

3-({[(2S,11S,19aS)-2-(acetylamino)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-11-yl]carbonyl}amino)propanoic acid Ex. 11

(2S,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-2-{[2-(1H-indol-3-yl)acetyl]amino}-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 12

(2S,11S,19aS)-15-fluoro-2-{[2-(1H-indol-3-yl)acetyl]amino}-N-[2-(1H-indol-3-yl)ethyl]-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 13

3-{[((2S,11S,19aS)-15-fluoro-2-{[2-(1H-indol-3-yl)acetyl]amino}-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-11-yl)carbonyl]amino}propanoic acid Ex. 14

(2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 15

(2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 16

(2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-15-fluoro-N-[2-(1H-indol-3-yl)ethyl]-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 17

3-{[((2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-11-yl)carbonyl]amino}propanoic acid Ex. 18

4-({(2S,11S,19aS)-15-fluoro-7,12-dimethyl-11-[(methylamino)carbonyl]-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl}amino)-4-oxobutanoic acid Ex. 19

4-{[(2S,11S,19aS)-11-({[2-(dimethylamino)ethyl]amino}carbonyl)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]amino}- 4-oxobutanoicacid Ex. 20

4-[((2S,11S,19aS)-15-fluoro-11-{[(3-hydroxy-3-oxopropyl)amino]carbonyl}-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)amino]- 4-oxobutanoicacid Ex. 21

(2S,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-2-{[2-(1H-indol-3-yl)acetyl]amino}-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 22

(2S,11S,19aS)-2-(acetylamino)-N-[2-(dimethylamino)ethyl]-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 23

NH₂ (2S,11S,19aS)-2-amino-N-[2-(dimethylamino)ethyl]-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 24

tert-butyl N-{(2S,11S,19aS)-15-fluoro-7,12-dimethyl-11-[(methylamino)carbonyl]-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl}carbamate Ex. 25

NH₂ (2S,11S,19aS)-2-amino-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11- carboxamideEx. 26

methyl 3-[({(2S,11S,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-11-yl}carbonyl)amino]propanoate Ex. 27

tert-butyl N-[(2S,11S,19aS)-11-({[2-(dimethylamino)ethyl]amino}carbonyl)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]carbamate Ex. 28

NH₂ (2S,11S,19aS)-2-amino-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 29

tert-butyl N-(2S,11S,19aS)-11-{[[2-(dimethylamino)ethyl]methyl)amino]carbonyl}-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl) carbamate Ex.30

tert-butyl N-[(2S,11S,19aS)-15-fluoro-11-({[2-(1H-indol-3-yl)ethyl]amino}carbonyl)-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2- yl]carbamate Ex.31

methyl 3-({[(2S,11S,19aS)-2-(acetylamino)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-11-yl]carbonyl}amino)propanoate Ex. 32

4-[((2S,11S,19aS)-15-fluoro-11-{[(3-methoxy-3-oxopropyl)amino]carbonyl}-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)amino]- 4-oxobutanoicacid Ex. 33

methyl 3-{[((2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-11-yl)carbonyl]amino}propanoate Ex. 34

methyl 3-{[((2S,11S,19aS)-15-fluoro-2-{[2-(1H-indol-3-yl)acetyl]amino}-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-11-yl)carbonyl]amino}propanoate Ex. 35

4-[((2S,11S,19aS)-11-{[[2-(dimethylamino)ethyl](methyl)amino]carbonyl}-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)amino]- 4-oxobutanoicacid Ex. 36

(2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-N-[2-(dimethylamino)ethyl]-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11- carboxamideEx. 37

N-[(2S,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]acetamide Ex. 38

N-[(2S,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]-2-(1H-indol-3-yl)acetamide Ex. 39

N-[(2S,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]-2-(dimethylamino)acetamide Ex. 40

4-{[(2S,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]amino}-4-oxobutanoic acid Ex. 41

tert-butyl N-[(2S,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]carbamate Ex. 42

NH₂ (2S,11S,19aS)-2-amino-15-fluoro-7,12-dimethyl-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,9,10,11,12,19,19a-decahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-5,8,13-trione Ex. 43

(2S,11S,19aS)-2-(diethylamino)-15-fluoro-7,12-dimethyl-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,9,10,11,12,19,19a-decahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-5,8,13-trione Ex. 44

(2S,11S,19aS)-2-(diethylamino)-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 45

(2S,11S,19aS)-15-fluoro-N,7,12-trimethyl-2-{[2-(2-naphthyl)acetyl]amino}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine- 11-carboxamideEx. 46

(2S,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-2-(2-naphthoylamino)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine- 11-carboxamideEx. 47

(2S,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-2-(1-naphthoylamino)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 48

(2S,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-2-{[2-(2-naphthyl)acetyl]amino}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine- 11-carboxamideEx. 49

(2S,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-2-{[2-(1-naphthyl)acetyl]amino}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine- 11-carboxamideEx. 50

(2S,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2-{[3-(trifluoromethyl)benzoyl]amino}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 51

NH₂ methyl 3-({[(2S,11S,19aS)-2-amino-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-11-yl]carbonyl}amino)propanoate Ex. 52OCH₂Ph

benzyl (2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate Ex. 53OCH₂Ph

benzyl (2S,11S,19aS)-2-(acetylamino)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate Ex. 54 OH

(2S,11S,19aS)-2-(acetylamino)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylic acid Ex. 55

NH₂ (2S,11S,19aS)-2-amino-15-fluoro-N-[2-(1H-indol-3-yl)ethyl]-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide

TABLE 22a Examples of Core 04 (Ex. 56-Ex. 84,) Yield, (iso- StartingGeneral Purification lated No R50 R2 material Procedure Reagent Methodsalt) Ex. 56-Ex 57: cf. experimental description Ex. 58

Ex. 57 L.2 N,N,N′- trimetylethylene- diamine FC (CH₂Cl₂/ MeOH/aq. NH₃)86% Ex. 59

Ex. 57 L.2 2-naphthyl- methylamine FC (CH₂Cl₂/ MeOH) 91% Ex. 60

Ex. 57 L.2 pyrrolidine FC (CH₂Cl₂/ MeOH) 79% Ex. 61

Ex. 57 L.2 4- (aminomethyl) pyridine FC (CH₂Cl₂/ MeOH) 81% Ex. 62

NH₂ Ex. 58 J HCl-dioxane crude product 98% (HCl salt) Ex. 63

NH₂ Ex. 59 J HCl-dioxane crude product 76% (HCl salt) Ex. 64

NH₂ Ex. 60 J HCl-dioxane crude product 94% (HCl salt) Ex. 65

NH₂ Ex. 61 J HCl-dioxane crude product 91% (HCl salt) Ex. 66

Ex. 62 L.1.3 2-naphthylacetic acid prep. HPLC, method 1 67% (TFA salt)Ex. 67

Ex. 62 L.1.2 3-(pyridine-4- yl)propanoic acid prep. HPLC, method 2 56%Ex. 68

Ex. 62 L.1.2 1-naphthylacetic acid (1.5 equiv.) prep. HPLC, method 1 24%(TFA salt) Ex. 69

Ex. 63 L.1.1 acetic anhydride (5 equiv.) prep. HPLC, method 1 75% Ex. 70

Ex. 63 L.1.3 1-pyrrolidinacetic acid prep. HPLC, method 1 62% (TFA salt)Ex. 71

Ex. 63 L.1.2 3-(pyridine-4- yl)propanoic acid prep. HPLC, method 1 22%(TFA salt) Ex. 72

Ex. 64 L.1.3 2-naphthylacetic acid prep. HPLC, method 2 51% Ex. 73

Ex. 64 L.1.2 1-pyrrolidinacetic acid (1.7 equiv.) prep. HPLC, method 139% (TFA salt) Ex. 74

Ex. 64 L.1.2 3-(pyridine-4- yl)propanoic acid prep. HPLC, method 2 29%Ex. 75

Ex. 65 L.1.3 2-naphthylacetic acid prep. HPLC, method 1 37% (TFA salt)Ex. 76

Ex. 65 L.1.2 1-pyrrolidinacetic acid (1.7 equiv.) prep. HPLC, method 245% Ex. 77

Ex. 65 L.1.2 3-(pyridine-4- yl)propanoic acid prep. HPLC, method 2 45%Ex. 78

Ex. 62 L.1.1 valeroyl chloride (1.6 equiv.) prep. HPLC, method 1 56% Ex.79

Ex. 63 L.1.1 valeroyl chloride (1.6 equiv.) prep. HPLC, method 1 77% Ex.80

Ex. 64 L.1.1 valeroyl chloride (1.3 equiv.) prep. HPLC, method 1 64% Ex.81

NH₂ Ex. 84 J HCl-dioxane crude product 99% (HCl salt) Ex. 82

Ex. 81 L.1.3 3-indoleacetic acid (1.5 equiv.) HATU (1.5 equiv.) HOAt(1.5 equiv.) i-Pr₂NEt (5 equiv.) prep. HPLC, method 1, then FC (CH₂Cl₂/MeOH/aq. NH₃) 15% Ex. 83

Ex. 81 L.1.3 2-naphthylacetic acid (1.2 equiv.) FC (CH₂Cl₂/ MeOH/aq.NH₃), then prep. HPLC, method 1 58% Ex. 84

Ex. 57 L.2 2-dimethyl- amino- ethylamine FC (CH₂Cl₂/ MeOH) 89%

TABLE 22b Examples of Core 04 (Ex. 56-Ex. 84,) Monoisotopic Rt (purity[M + H]⁺ LC-MS- No R50 R2 Formula Mass at 220 nm) found Method Ex. 56-Ex57: cf. experimental description Ex. 58

C31H47FN6O7 634.4 1.44 (91) 635.5 Method 2 Ex. 59

C37H44FN5O7 689.3 1.89 (87) 690.5 Method 2 Ex. 60

C30H42FN5O7 603.3 1.67 (84) 604.4 Method 2 Ex. 61

C32H41FN6O7 640.3 1.42 (92) 641.4 Method 2 Ex. 62

NH₂ C26H39FN6O5 534.3 0.97 (91) 535.4 Method 2 Ex. 63

NH₂ C32H36FN5O5 589.3 1.53 (95) 590.4 Method 2 Ex. 64

NH₂ C25H34FN5O5 503.3 1.23 (82) 504.3 Method 2 Ex. 65

NH₂ C27H33FN6O5 540.3 0.97 (97) 541.4 Method 2 Ex. 66

C38H47FN6O6 702.4 1.51 (97) 703.5 Method 2 Ex. 67

C34H46FN7O6 667.4 1.08 (94) 668.5 Method 2 Ex. 68

C38H47FN6O6 702.4 1.51 (88) 703.5 Method 2 Ex. 69

C34H38FN5O6 631.3 1.66 (90) 632.3 Method 2 Ex. 70

C38H45FN6O6 700.3 1.56 (95) 701.5 Method 2 Ex. 71

C40H43FN6O6 722.3 1.55 (93) 723.5 Method 2 Ex. 72

C37H42FN5O6 671.3 1.73 (87) 672.4 Method 2 Ex. 73

C31H43FN6O6 614.3 1.28 (90) 615.4 Method 2 Ex. 74

C33H41FN6O6 636.3 1.29 (91) 637.4 Method 2 Ex. 75

C39H41FN6O6 708.3 1.50 (92) 709.4 Method 2 Ex. 76

C33H42FN7O6 651.3 1.07 (91) 652.4 Method 2 Ex. 77

C35H40FN7O6 673.3 1.07 (90) 674.5 Method 2 Ex. 78

C31H47FN6O6 618.4 1.33 (98) 619.4 Method 2 Ex. 79

C37H44FN5O6 673.3 1.81 (91) 674.4 Method 2 Ex. 80

C30H42FN5O6 587.3 1.56 (93) 588.4 Method 2 Ex. 81

NH₂ C25H37FN6O5 520.3 1.10 (88) 521.4 Method 2 Ex. 82

C35H44FN7O6 677.3 1.36 (93) 678.5 Method 2 Ex. 83

C37H45FN6O6 688.3 1.49 (93) 689.5 Method 2 Ex. 84

C30H45FN6O7 620.3 1.38 (87) 621.5 Method 2

TABLE 22c Examples of Core 04 (Ex. 56-Ex. 84,) No R50 R2 IUPAC name Ex.56 OCH₂Ph

benzyl (2R,11S,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate Ex. 57 OH

(2R,11S,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylic acid Ex. 58

tert-butyl N-((2R,11S,19aS)-11-{[[2-(dimethylamino)ethyl](methyl)amino]carbonyl}-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)carbamate Ex. 59

tert-butyl N-((2R,11S,19aS)-15-fluoro-7,12-dimethyl-11-{[(2-naphthylmethyl)amino]carbonyl}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)carbamate Ex. 60

tert-butyl N-[(2R,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]carbamate Ex. 61

tert-butyl N-((2R,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-{[(4-pyridinylmethyl)amino]carbonyl}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)carbamate Ex. 62

NH₂ (2R,11S,19aS)-2-amino-N-[2-(dimethylamino)ethyl]-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 63

NH₂ (2R,11S,19aS)-2-amino-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 64

NH₂ (2R,11S,19aS)-2-amino-15-fluoro-7,12-dimethyl-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,9,10,11,12,19,19a-decahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-5,8,13-trione Ex. 65

NH₂ (2R,11S,19aS)-2-amino-15-fluoro-7,12-dimethyl-5,8,13-trioxo-N-(4-pyridinylmethyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 66

(2R,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-N,7,12-trimethyl-2-{[2-(2-naphthyl)acetyl]amino}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 67

(2R,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2-{[3-(4-pyridinyl)propanoyl]amino}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 68

(2R,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-N,7,12-trimethyl-2-{[2-(1-naphthyl)acetyl]amino}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 69

(2R,11S,19aS)-2-(acetylamino)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 70

(2R,11S,19aS)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2-{[2-(1-pyrrolidinyl)acetyl]amino}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 71

(2R,11S,19aS)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2-{[3-(4-pyridinyl)propanoyl]amino}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 72

N-[(2R,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]-2-(2-naphthyl)acetamide Ex. 73

N-[(2R,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]-2-(1-pyrrolidinyl)acetamide Ex. 74

N-[(2R,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]-3-(4-pyridinyl)propanamide Ex. 75

(2R,11S,19aS)-15-fluoro-7,12-dimethyl-2-{[2-(2-naphthyl)acetyl]amino}-5,8,13-trioxo-N-(4-pyridinylmethyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 76

(2R,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-N-(4-pyridinylmethyl)-2-{[2-(1-pyrrolidinyl)acetyl]amino}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 77

(2R,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-N-(4-pyridinylmethyl)-2-{[3-(4-pyridinyl)propanoyl]amino}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 78

(2R,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2-(pentanoylamino)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 79

(2R,11S,19aS)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2-(pentanoylamino)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 80

N-[(2R,11S,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]pentanamide Ex. 81

NH₂ (2R,11S,19aS)-2-amino-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 82

(2R,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-2-{[2-(1H-indol-3-yl)acetyl]amino}-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 83

(2R,11S,19aS)-N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-2-{[2-(2-naphthyl)acetyl]amino}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 84

tert-butyl N-[(2R,11S,19aS)-11-({[2-(dimethylamino)ethyl]amino}carbonyl)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]carbamate

TABLE 23a Examples of Core 05 (Ex. 85-Ex. 103,) Yield, (iso- StartingGeneral Purification lated No R2 R50 material Procedure Reagent Methodsalt) Ex. 85-Ex 86: cf. experimental description Ex. 87

Ex. 86 L.2 methyl- amine- hydro- chloride (10 equiv.) HATU (1.5 equiv.)HOAt (1.5 equiv.) i-Pr₂NEt (13 equiv.) FC (CH₂Cl₂/ MeOH) 76% Ex. 88

Ex. 86 L.2 pyrrolidine FC (CH₂Cl₂/ MeOH) then prep. HPLC, method 2 64%Ex. 89

Ex. 86 L.2 2- naphthyl- methyl- amine FC (EtOAc/ MeOH) 93% Ex. 90 NH₂

Ex. 87 J HCl-dioxane crude product 86% (HCl salt) Ex. 91 NH₂

Ex. 89 J HCl-dioxane crude product 98% (HCl salt) Ex. 92 NH₂

Ex. 88 J HCl-dioxane crude product 94% (HCl salt) Ex. 93

Ex. 90 L.1.2 2-naphthyl- acetic acid prep. HPLC, method 3 66% Ex. 94

Ex. 91 L.1.2 1-pyrrolidine- acetic acid (1.7 equiv.) prep. HPLC, method1 46% (TFA salt) Ex. 95

Ex. 91 L.1.1 succinic anhydride (1.05 equiv.) prep. HPLC, method 2 47%(NH4⁺ salt) Ex. 96

Ex. 91 L.1.2 3-(pyridine-4- yl)propanoic acid (3.7 equiv.) FC (CH₂Cl₂/MeOH) 74% Ex. 97

Ex. 91 L.1.2 1-naphthyl- acetic acid (1.7 equiv.) prep. HPLC, method 372% Ex. 98

Ex. 92 L.1.2 1-pyrrolidine- acetic acid prep. HPLC, method 1 68% (TFAsalt) Ex. 99

Ex. 92 L.1.1 succinic anhydride (1.05 equiv.) prep. HPLC, method 2 40%(NH4⁺ salt) Ex. 100

Ex. 92 L.1.2 1-naphthyl- acetic acid FC (EtOAc/ MeOH) 83% Ex. 101

Ex. 92 L.1.1 2-naphthoyl chloride (1.6 equiv.) FC (EtOAc/ MeOH) 84% Ex.102

Ex. 91 L.1.1 decanoyl chloride (4.1 equiv.) pyridine (15 equiv.) prep.HPLC, method 3 64% Ex. 103

Ex. 91 L.1.1 valeroyl chloride (2.0 equiv.) prep. HPLC, method 3 87%

TABLE 23b Examples of Core 05 (Ex. 85-Ex. 103,) Monoiso- Rt [M + topic(purity at H]⁺ LC-MS- No R2 R50 Formula Mass 220 nm) found Method Ex.85-Ex 86: cf. experimental description Ex. 87

C27H38FN5O7 563.3 1.52 (78) 564.4 Method 2 Ex. 88

C30H42FN5O7 603.3 1.59 (64), 1.63 (27) 604.4/ 604.4 Method 2 Ex. 89

C37H44FN5O7 689.3 1.89 (97) 690.5 Method 2 Ex. 90 NH₂

C22H30FN5O5 463.2 1.02 (95) 464.3 Method 2 Ex. 91 NH₂

C32H36FN5O5 589.3 1.51 (98) 590.4 Method 2 Ex. 92 NH₂

C25H34FN5O5 503.3 1.20 (97) 504.3 Method 2 Ex. 93

C34H38FN5O6 631.3 1.65 (98) 632.3 Method 2 Ex. 94

C38H45FN6O6 700.3 1.55 (100) 701.5 Method 2 Ex. 95

C36H40FN5O8 689.3 1.65 (98) 690.5 Method 2 Ex. 96

C40H43FN6O6 722.3 1.51 (96) 723.5 Method 2 Ex. 97

C44H44FN5O6 757.3 1.96 (92) 758.5 Method 2 Ex. 98

C31H43FN6O6 614.3 1.25 (98) 615.3 Method 2 Ex. 99

C29H38FN5O8 603.3 1.34 (100) 604.4 Method 2 Ex. 100

C37H42FN5O6 671.3 1.73 (85) 672.4 Method 3 Ex. 101

C36H40FN5O6 657.3 1.73 (98) 658.4 Method 2 Ex. 102

C42H54FN5O6 743.4 2.16 (95) 744.6 Method 3 Ex. 103

C37H44FN5O6 673.3 1.83 (96) 674.5 Method 2

TABLE 23c Examples of Core 05 (Ex. 85-Ex. 103,) No R2 R50 IUPAC name Ex.85

OCH₂Ph benzyl (2S,11R,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate Ex. 86

OH (2S,11R,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylic acid Ex. 87

tert-butyl N-{(2S,11R,19aS)-15-fluoro-7,12-dimethyl-11-[(methylamino)carbonyl]-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl}carbamate Ex. 88

tert-butyl N-[(2S,11R,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl] carbamate Ex.89

tert-butyl N-((2S,11R,19aS)-15-fluoro-7,12-dimethyl-11-{[(2-naphthylmethyl)amino]carbonyl}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)carbamate Ex. 90 NH₂

(2S,11R,19aS)-2-amino-15-fluoro-N,7,12-trimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11- carboxamideEx. 91 NH₂

(2S,11R,19aS)-2-amino-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 92 NH₂

(2S,11R,19aS)-2-amino-15-fluoro-7,12-dimethyl-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,9,10,11,12,19,19a-decahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-5,8,13-trione Ex. 93

(2S,11R,19aS)-15-fluoro-N,7,12-trimethyl-2-{[2-(2-naphthyl)acetyl]amino}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 94

(2S,11R,19aS)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2-{[2-(1-pyrrolidinyl)acetyl]amino}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 95

4-[((2S,11R,19aS)-15-fluoro-7,12-dimethyl-11-{[(2-naphthylmethyl)amino]carbonyl}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)amino]- 4-oxobutanoicacid Ex. 96

(2S,11R,19aS)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2-{[3-(4-pyridinyl)propanoyl]amino}-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 97

(2S,11R,19aS)-15-fluoro-7,12-dimethyl-2-{[2-(1-naphthyl)acetyl]amino}-N-(2-naphthylmethyl)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 98

N-[(2S,11R,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]-2-(1-pyrrolidinyl)acetamide Ex. 99

4-{[(2S,11R,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]amino}-4-oxobutanoic acid Ex. 100

N-[(2S,11R,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]-2-(1-naphthyl)acetamide Ex. 101

N-[(2S,11R,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-(1-pyrrolidinylcarbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]-2-naphthamide Ex. 102

(2S,11S,19aS)-2-(decanoylamino)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 103

(2S,115,19aS)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2-(pentanoylamino)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide

TABLE 24a Examples of Core 06 (Ex. 104-Ex. 114,) Yield, Starting GeneralPurification (isolated No R2 R50 material Procedure Reagent Method salt)Ex. 104-Ex. 105: cf. experimental description Ex. 106

Ex. 105 L.2 N-(2- aminoethyl)pyrolidine FC (CH₂Cl₂/ MeOH/ aq. NH₃) 78%Ex. 107

Ex. 105 L.2 2-naphthylmethyl- amine FC (CH₂Cl₂/ MeOH) 96% Ex. 108 NH₂

Ex. 106 J HCl-dioxane crude product 99% (HCl salt) Ex. 109 NH₂

Ex. 107 J HCl-dioxane crude product 95% (HCl salt) Ex. 110

Ex. 108 L.1.2 2-naphthylacetic acid prep. HPLC, method 1 and workup(CHCl₃/aq. NaHCO₃ soln.) 51% Ex. 111

Ex. 108 L.1.2 1-naphthylacetic acid prep. HPLC, method 1 55% (TFA salt)Ex. 112

Ex. 108 M acetaldehyde FC (CH₂Cl₂/ MeOH/ aq. NH₃) 48% Ex. 113

Ex. 109 L.1.2 1-naphthylacetic acid (3.7 equiv.) prep. HPLC, method 377% Ex. 114

Ex. 109 L.1.1 valeroyl chloride (2 equiv.) prep. HPLC, method 3 84%

TABLE 24b Examples of Core 06 (Ex. 104-Ex. 114,) Rt Monoisotopic (purityat [M + H]⁺ LC-MS- No R2 R50 Formula Mass 220 nm) found Method Ex.104-Ex. 105: cf. experimental description Ex. 106

C32H47FN6O7 646.4 1.36 (43), 1.42 (27), 1.44 (27) 647.5/647.5 647.5Method 2 Ex. 107

C37H44FN5O7 689.3 1.94 (42)/ 1.98 (50) 690.5/690.5 Method 2 Ex. 108 NH₂

C27H39FN6O5 546.3 1.37 (50), 1.44 (38) 547.5/547.5 Method 3 Ex. 109 NH₂

C32H36FN5O5 589.3 1.55 (96) 590.3 Method 2 Ex. 110

C39H47FN6O6 714.4 1.62 (44), 1.66 (52) 715.4/715.4 Method 2 Ex. 111

C39H47FN6O6 714.4 1.51 (46), 1.56 (54) 715.5/715.5 Method 2 Ex. 112

C31H47FN6O5 602.4 1.14 (57), 1.18 (39) 603.4/603.5 Method 2 Ex. 113

C44H44FN5O6 757.3 2.15 (52), 2.19 (41) 758.4/758.4 Method 4a Ex. 114

C37H44FN5O6 673.3 2.00 (58), 2.05 (41) 674.4/674.4 Method 4a

TABLE 24c Examples of Core 06 (Ex. 104-Ex. 114,) No R2 R50 IUPAC nameEx. 104

OCH₂Ph benzyl (2R,11R,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H, 5H-pyrrolo [2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylate Ex. 105

OH (2R,11R,19aS)-2-[(tert-butoxycarbonyl)amino]-15-fluoro-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxylic acid Ex. 106

tert-butyl N-[(2R,11R,19aS)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-11-({[2-(1-pyrrolidinyl)ethyl]amino}carbonyl)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]carbamate Ex. 107

tert-butyl N-((2R,11R,19aS)-15-fluoro-7,12-dimethyl-11-{[(2-naphthylmethyl)amino]carbonyl}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl)carbamate Ex. 108 NH₂

(2R,11R,19aS)-2-amino-15-fluoro-7,12-dimethyl-5,8,13-trioxo-N-[2-(1-pyrrolidinyl)ethyl]-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 109 NH₂

(2R,11R,19aS)-2-amino-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 110

(2R,11R,19aS)-15-fluoro-7,12-dimethyl-2-{[2-(2-naphthyl)acetyl]amino}-5,8,13-trioxo-N-[2-(1-pyrrolidinyl)ethyl]-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11- carboxamideEx. 111

(2R,11R,19aS)-15-fluoro-7,12-dimethyl-2-{[2-(1-naphthyl)acetyl]amino}-5,8,13-trioxo-N-[2-(1-pyrrolidinyl)ethyl]-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11- carboxamideEx. 112

(2R,11R,19aS)-2-(diethylamino)-15-fluoro-7,12-dimethyl-5,8,13-trioxo-N-[2-(1-pyrrolidinyl)ethyl]-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide Ex. 113

(2R,11R,19aS)-15-fluoro-7,12-dimethyl-2-{[2-(1-naphthyl)acetyl]amino}-N-(2-naphthylmethyl)-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11- carboxamideEx. 114

(2R,11R,19aS)-15-fluoro-7,12-dimethyl-N-(2-naphthylmethyl)-5,8,13-trioxo-2-(pentanoylamino)-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide

TABLE 25a Examples of Core 07 (Ex. 115-Ex. 131,) Yield, Starting GeneralPurification (isolated No R11 R50 material Procedure Reagent Methodsalt) Ex. 115-Ex. 116: cf. experimental description Ex. 117

Ex. 116 L.2 N,N- dimethylethylendi- amine FC (CH₂Cl₂/MeOH/aq. NH₃) 73%Ex. 118

Ex. 116 L.2 tryptamine FC (CH₂Cl₂/MeOH) 98% Ex. 119

Ex. 116 L.2 N,N,N′- trimethylethylene- diamine FC (CH₂Cl₂/MeOH) 79% Ex.120

Ex. 116 L.2 D-(+)-α- methylbenzylamine prep. HPLC, method 1 70% Ex. 121H

Ex. 117 J HCl-dioxane crude product 98% (HCl salt) Ex. 122 H

Ex. 118 J HCl-dioxane crude product 98% (HCl salt) Ex. 123 H

Ex. 119 J HCl-dioxane THF/CH₂Cl₂ as cosolvent crude product quant. (HClsalt) Ex. 124 H

Ex. 120 J HCl-dioxane crude product 95% (HCl salt) Ex. 125

Ex. 122 L.1.1 acetic anhydride (1.1 equiv.) pyridine/CH₂Cl₂ 1:1 (3 mL)prep. HPLC, method 1 62% Ex. 126

Ex. 121 L.1.3 N,N-dimethylglycine prep. HPLC, method 1 39% (TFA salt)Ex. 127

Ex. 121 L.1.3 3-indoleacetic acid prep. HPLC, method 1 20% (TFA salt)Ex. 128

Ex. 122 L.1.3 N,N-dimethylglycine prep. HPLC, method 1 21% (TFA salt)Ex. 129

Ex. 122 L.1.3 3-Indoleacetic acid prep. HPLC, method 1 45% Ex. 130

Ex. 123 L.1.1 acetic anhydride (5 equiv.) prep. HPLC, method 1 14% (TFAsalt) Ex. 131

Ex. 123 L.1.3 N,N-dimethylglycine prep. HPLC, method 1 44% (TFA salt)

TABLE 25b Examples of Core 07 (Ex. 115-Ex. 131,) Monoisotopic Rt (purityat [M + H]⁺ LC-MS- No R11 R50 Formula Mass 220 nm) found Method Ex.115-Ex. 116: cf. experimental description Ex. 117

C30H45FN6O7 620.3 1.45 621.2 Method 9c Ex. 118

C36H45FN6O7 692.3 1.94 693.1 Method 9c Ex. 119

C31H47FN6O7 634.4 1.48 635.4 Method 9c Ex. 120

C34H44FN5O7 653.3 1.99 653.9 Method 9c Ex. 121 H

C25H37FN6O5 520.3 1.23 (17), 1.29 (80) 521.3/521.3 Method 3 Ex. 122 H

C31H37FN6O5 592.3 1.40 (89) 593.3 Method 2 Ex. 123 H

C26H39FN6O5 534.3 1.32 (96) 535.3 Method 3 Ex. 124 H

C29H36FN5O5 553.3 1.41 (98) 554.3 Method 2 Ex. 125

C33H39FN6O6 634.3 1.54 (100) 635.3 Method 2 Ex. 126

C29H44FN7O6 605.3 1.37 (83) 606.4 Method 3 Ex. 127

C35H44FN7O6 677.3 1.32 (12), 1.38 (84) 678.3/678.3 Method 2 Ex. 128

C35H44FN7O6 677.3 1.40 (98) 678.4 Method 2 Ex. 129

C41H44FN7O6 749.3 1.73 (85) 750.4 Method 2 Ex. 130

C28H41FN6O6 576.3 1.10 (98) 577.3 Method 2 Ex. 131

C30H46FN7O6 619.4 1.41 (96) 620.4 Method 3

TABLE 25c Examples of Core 07 (Ex. 115-Ex. 131,) No R11 R50 IUPAC nameEx. 115

OCH₂Ph 12-benzyl 2-(tert-butyl)(12S,20aS)-16-fluoro-8,13-dimethyl-6,9,14-trioxo-3,4,7,8,9,10,11,12,13,14,20,20a-dodecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-2,12(1H)-dicarboxylate Ex. 116

OH(12S,20aS)-2-(tert-butoxycarbonyl)-16-fluoro-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxylic acid Ex. 117

tert-butyl (12S,20aS)-12-({[2-(dimethylamino)ethyl]amino}carbonyl)-16-fluoro-8,13-dimethyl-6,9,14-trioxo-3,4,7,8,9,10,11,12,13,14,20,20a-dodecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-2(1H)-carboxylate Ex. 118

tert-butyl(12S,20aS)-16-fluoro-12-({[2-(1H-indol-3-yl)ethyl]amino}carbonyl)-8,13-dimethyl-6,9,14-trioxo-3,4,7,8,9,10,11,12,13,14,20,20a-dedecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-2(1H)-carboxylateEx. 119

tert-butyl(12S,20aS)-12-{[[2-(dimethylamino)ethyl]methyl)amino]carbonyl}-16-fluoro-8,13-dimethyl-6,9,14-trioxo-3,4,7,8,9,10,11,12,13,14,20,20a-dodecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-2(1H)-carboxylate Ex. 120

tert-butyl(12S,20aS)-16-fluoro-8,13-dimethyl-6,9,14-trioxo-12-({[(1R)-1-phenylethyl]amino}carbonyl)-3,4,7,8,9,10,11,12,13,14,20,20a-dodecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-2(1H)-carboxylateEx. 121 H

(12S,20aS)-N-[2-(dimethylamino)ethyl]-16-fluoro-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 122 H

(12S,20aS)-16-fluoro-N-[2-(1H-indol-3-yl)ethyl]-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 123 H

(12S,20aS)-N-[2-(dimethylamino)ethyl]-16-fluoro-N,8,13-trimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 124 H

(12S,20aS)-16-fluoro-8,13-dimethyl-6,9,14-trioxo-N-[(1R)-1-phenylethyl]-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 125

(12S,20aS)-2-acetyl-16-fluoro-N-[2-(1H-indol-3-yl)ethyl]-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 126

(12S,20aS)-2-[2-(dimethylamino)acetyl]-N-[2-(dimethylamino)ethyl]-16-fluoro-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamideEx. 127

(12S,20aS)-N-[2-(dimethylamino)ethyl]-16-fluoro-2-[2-(1H-indol-3-yl)acetyl]-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamideEx. 128

(12S,20aS)-2-[2-(dimethylamino)acetyl]-16-fluoro-N-[2-(1H-indol-3-yl)ethyl]-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamideEx. 129

(12S,20aS)-16-fluoro-2-[2-(1H-indol-3-yl)acetyl]-N-[2-(1H-indol-3-yl)ethyl]-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamideEx. 130

(12S,20aS)-2-acetyl-N-[2-(dimethylamino)ethyl]-16-fluoro-N,8,13-trimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamideEx. 131

(12S,20aS)-2-[2-(dimethylamino)acetyl]-N-[2-(dimethylamino)ethyl]-16-fluoro-N,8,13-trimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide

TABLE 26a Examples of Core 08 (Ex. 132-Ex. 141,) Yield, Starting GeneralPurification (isolated No R11 R50 material Procedure Reagent Methodsalt) Ex. 132-Ex. 133: cf. experimental description Ex. 134

Ex. 133 L.2 N,N- dimethylethylene- diamine FC (CH₂Cl₂/ MeOH/ aq. NH₃)80% Ex. 135 H

Ex. 134 J HCl-dioxane crude product 100 % (HCl salt) Ex. 136

Ex. 133 L.2 tryptamine FC (CH₂Cl₂/ MeOH/ aq. NH₃) 89% Ex. 137 H

Ex. 136 J HCl-dioxane crude product 100%  (HCl salt) Ex. 138

Ex. 135 L.1.2 2-naphthylacetic acid prep. HPLC, method 1 71% (TFA salt)Ex. 139

Ex. 137 L.1.2 N,N-dimethyl glycine prep. HPLC, method 1 40% (TFA salt)Ex. 140

Ex. 137 L.1.1 acetic anhydride (5 equiv.) prep. HPLC, method 1 50% Ex.141

Ex. 137 L.1.2 2-naphthylacetic acid prep. HPLC, method 3, then FC(EtOAc/ MeOH) 39%

TABLE 26b Examples of Core 08 (Ex. 132-Ex. 141,) Rt Monoisotopic (purityat [M + H]⁺ LC-MS- No R11 R50 Formula Mass 220 nm) found Method Ex.132-Ex. 133: cf. experimental description Ex. 134

C30H45FN6O7 620.3 1.40 (20), 1.45 (77) 621.5/621.5 Method 2 Ex. 135 H

C25H37FN6O5 520.3 0.94 (85) 521.4 Method 2 Ex. 136

C36H45FN6O7 692.3 1.83 (91) 693.5 Method 2 Ex. 137 H

C31H37FN6O5 592.3 1.41 (80) 593.4 Method 2 Ex. 138

C37H45FN6O6 688.3 1.46 (15), 1.51 (84) 689.5/689.5 Method 2 Ex. 139

C35H44FN7O6 677.3 1.43 (92) 678.5 Method 2 Ex. 140

C33H39FN6O6 634.3 1.57 (97) 635.5 Method 2 Ex. 141

C43H45FN6O6 760.3 1.86 (95) 761.5 Method 2

TABLE 26c Examples of Core 08 (Ex. 132-Ex. 141,) No R11 R50 IUPAC nameEx. 132

OCH₂Ph 12-benzyl 2-(tert-butyl)(12R,20aR)-16-fluoro-8,13-dimethyl-6,9,14-trioxo-3,4,7,8,9,10,11,12,13,14,20,20a-dodeeanydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-2,12(1H)-dicarboxylate Ex. 133

OH (12R,20aR)-2-(tert-butoxycarbonyl)-16-fluoro-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxylic acid Ex.134

tert-butyl (12R,20aR)-12-({[2-(dimethylamino)ethyl]amino}carbonyl)-16-fluoro-8,13-dimethyl-6,9,14-trioxo-3,4,7,8,9,10,11,12,13,14,20,20a-dodecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-2(1H)-carboxylate Ex. 135 H

(12R,20aR)-N-[2-(dimethylamino)ethyl]-16-fluoro-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 136

tert-butyl (12R,20aR)-16-fluoro-12-({[2-(1H-indol-3-yl)ethyl]amino}carbonyl)-8,13-dimethyl-6,9,14-trioxo-3,4,7,8,9,10,11,12,13,14,20,20a-dodecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-2(1H)-carboxylate Ex. 137 H

(12R,20aR)-16-fluoro-N-[2-(1H-indol-3-yl)ethyl]-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 138

(12R,20aR)-N-[2-(dimethylamino)ethyl]-16-fluoro-8,13-dimethyl-2-[2-(2-naphthyl)acetyl]-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 139

(12R,20aR)-2-[2-(dimethylamino)acetyl]-16-fluoro-N-[2-(1H-indol-3-yl)ethyl]-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide Ex. 140

(12R,20aR)-2-acetyl-16-fluoro-N-[2-(1H-indol-3-yl)ethyl]-8,13-dimethyl-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamideEx. 141

(12R,20aR)-16-fluoro-N-[2-(1H-indol-3-yl)ethyl]-8,13-dimethyl-2-[2-(2-naphthyl)acetyl]-6,9,14-trioxo-1,2,3,4,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-6H-pyrazino[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-12-carboxamide

TABLE 27a Examples of Core 09 (Ex. 142-Ex. 163,) Yield, Starting GeneralPurification (isolated No R2 R50 material Procedure Reagent Method salt)Ex. 142-Ex. 143: cf. experimental description Ex. 144

Ex. 143 L.2 pyrrolidine FC (CH₂Cl₂/ MeOH) 91% Ex. 145

Ex. 143 L.2 2-naphthyl- methylamine FC (CH₂Cl₂/ MeOH) 72% Ex. 146

Ex. 143 L.2 4- (aminomethyl) pyridine FC (CH₂Cl₂/ MeOH) 87% Ex. 147 NH₂

Ex. 144 J HCl-dioxane crude product 100%  (HCl salt) Ex. 148 NH₂

Ex. 145 J HCl-dioxane crude product 97% (HCl salt) Ex. 149 NH₂

Ex. 146 J HCl-dioxane crude product 87% (HCl salt) Ex. 150

Ex. 147 L.1.2 2-naphthylacetic acid Prep. HPLC, method 3 72% Ex. 151

Ex. 147 L.1.1 valeroyl chloride (2.0 equiv.) Prep. HPLC, method 3 73%Ex. 152

Ex. 147 L.1.2 1-pyrriolidin- acetic acid Prep. HPLC, method 2 26% Ex.153

Ex. 148 L.1.2 2-naphthylacetic acid Prep. HPLC, method 3 68% Ex. 154

Ex. 148 L.1.1 valeroyl chloride (2.0 equiv.) Prep. HPLC, method 3 76%Ex. 155

Ex. 148 L.1.1 acetic anhydride (5.0 equiv.) Prep. HPLC, method 3 72% Ex.156

Ex. 148 L.1.1 succinic anhydride (1.05 equiv.) Prep. HPLC, method 2 69%(NH4⁺ salt) Ex. 157

Ex. 149 L.1.2 2-naphthylacetic acid (1.7 equiv.) Prep. HPLC, method 224% Ex. 158

Ex. 149 L.1.1 valeroyl chloride (2.0 equiv.) Prep. HPLC, method 2 42%Ex. 159

Ex. 149 L.1.2 1-pyrriolidin- acetic acid (2.5 equiv.) Prep. HPLC, method2 55% Ex. 160

Ex. 149 L.1.1 succinic anhydride (1.05 equiv.) Prep. HPLC, method 2 69%(NH4⁺ salt) Ex. 161

Ex. 147 L.1.2 3-(pyridine-4- yl)propanoic acid Prep. HPLC, method 2 53%Ex. 162

Ex. 148 L.1.2 3-(pyridine-4- yl)propanoic acid Prep. HPLC, method 2 48%Ex. 163

Ex. 149 L.1.2 3-(pyridine-4- yl)propanoic acid (1.7 equiv.) Prep. HPLC,method 2 63%

TABLE 27b Examples of Core 09 (Ex. 142-Ex. 163,) Rt Monoisotopic (purityat [M + H]⁺ LC-MS- No R2 R50 Formula Mass 220 nm) found Method Ex.142-Ex. 143: cf. experimental description Ex. 144

C31H44FN5O7 617.3 1.66 (90) 618.4 Method 2 Ex. 145

C38H46FN5O7 703.3 1.90 (90) 704.5 Method 2 Ex. 146

C33H43FN6O7 654.3 1.39 (92) 655.5 Method 2 Ex. 147 NH₂

C26H36FN5O5 517.3 1.36 (79) 518.4 Method 3 Ex. 148 NH₂

C33H38FN5O5 603.3 1.53 (98) 604.4 Method 2 Ex. 149 NH₂

C28H35FN6O5 554.3 1.25 (8), 1.31 (85) 555.4 Method 3 Ex. 150

C38H44FN5O6 685.3 1.72 (98) 686.5 Method 2 Ex. 151

C31H44FN5O6 601.3 1.55 (98) 602.5 Method 2 Ex. 152

C32H45FN6O6 628.3 1.52 (94) 629.5 Method 3 Ex. 153

C45H46FN5O6 771.3 1.94 (96) 772.5 Method 2 Ex. 154

C38H46FN5O6 687.3 1.82 (97) 688.5 Method 2 Ex. 155

C35H40FN5O6 645.3 1.67 (99) 646.4 Method 2 Ex. 156

C37H42FN5O8 703.3 1.65 (99) 704.5 Method 2 Ex. 157

C40H43FN6O6 722.3 1.48 (94) 723.8 Method 2 Ex. 158

C33H43FN6O6 638.3 1.50 (95) 639.5 Method 3 Ex. 159

C34H44FN7O6 665.3 1.47 (96) 666.5 Method 3 Ex. 160

C32H39FN6O8 654.3 1.04 (96) 655.4 Method 3 Ex. 161

C34H43FN6O6 650.3 1.47 (91) 651.5 Method 3 Ex. 162

C41H45FN6O6 736.3 1.55 (96) 737.6 Method 2 Ex. 163

C36H42FN7O6 687.3 1.42 (99) 688.5 Method 3

TABLE 27c Examples of Core 09 (Ex. 142-Ex. 163,) No R2 R50 IUPAC nameEx. 142

OCH₂Ph benzyl (2R,12S,20aS)-2-[(tert-butoxycarbonyl)amino]-16-fluoro-8,13-dimethyl-5,9,14-trioxo-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxylate Ex. 143

OH (2R,12S,20aS)-2-[(tert-butoxycarbonyl)amino]-16-fluoro-8,13-dimethyl-5,9,14-trioxo-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxylic acid Ex. 144

tert-butyl N-[(2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-12-(1-pyrrolidinylcarbonyl)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2-yl]carbamate Ex. 145

tert-butyl N-((2R,12S,20aS)-16-fluoro-8,13-dimethyl-12-{[(2-naphthylmethyl)amino]carbonyl}-5,9,14-trioxo-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2-yl)carbamate Ex. 146

tert-butyl N-((2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-12-{[(4-pyridinylmethyl)amino]carbonyl}-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2- yl)carbamate Ex.147 NH₂

(2R,12S,20aS)-2-amino-16-fluoro-8,13-dimethyl-12-(1-pyrrolidinylcarbonyl)-2,3,7,8,10,11,12,13,20,20a-decahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-5,9,14(6H)-trione Ex. 148 NH₂

(2R,12S,20aS)-2-amino-16-fluoro-8,13-dimethyl-N-(2-naphthyl-methyl)-5,9,14-trioxo-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxamide Ex. 149 NH₂

(2R,12S,20aS)-2-amino-16-fluoro-8,13-dimethyl-5,9,14-trioxo-N-(4-pyridinylmethyl)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxamide Ex. 150

N-[(2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-12-(1-pyrrolidinylcarbonyl)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2-yl]-2-(2-naphthyl)acetamide Ex. 151

N-[(2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-12-(1-pyrrolidinylcarbonyl)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2-yl]pentanamide Ex. 152

N-[(2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-12-(1-pyrrolidinylcarbonyl)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2-yl]-2-(1-pyrrolidinyl)acetamide Ex. 153

(2R,12S,20aS)-16-fluoro-8,13-dimethyl-2-{[2-(2-naphthyl)acetyl]amino}-N-(2-naphthylmethyl)-5,9,14-trioxo-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12- carboxamideEx. 154

(2R,12S,20aS)-16-fluoro-8,13-dimethyl-N-(2-naphthylmethyl)-5,9,14-trioxo-2-(pentanoylamino)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12- carboxamide Ex.155

(2R,12S,20aS)-2-(acetylamino)-16-fluoro-8,13-dimethyl-N-(2-naphthylmethyl)-5,9,14-trioxo-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxamide Ex. 156

4-[((2R,12S,20aS)-16-fluoro-8,13-dimethyl-12-{[(2-naphthylmethyl)amino]carbonyl}-5,9,14-trioxo-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2-yl)amino]-4- oxobutanoicacid Ex. 157

(2R,12S,20aS)-16-fluoro-8,13-dimethyl-2-{[2-(2-naphthyl)acetyl]amino}-5,9,14-trioxo-N-(4-pyridinylmethyl)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxamide Ex. 158

(2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-2-(pentanoylamino)-N-(4-pyridinylmethyl)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12- carboxamide Ex.159

(2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-N-(4-pyridinylmethyl)-2-{[2-(1-pyrrolidinyl)acetyl]amino}-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxamide Ex. 160

4-[((2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-12-{[(4-pyridinylmethyl)amino]carbonyl}-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2-yl)amino]-4-oxobutanoic acid Ex. 161

N-[(2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-12-(1-pyrrolidinylcarbonyl)-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecin-2-yl]-3-(4-pyridinyl)propanamide Ex. 162

(2R,12S,20aS)-16-fluoro-8,13-dimethyl-N-(2-naphthylmethyl)-5,9,14-trioxo-2-{[3-(4-pyridinyl)propanoyl]amino}-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxamide Ex. 163

(2R,12S,20aS)-16-fluoro-8,13-dimethyl-5,9,14-trioxo-N-(4-pyridinylmethyl)-2-{[3-(4-pyridinyl)propanoyl]amino}-2,3,5,6,7,8,9,10,11,12,13,14,20,20a-tetradecahydro-1H-pyrrolo[2,1-c][1,4,8,13]benzoxatriazacyclohexadecine-12-carboxamide

TABLE 28a Examples of Core 10 (Ex. 164-Ex. 180,) Yield, Starting GeneralPurification (isolated No R2 R5 material Procedure Reagent Method salt)Ex. 164-Ex. 165: cf. experimental description Ex. 166

Ex. 165 L.1.1 valeroyl chloride (2.0 equiv.) FC (EtOAc/ MeOH) ca.70% Ex.167

NH₂ Ex. 166 K H₂, Pd(OH)₂—C crude product quant. Ex. 168

Ex. 165 L.1.3 2-naphthylacetic acid FC (EtOAc) 68% Ex. 169

Ex. 165 L.1.3 1-pyrrolidinacetic acid FC (EtOAc/ MeOH) 76% Ex. 170

Ex. 167 L.1.2 3-(pyridine-4- yl)propanoic acid FC (CH₂Cl₂/ MeOH) 78% Ex.171

Ex. 167 L.1.1 2-naphthoyl chloride (2.6 equiv.) Prep. HPLC, method 3 42%Ex. 172

NH₂ Ex. 168 K H₂, Pd(OH)₂—C crude product 97% Ex. 173

NH₂ Ex. 169 K H₂, Pd(OH)₂—C crude product 96% Ex. 174

Ex. 172 L.1.1 acetic anhydride (5 equiv.) Prep. HPLC, method 3 97% Ex.175

Ex. 172 L.1.2 1-pyrrolidinacetic acid (2.2 equiv.) Prep. HPLC, method 358% Ex. 176

Ex. 172 L.1.2 3-(pyridine-4- yl)propanoic acid Prep. HPLC, method 3 71%Ex. 177

Ex. 172 L.1.2^(*)) 1-naphthylacetic acid Prep. HPLC, method 3 68% Ex.178

Ex. 173 L.1.2 3-(pyridine-4- yl)propanoic acid Prep. HPLC, method 2 48%Ex. 179

Ex. 173 L.1.2^(*)) 1-naphthylacetic acid Prep. HPLC, method 3 84% Ex.180

Ex. 173 L.1.1^(*)) 2-naphthoyl chloride (1.5 equiv.) Prep. HPLC, method3 78% ^(*))The treatment with (polystyrylmethyl)trimethylammoniumbicarbonate was replaced by an aqueous workup (CHCl₃, sat. aq. NaHCO₃soln)

TABLE 28b Examples of Core 10 (Ex. 164-Ex. 180,) Rt Monoisotopic (purityat [M + H]⁺ LC-MS- No R2 R5 Formula Mass 220 nm) found Method Ex.164-Ex. 165: cf. experimental description Ex. 166

C30H38N4O6 550.3 1.96 (99) 551.3 Method 4a Ex. 167

NH₂ C22H32N4O4 416.2 1.4 (99) 417.3 Method 4a Ex. 168

C37H38N4O6 634.3 2.2 (98) 635.3 Method 4a Ex. 169

C31H39N5O6 577.3 1.57 (99) 578.4 Method 4a Ex. 170

C30H39N5O5 549.3 1.47 (97) 550.4 Method 4a Ex. 171

C33H38N4O5 570.3 2.1 (100) 571.3 Method 4a Ex. 172

NH₂ C29H32N4O4 500.2 1.60 (91) 501.3 Method 4a Ex. 173

NH₂ C23H33N5O4 443.3 1.48 (99) 444.2 Method 5a Ex. 174

C31H34N4O5 542.3 1.82 (99) 543.2 Method 4a Ex. 175

C35H41N5O5 611.3 1.69 (96) 612.2 Method 4a Ex. 176

C37H39N5O5 633.3 1.68 (99) 634.3 Method 4a Ex. 177

C41H40N4O5 668.3 2.24 (92) 669.3 Method 4a Ex. 178

C31H40N6O5 576.3 1.07 (98) 577.3 Method 4a Ex. 179

C35H41N5O5 611.3 1.69 (93) 612.3 Method 4a Ex. 180

C34H39N5O5 597.3 1.69 (97) 597.8 Method 4a

TABLE 28c Examples of Core 10 (Ex. 164-Ex. 180,) No R2 R5 IUPAC name Ex.164

benzyl N-[(4S,6S,10S)-13-methyl-9,14-dioxo-6-({[2-(trimethylsilyl)ethoxy]carbonyl}amino)-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl] carbamateEx. 165 NH₂

benzyl N-[(4S,6S,10S)-6-amino-13-methyl-9,14-dioxo-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]carbamate Ex. 166

benzyl N-[(4S,6S,10S)-13-methyl-9,14-dioxo-6-(pentanoyl-amino)-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]carbamate Ex. 167

NH₂ N-[(4S,6S,10S)-10-amino-13-methyl-9,14-dioxo-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-6-yl]pentanamide Ex. 168

benzyl N-[(4S,6S,10S)-13-methyl-6-{[2-(2-naphthyl)acetyl]amino}-9,14-dioxo-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]carbamate Ex. 169

benzyl N-[(4S,6S,10S)-13-methyl-9,14-dioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]carbamate Ex. 170

N-[(4S,6S,10S)-13-methyl-9,14-dioxo-10-{[3-(4-pyridinyl)propanoyl]amino}-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-6-yl]pentanamide Ex. 171

N-[(4S,6S,10S)-13-methyl-9,14-dioxo-6-(pentanoylamino)-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]-2-naphthamide Ex. 172

NH₂ N-[(4S,6S,10S)-10-amino-13-methyl-9,14-dioxo-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-6-yl]-2-(2-naphthyl)acetamide Ex. 173

NH₂ N-[(4S,6S,10S)-10-amino-13-methyl-9,14-dioxo-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-6-yl]-2-(1-pyrrolidinyl) acetamide Ex. 174

N-[(4S,6S,10S)-10-(acetylamino)-13-methyl-9,14-dioxo-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-6-yl]-2-(2-naphthyl)acetamide Ex. 175

N-[(4S,6S,10S)-13-methyl-9,14-dioxo-10-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-6-yl]-2-(2-naphthyl) acetamide Ex. 176

N-[(4S,6S,10S)-13-methyl-6-{[2-(2-naphthyl)acetyl]amino}-9,14-dioxo-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]-3-(4-pyridinyl)propanamide Ex. 177

N-[(4S,6S,10S)-13-methyl-6-{[2-(2-naphthyl)acetyl]amino}-9,14-dioxo-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]-2-(1-naphthyl) acetamide Ex. 178

N-[(4S,6S,10S)-13-methyl-9,14-dioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]-3-(4-pyridinyl)propanamide Ex. 179

N-[(4S,6S,10S)-13-methyl-9,14-dioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]-2-(1-naphthyl)acetamide Ex. 180

N-[(4S,6S,10S)-13-methyl-9,14-dioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,13-diazatricyclo[13.3.1.0^(4,8)]nonadeca-1(19),15,17-trien-10-yl]-2-naphthamide

TABLE 29a Examples of Core 11 (Ex. 181-Ex. 195) Yield, Starting GeneralPurification (isolated No R2 R5 material Procedure Reagent Method salt)Ex. 181-Ex. 182: cf. experimental description Ex. 183

Ex. 182 L.1.1 acetic anhydride (5 equiv.) FC (CH₂Cl₂/MeOH) 75% Ex. 184

Ex. 182 L.1.3 2- naphthylacetic acid (1.2 equiv.) FC (EtOAc, thenCH₂Cl₂/MeOH) 94% Ex. 185

NH₂ Ex. 184 K H₂, Pd(OH)₂—C crude product 99% Ex. 186

Ex. 185 L.1.3 2- naphthylacetic acid (1.2 equiv.) prep. HPLC, method 360% Ex. 186

139 Synthesis on solid support 2- naphthylacetic acid prep. HPLC, method3 32% Ex. 187

Ex. 185 L.1.3 pyrrolidin- 1-acetic acid (1.2 equiv.) prep. HPLC, method3 then prep. HPLC, method 1 38% (TFA salt) Ex. 188

Ex. 185 L.1.3 3-(pyridine-4- yl)propanoic acid (1.2 equiv.) prep. HPLC,method 3 then prep. HPLC, method 1 32% (TFA salt) Ex. 189

Ex. 185 L.1.1 valeroyl chloride (2 equiv.) prep. HPLC, method 3 52% Ex.190 NH₂

Ex. 193 1.2 TBAF (4 equiv.) in THF crude product, contaminated with TBAFca 70% Ex. 191

Ex. 190 L.1.1 Acetic anhydride (10 equiv.) Pyridine/ CH₂Cl₂ 1:1 (3 mL)prep. HPLC, method 3 62% Ex. 192

Ex. 190 L.1.3 3-(pyridine-4- yl)propanoic acid (1.2 equiv.) prep. HPLC,method 3 63% Ex. 193

Ex. 194 L.1.1 3,5- difluorbenzoyl chloride (2 equiv.) FC (EtOAc) 85% Ex.194

NH₂ Ex. 181 K H₂, Pd(OH)₂—C crude product quant. Ex. 195

Ex. 190 L.1.1 benzoyl chloride (2 equiv.) preparative HPLC method 3 78%

TABLE 29b Examples of Core 11 (Ex. 181-Ex. 195, continued on thefollowing pages) Mono- Rt isotopic (purity at [M + H]⁺ LC-MS- No R2 R5Formula Mass 220 nm) found Method Ex. 181-Ex. 182: of. experimentaldescription Ex. 183

C28H34N4O6 522.3 1.56 (99) 523.3 Method 2 Ex. 184

C38H40N4O6 648.3 1.92 (96) 649.5 Method 2 Ex. 185

NH₂ C30H34N4O4 514.3 1.48 (98) 515.4 Method 2 Ex. 186

C42H42N4O5 682.3 2.00 (91) 683.5 Method 2 Ex. 186

C42H42N4O5 682.3 2.26 (98) 683.3 Method 4a Ex. 187

C36H43N5O5 625.3 1.62 (100) 626.4 Method 2 Ex. 188

C38H41N5O5 647.3 1.60 (99) 648.3 Method 2 Ex. 189

C35H42N4O5 598.3 1.88 (85), 1.93 (8) 599.5 Method 2 Ex. 190 NH₂

C25H28F2N4O4 486.2 1.42 (98) 487.3 Method 4a Ex. 191

C27H30F2N4O5 528.2 1.69 (99) 529.3 Method 4a Ex. 192

C33H35F2N5O5 619.3 1.50 (99) 620.3 Method 4a Ex. 193

C31H40F2N4O6Si 630.3 2.13 (97) 631.4 Method 2 Ex. 194

NH₂ C24H38N4O5Si 490.3 1.62 (99) 491.3 Method 2 Ex. 195

C32H32F2N4O5 590.2 1.99 (98) 591.3 Method 4a

TABLE 29c Examples of Core 11 (Ex. 181-Ex. 195, continued on thefollowing pages) No R2 R5 IUPAC name Ex. 181

benzyl N-[(4S,6S,10S)-14-methyl-9,15-dioxo-6({[2-(trimethylsily)ethoxy]carbonyl}amino)-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien- 10-yl]carbamateEx. 182 NH₂

benzyl N-[(4S,6S,10S)-6-amino-14-methyl-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-10-yl]carbamate Ex. 183

benzyl N-[(4S,6S,10S)-6-(acetylamino)-14-methyl-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-10-yl]carbamate Ex. 184

benzyl N-[(4S,6S,10S)-14-methyl-6-{[2-(2-naphthyl)acetyl]amino}-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18- trien-10-yl]carbamateEx. 185

NH₂ N-[(4S,6S,10S)-10-amino-14-methyl-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-6-yl]-2-(2-naphthyl)acetamide Ex. 186

N-[(4S,6S,10S)-14-methyl-10-{[2-(2-naphthy)acetyl]amino}-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa- 1(20),16,18-trien-6-yl]-2-(2-naphthyl)acetamide Ex. 187

N-[(4S,6S,10S)-14-methyl-9,15-dioxo-10-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-6-yl]-2-(2-naphthyl)acetamide Ex. 188

N-[(4S,6S,10S)-14-methyl-6-{[2-(2-naphthyl)acetyl]amino}-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-10-yl]-3-(4-pyridinyl)propanannide Ex. 189

N-[(4S,6S,10S)-14-methyl-6-{[2-(2-naphthyl)acetyl]amino}-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-10-yl]pentanamide Ex. 190 NH₂

N-[(4S,6S,10S)-6-amino-14-methyl-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-10-yl]-3,5-difluorobenzamide Ex. 191

N-[(4S,6S,10S)-6-(acetylamino)-14-methyl-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-10-yl]-3,5-difluorobenzamide Ex. 192

3,5-difluoro-N-[(4S,6S,10S)-14-methyl-9,15-dioxo-6-{[3-(4-pyridinyl)propanoyl]amino}-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-10-yl]benzamide Ex. 193

2-(trimethylsilyl)ethyl N-[(4S,6S,10S)-10-[(3,5-difluorobenzoyl)amino]-14-methyl-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-6-yl]carbamate Ex.194

NH₂ 2-(trimethylsilyl)ethyl N-[(4S,6S,10S)-10-amino-14-methyl-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-6-yl]carbamate Ex. 195

N-[(4S,65,10S)-6-(benzoylamino)-14-methyl-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0^(4,8)]icosa-1(20),16,18-trien-10-yl]-3,5-difluorobenzamide

TABLE 30a Examples of Core 12 (Ex. 196-Ex. 214 continued on thefollowing pages) General Yield, Starting Pro- Purification (isolated NoR2 R5 material cedure Reagent Method salt) Ex. 196-Ex. 198: cf.experimental description Ex. 199

Ex. 197•HCl L.1.1 acetic anhydride (10 equiv.) pyridine (2 mL) FC(CH₂Cl₂/MeOH) then prep HPLC, method 1 36% Ex. 200

Ex. 197•HCl L.1.3 3-indoleacetic acid (1.5 equiv.), HATU (1.5 equiv.),HOAt (1.5 equiv), i-Pr₂NEt (5 equiv.) FC (CH₂Cl₂/MeOH) then prep HPLC,method 1 22% Ex. 200

Ex. 197•TFA L.1.3 3-indoleacetic acid (1.5 equiv.), HATU (1.5 equiv.),HOAt (1.5 equiv), i-Pr²NEt (5 equiv.) FC (EtOAc, then CH₂Cl₂/MeOH) 78%Ex. 201

Ex. 197•HCl L.1.3 N,N-dimethyl glycine (1.7 equiv.) FC (CH₂Cl₂/MeOH) andprep HPLC, method 1 91% *) (TFA salt) Ex. 202

NH₂ Ex. 200 K H₂, Pd(OH)₂—C crude product 97% Ex. 203

NH₂ Ex. 201 K H₂, Pd(OH)₂—C crude product 99% Ex. 204

Ex. 214 L.1.3 3-indoleacetic acid (1.2 equiv.), HATU (1.5 equiv.), HOAt(1.5 equiv), i-Pr₂NEt (3 equiv.) FC (CH₂Cl₂/MeOH) 64% Ex. 205

Ex. 214 L.1.3 N,N-dimethyl glycine (1.7 equiv.) prep HPLC, method 1 47%(TFA salt) Ex. 206

Ex. 202 L.1.3 N,N-dimethyl glycine (1.7 equiv.) prep HPLC, method 1 39%(TFA salt) Ex. 207

Ex. 202 L.1.1 succinic anhydride (1.05 equiv.) pyridine (49 equiv.) prepHPLC, method 2 48% Ex. 208

Ex. 203 L.1.1 acetic anhydride (10 equiv.) pyridine/CH₂Cl₂ 1.1 (3 mL)prep HPLC, method 2 59% Ex. 209

L.1.1 Ex. 203 succinic anhydride (1.05 equiv.) pyridine (49 equiv.) prepHPLC, method 2 35% Ex. 210

Ex. 203 L.1.3 2-naphthylacetic acid (1.2 equiv.) prep HPLC, method 1 38%(TFA salt) Ex. 211

Ex. 202 L.1.2 3-(pyridine- 4-yl) propanoic acid prep HPLC, method 1 44%(TFA salt) Ex. 212

Ex. 202 L.1.3 2-naphthylacetic acid (1.2 equiv.) prep HPLC, method 1then FC (EtOAc/MeOH) 53% Ex. 213

CH₃(CH₂)₈CONH Ex. 202 L.1.1 decanoyl chloride (2 equiv.) prep HPLC,method 1 then FC (EtOAc/MeOH) 35% Ex. 214

NH₂ Ex. 199 K H₂, Pd(OH)₂—C crude product 98% *)An analytical sample wasfurther purified by prep. HPLC (method 1), to afford the TFA salt of thecorresponding product

TABLE 30b Examples of Core 12 (Ex. 196-Ex. 214, continued on thefollowing pages) Monoisotopic Rt (purity at [M + H]⁺ LC-MS- No R2 R5Formula Mass 220 nm) found Method Ex. 196-Ex. cf.198: experimentaldescription Ex. 199

C29H35N5O7 565.3 1.92 (100) 566.4 Method la Ex. 200

C37H40N6O7 680.3 2.23 (98) 681.4 Method la Ex. 200

C37H40N6O7 680.3 1.68 (93) 681.5 Method 2 Ex. 201

C31H40N6O7 608.3 1.28 (99) 609.4 Method 2 Ex. 202

NH₂ C29H34N6O5 546.3 1.32 (76) 547.4 Method 2 Ex. 203

NH₂ C23H34N6O5 474.3 0.77 475.5 Method 9c Ex. 204

C31H36N6O6 588.3 1.49 (87) 589.2 Method 4a Ex. 205

C25H36N6O6 516.3 1.42 (100) 517.3 Method 1a Ex. 206

C33H41N7O6 631.3 1.84 (97) 632.4 Method 1a Ex. 207

C33H38N6O8 646.3 1.42 (100) 647.4 Method 2 Ex. 208

C25H36N6O6 516.3 0.95 (100) 517.4 Method 2 Ex. 209

C27H38N6O8 574.3 1.02 (92) 575.4 Method 3 Ex. 210

C35H42N6O6 642.3 1.37 (100) 643.4 Method 2 Ex. 211

C37H41N7O6 679.3 1.34 (92) 680.5 Method 2 Ex. 212

C41H42N6O6 714.3 1.75 (86) 715.5 Method 2 Ex. 213

CH₃(CH₂)₈CONH C39H52N6O6 700.4 1.96 (99) 701.6 Method 2 Ex. 214

NH₂ C21H29N5O5 431.2 0.81*) 432.2 Method 9c *) Analytical HPLC (5%CH₃CN): 2.52 (93)

TABLE 30c Examples of Core 12 (Ex. 196-Ex. 214, continued on thefollowing pages) No R2 R5 IUPAC name Ex. 196

benzyl N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-6-({[2-(trimethylsilypethoxy]carbonyllamino)-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 197 NH₂

benzyl N-[(4S,6S,13S)-6-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 198

benzyl N-[(4S,6S,13S)-6-[(tert-butolcarbonyl)amino]-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 199

benzyl N-[(4S,6S,13S)-6-(acetylamino)-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 200

benzyl N-[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 201

benzyl N-[(4S,6S,13S)-6-{[2-(dimethylamino)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 202

NH₂ N-[(4S,6S,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1H-indol-3-yl)acetamide Ex. 203

NH₂ N-[(4S,6S,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(dimethylamino)acetamide Ex. 204

N-[(4S,6S,13S)-6-(acetylamino)-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-2-(1H-indol-3-yl)acetamide Ex. 205

N-[(4S,6S,13S)-6-(acetylamino)-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-2-(dimethylamino)acetamide Ex. 206

2-(dimethylamino)-N-[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]acetamide Ex. 207

4-{[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]amino}-4-oxobutanoic acid Ex. 208

N-[(4S,6S,13S)-13-(acetylamino)-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(dimethylamino)acetamide Ex. 209

4-{[(4S,6S,13S)-6-{[2-(dimethylamino)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]amino}-4-oxobutanoic acid Ex. 210

2-(dimethylamino)-N-[(4S,6S,13S)-11,15-dimethyl-13-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6- yl]acetamideEx. 211

N-[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-3-(4-pyridinyl)propanamide Ex. 212

N-[(4S,6S,13S)-11,15-dimethyl-13-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.04,8]henicosa-1(21),17,19-trien-6-yl]-2-(1H-indol-3-yl)acetamide Ex. 213

CH₃(CH₂)₈CONH N-[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino)-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]decanamide Ex. 214

NH₂ N-[(4S,6S,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]acetamide

TABLE 31a Examples of Core 13 (Ex. 215-Ex. 230, continued on thefollowing pages) Yield, Starting General Purification (isolated No R2 R5material Procedure Reagent Method salt) Ex. 215-Ex. 216: cf experimentaldescription Ex. 217

Ex. 221 L.1.1 acetic anhydride (10 equiv.) pyridine/CH₂Cl₂ 1:1 (2 mL)prep. HPLC, method 1 41% Ex. 218

Ex. 216 •HCl L.1.3 N,N-dimetyl glycine (1.7 equiv.) FC (CH₂Cl₂/MeOH)85%*) Ex. 219

Ex. 216 •HCl L.1.3 3-indoleacetic acid (1.1 equiv.) HATU (1.5 equiv.)HOAt (1.5 equiv.) i-Pr₂NEt (5 equiv.) FC (CH₂Cl₂/MeOH) 63% Ex. 220

NH₂ Ex. 218 K H₂, Pd(OH)_(2—)C crude product 93%*) Ex. 221

NH₂ Ex. 219 K H₂, Pd(OH)₂—C crude product 94%*) Ex. 222

Ex. 220 L.1.1 acetic anhydride (5 equiv.) prep. HPLC, method 1 25% (TFAsalt) Ex. 223

Ex. 220 L.1.3 N,N-dimetyl glycine (1.7 equiv.) prep. HPLC, method 1 24%(TFA salt) Ex. 224

Ex. 220 L.1.1 succinic anhydride (1.05 equiv.) prep. HPLC, method 1 37%(TFA salt) Ex. 225

Ex. 220 L.1.3 3-indoleacetic acid (1.2 equiv.) HATU (1.5 equiv.) HOAt(1.5 equiv.) i-Pr₂NEt (3 equiv.) prep. HPLC, method 1 28% (TFA salt) Ex.226

Ex. 221 L.1.3 N,N-dimetyl glycine (1.7 equiv.) prep. HPLC, method 1 45%(TFA salt) Ex. 227

Ex. 221 L.1.1 succinic anhydride (1.05 equiv.) pyridine (49 equiv.)prep. HPLC, method 1 49% Ex. 228

Ex. 221 L.1.3 3-indoleacetic acid (1.2 equiv.) HATU (1.5 equiv.) HOAt(1.5 equiv.) i-Pr₂NEt (3 equiv.) prep. HPLC, method 1 33% Ex. 229

Ex. 221 L.1.3 2-naphthylacetic acid (1.2 equiv.) prep. HPLC, method 156% Ex. 230

Ex. 220 L.1.3 2-naphthylacetic acid (1.2 equiv.) prep. HPLC, method 152% (TEA salt) *) Analytical sample further purified by prep. HPLC,method 1 to afford the TFA salt of the corresponding product

TABLE 31b Examples of Core 13 (Ex. 215-Ex. 230, continued on thefollowing pages) Monoisotopic Rt (purity at [M + H]⁺ LC-MS- No R2 R5Formula Mass 220 nm) found Method Ex. 215-Ex. 216: cf. experimentaldescription Ex. 217

C31H36N6O6 588.3 1.82 (94) 589.2 Method 1b Ex. 218

C31H40N6O7 608.3 1.36 (100) 609.2 Method 4b Ex. 219

C37H40N6O7 680.3 1.64 (96) 681.3 Method 2 Ex. 220

NH₂ C23H34N6O5 474.3 1.19 (92) 475.2 Method 5b Ex. 221

NH₂ C29H34N6O5 546.3 1.38 (96) 547.2 Method 4b Ex. 222

C25H36N6O6 516.3 1.23 (97) 517.2 Method 5b Ex. 223

C27H41N7O06 559.3 1.33 (94) 560.3 Method 5b Ex. 224

C27H38N6O8 574.3 1.04 (100) 575.2 Method 5b Ex. 225

C33H41N7O6 631.3 1.30 (97) 632.3 Method 4b Ex. 226

C33H41N7O6 631.3 1.39 (92) 632.2 Method 4b Ex. 227

C33H38N6O8 646.3 1.49 (94) 647.2 Method 4b Ex. 228

C39H41N7O6 703.3 1.75 (91) 704.3 Method 4b Ex. 229

C41H42N6O6 714.3 1.91 (92) 715.3 Method 4b Ex. 230

C35H42N6O6 642.3 1.50 (100) 643.2 Method 4b

TABLE 31c Examples of Core 13 (Ex. 215-Ex. 230) No R2 R5 IUPAC name Ex.215

benzyl N-[(4S,6R,13S)-11,15-dimethyl-9,12,16-trioxo-6-({[2-(trimethylsilyl)ethoxy]carbonyl}amino)-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 216 NH₂

benzyl N-[(4S,6R,13S)-6-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 217

N-[(4S,6R,13S)-13-(acetylamino)-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1H-indol-3-yl)acetamide Ex. 218

benzyl N-[(4S,6R,13S)-6-{[2-(dimethylamino)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 219

benzyl N-[(4S,6R,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 220

NH₂ N-[(4S,6R,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(dimethylamino)acetamide Ex. 221

NH₂ N-[(4S,6R,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1H-indol-3-yl)acetamide Ex. 222

N-[(4S,6R,13S)-13-(acetylamino)-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(dimethylamino)acetamide Ex. 223

2-(dimethylamino)-N-[(4S,6R,13S)-13-{[2-(dimethylamino)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]acetamide Ex. 224

4-{[(4S,6R,13S)-6-{[2-(dimethylamino)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]amino}-4-oxobutanoic acid Ex. 225

2-(dimethylamino)-N-[(4S,6R,13S)-13-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-11-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]acetamideEx. 226

2-(dimethylamino)-N-[(4S,6R,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]acetamide Ex. 227

4-{[(4S,6R,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]amino}-4-oxobutanoic acid Ex. 228

2-(1H-indol-3-yl)-N-[(4S,6R,13S)-13-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]acetamideEx. 229

N-[(4S,6R,13S)-11,15-dimethyl-13-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1H-indol-3-yl)acetamide Ex. 230

2-(dimethylamino)-N-[(4S,6R,13S)-11,15-dimethyl-13-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien- 6-yl]acetamide

TABLE 32a Examples of Core 14 (Ex. 231-Ex. 237) Yield, Starting GeneralPurification (isolated No R2 R5 material Procedure Reagent Method salt)Ex. 231-Ex. 232: cf. experimental description Ex. 233

Ex. 232•TFA L.1.3 3-indoleacetic acid (1.5 equiv.) HATU (1.5 equiv.)HOAt (1.5 equiv.) i-Pr₂NEt (5 equiv) FC (EtOAc, then CH₂Cl₂/ MeOH) 68%Ex. 234

NH₂ Ex. 233 K H₂, Pd(OH)₂—C crude product 99% Ex. 235

Ex. 234 L.1.3 2-naphthylacetic acid (1.2 equiv.) prep. HPLC, method 368% Ex. 236

Ex. 234 L.1.3 pyrrolidin-1- acetic acid (1.2 equiv.) prep. HPLC, method3 28% Ex. 237

Ex. 234 L.1.3 3-phenylpropionic acid prep. HPLC, method 3 66%

TABLE 32b Examples of Core 14 (Ex. 231-Ex. 237) Monoisotopic Rt (purityat [M + H]⁺ LC-MS- No R2 R5 Formula Mass 220 nm) found Method Ex.231-Ex. 232: cf. experimental description Ex. 233

C37H40N6O7 680.3 1.80 (96) 681.4 Method 2 Ex. 234

NH₂ C29H34N6O5 546.3 1.47 (93) 547.3 Method 2 Ex. 235

C41H42N6O6 714.3 1.80 (90) 715.4 Method 2 Ex. 236

C35H43N7O6 657.3 1.45 (94) 658.4 Method 2 Ex. 237

C38H42N6O6 678.3 1.81 (96) 679.4 Method 2

TABLE 32c Examples of Core 14 (Ex. 231-Ex. 237) No R2 R5 IUPAC name Ex.231

benzyl N-[(4S,6S,13R)-6-[(tert-butoxycarbonyl)amino]-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 232 NH₂

benzyl N-[(4S,6S,13R)-6-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 233

benzyl N-[(4S,65,13R)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 234

NH₂ N-[(4S,6S,13R)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1H-indol-3-yl)acetamide Ex. 235

N-[(4S,6S,13R)-11,15-dimethyl-13-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1H-indol-3-yl)acetamide Ex. 236

N-[(4S,6S,13R)-11,15-dimethyl-9,12,16-trioxo-13-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1H-indol-3-yl)acetamide Ex. 237

N-[(4S,6S,13R)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-3-phenylpropanamide

Table 33a Examples of Core 15 and Core 16 (Ex. 238-Ex. 247) Yield,Starting General Purification (isolated No R2 R5 material ProcedureReagent Method salt) Ex. 238-Ex. 239: cf. experimental description Ex.240

Ex. 239 L.1.3 3-phenylpoanoic acid FC (EtOAc/ MeOH)^(*)) 47% Ex. 241

Ex. 239 L.1.3 pyrrolidin-1- acetic acid FC (CH₂Cl₂/ MeOH/aq. NH₃) 56%Ex. 242 NH₂

Ex. 240 J HCl-dioxane crude product quant. (HCl salt) Ex. 243 NH₂

Ex.241 J HCl-dioxane crude product quant. (HCl salt) Ex. 244

Ex. 242 L.1.3 pyrrolidin-1- acetic acid FC (CH₂Cl₂/ MeOH/aq. NH₃) 81%Ex. 245

Ex. 242 L.1.3 3-indoleacetic acid FC (CH₂Cl₂/ MeOH/aq. NH₃) 59% Ex. 246

Ex. 243 L.1.3 2-naphthylacetic acid FC (CH₂Cl₂/ MeOH/aq. NH₃) 51% Ex.247

Ex. 243 L.1.3 3-indoleacetic acid FC (CH₂Cl₂/ MeOH/aq. NH₃) 58% ^(*))Ananalytical sample was further purified by prep. HPLC, method 2

TABLE 33b Examples of Core 15 and Core 16 (Ex. 238-Ex. 247) MonoisotopicRt (purity at [M + H]⁺ LC-MS- No R2 R5 Formula Mass 220 nm) found MethodEx. 238-Ex. 239: cf. experimental description Ex. 240

C33H44N4O6 592.3 2.12 (90) 593.3 Method 4a Ex. 241

C30H45N5O6 571.3 1.58 (91) 572.3 Method 4a Ex. 242 NH₂

C28H36N4O4 492.3 1.53 (88), 1.59 (6) 493.2 Method 4a Ex. 243 NH₂

C25H37N5O4 471.3 1.08 (91) 472.4 Method 4a Ex. 244

C34H45N5O5 603.3 1.63 (93) 604.4 Method 4a Ex. 245

C38H43N5O5 649.3 2.01 (91) 650.3 Method 4a Ex. 246

C37H45N5O5 639.3 1.69 (90) 640.3 Method 4a Ex. 247

C35H44N6O5 628.3 1.52 (94) 629.3 Method 4a

TABLE 33c Examples of Core 15 and Core 16 (Ex. 238-Ex. 247) No R2 R5IUPAC name Core 15 Ex. 238

benzyl N-[(4S,6S,10S)-6-[(tert-butoxycarbonyl)amino]-15-methyl-9,16-dioxo-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),12,17,19-tetraen-10-yl]carbamate Core 16 Ex. 239

NH₂ tert-butyl N-[(4S,6S,10S)-10-amino-15-methyl-9,16-dioxo-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]carbamate Ex. 240

tert-butyl N-[(4S,6S,10S)-15-methyl-9,16-dioxo-10-[(3-phenylpropanoyl)amino]-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]carbamate Ex. 241

tert-butyl N-[(4S,6S,10S)-15-methyl-9,16-dioxo-10-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]carbamate Ex. 242 NH₂

N-[(4S,6S,10S)-6-amino-15-methyl-9,16-dioxo-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-10-yl]-3-phenylpropanamide Ex. 243 NH₂

N-[(4S,6S,10S)-6-amino-15-methyl-9,16-dioxo-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-10-yl]-2-(1-pyrrolidinyl) acetamide Ex. 244

N-[(4S,6S,10S)-15-methyl-9,16-dioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-10-yl]-3-phenylpropanamide Ex. 245

N-[(4S,6S,10S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-15-methyl-9,16-dioxo-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-10-yl]-3-phenylpropanamide Ex. 246

N-[(4S,6S,10S)-15-methyl-9,16-dioxo-10-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(2-naphthyl) acetamide Ex. 247

2-(1H-indol-3-yl)-N-[(4S,6S,10S)-15-methyl-9,16-dioxo-10-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,15-diazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]acetamide

TABLE 34a Examples of Core 17 (Ex. 248-Ex. 271) Yield, Starting GeneralPurification (isolated No R2 R50 material Procedure Reagent Method salt)Ex. 248-Ex. 249: cf. experimental description Ex. 250

Ex. 249 L.2 pyrrolidine FC (CH₂Cl₂/ MeOH) 81% Ex. 251

Ex. 249 L.2 N-(2-aminoethyl) pyrrolidine FC (CH₂Cl₂/ MeOH/ aq. NH₃soln.) 88% Ex. 252

Ex. 249 L.2 2- naphthylmethylamine (1.5 equiv.) HATU (1.5 equiv.) HOAt(1.5 equiv.) i-Pr₂NEt (3 equiv.) FC (CH₂Cl₂/ MeOH) 91% Ex. 253

Ex. 249 L.2 4- (aminomethyl)pyridine (1.5 equiv.) HATU (1.5 equiv.) HOAt(1.5 equiv.) i-Pr₂NEt (3 equiv.) FC (CH₂Cl₂/ MeOH)^(*)) 97% Ex. 254 NH₂

Ex. 251 J HCl-dioxane crude product 96% (HCl salt) Ex. 255 NH₂

Ex. 252 J HCl-dioxane crude product 100%  (HCl salt) Ex. 256 NH₂

Ex. 250 J HCl-dioxane crude product 93% (HCl salt) Ex. 257 NH₂

Ex. 253 J HCl-dioxane crude product 91% (HCl salt) Ex. 258

Ex. 255 L.1.2 1-pyrrolidinacetic acid (2.7 equiv.) i-Pr₂NEt v(4 equiv.)FC (CH₂Cl₂/ MeOH) 61% Ex. 259

Ex. 255 L.1.1 succininc anhydride (1.05 equiv.) pyridine (49 equiv.)prep. HPLC, method 1 15% Ex. 260

Ex. 255 L.1.2 3-(pyridine-4- yl)propanoic acid prep. HPLC, method 1 55%(TFA salt) Ex. 261

Ex. 255 L.1.3 1-naphthylacetic acid (1.2 equiv.) prep. HPLC, method 169% Ex. 262

Ex. 255 M acetaldehyde prep. HPLC, method 1 76% (TFA salt) Ex. 263

Ex. 256 L.1.1 acetic anhydride (10 equiv.) Pyridine/CH₂Cl₂ 1:1 (3 mL)prep. HPLC, method 1 82% Ex. 264

Ex. 256 L.1.3 2-naphthylacetic acid (1.2 equiv.) prep. HPLC, method 161% Ex. 265

Ex. 257 L.1.3 2-naphthylacetic acid (1.2 equiv.) prep. HPLC, method 159% (TFA salt) Ex. 266

Ex. 257 L.1.2 1-pyrrolidinacetic acid prep. HPLC, method 2 71% Ex. 267

Ex. 257 L.1.1 succininc anhydride (1.5 equiv.) pyridine (49 equiv.)prep. HPLC, method 1 89% (TFA salt) Ex. 268

Ex. 257 L.1.3 1-naphthylacetic acid (1.2 equiv.) prep. HPLC, method 245% Ex. 269

Ex. 257 M Acetaldehyde (0.75 mL) prep. HPLC, method 2 70% Ex. 270

Ex. 255 L.1.1 valeroyl chloride (2 equiv.) prep. HPLC, method 1 77% Ex.271

Ex. 257 L.1.1 valeroyl chloride (2 equiv.) prep. HPLC, method 1 58% (TFAsalt) ^(*))An analytical sample was further purified by prep HPLC,method 1

TABLE 34b Examples of Core 17 (Ex. 248-Ex. 271) Monoisotopic Rt (purity[M + H]⁺ LC-MS- No R2 R50 Formula Mass at 220 nm) found Method Ex.248-Ex. 249: cf. experimental description Ex. 250

C30H43N5O7 585.4 1.58 (96) 586.4 Method 2 Ex. 251

C32H48N6O7 628.4 1.35 (98) 629.5 Method 2 Ex. 252

C37H45N5O7 671.3 1.86 (88) 672.4 Method 2 Ex. 253

C32H42N6O7 622.3 1.29 (92) 623.4 Method 2 Ex. 254 NH₂

C27H40N6O5 528.3 1.31 (97) 529.5 Method 3 Ex. 255 NH₂

C32H37N5O5 571.3 1.45 (94) 572.4 Method 2 Ex. 256 NH₂

C25H35N5O5 485.3 1.06 (96) 486.4 Method 2 Ex. 257 NH₂

C27H34N6O5 522.3 0.85 (96) 523.3 Method 2 Ex. 258

C38H46N6O6 682.4 1.47 (95) 683.5 Method 2 Ex. 259

C36H41N5O8 671.3 1.59 (87) 672.4 Method 2 Ex. 260

C40H44N6O6 704.3 1.47 (100) 705.5 Method 2 Ex. 261

C44H45N5O6 739.3 1.93 (99) 740.5 Method 2 Ex. 262

C36H45N5O5 627.3 1.50 (100) 628.5 Method 2 Ex. 263

C27H37N5O6 527.3 1.23 (99) 528.3 Method 2 Ex. 264

C37H43N5O6 653.3 1.68 (100) 654.4 Method 2 Ex. 265

C39H42N6O6 690.3 1.44 (99) 691.5 Method 2 Ex. 266

C33H43N7O6 633.3 0.99 (94) 634.5 Method 2 Ex. 267

C31H38N6O8 622.3 1.05 (94) 623.3 Method 2 Ex. 268

C39H42N6O6 690.3 1.68 (93) 691.5 Method 3 Ex. 269

C31H42N6O5 578.3 0.96 (96) 579.5 Method 2 Ex. 270

C37H45N5O6 655.3 1.81 (100) 656.4 Method 2 Ex. 271

C32H42N6O6 606.3 1.25 (100) 607.4 Method 2

TABLE 34c Examples of Core 17 (Ex. 248-Ex. 271) No R2 R50 IUPAC name Ex.248

OCH₂Ph benzyl (4S,6R,15S)-6-[(tert-butoxycarbonyl)amino]-11,16-dimethyl-9,12,17-trioxo-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxylate Ex. 249

OH (4S,6R,15S)-6-[(tert-butoxycarbonyl)amino]-11,16-dimethyl-9,12,17-trioxo-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxylic acid Ex. 250

tert-butyl N-[(4S,6R,15S)-11,16-dimethyl-9,12,17-trioxo-15-(1-pyrrolidinylcarbonyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-trien-6-yl]carbamate Ex. 251

tert-butyl N-[(4S,6R,15S)-11,16-dimethyl-9,12,17-trioxo-15-({[2-(1-pyrrolidinyl)ethyl]amino}carbonyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-trien-6-yl]carbamateEx. 252

tert-butyl N-[(4S,6R,15S)-11,16-dimethyl-15-{[(2-naphthylmethyl)amino]carbonyl}-9,12,17-trioxo-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-trien-6-yl]carbamateEx. 253

tert-butyl N-[(4S,6R,15S)-11,16-dimethyl-9,12,17-trioxo-15-{[(4-pyridinylmethyl)amino]carbonyl}-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-trien-6-yl]carbamate Ex. 254 NH₂

(4S,6R,15S)-6-amino-11,16-dimethyl-9,12,17-trioxo-N-[2-(1-pyrrolidinyl)ethyl]-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 255 NH₂

(4S,6R,15S-6-amino-11,16-dimethyl-N-(2-naphthylmethyl)-9,12,17-trioxo-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 256 NH₂

(4S,6R,15S)-6-amino-11,16-dimethyl-15-(1-pyrrolidinylcarbonyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-9,12,17-trione Ex. 257 NH₂

(4S,6R,15S)-6-amino-11,16-dimethyl-9,12,17-trioxo-N-(4-pyridinylmethyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 258

(4S,6R,15S)-11,16-dimethyl-N-(2-naphthylmethyl)-9,12,17-trioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamideEx. 259

4-{[(4S,6R,15S )-11,16-dimethyl-15-{[(2-naphthylmethyl) amino]carbonyl}-9,12,17-trioxo-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-trien-6-yl]amino}-4-oxobutanoic acidEx. 260

(4S,6R,15S)-11,16-dimethyl-N-(2-naphthylmethyl)-9,12,17-trioxo-6-{[3-(4-pyridinyl)propanoyl]amino}-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamideEx. 261

(4S,6R,15S)-11,16-dimethyl-6-{[2-(1-naphthyl)acetyl]amino}-N-(2-naphthylmethyl)-9,12,17-trioxo-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 262

(4S,6R,15S)-6-(diethylamino)-11,16-dimethyl-N-(2-naphthylmethyl)-9,12,17-trioxo-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 263

N-[(4S,6R,15S)-11,16-dimethyl-9,12,17-trioxo-15-(1-pyrrolidinylcarbonyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-trien-6-yl]acetamide Ex. 264

N-[(4S,6R,15S)-11,16-dimethyl-9,12,17-trioxo-15-(1-pyrrolidinylcarbonyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-trien-6-yl]-2-(2-naphthyl)acetamide Ex. 265

(4S,6R,15S)-11,16-dimethyl-6-{[2-(2-naphthyl)acetyl]amino}-9,12,17-trioxo-N-(4-pyridinylmethyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 266

(4S,6R,15S)-11,16-dimethyl-9,12,17-trioxo-N-(4-pyridinylmethyl)-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex.267

4-{[(4S,6R,15S)-11,16-dimethyl-9,12,17-trioxo-15-{[(4-pyridinylmethyl)amino]carbonyl}-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-trien-6-yl]amino}-4- oxobutanoic acidEx. 268

(4S,6R,15S)-11,16-dimethyl-6-{[2-(1-naphthyl)acetyl]amino}-9,12,17-trioxo-N-(4-pyridinylmethyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 269

(4S,6R,15S)-6-(diethylamino)-11,16-dimethyl-9,12,17-trioxo-N-(4-pyridinylmethyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 270

(4S,6R,15S)-11,16-dimethyl-N-(2-naphthylmethyl)-9,12,17-trioxo-6-(pentanoylamino)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide Ex. 271

(4S,6R,15S)-11,16-dimethyl-9,12,17-trioxo-6-(pentanoylamino)-N-(4-pyridinylmethyl)-2-oxa-8,11,16-triazatricyclo[16.2.2.0^(4,8)]docosa-1(20),18,21-triene-15-carboxamide

TABLE 35a Examples of Core 18 (Ex. 272-Ex. 296) Yield, Starting GeneralPurification (isolated No R2 R5 material Procedure Reagent Method salt)Ex. 272-Ex. 274: cf. experimental description Ex. 275

Ex. 273 (HCl salt) L.1.3 3-indoleacetic acid (1.1 equiv.) HATU (1.5equiv.) HOAt (1.5 equiv.) i-Pr₂NEt (5 equiv.) FC (CH₂Cl₂/ MeOH) 53% Ex.276

Ex. 274 L.1.3 3-phenylpropanoic acid (1.2 equiv.) HATU (1.5 equiv.) HOAt(1.5 equiv.) i-Pr₂NEt (3 equiv.) FC (CH₂Cl₂/ MeOH) 72% Ex. 277 NH₂

Ex. 276 J HCl-dioxane crude product quant. (HCl salt) Ex. 278

Ex. 277 L.1.3 3-indoleacetic acid (1.1 equiv.) HATU (1.5 equiv.) HOAt(1.5 equiv.) i-Pr₂NEt (5 equiv.) FC (CH₂Cl₂/ MeOH) 75% Ex. 279

Ex. 273 (HCl salt) L.1.3 pyrrolidine-1-acetic acid (1.2 equiv.) FC(EtOAc/ MeOH) 67% Ex. 280

Ex. 273 (HCl salt) L.1.1 valeroyl chloride (2 equiv.) FC (EtOAc/ MeOH)71% Ex. 281

NH₂ Ex. 279 K H₂, Pd(OH)₂—C crude product quant. Ex. 282

NH₂ Ex. 280 K H₂, Pd(OH)₂—C crude product quant. Ex. 283

Ex. 281 L.1.3 2-naphthylacetic acid (1.2 equiv.) Prep. HPLC, method 327% Ex. 284

Ex. 281 L.1.1 succinic anhydride (1.5 equiv.) Pyridine (49 equiv.) Prep.HPLC, method 2 51% Ex. 285

Ex. 281 L.1.3 3-(pyridine-4- yl)propanoic acid (1.2 equiv.) Prep. HPLC,method 2 12% Ex. 286

Ex. 281 L.1.3 pyrrolidine-1-acetic acid (1.2 equiv.) Prep. HPLC, method2 16% Ex. 287

Ex. 282 L.1.3 2-naphthylacetic acid (1.2 equiv.) FC (CH₂Cl₂/ MeOH/ aq.NH₃) 79% Ex. 288

Ex. 282 L.1.1 succinic anhydride (1.5 equiv.) Pyridine (49 equiv.) Prep.HPLC, method 2 57% Ex. 289

Ex. 282 L.1.3 3-(pyridine-4- yl)propanoic acid (1.2 equiv.) Prep. HPLC,method 3 17% Ex. 290

Ex. 282 L.1.3 pyrrolidine-1-acetic acid (1.2 equiv.) FC (CH₂Cl₂/ MeOH/aq. NH₃) 65% Ex. 291

Ex. 292 (HCl salt) L.1.3 2-naphthylacetic acid (1.2 equiv.) FC (EtOAc/MeOH)^(*)) 79% Ex. 292

NH₂ Ex. 291 K H₂, Pd(OH)₂—C FC (EtOAc/ MeOH) 69% Ex. 293

Ex. 292 L.1.3 pyrrolidine-1-acetic acid (1.2 equiv.) Prep. HPLC, method3 64% Ex. 294

Ex. 292 L.1.3 3-(pyridine-4- yl)propanoic acid (1.2 equiv.) Prep. HPLC,method 3 70% Ex. 295

Ex. 292 L.1.1 succinic anhydride (1.5 equiv.) Pyridine (49 equiv.) Prep.HPLC, method 2 73% Ex. 296

CH₃(CH₂)₈ CONH Ex. 292 L.1.1 decanoyl chloride (2 equiv.) Prep. HPLC,method 3 40% ^(*))An analytical sample was further purified by prep.HPLC, method 3

TABLE 35b Examples of Core 18 (Ex. 272-Ex. 296) Monoisotopic Rt (purityat [M + H]⁺ LC-MS- No R2 R5 Formula Mass 220 nm) found Method Ex.272-Ex. 274: cf. experimental description Ex. 275

C36H39N7O7 681.3 1.53 (97) 682.5 Method 2 Ex. 276

C32H42N6O7 622.3 1.57 (95) 623.4 Method 2 Ex. 277 NH₂

C27H34N6O5 522.3 1.10 (98) 523.4 Method 2 Ex. 278

C37H41N7O6 679.3 1.50 (98) 680.5 Method 2 Ex. 279

C32H41N7O7 635.3 1.32 (98) 636.3 Method 2 Ex. 280

C31H40N6O7 608.3 1.54 (98) 609.3 Method 2 Ex. 281

NH₂ C24H35N7O5 501.3 1.32 (98) 502.3 Method 5a Ex. 282

NH₂ C23H34N6O5 474.3 1.24 (94) 475.1 Method 4a Ex. 283

C36H43N7O6 669.3 1.42 (95) 670.3 Method 4a Ex. 284

C28H39N7O8 601.3 0.99 (100) 602.2 Method 5a Ex. 285

C32H42N8O6 634.3 1.47 (98) 635.2 Method 5a Ex. 286

C30H44N8O6 612.3 1.55 (99) 613.3 Method 5a Ex. 287

C35H42N6O6 642.3 1.77 (98) 643.3 Method 4a Ex. 288

C27H38N6O8 574.3 1.32 (100) 575.2 Method 4a Ex. 289

C31H41N7O6 607.3 1.25 (95) 608.3 Method 4a Ex. 290

C29H43N7O6 585.3 1.30 (95) 586.4 Method 4a Ex. 291

C38H40N6O7 692.3 1.91 (97) 693.3 Method 4a Ex. 292

NH₂ C30H34N6O5 558.3 1.55 (99) 559.3 Method 4a Ex. 293

C36H43N7O6 669.3 1.52 (96) 670.3 Method 4a Ex. 294

C38H41N7O6 691.3 1.46 (97) 692.3 Method 4a Ex. 295

C34H38N6O8 658.3 1.58 (99) 659.2 Method 4a Ex. 296

CH₃(CH₂)₈CONH C40H52N6O6 712.4 2.22 (99) 713.4 Method 4a

TABLE 35c Examples of Core 18 (Ex. 272-Ex. 296) No R2 R5 IUPAC name Ex.272

benzyl N-[(4S,6S,13S)-6-[(tert-butoxycarbonyl)amino]-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 273 NH₂

benzyl N-[(4S,6S,13S)-6-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 274

NH₂ tert-butyl N-[(4S,6S,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]carbamate Ex. 275

benzyl N-[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 276

tert-butyl N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-13-[(3-phenylpropanoyl)amino]-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]carbamate Ex. 277 NH₂

N-[(4S,6S,13S)-6-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-3-phenylpropanamide Ex. 278

N-[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-3- phenylpropanamideEx. 279

benzyl N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 280

benzyl N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-6-(pentanoylamino)-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 281

NH₂ N-[(4S,6S,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1-pyrrolidinyl)acetamide Ex. 282

NH₂ N-[(4S,6S,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]pentanamide Ex. 283

N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-2-(2-naphthyl)acetamide Ex. 284

4-{[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]amino}-4-oxobutanoic acid Ex. 285

N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-6-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-3-(4-pyridinyl)propanamide Ex. 286

N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-13-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(1-pyrrolidinyl)acetamide Ex. 287

N-[(4S,6S,13S)-11,15-dimethyl-13-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]pentanamide Ex. 288

4-{[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-6-(pentanoylamino)-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]amino}-4- oxobutanoicacid Ex. 289

N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-13-{[3-(4-pyridinyl)propanoyl]amino}-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]pentanamide Ex. 290

N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-13-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]pentanamide Ex. 291

benzyl N-[(4S,6S,13S)-11,15-dimethyl-6-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]carbamate Ex. 292

NH₂ N-[(4S,6S,13S)-13-amino-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(2-naphthyl)acetamide Ex. 293

N-[(4S,6S,13S)-11,15-dimethyl-9,12,16-trioxo-13-{[2-(1-pyrrolidinyl)acetyl]amino}-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-6-yl]-2-(2-naphthyl)acetamide Ex. 294

N-[(4S,6S,13S)-11,15-dimethyl-6-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]-3-(4-pyridinyl)propanamide Ex. 295

4-{[(4S,6S,13S)-11,15-dimethyl-6-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]amino}-4- oxobutanoicacid Ex. 296

CH₃(CH₂)₈CONH N-[(4S,6S,13S)-11,15-dimethyl-6-{[2-(2-naphthyl)acetyl]amino}-9,12,16-trioxo-2-oxa-8,11,15,19-tetraazatricyclo[15.3.1.0^(4,8)]henicosa-1(21),17,19-trien-13-yl]decanamide

TABLE 36a Examples of Core 19 (Ex. 297-Ex. 310) Yield, Starting GeneralPurification (isolated No R2 R50 material Procedure Reagent Method salt)Ex. 297-Ex. 298: cf. experimental description Ex. 299

Ex. 298 L.2 N,N-dimethylethylene- diamine Flash Chroma- tography 80% Ex.300 NH₂

Ex. 299 J HCl-dioxane No purification quant. (HCl salt) Ex. 301

Ex. 298 L.2 1-naphthylmethyl- amine FC (CH₂Cl₂/ MeOH) 75% Ex. 302 NH₂

Ex. 301 J HCl-dioxane Crude product quant. (HCl salt) Ex. 303

Ex. 302 M acetaldehyde Prep. HPLC, method 2 45% Ex. 304

Ex. 302 L.1.1 valeroyl chloride (5 equiv.) Prep. HPLC, method 2 22% Ex.305

Ex. 302 L.1.2 3-(pyridine-4- yl)propanoic acid (3.7 equiv.) i-Pr₂NEt (4equiv.) bicarbonate resin (4 equiv.) FC (CH₂Cl₂/ MeOH/ aq. NH₃) thenPrep. HPLC, method 3 55% Ex. 306

Ex. 302 L.1.2 N,N-dimethyl glycine (6.2 equiv.) carbodiimide resin (2.5equiv.) i-Pr₂NEt (5 equiv.) bicarbonate resin (5 equiv.) FC (CH₂Cl₂/MeOH) 43% Ex. 307

Ex. 300 L.1.1 valeroyl chloride (2 equiv.) Prep. HPLC, method 2 36% Ex.308

Ex. 300 L.1.2 3-(pyridine-4- yl)propanoic acid (1.2 equiv.) i-Pr₂NEt (4equiv.), bicarbonate resin (4 equiv.) FC (CH₂Cl₂/ MeOH) 77% Ex. 309

Ex. 300 L.1.2^(*)) 2-naphthylacetic acid i-Pr₂NEt (4 equiv.) Prep. HPLC,method 2 58% Ex. 310

Ex. 300 L.1.2 3-indoleacetic acid (3.7 equiv.) i-Pr₂NEt (4 equiv.) DMF(0.2 mL) bicarbonate resin (4 equiv.) Prep. HPLC, method 2 28% ^(*))Thetreatment with (polystyrylmethyl)trimethylammonium bicarbonate wasreplaced by an aqueous workup (CHCl₃, sat. aq. NaHCO₃ soln)

TABLE 36b Examples of Core 19 (Ex. 297-Ex. 310) Rt Monoisotopic (purityat [M + H] ⁺ LC-MS- No R2 R5 Formula Mass 220 nm) found Method Ex.297-Ex. 298: cf. experimental description Ex. 299

C33H47N7O7 653.4 1.62 (97) 654.4 Method 4a Ex. 300 NH₂

C28H39N7O5 553.3 1.11 (64), 1.08 (35) 554.3 Method 4a Ex. 301

C40H46N6O7 722.3 2.19 (89) 723.4 Method 4a Ex. 302 NH₂

C35H38N6O5 622.3 1.70 (79) 623.3 Method 4a Ex. 303

C39H46N6O5 678.4 1.75 (100) 679.4 Method 4a Ex. 304

C40H46N6O6 706.4 2.09 (100) 707.4 Method 4a Ex. 305

C43H45N7O6 755.3 1.67 (57), 1.70 (38) 756.4 Method 4a Ex. 306

C39H45N7O6 707.3 1.71 (86) 708.3 Method 4a Ex. 307

C33H47N7O6 637.4 1.50 (638.3) 638.3 Method 4a Ex. 308

C36H46N8O6 686.4 1.57 (92) 687.4 Method 5a Ex. 309

C40H47N7O6 721.4 1.68 (98) 722.4 Method 4a Ex. 310

C38H46N8O6 710.4 1.52 (97) 711.4 Method 4a

TABLE 36c Examples of Core 19 (Ex. 297-Ex. 310) No R2 R5 IUPAC name Ex.297

OCH₂Ph benzyl (4S,6S,15S)-6-[(tert-butoxycarbonyl)amino]-11,16-dimethyl-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(24),18,20,22,25-pentaene-15-carboxylate Ex. 298

OH (4S,6S,15S)-6-[(tert-butoxycarbonyl)amino]-11,16-dimethyl-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(24),18,20,22,25-pentaene-15-carboxylic acid Ex. 299

tert-butyl N-[(4S,6S,15S)-15-({[2-(dimethylamino)ethyl]amino}carbonyl)-11,16-dimethyl-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(24),18,20,22,25-pentaen-6-yl]carbamate Ex. 300 NH₂

(4S,6S,15S)-6-amino-N-[2-(dimethylamino)ethyl]-11,16-dimethyl-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(24),18,20,22,25-pentaene-15-carboxamide Ex. 301

tert-butyl N-[(4S,6S,15S)-11,16-dimethyl-15-{[(1-naphthylmethyl)amino]carbonyl}-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaen-6-yl]carbamate Ex. 302 NH₂

(4S,6S,15S)-6-amino-11,16-dimethyl-N-(1-naphthylmethyl)-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide Ex. 303

(4S,6S,15S)-6-(diethylamino)-11,16-dimethyl-N-(1-naphthylmethyl)-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide Ex. 304

(4S,6S,15S )-11,16-dimethyl-N-(1-naphthylmethyl)-9,12,17-trioxo-6-(pentanoylamino)-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide Ex. 305

(4S,6S,15S)-11,16-dimethyl-N-(1-naphthylmethyl)-9,12,17-trioxo-6-{[3-(4-pyridinyl)propanoyl]amino}-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide Ex. 306

(4S,6S,15S)-6-{[2-(dimethylamino)acetyl]amino}-11,16-dimethyl-N-(1-naphthylmethyl)-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide Ex. 307

(4S,6S,15S)-N-[2-(dimethylamino)ethyl]-11,16-dimethyl-9,12,17-trioxo-6-(pentanoylamino)-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide Ex. 308

(4S,6S,15S)-N-[2-(dimethylamino)ethyl]-11,16-dimethyl-9,12,17-trioxo-6-{[3-(4-pyridinyl)propanoyl]amino}-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide Ex. 309

(4S,6S,15S)-N-[2-(dimethylamino)ethyl]-11,16-dimethyl-6-{[2-(2-naphthyl)acetyl]amino}-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyclo[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide Ex. 310

(4S,6S,15S)-N-[2-(dimethylamino)ethyl]-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,16-dimethyl-9,12,17-trioxo-2-oxa-8,11,16,26-tetraazatetracyc1o[16.6.2.0^(4,8).0^(21,25)]hexacosa-1(25),18(26),19,21,23-pentaene-15-carboxamide

TABLE 37 Examples of Core 20 and Core 21 (Ex. 311-Ex. 313) No Core 20 R2R5 R38 IUPAC name Ex. 311

benzyl N-[(4S,6S,13S,17S)-17-[(tert-butoxycarbonyl)amino]-11,15-dimethyl-9,12,16-trioxo-6-({[2-(trimethylsilyl)ethoxy]carbonyl}amino)-2-oxa-8,11,15-triazatetracyclo[15.6.2.0^(4,8).0^(20,24)] pentacosa-1(24),20,22-trien-13-yl]carbamate No Core 21 R2 R50 IUPAC name Ex. 312

OCH₂Ph benzyl (4S,6R,15S)-6-[(tert-butoxycarbonyl)amino]-11,16-dimethyl-9,12,17-trioxo-2-thia-8,11,16-triazatricyclo[16.3.1.0^(4,8)]docosa-1(22),18,20-triene-15- carboxylateEx. 313

OCH₂Ph benzyl (4S,6R,15S)-6-[(tert-butoxycarbonyl)amino]-11,16-dimethyl-2,2,9,12,17-pentaoxo-2λ⁶-thia-8,11,16-triazatricyclo[16.3.1.0^(4,8)]docosa-1(22),18,20-triene-15- carboxylate

Biological Methods1. Preparation of the Example Compounds

Example compounds were weighed on a Microbalance (Mettler MX5) anddissolved in 100% DMSO to a final concentration of 2.5 mM for Ca²⁺assays.

Example compounds were dissolved in DMSO/H₂O 90:10 to a finalconcentration of 10 mM for plasma stability determination and metabolicstability determination.

2. Ca²⁺ Assays: GPCR Assays for Motilin Receptor, Prostaglandin F (FP)Receptor and 5-Hydroxytryptamine 2B (5-HT_(2B)) Receptor

Assays were performed using a FLIPR Tetra (Molecular Devices); the dataanalysis and FLIPR Tetra Operating-Soft ware was ScreenWorks version 2(Molecular Devices).

Dose dependent agonist and antagonist activities were determined.Percentage activation and percentage inhibition values were determined.

Percentage activation was determined upon initial addition of the samplecompounds followed by 10 minutes incubation at 25° C. Following compoundincubation, reference agonists were added at EC₈₀ to determinepercentage inhibition.

Reference agonists were purchased from reputable commercial vendors andprepared according to specifications specific to each ligand. Allhandling of ligands were done to ensure proper control throughout theexperiments.

Test compounds were serially diluted with DMSO. Once the appropriateconcentrations were attained, the compounds were diluted into assaybuffer.

GPCR Assay Buffer:

Assay buffer was a supplemented HBSS (Hank's Balanced Salt Solution).HBSS was supplemented with 20 mM HEPES(4-(2-hydroxyethyl)-piperazin-1-ethansulfonic acid) and 2.5 mMProbenecid (Sigma P8761).

Assay Plate Seeding:

GPCR assays were performed using Ca²⁺ optimized hematopoietic cell lines(rat) with cultures never exceeding 90% confluency. Cells were harvestedand seeded (from cultures at less than 90% confluency) at 50000cells/well for a 96-well plate (12500 cells/well for 384). Afterseeding, the assay plates were incubated for forty-five (45) minutes atroom temperature. After room temperature incubation, the assay plateswere incubated at 37° C. 5% CO₂ for 24 hours prior to assaying.

Calcium Dye Loading:

All GPCR assays were performed using Fluo-8 Ca²⁺ dye. Ca²⁺ dye wasprepared at 1× dye concentration in GPCR assay buffer. After 24 hours ofincubation, cells were washed with GPCR assay buffer, then Ca²⁺-dye (100μL/well) was added. The plates were incubated for 90 minutes at 30° C.5% CO₂ prior to FLIPR assay.

Agonist Assay:

Compound plates were prepared to add 50 μL/well during the agonist assaymode. During the FLIPR assay, 50 μL/well from the compound plate wasdiluted 3-fold into the existing 100 μL/well from the dye loading step.Therefore all compounds were prepared as 3× the final concentrationdesired in the assay.

After completion of the first single addition assay run, assay plate wasremoved from the FLIPR Tetra and placed at 25° C. for seven (7) minutesbefore antagonist assay.

Antagonist Assay:

Using the EC₈₀ values determined during the agonist assay, allpre-incubated sample compound and reference antagonist (if applicable)wells were stimulated with EC₈₀ of reference agonist (motilin;prostaglandin F2α).

After the addition of the reference agonist fluorescence was monitoredfor 180 sec using FLIPR Tetra.

Data Analysis:

From the FLIPR data, with negative control correction enabled, themaximum statistic for each well was exported and percentage activationrelative to E_(max) control was calculated.

3. Plasma Stability

Human plasma (3-5 donors, Blutspendedienst SRK, Basel) and CD-1 mouseplasma (mixed gender pool>50 animals, Innovative Research, CA, USA) areboth sodium citrate stabilized. The assay is performed in triplicates at10 μM compound concentration and 37° C. Samples are taken at 0, 15, 60,and 240 minutes and stopped by precipitation with 2 volumes ofacetonitrile. The supernatant is collected, evaporated and reconstitutedin a 5% acetonitrile solution to be analyzed by HPLC/MS/MS. Theresulting peak area counts are expressed in percent of the 0 value andused to determine the endpoint stability in % and the half life T½ inminutes. In order to monitor assay integrity the degradation ofpropantheline is assayed with every experimental set

4. Metabolic Stability

Microsomes from a human 50 donor mixed gender pool and 1:1 mixtures ofmicrosomes from CD-1 mouse single-gender pools are purchased from Celsis(Belgium). The enzymatic reaction is performed in a buffer containing anNADPH regeneration system and microsomes with the following endconcentrations: 100 mM potassium phosphate buffer (all from Sigma), 1mg/mL glucose-6-phosphate, 1 mg/mL β-nicotinamide adenine dinucleotidephosphate (NADP), 0.65 mg/mL magnesium chloride, 0.8 units/mL ofglucose-6-phosphate dehydrogenase (prediluted with 5 mM citrate buffer),10 μM compound and 1 mg/ml microsomal protein. Compounds are incubatedat 37° C. in duplicates and samples are taken after 0, 20 and 60minutes. After acetonitrile precipitation (2 volumes) and HPLC/MS/MSanalysis metabolic turnover is expressed in % of the initial 0 minutesvalue and half life T½ (min) is calculated. Verapamil for human andpropranolol for mouse are used as reference and are assayed with everyexperimental set.

-   -   F. P. Guengerich, Analysis and Characterization of Enzymes; in:        Principles and Methods of Toxicology; A. W. Hayes (Ed.) Raven        Press: New York, 1989, 777-813.    -   R. Singh et al., In vitro metabolism of a potent HIV-protease        inhibitor (141W94) using rat, monkey and human liver S9, Rapid        Commun. Mass Spectrom. 1996, 10, 1019-1026.        5. Results

The results of the experiments described under 1.-4. (above) areindicated in Table 38 and Table 39 herein below.

TABLE 38 Biological Data Motilin receptor FP receptor 5-HT_(2B) receptorantagonist activity Motilin receptor antagonist activity FP receptoragonist activity 5-HT_(2B) receptor [% inhibition antagonist activity [%inhibition antagonist activity [% activation agonist activity No at 10μM] IC₅₀ [μM]] at 10 μM] IC₅₀ [μM] at 12.5 μM] EC₅₀[μM] Ex. 9 n.d. n.d.n.d. n.d. 48 12 Ex. 11 79 0.78 n.d. n.d. n.d. n.d. Ex. 12 95 2.7  44n.d. 36 3.3 Ex. 16 n.d. n.d. n.d. n.d. 45 6.6 Ex. 30 n.d. n.d. n.d. n.d.48 3.3 Ex. 49 98 0.16 n.d. n.d. n.d. n.d. Ex. 184 n.d. n.d. 74 0.52 n.d.n.d. Ex. 200 n.d. n.d. 38 28 n.d. n.d. Ex. 213 n.d. n.d. 78 1.7 n.d.n.d. n.d. not determined

TABLE 39 Plasma Stability and Metabolic Stability Plasma StabilityMetabolic Stability T ½ [min] 240 min T ½ min] 240 min T ½ [min] 60 minT ½ [min] 60 min No hum hum mouse mouse hum hum mouse mouse Ex. 9 240 99240 93 32 20 60 80 Ex. 11 240 100 240 100 60 74 60 77 Ex. 12 240 99 240100 17 7 35 33 Ex. 16 240 95 240 97 38 31 60 79 Ex. 30 240 85 240 100 222 60 55 Ex. 37 240 77 240 100 60 100 60 100 Ex. 43 240 82 240 89 60 10060 98 Ex. 49 240 83 240 96 24 10 60 83 Ex. 78 240 65 240 100 60 78 60100 Ex. 91 240 96 240 88 60 91 60 95 Ex. 93 240 100 240 100 24 1 29 15Ex. 95 240 100 240 93 60 76 60 94 Ex. 98 240 100 240 78 60 97 60 100 Ex.102 240 65 240 75 23 4 42 39 Ex. 103 240 97 240 75 35 22 36 25 Ex. 138240 89 240 78 60 62 60 99 Ex. 184 240 66 240 58 15 0 22 0 Ex. 200 240 91240 100 27 12 30 26 Ex. 208 240 98 240 90 60 84 60 100 Ex. 213 n.d. n.d.n.d. n.d. 16 0 17 4 Ex. 230 240 100 240 95 60 61 60 90 Ex. 260 240 100240 100 37 19 60 69 Ex. 262 240 100 240 93 21 0 23 4 Ex. 264 240 94 24088 n.d. n.d. 42 32 Ex. 266 240 92 240 74 60 100 60 98 Ex. 267 240 75 24079 60 99 60 100 Ex. 272 240 95 240 92 60 65 60 81 n.d. not determined

The invention claimed is:
 1. Compounds of the general formula I incorporating the building blocks A, B and C

wherein the encircled moiteties a, b and c in building blocks A, B and C are selected from Tables 1, 2 and 3, respectively, and are appropriately and independently substituted as defined below: TABLE 1

a1

a2

a3

a4

a5

a6

a7

a8

a9

a10

a11

a12

a13

a14

a15

a16

a17

a18

a19

a20

a21

a22

a23

a24

a25

TABLE 2

B1 (b1)

B2 (b2)

B3 (b2)

B4 (b3)

B5 (b3)

B6 (b3)

B7 (b3)

B8 (b3)

B9 (b3)

B10 (b3)

B11 (b4 )

B12 (b4)

B13 (b4)

B14 (b4)

B15 (b4)

B16 (b4)

B17 (b5)

B18 (b8)

B19 (b10)

B20 (b11)

B21 (b11)

the encircled parts of the bridge subunits c1-c3 representing optionally substitued groups, definitions of c1-c3 being depicted in Table 3, below, each reading from the N-terminus to the C-terminus of the linker C, said linker C being, in the simplest case, constituted by one subunit c1, i.e. c1-1 to c1-6, and for the embodiments consisting of two or three subunits all possible combinations of the subunits c1-c3 and the connectivities U, V and W being possible; TABLE 3 Scope of Subunits of c1-c3 of the Linker Group C C

U =

V, W =

c1-1 c1-2 c1-3

c1-4 c1-5 c1-6

c2-1 c2-2 c2-3

c2-4 c2-5 c2-6

c3-1 c3-2 c3-3

the substituents directly attached to building blocks A, B and C, i.e. R¹-R¹⁷, being defined as follows: R¹ is H; F; Cl; Br; I; CF₃; OCF₃; OCHF₂; NO₂; CN; alkyl; alkenyl; alkynyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)SR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)OCONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)OCOOR²¹; —(CR¹⁸R¹⁹)_(q)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂; —(CR¹⁸R¹⁹)_(q)OPO(OR²¹)₂; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)OSO₃R²¹; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R² is H; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)SR²⁰; —(CR¹⁸R1⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)OCONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)OCOOR²¹; —(CR¹⁸R¹⁹)_(q)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R³ is H; CF₃; alkyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; R⁴ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; or heteroarylalkyl; R⁵, R⁷ and R⁹ are independently defined as H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR¹⁸R¹⁹)_(s)OR²⁰; —(CR¹⁸R¹⁹)_(s)SR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)OCONR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)OCOOR²¹; —(CR¹⁸R¹⁹)_(s)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R⁶, R⁸ and R¹⁰ are independently defined as H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; or heteroarylalkyl; R¹¹ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR¹⁸R¹⁹)_(r)OR²⁰; —(CR¹⁸R¹⁹)_(r)SR²⁰; —(CR¹⁸R¹⁹)_(r)NR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)OCONR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)OCOOR²¹; —(CR¹⁸R¹⁹)_(r)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(r)NR⁴CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(r)NR⁴SO₂NR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(s)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R¹² and R¹³ are independently defined as H; or alkyl; R¹⁴ and R¹⁶ are independently defined as H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR¹⁸R¹⁹)_(s)OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; or —(CR¹⁸R¹⁹)_(q)COR²²; R¹⁵ and R¹⁷ are independently defined as H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; or heteroarylalkyl; substituents introduced in the sub-definitions of the radical R¹-R¹⁷ being defined as follows: R¹⁸ is H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)SR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)OCONR²⁸R³¹; —(CR²⁹R³⁰)_(s)OCOOR²¹; —(CR²⁹R³⁰)_(s)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(s)NR²⁸SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)PO(OR²¹)₂; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or —(CR²⁹R³⁰)_(q)R²⁶; R¹⁹ is H; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; R²⁰ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)SR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)_(r)OCONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹; —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(r)NR²⁸SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or —(CR²⁹R³⁰)_(q)R²⁶; R²¹ is alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; or heteroarylalkyl; R²² is alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)SR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)OCONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(s)NR²⁸SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(s)COOR²¹; —(CR²⁹R³⁰)_(s)CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(t)COR³¹; —(CR²⁹R³⁰)_(s)SO₂R²³; —(CR²⁹R³⁰)_(t)R²⁴; —(CR²⁹R³⁰)_(t)R²⁵; or —(CR²⁹R³⁰)_(t)R²⁶; R²³ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; or —(CR³²R³³)_(t)R²⁴; R²⁴ is aryl, an optionally substituted phenyl group of type C₆H₂R³⁴R³⁵R³¹; or a heteroaryl group, one of the groups of formulae H1-H34 (Table 4), below; TABLE 4 Groups of Formulae H1-H34

H1

H2

H3

H4

H5

H6

H7

H8

H9

H10

H11

H12

H13

H14

H15

H16

H17

H18

H19

H20

H21

H22

H23

H24

H25

H26

H27

H28

H29

H30

H31

H32

H33

H34

R²⁵ is one of the groups of formulae H35-H41 as shown in Table 5, below; TABLE 5 Radicals of formulae H35-H41

H35

H36

H37

H38

H39

H40

H41

R²⁶ is one of the groups of formulae H42-H50 as shown in Table 6, below; TABLE 6 Groups of Formulae H43-H50

H42

H43

H44

H45

H46

H47

H48

H49

H50

R²⁷ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; or —(CR²⁹R³⁰)R²⁴; R²⁸ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR³²R³³)_(s)OR²¹; —(CR³²R³³)_(s)NR⁴³R⁴²; —(CR³²R³³)_(s)NR⁴²CONR⁴³R⁴²; —(CR³²R³³)_(s)NR⁴²COR²¹; —(CR³²R³³)_(s)NR⁴²SO₂NR²¹; —(CR³²R³³)_(q)COOR²¹; —(CR³²R³³)_(q)COR²³; —(CR³²R³³)_(q)SO₂R²¹; R²⁹ is H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR³²R³³)_(s)OR³¹; —(CR³²R³³)_(s)SR³¹; —(CR³²R³³)_(s)NR²⁸R³¹; —(CR³²R³³)_(s)OCONR²⁸R³¹; —(CR³²R³³)_(s)OCOOR²¹; —(CR³²R³³)_(s)NR²⁸COOR²¹; —(CR³²R³³)_(s)NR²⁸COR³¹; —(CR³²R³³)_(s)NR²⁸CONR²⁸R³¹; —(CR³²R³³)_(s)NR²⁸SO₂R²³; —(CR³²R³³)_(s)NR²⁸SO₂NR²⁸R³¹; —(CR³²R³³)_(q)COOR²¹; —(CR³²R³³)_(q)CONR²⁸R³¹; —(CR³²R³³)_(q)SO₂NR²⁸R³¹; —(CR³²R³³)₂PO(OR²¹)₂; —(CR³²R³³)_(q)COR³¹; —(CR³²R³³)_(q)SO₂R²³; —(CR³²R³³)_(q)R³¹; R³⁰ is H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; R³¹ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; or one of the groups of formulae H51-H55 as shown in Table 7 below; TABLE 7 Groups of Formulae H51-H55

H51

H52

H53

H54

H55

R³² and R³³ are independently defined as H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; R³⁴ and R³⁵ are independently defined as H; F; Cl; CF₃; OCF₃; OCHF₂; NO₂; CN; alkyl; alkenyl; alkynyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; ——(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)SR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹; —(CR²⁹R³⁰)_(q)OCONR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹; —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)NR²⁸SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹; R³⁶ H; alkyl; alkenyl; alkynyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; or —NR²⁸R³¹; R³⁷ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)SR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)_(r)OCONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹; —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(r)NR²⁸SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹; R³⁸ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)SR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹; —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; or —(CR²⁹R³⁰)_(q)R³¹; R³⁹ is H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR³²R³³)_(u)OR²¹; —(CR³²R³³)_(u)NR²⁸R⁴³; —(CR³²R³³)_(t)COOR²¹; or —(CR³²R³³)_(t)CONR²⁸R⁴³; R⁴⁰ is H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR³²R³³)_(u)OR²¹; —(CR³²R³³)_(u)NR²⁸R⁴³; —(CR³²R³³)_(t)COOR²¹; or —(CR³²R³³)_(t)CONR²⁸R⁴³; R⁴¹ is H; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —OR²¹; —NR²⁸R⁴³; —NR²⁸COR²³; —NR²⁸COOR²¹; —NR²⁸SO₂R²³; —NR²⁸CONR²⁸R⁴³; —COOR²¹; —CONR²⁸R⁴³; —C(═NR⁴³)NR²⁸N⁴³; —NR²⁸C(═NR⁴³)NR²⁸N⁴³; or one of the groups of formulae H56-H110 as shown in Table 8 below; TABLE 8 Groups of Formulae H56-H110

H56

H57

H58

H59

H60

H61

H62

H63

H64

H65

H66

H67

H68

H69

H70

H71

H72

H73

H74

H75

H76

H77

H78

H79

H80

H81

H82

H83

H84

H85

H86

H87

H88

H89

H90

H91

H92

H93

H94

H95

H96

H97

H98

H99

H100

H101

H102

H103

H104

H105

H106

H106

H108

H109

H110

R⁴² is H; alkyl; alkenyl; cycloalkyl; cycloheteroalkyl; aryl; heteroaryl; —(CR²³R³³)_(s)OR²¹; —(CR²³R³³)_(s)NR²⁸R⁴³; —(CR²³R³³)_(q)COOR²¹; or —(CR²³R³³)_(q)CONR²¹R⁴³; R⁴³ is H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; or heteroarylalkyl; R⁴⁴, R⁴⁵ and R⁴⁶ are independently defined as H; F; CF₃; OCF₃; OCHF₂; NO₂; CN; alkyl; alkenyl; alkynyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —OR²³; —NR²⁸R⁴³; —NR²⁸COR²³; —NR²⁸SO₂R²³; —NR²⁸CONR²⁸R⁴³; —COR²³; —SO₂R²³; R⁴⁷ is H; CF₃; alkyl; alkenyl; alkynyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —COOR²¹; or —CONR²⁸R⁴³; R⁴⁸ is H; F; CF₃; alkyl; alkenyl; cycloalkyl; cycloheteroalkyl; aryl; heteroaryl; —(CR²³R³³)_(t)OR²¹; —(CR²³R³³)_(t)NR²⁸R⁴³; —(CR²³R³³)_(t)COOR²¹; —(CR²³R³³)_(t)CONR²¹R⁴³; R⁴⁹ and R⁵⁰ are independently defined as H; F; CF₃; alkyl; alkenyl; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; —(CR³²R³³)_(q)OR²¹; —(CR³²R³³)_(q)NR²⁸R⁴³; —(CR³²R³³)_(q)COOR²¹; or —(CR³²R³³)_(q)CONR²⁸R⁴³; taken together the following pairs of said substituents can define cyclic structural elements: (R⁴ and R¹¹); (R⁴ and R²⁷); (R⁵ and R⁶); (R⁵ and R⁷); (R⁵ and R⁹); (R⁵ and R¹⁴); (R⁵ and R¹⁶); (R⁷ and R⁸); (R⁷ and R⁹); (R⁷ and R¹⁶); (R⁹ and R¹⁰); (R¹⁴ and R¹⁵); (R¹⁶ and R¹⁷); (R¹⁸ and R¹⁹); (R²⁷ and R²⁸); (R²⁸ and R³¹); (R²⁸ and R⁴³); (R²⁹ and R³⁰); (R³² and R³³); (R³⁴ and R³⁵); (R³⁷ and R³⁸); (R³⁹ and R⁴⁰); (R³⁹ and R⁴¹); (R³⁹ and R⁴⁹); (R⁴² and R⁴³); (R⁴⁴ and R⁴⁵); or (R⁴⁴ and R⁴⁶) can form optionally substituted cycloalkyl or heterocycloalkyl moieties; in addition, the structural elements —NR⁴R¹¹; —NR²⁷R²⁸; —NR²⁸R³¹ or —NR²⁸R⁴³ can form one of the groups of formulae H111-H118 as shown in Table 9, below; TABLE 9 Heterocyclic Groups Defined by Linking the Residues of the Disubstituted Amino Groups —NR⁴R¹¹; —NR²⁷R²⁸; —NR²⁸R³¹ or —NR²⁸R⁴³.

H111

H112

H113

H114

H115

H116

H117

H118

varibale heteroatoms and connector groups in the aforementioned structures being as follows: Z: O; S; S(═O); S(═O)₂; or NR²⁸; Y: O; S; or NR³⁷; X: O; S; S(═O); or S(═O)₂; Q: O; S; or NR²⁸; U, V and W: as defined in Table 3, above; T: CR⁴⁶ or N; in case T occurs several times in the same ring structure each T being defined independently of the other; and the indices being defined as follows: q=0-4; r=2-4; s=1-4; t=0-2; and u=1-2; all possible stereoismers and pharmaceutical acceptable salts thereof.
 2. Compounds according to claim 1 wherein A, B and C are selected from Tables 10, 2 and 12, and are appropriately and independently substituted as defined below: TABLE 10 Radicals A1(a1)-A626(a25)

A1(a1)

A2(a1)

A3(a1)

A4(a1)

A5(a1)

A6(a1)

A7(a1)

A8(a1)

A9(a1)

A10(a1)

A11(a1)

A12(a1)

A13(a1)

A14(a1)

A15(a1)

A16(a1)

A17(a1)

A18(a1)

A19(a1)

A20(a1)

A21(a1)

A22(a1)

A23(a1)

A24(a1)

A25(a1)

A26(a1)

A27(a1)

A28(a1)

A29(a1)

A30(a1)

A31(a1)

A32(a1)

A33(a1)

A34(a1)

A35(a1)

A36(a1)

A37(a1)

A38(a1)

A39(a1)

A40(a1)

A41(a1)

A42(a1)

A43(a1)

A44(a1)

A45(a1)

A46(a1)

A47(a1)

A48(a1)

A49(a1)

A50(a1)

A51(a1)

A52(a1)

A53(a1)

A54(a1)

A55(a1)

A56(a1)

A57(a1)

A58(a1)

A59(a1)

A60(a2)

A61(a2)

A62(a2)

A63(a2)

A64(a2)

A65(a2)

A66(a2)

A67(a2)

A68(a2)

A69(a2)

A70(a2)

A71(a2)

A72(a2)

A73(a2)

A74(a2)

A75(a2)

A76(a2)

A77(a2)

A78(a2)

A79(a2)

A80(a2)

A81(a2)

A82(a2)

A83(a2)

A84(a2)

A85(a2)

A86(a2)

A87(a2)

A88(a2)

A89(a2)

A90(a2)

A91(a2)

A92(a2)

A93(a2)

A94(a2)

A95(a2)

A96(a2)

A97(a2)

A98(a2)

A99(a2)

A100(a2)

A101(a2)

A102(a2)

A103(a2)

A104(a2)

A105(a2)

A106(a2)

A107(a2)

A108(a2)

A109(a2)

A110(a2)

A111(a2)

A112(a2)

A113(a2)

A114(a2)

A115(a2)

A116(a2)

A117(a2)

A118(a2)

A119(a2)

A120(a2)

A121(a2)

A122(a2)

A123(a2)

A124(a2)

A125(a2)

A126(a2)

A127(a2)

A128(a2)

A129(a2)

A130(a2)

A131(a2)

A132(a2)

A133(a2)

A134(a2)

A135(a2)

A136(a2)

A137(a2)

A138(a2)

A139(a2)

A140(a2)

A141(a2)

A142(a2)

A143(a2)

A144(a3)

A145(a3)

A146(a3)

A147(a3)

A148(a3)

A149(a3)

A150(a3)

A151(a3)

A152(a3)

A153(a3)

A154(a3)

A155(a3)

A156(a3)

A157(a3)

A158(a3)

A159(a3)

A160(a3)

A161(a3)

A162(a3)

A163(a3)

A164(a3)

A165(a3)

A166(a4)

A167(a4)

A168(a4)

A169(a4)

A170(a4)

A171(a4)

A172(a4)

A173(a4)

A174(a4)

A175(a4)

A176(a4)

A177(a4)

A178(a4)

A179(a4)

A180(a4)

A181(a4)

A182(a4)

A183(a4)

A184(a4)

A185(a4)

A186(a4)

A187(a4)

A188(a4)

A189(a5)

A190(a5)

A191(a5)

A192(a5)

A193(a5)

A194(a5)

A195(a5)

A196(a5)

A197(a5)

A198(a5)

A199(a5)

A200(a5)

A201(a6)

A202(a6)

A203(a6)

A204(a6)

A205(a6)

A206(a6)

A207(a7)

A208(a7)

A209(a7)

A210(a7)

A211(a7)

A212(a7)

A213(a7)

A214(a7)

A215(a7)

A216(a7)

A217(a7)

A218(a7)

A219(a7)

A220(a7)

A221(a7)

A222(a7)

A223(a7)

A224(a7)

A225(a7)

A226(a7)

A227(a7)

A228(a7)

A229(a8)

A230(a8)

A231(a8)

A232(a8)

A233(a8)

A234(a8)

A235(a9)

A236(a9)

A237(a9)

A238(a9)

A239(a9)

A240(a10)

A241(a10)

A242(a10)

A243(a10)

A244(a10)

A245(a10)

A246(a10)

A247(a10)

A248(a10)

A249(a10)

A250(a10)

A251(a10)

A252(a10)

A253(a10)

A254(a10)

A255(a10)

A256(a10)

A257(a10)

A258(a10)

A259(a10)

A260(a10)

A261(a10)

A262(a10)

A263(a10)

A264(a10)

A265(a10)

A266(a10)

A267(a10)

A268(a10)

A269(a10)

A270(a10)

A271(a10)

A272(a10)

A273(a10)

A274(a10)

A275(a10)

A276(a10)

A277(a10)

A278(a10)

A279(a10)

A280(a10)

A281(a10)

A282(a10)

A283(a10)

A284(a10)

A285(a10)

A286(a10)

A287(a10)

A288(a10)

A280(a10)

A290(a10)

A291(a10)

A292(a10)

A293(a10)

A294(a10)

A295(a10)

A296(a10)

A297(a10)

A298(a10)

A299(a10)

A300 (a10)

A301 (a10)

A302 (a10)

A303 (a10)

A304 (a10)

A305 (a10)

A306 (a10)

A307 (a10)

A308 (a10)

A309 (a10)

A310 (a10)

A311 (a10)

A312 (a10)

A313 (a10)

A314 (a10)

A315 (a10)

A316 (a10)

A317 (a10)

A318 (a10)

A319 (a10)

A320 (a10)

A321 (a10)

A322 (a10)

A323 (a10)

A324 (a10)

A325 (a10)

A326 (a10)

A327 (a10)

A328 (a10)

A329 (a10)

A330 (a10)

A331 (a10)

A332 (a10)

A333 (a10)

A334 (a10)

A335 (a10)

A336 (a10)

A337 (a10)

A338 (a10)

A339 (a10)

A340 (a10)

A341 (a10)

A342 (a10)

A343 (a10)

A344 (a10)

A345 (a10)

A346 (a10)

A347 (a10)

A348 (a10)

A349 (a10)

A350 (a10)

A351 (a10)

A352 (a10)

A353 (a10)

A354 (a10)

A355 (a10)

A356 (a10)

A357 (a10)

A358 (a11)

A359 (a11)

A360 (a11)

A361 (a11)

A362 (a11)

A363 (a11)

A364 (a11)

A365 (a11)

A366 (a11)

A367 (a11)

A368 (a11)

A369 (a11)

A370 (a11)

A371 (a11)

A372 (a11)

A373 (a12)

A374 (a12)

A375 (a12)

A376 (a12)

A377 (a12)

A378 (a12)

A379 (a12)

A380 (a12)

A381 (a12)

A382 (a12)

A383 (a12)

A384 (a12)

A385 (a12)

A386 (a13)

A387 (a13)

A388 (a13)

A389 (a13)

A390 (a13)

A391 (a13)

A392 (a13)

A393 (a13)

A394 (a13)

A395 (a13)

A396 (a13)

A397 (a13)

A398 (a13)

A399 (a14)

A400 (a14)

A401 (a14)

A402 (a14)

A403 (a14)

A404 (a14)

A405 (a14)

A406 (a14)

A407 (a14)

A408 (a14)

A409 (a14)

A410 (a14)

A411 (a14)

A412 (a14)

A413 (a14)

A414 (a15)

A415 (a15)

A416 (a15)

A417 (a15)

A418 (a15)

A419 (a15)

A420 (a15)

A421 (a15)

A422 (a15)

A423 (a15)

A424 (a15)

A425 (a15)

A426 (a15)

A427 (a15)

A428 (a15)

A429 (a15)

A430 (a15)

A431 (a15)

A432 (a15)

A433 (a15)

A434 (a15)

A435 (a15)

A436 (a15)

A437 (a15)

A438 (a15)

A439 (a15)

A440 (a15)

A441 (a15)

A442 (a15)

A443 (a15)

A444 (a15)

A445 (a15)

A446 (a15)

A447 (a15)

A448 (a15)

A449 (a15)

A450 (a16)

A451 (a16)

A452 (a16)

A453 (a16)

A454 (a16)

A455 (a16)

A456 (a16)

A457 (a16)

A458 (a16)

A459 (a16)

A460 (a17)

A461 (a17)

A462 (a17)

A463 (a17)

A464 (a17)

A465 (a17)

A466 (a17)

A467 (a17)

A468 (a17)

A469 (a17)

A470 (a17)

A471 (a17)

A472 (a17)

A473 (a17)

A474 (a17)

A475 (a17)

A476 (a17)

A477 (a17)

A478 (a17)

A479 (a17)

A480 (a17)

A481 (a17)

A482 (a17)

A483 (a17)

A484 (a17)

A485 (a17)

A486 (a17)

A487 (a17)

A488 (a17)

A489 (a17)

A490 (a17)

A491 (a17)

A492 (a17)

A493 (a17)

A494 (a17)

A495 (a17)

A496 (a17)

A497 (a17)

A498 (a17)

A499 (a17)

A500 (a17)

A501 (a17)

A502 (a17)

A503 (a17)

A504 (a17)

A505 (a17)

A506 (a17)

A507 (a17)

A508 (a17)

A509 (a17)

A510 (a17)

A511 (a17)

A512 (a17)

A513 (a17)

A514 (a17)

A515 (a17)

A516 (a18)

A517 (a18)

A518 (a18)

A519 (a18)

A520 (a18)

A521 (a18)

A522 (a18)

A523 (a18)

A524 (a18)

A525 (a18)

A526 (a18)

A527 (a18)

A528 (a18)

A529 (a18)

A530 (a18)

A531 (a18)

A532 (a18)

A533 (a18)

A534 (a18)

A535 (a18)

A536 (a18)

A537 (a18)

A538 (a18)

A539 (a18)

A540 (a18)

A541 (a18)

A542 (a18)

A543 (a18)

A544 (a18)

A545 (a18)

A546 (a18)

A547 (a18)

A548 (a18)

A549 (a19)

A550 (a19)

A551 (a19)

A552 (a19)

A553 (a19)

A554 (a19)

A555 (a19)

A556 (a19)

A557 (a19)

A558 (a19)

A559 (a19)

A560 (a19)

A561 (a19)

A562 (a19)

A563 (a19)

A564 (a19)

A565 (a20)

A566 (a20)

A567 (a20)

A568 (a20)

A569 (a20)

A570 (a20)

A571 (a20)

A572 (a20)

A573 (a20)

A574 (a20)

A575 (a20)

A576 (a20)

A577 (a20)

A578 (a21)

A579 (a21)

A580 (a21)

A581 (a21)

A582 (a21)

A583 (a21)

A584 (a21)

A585 (a21)

A586 (a21)

A587 (a21)

A588 (a22)

A589 (a22)

A590 (a22)

A591 (a22)

A592 (a22)

A593 (a22)

A594 (a22)

A595 (a22)

A596 (a22)

A597 (a22)

A598 (a22)

A599 (a22)

A600 (a22)

A601 (a22)

A602 (a23)

A603 (a23)

A604 (a23)

A605 (a23)

A606 (a23)

A607 (a23)

A608 (a23)

A609 (a24)

A610 (a24)

A611 (a24)

A612 (a24)

A613 (a24)

A614 (a24)

A615 (a24)

A616 (a24)

A617 (a24)

A618 (a24)

A619 (a25)

A620 (a25)

A621 (a25)

A622 (a25)

A623 (a25)

A624 (a25)

A625 (a25)

A626 (a25)

B is selected from the divalent building blocks B1-B21 shown in Table 2, below which are based on optionally substituted cyclic secondary amines carrying a moiety of type —CHR³-LG, wherein LG is a suitable leaving group that can be replaced by the nucleophilic groups of building blocks A thus forming an ether (—O—) or a thioether (—S—) linkage between building blocks of type A and B; TABLE 2

B1(b1)

B2(b2)

B3(b2)

B4(b3)

B5(b3)

B6(b3)

B7(b3)

B8(b3)

B9(b3)

B10(b3)

B11(b4)

B12(b4)

B13(b4)

B14(b4)

B15(b4)

B16(b4)

B17(b5)

B18(b8)

B19(b10)

B20(b11)

B21(b11)

TABLE 12 Embodiments of Linker C

C1

C2

C3

C4

C5

C6

C7

C8

C9

C10

C11

C12

C13

C14

C15

C16

C17

C18

C19

C20

C21

C22

C23

C24

C25

C26

C27

C28

C29

C30

C31

C32

C33

C34

C35

C36

C37

C38

C39

C40

C41

C42

C43

C44

C45

C46

C47

C48

C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C59

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

C71

C72

C73

C74

C75

C76

C77

C78

C79

C80

C81

C82

C83

C84

C85

C86

C87

C88

C89

C90

C91

C92

C93

C94

C95

C96

C97

C98

C99

C100

C101

R¹ is H; F; Cl; Br; I; CF₃; OCF₃; OCHF₂; NO₂; CN; lower alkyl; lower alkenyl; lower alkynyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)OSO₃R²¹; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R² is H; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R³ is defined as in claim 1; R⁴ is H; lower alkyl; lower alkenyl; or lower cycloalkyl; R⁵, R⁷ and R⁹ are independently defined as H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)₃OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)PO(OR²¹)₂; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R⁶, R⁸ and R¹⁰ are independently defined as H; CF₃; or lower alkyl; R¹¹ is H; lower alkyl; lower alkenyl; lower cycloalkyl lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(r)OR²⁰; —(CR¹⁸R¹⁹)_(r)NR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(r)NR⁴CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(r)NR⁴SO₂NR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(s)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R¹² and R¹³ are independently defined as H; or lower alkyl; R¹⁴ and R¹⁶ are independently defined as H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(s)OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COOR²¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COR²²; R¹⁵ and R¹⁷ are independently defined as H; CF₃; lower alkyl; R¹⁸ is H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COOR²¹; —(CR²⁹R3⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(s)NR²⁸SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)PO(OR²¹)₂; (CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or —(CR²⁹R³⁰)_(q)R²⁶; R¹⁹ is H; CF₃; or lower alkyl; R²⁰ is H; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹; —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or —(CR²⁹R³⁰)_(q)R²⁶; R²¹ and R²³ are as defined in claim 1; R²² lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸SO₂—R²³; —(CR²⁹R³⁰)_(s)COOR²¹; —(CR²⁹R³⁰)_(s)CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(t)COR³¹; —(CR²⁹R³⁰)_(s)SO₂R²³; —(CR²⁹R³⁰)_(t)R²⁴; —(CR²⁹R³⁰)_(t)R²⁵; or —(CR²⁹R³⁰)_(t)R²⁶; R²⁴, R²⁵ and R²⁶, R²⁷ and R²⁸ are as defined in claim 1; R²⁹ is H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR³²R³³)_(s)OR³¹; —(CR³²R³³)_(s)NR²⁸R³¹; —(CR³²R³³)_(s)NR²⁸COOR²¹; —(CR³²R³³)_(s)NR²⁸COR³¹; —(CR³²R³³)_(s)NR²⁸CONR²⁸R³¹; —(CR³²R³³)_(s)NR²⁸SO₂R²³; —(CR³²R³³)_(q)COOR²¹; —(CR³²R³³)_(q)CONR²⁸R³¹; —(CR³²R³³)_(q)SO₂NR²⁸R³¹; —(CR³²R³³)_(q)PO(OR²¹)₂; —(CR³²R³³)_(q)COR³¹; —(CR³²R³³)_(q)SO₂R²³; —(CR³²R³³)_(q)R³¹; R³⁰ and R³³ are H; CF₃; lower alkyl; R³¹ and R³² are as defined in claim 1; R³⁴ and R³⁵ are independently defined as H; F; Cl; CF₃; OCF₃; OCHF₂; NO₂; CN; lower alkyl; lower alkenyl; lower alkynyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹; —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹; R³⁶ is as defined in claim 1; R³⁷ is H; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹; —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹; R³⁸ is H; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸COOR²¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹; —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; or —(CR²⁹R³⁰)_(q)R³¹; R³⁹; R⁴⁰; R⁴¹; R⁴²; R⁴³; R⁴⁴; R⁴⁵; R⁴⁶; R⁴⁷; R⁴⁸; R⁴⁹ and R⁵⁰ are as defined in claim 1; the variable heteroatom Z and the connector U are defined as: Z being O; S(═O); or S(═O)₂; and U being —C(═O)—; —NR⁴—C(═O)—; —C(═O)—C(═O)—; or —C(—OR²⁰)₂—C(═O)—; and substituents that can be pairwise taken together and form optionally substituted cycloalkyl or heterocycloalkyl moieties; structural elements that can form one of the groups of formulae H111-H118 (Table 9); variable heteroatoms Q, T, X and Y; and indices q-u being defined as in claim
 1. 3. Compounds according to claim 2 wherein A is A1(a1); A2(a1); A3(a1); A4(a1); A5(a1); A6(a1); A7(a1); A9(a1); A10(a1); A73(a2); A170(a4); A209(a7); A240(a10); A272(a10); A532(a18); A609(a24); A612(a24) and A614(a24) as shown in Table 13, below; TABLE 13 Building Blocks of Type A

A1(a1)

A2(a1)

A3(a1)

A4(a1)

A5(a1)

A6(a1)

A7(a1)

A9(a1)

A10(a1)

A73(a2)

A170(a4)

A209(a7)

A240(a10)

A272(a10)

A532(a18)

A609(a24)

A612(a24)

A614(a24)

B is B4(b3); B5(b3); B6(b3); B7(b3); B8(b3); B9(b3); B10(b3); B12(b4); B13(b4); B14(b4); B15(b4); B16(b4) or B17(b5) as shown in Table 14, below; TABLE 14 Building Blocks of Type B

B4(b3)

B5(b3)

B6(b3)

B7(b3)

B8(b3)

B9(b3)

B10(b3)

B12(b4)

B13(b4)

B14(b4)

B15(b4)

B16(b4)

B17(b5)

linker C is one of the groups shown in Table 15, below; TABLE 15 Linkers of type C

C1

C2

C3

C4

C5

C6

C7

C8

C9

C10

C11

C12

C13

C14

C15

C16

C17

C18

C19

C20

C21

C25

C26

C27

C28

C29

C30

C34

C35

C36

C37

C38

C39

C43

C44

C45

C46

C47

C48

C49

C50

C51

C52

C53

C54

C55

C56

C57

C58

C59

C60

C61

C62

C63

C64

C65

C66

C67

C68

C69

C70

C71

C72

C73

C74

C75

C76

C77

C78

C79

C80

C81

C86

C87

C88

C89

C90

C91

C92

C93.


4. Compounds according to claim 3 wherein the building blocks of type A are A1(a1); A2(a1); A3(a1); A4(a1); A5(a1); A6(a1); A7(a1); A9(a1); A10(a1); A73(a2); A170(a4); A209(a7); A240(a10); A272(a10); A532(a18); A614(a24) as shown in Table 16, below; TABLE 16 Building Blocks of Type A

A1(a1)

A2(a1)

A3(a1)

A4(a1)

A5(a1)

A6(a1)

A7(a1)

A9(a1)

A10(a1)

A73(a2)

A170(a4)

A209(a7)

A272(a10)

A532(a18)

A614(a24)

the building blocks of type B are B7, B8, B9 and B-17 as shown in Table 17, below; TABLE 17 Building Blocks of Type B

B7-1

B7-2

B7-3

B7-4

B8-1

B8-2

B8-3

B8-4

B9-1

B9-2

B9-3

B9-4

B17-1

B17-2

the linkers C are those listed in Table 18, below; TABLE 18 Embodiments of Linker C

C1

C2

C3

C4

C5

C6

C7

C8

C9

C10

C11

C12

C13

C14

C15

C16

C17

C18

C19

C20

C21

C25

C26

C27

C28

C29

C30

C34

C35

C36

C37

C38

C39

C43

C44

C45

C46

C47

C48

C49

C54

C55

C56

C57

C58

C59

C60

C61

C62

C63

C64

C65

C70

C71

C72

C73

C74

C75

C76

C77

C90

C91

C92

C93

R¹ is H; F; Cl; CF₃; OCF₃; OCHF₂; NO₂; CN; lower alkyl; lower alkenyl; lower alkynyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R² is H; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(q)OR²⁰; —(CR¹⁸R¹⁹)_(q)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)NR⁴SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶, R³ is as defined in claim 1; R⁴ is H; lower alkyl; lower alkenyl; R⁵, R⁷ and R⁹ are independently defined as H; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(s)OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(s)NR⁴CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)SO₂NR⁴R¹¹; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)SO₂R²³; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(q)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R⁶, R⁸ and R¹⁰ are independently defined as H; CF₃; or CH₃; R¹¹ is H; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(r)OR²⁰; —(CR¹⁸R¹⁹)_(r)NR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)NR⁴CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(r)NR⁴SO₂R²³; —(CR¹⁸R¹⁹)_(q)COOR²¹; —(CR¹⁸R¹⁹)_(q)CONR⁴R²⁷; —(CR¹⁸R¹⁹)_(q)COR²²; —(CR¹⁸R¹⁹)_(q)R²⁴; —(CR¹⁸R¹⁹)_(s)R²⁵; or —(CR¹⁸R¹⁹)_(q)R²⁶; R¹² and R¹³ are independently defined as H; or lower alkyl; R¹⁴ and R¹⁶ are independently defined as H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR¹⁸R¹⁹)_(s)OR²⁰; —(CR¹⁸R¹⁹)_(s)NR⁴R¹¹; —(CR¹⁸R¹⁹)_(s)NR⁴COR²²; —(CR¹⁸R¹⁹)_(q)COOR²¹; or —(CR¹⁸R¹⁹)_(q)CONR⁴R¹¹; R¹⁵ and R¹⁷ are independently defined as H; CF₃; or CH₃; R¹⁸ is H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or —(CR²⁹R³⁰)_(q)R²⁶; R¹⁹ is H; CF₃; or CH₃; R²⁰ is H; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹; —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(r)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; —(CR²⁹R³⁰)_(q)R²⁴; —(CR²⁹R³⁰)_(q)R²⁵; or —(CR²⁹R³⁰)_(q)R²⁶; R²¹ and R²³ are as defined in claim 1; R²² is lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(s)OR³¹; —(CR²⁹R³⁰)_(s)NR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸COR³¹; —(CR²⁹R³⁰)_(s)N^(R28)CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(s)COOR²¹; —(CR²⁹R³⁰)_(s)CONR²⁸R³¹; —(CR²⁹R³⁰)_(s)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(t)COR³¹; —(CR²⁹R³⁰)_(s)SO₂R²³; —(CR²⁹R³⁰)_(t)R²⁴; —(CR²⁹R³⁰)_(t)R²⁵; or —(CR²⁹R³⁰)_(t)R²⁶; R²⁴, R²⁵, R²⁶, R²⁷ and R²⁸ are as defined in claim 1; R²⁹ is H; F; CF₃; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR³²R³³)_(s)OR³¹; —(CR³²R³³)_(s)NR²⁸R³¹; —(CR³²R³³)_(s)NR²⁸COR³¹; —(CR³²R³³)_(s)NR²⁸CONR²⁸R³¹; —(CR³²R³³)_(q)COOR²¹; —(CR³²R³³)_(q)CONR²⁸R³¹; —(CR³²R³³)_(q)COR³¹; or —(CR³²R³³)_(q)R³¹; R³⁰ and R³³ are H; CF₃; or CH₃; R³¹ and R³² are as defined in claim 1; R³⁴ and R³⁵ are independently defined as H; F; Cl; CF₃; OCF₃; OCHF₂; lower alkyl; lower alkenyl; lower alkynyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹; —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸SO₂R²³; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(g)SO₂NR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; —(CR²⁹R³⁰)_(q)SO₂R²³; or —(CR²⁹R³⁰)_(q)R³¹; R³⁶ is as defined in claim 1; R³⁷ is H; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(r)OR³¹; —(CR²⁹R³⁰)_(r)NR²⁸R³¹; —(CR²⁹R³⁰)₁NR²⁸COOR²¹; —(CR²⁹R³⁰)_(r)NR²⁸COR³¹; —(CR²⁹R³⁰)_(r)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)_(q)CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; or —(CR²⁹R³⁰)_(q)R³¹; R³⁸ is H; lower alkyl; lower alkenyl; lower cycloalkyl; lower heterocycloalkyl; aryl; heteroaryl; lower arylalkyl; lower heteroarylalkyl; —(CR²⁹R³⁰)_(q)OR³¹; —(CR²⁹R³⁰)_(q)NR²⁸R³¹; —(CR²⁹R³⁰)_(q)NR²⁸COR³¹; —(CR²⁹R³⁰)_(q)NR²⁸CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COOR²¹; —(CR²⁹R³⁰)₉CONR²⁸R³¹; —(CR²⁹R³⁰)_(q)COR³¹; or —(CR²⁹R³⁰)_(q)R³¹; R³⁹; R⁴⁰; R⁴¹; R⁴²; R⁴³; R⁴⁴; R⁴⁵; R⁴⁶; R⁴⁷; R⁴⁸; R⁴⁹; and R⁵⁰ are as defined in claim 1; the variable heteroatom Z and the connector U are defined as: Z: O; or S(═O); U: —C(═O)—; —NR⁴—C(═O)—; or —C(═O)—C(═O)—; and substituents that can be pairwise taken together and form optionally substituted cycloalkyl or heterocycloalkyl moieties; structural elements that can form one of the groups of formulae H111-H118 as shown in Table 9; and variable heteroatoms Q, T, X and Y; indices q-u; are as defined in claim
 1. 5. Compounds according to claim 1 wherein readily accessible substances that define possible subunits of the linker C are those listed in Table 19, below; TABLE 19 Code Chemical Name Ala L-Alanine ^(D)Ala D-Alanine Arg L-Arginine ^(D)Arg D-Arginine Asn L-Asparagine ^(D)Asn D-Asparagine Asp L-Aspartic acid ^(D)Asp D-Aspartic acid Cys L-Cysteine ^(D)Cys D-Cysteine Glu L-Glutamic acid ^(D)Glu D-Glutamic acid Gln L-Glutamine ^(D)Gln D-Glutamine Gly Glycine His L-Histidine ^(D)His D-Histidine Ile L-Isoleucine ^(D)Ile D-Isoleucine Leu L-Leucine ^(D)Leu D-Leucine Lys L-Lysine ^(D)Lys D-Lysine Met L-Methionine ^(D)Met D-Methionine Phe L-Phenylalanine ^(D)Phe D-Phenylalanine Pro L-Proline ^(D)Pro D-Proline Ser L-Serine ^(D)Ser D-Serine Thr L-Threonine ^(D)Thr D-Threonine Trp L-Tryptophan ^(D)Trp D-Tryptophan Tyr L-Tyrosine ^(D)Tyr D-Tyrosine Val L-Valine ^(D)Val D-Valine Apa 3-Amino-propanoic acid H-β³-HAla-OH (3S)-3-Amino-butyric acid H-β³-HVal-OH (3R)-3-Amino-4-methyl-valeric acid H-β³-HIle-OH (3R,4S)-3-Amino-4-methyl-hexanoic acid H-β³-HLeu-OH (3S)-3-Amino-5-methyl-hexanoic acid H-β³-HMet-OH (3S)-3-Amino-5-methylthio pentanoic acid H-β³-HTyr-OH (3S)-3-Amino-4-(4′-hydroxyphenyl)-butyric acid H-β³-HHis-OH (3S)-3-Amino-4-(imidazole-4′-yl)-butyric acid H-β³-HPhe-OH (3S)-3-Amino-4-phenyl butyric acid H-β³-HTrp-OH (3S)-3-Amino-4-(indol-3′-yl)-butyric acid H-β³-HSer-OH (3R)-3-Amino-4-hydroxy-butyric acid H-β³-HAsp-OH 3-Amino-pentanedioic acid H-β³-HGlu-OH (3S)-3-Amino-hexanedioic acid H-β³-HLys-OH (3S)-3,7-Diamino-heptanoic acid H-β³-HArg-OH (3S)-3-Amino-6-guanidino-hexanoic-acid H-β³-HCys-OH (3R)-3-Amino-4-mercapto-butyric acid H-β³-HAsn-OH (3S)-3-Amino-4-carbamoyl-butyric acid H-β³-HGln-OH (3S)-3-Amino-5-carbamoyl-pentanoic acid H-β³-HThr-OH (3R,4R)-3-Amino-4-hydroxy-pentanoic acid Gaba 4-Amino-butyric acid H-γ⁴-DiHAla-OH (4S)-4-Amino-pentanoic acid H-γ⁴-DiHVal-OH (4R)-4-Amino-5-methyl-hexanoic acid H-γ⁴-DiHIle-OH (4R,5S)-4-Amino-5-methyl-heptanoic acid H-γ⁴-DiHLeu-OH (4R)-4-Amino-6-methyl-heptanoic acid H-γ⁴-DiHMet-OH (4R)-4-Amino-6-methylthio-hexanoic acid H-γ⁴-DiHTyr-OH (4R)-4-Amino-5-(4′-hydroxyphenyl)- pentanoic acid H-γ⁴-DiHHis-OH (4R)-4-Amino-5-(imidazole-4′-yl)- pentanoic acid H-γ⁴-DiHPhe-OH (4R)-4-Amino-5-phenyl-pentanoic acid H-γ⁴-DiHTrp-OH (4R)-4-Amino-5-(indol-3′-yl)-pentanoic acid H-γ⁴-DiHSer-OH (4R)-4-Amino-5-hydroxy-pentanoic acid H-γ⁴-DiHAsp-OH (4R)-4-Amino-hexanedioic acid H-γ⁴-DiHGlu-OH 4-Amino-heptanedioic acid H-γ⁴-DiHLys-OH (4S)-4,8-Diamino-octanoic acid H-γ⁴-DiHArg-OH (4S)-4-Amino-7-guanidino-heptanoic-acid H-γ⁴-DiHCys-OH (4R)-4-Amino-5-mercapto-pentanoic acid H-γ⁴-DiHAsn-OH (4R)-4-Amino-5-carbamoyl-pentanoic acid H-γ⁴-DiHGln-OH (3S)-3-Amino-5-carbamoyl-hexanoic acid H-γ⁴-DiHThr-OH (4R,5R)-4-Amino-5-hydroxy-hexanoic acid Cit L-Citrulline ^(D)Cit D-Citrulline Orn L-Ornithine ^(D)Orn D-Ornithine tBuA L-t-Butylalanine ^(D)tBuA D-t-Butylalanine Sar Sarcosine Pen L-Penicillamine ^(D)Pen D-Penicillamine tBuG L-tert.-Butylglycine ^(D)tBuG D-tert.-Butylglycine 4AmPhe L-para-Aminophenylalanine ^(D)4AmPhe D-para-Aminophenylalanine 3AmPhe L-meta-Aminophenylalanine ^(D)3AmPne D-meta-Aminophenylalanine 2AmPhe L-ortho-Aminophenylalanine ^(D)2AmPhe D-ortho-Aminophenylalanine Phe(mC(NH₂)═NH) L-meta-Amidinophenylalanine ^(D)Phe(mC(NH₂)═NH) D-meta-Amidinophenylalanine Phe(pC(NH₂)═NH) L-para-Amidinophenylalanine ^(D)Phe(pC(NH₂)═NH) D-para-Amidinophenylalanine Phe(mNHC(NH₂)═NH) L-meta-Guanidinophenylalanine ^(D)Phe(mNHC(NH₂)═NH) D-meta-Guanidinophenylalanine Phe(pNHC(NH₂)═NH) L-para-Guanidinophenylalanine ^(D)Phe(pNHC(NH₂)═NH) D-para-Guanidinophenylalanine 2Pal (2S)-2-Amino-3-(pyridine-2′-yl)-propionic acid ^(D)2Pal (2R)-2-Amino-3-(pyridine-2′-yl)-propionic acid 4Pal (2S)-2-Amino-3-(pyridine-4′-yl)-propionic acid ^(D)4Pal (2R)-2-Amino-3-(pyridine-4′-yl)-propionic acid Phg L-Phenylglycine ^(D)Phg D-Phenylglycine Cha L-Cyclohexylalanine ^(D)Cha D-Cyclohexylalanine C₄al L-3-Cyclobutylalanine ^(D)C₄al D-3-Cyclobutylalanine C₅al L-3-Cyclopentylalanine ^(D)C₅al D-3-Cyclopentylalanine Nle L-Norleucine ^(D)Nle D-Norleucine 2-Nal L-2-Naphthylalanine ^(D)2Nal D-2-Naphthylalanine 1-Nal L-1-Naphthylalanine ^(D)1Nal D-1-Naphthylalanine 4ClPhe L-4-Chlorophenylalanine ^(D)4ClPhe D-4-Chlorophenylalanine 3ClPhe L-3-Chlorophenylalanine ^(D)3ClPhe D-3-Chlorophenylalanine 2ClPhe L-2-Chlorophenylalanine ^(D)2ClPhe D-2-Chlorophenylalanine 3,4Cl₂Phe L-3,4-Dichlorophenylalanine ^(D)3,4Cl₂Phe D-3,4-Dichlorophenylalanine 4FPhe L-4-Fluorophenylalanine ^(D)4FPhe D-4-Fluorophenylalanine 3FPhe L-3-Fluorophenylalanine ^(D)3FPhe D-3-Fluorophenylalanine 2FPhe L-2-Fluorophenylalanine ^(D)2FPhe D-2-Fluorophenylalanine Thi L-β-2-Thienylalanine ^(D)Thi D-β-2-Thienylalanine Tza L-2-Thiazolylalanine ^(D)Tza D-2-Thiazolylalanine Mso L-Methionine sulfoxide ^(D)Mso D-Methionine sulfoxide AcLys N-Acetyllysine ^(D)AcLys N-Acetyl-D-lysine Dap 2,3-Diaminopropionic acid ^(D)Dap D-2,3-Diaminopropionic acid Dab 2,4-Diaminobutyric acid ^(D)Dab (2R)-2,4-Diaminobutyric acid Dbu (2S)-2,3-Diamino-butyric acid ^(D)Dbu (2R)-2,3-Diamino-butyric acid Abu γ-Aminobutyric acid (GABA) Aha ε-Aminohexanoic acid Aib α-Aminoisobutyric acid Cyp 1-Amino cyclopentane carboxylic acid Y(Bzl) L-O-Benzyltyrosine ^(D)Y(Bzl) D-O-Benzyltyrosine H(Bzl) (3S)-2-Amino-3-(1′-benzylimidazole-4′- yl)-propionic acid ^(D)H(Bzl) (3R)-2-Amino-3-(1′-benzylimidazole-4′- yl)-propionic acid Bip L-(4-phenyl)phenylalanine ^(D)Bip D-(4-phenyl)phenylalanine S(Bzl) L-O-Benzylserine ^(D)S(Bzl) D-O-Benzylserine T(Bzl) L-O-Benzylthreonine ^(D)T(Bzl) D-O-Benzylthreonine alloT (2S,3S)-2-Amino-3-hydroxy-butyric acid ^(D)alloT (2R,3S)-2-Amino-3-hydroxy-butyric acid Leu3OH (2S,3R)-2-Amino-3-hydroxy-4-methyl- pentanoic acid ^(D)Leu3OH (2R,3R)-2-Amino-3-hydroxy-4-methyl- pentanoic acid hAla L-Homo-alanine ^(D)hAla D-Homo-alanine hArg L-Homo-arginine ^(D)hArg D-Homo-arginine hCys L-Homo-cysteine ^(D)hCys D-Homo-cysteine hGlu L-Homo-glutamic acid ^(D)hGlu D-glutamic acid hGln L-Homo-glutamine ^(D)hGln D-Homo-glutamine hHis L-Homo-histidine ^(D)hHis D-Homo-histidine hIle L-Homo-isoleucine ^(D)hIle D-Homo-isoleucine hLeu L-Homo-leucine ^(D)hLeu D-Homo-leucine hNle L-Homo-norleucine ^(D)hNle D-Homo-norleucine hLys L-Homo-lysine ^(D)hLys D-Homo-lysine hMet L-Homo-Methionine ^(D)hMet D-Homo-Methionine hPhe L-Homo-phenylalanine ^(D)hPhe D-Homo-phenylalanine hSer L-Homo-serine ^(D)hSer D-Homo-serine hThr L-Homo-threonine ^(D)hThr D-Homo-threonine hTrp L-Homo-tryptophan ^(D)hTrp D-Homo-tryptophan hTyr L-Homo-tyrosine ^(D)hTyr D-Homo-tyrosine hVal L-Homo-valine ^(D)hVal D-Homo-valine hCha L-Homo-cyclohexylalanine ^(D)hCha D-Homo-cyclohexylalanine Bpa L-4-Benzoylphenylalanine ^(D)Bpa D-4-Benzoylphenylalanine OctG L-Octylglycine ^(D)OctG D-Octylglycine Tic (3S)-1,2,3,4-Tetrahydroisoquinoline-3- carboxylic acid ^(D)Tic (3R)-1,2,3,4-Tetrahydroisoquinoline-3- carboxylic acid Tiq (1S)-1,2,3,4-Tetrahydroisoquinoline-1- carboxylic acid ^(D)Tiq (1R)-1,2,3,4-Tetrahydroisoquinoline-1- carboxylic acid Oic (2S,3aS,7aS)-1-Octahydro-1H-indole-2- carboxylic acid ^(D)Oic (2R,3aS,7aS)-1-Octahydro-1H-indole-2- carboxylic acid 4AmPyrr1 (2S,4S)-4-Amino-pyrrolidine-2-carboxylic acid ^(D)4AmPyrr1 (2R,4S)-4-Amino-pyrrolidine-2-carboxylic acid 4AmPyrr2 (2S,4R)-4-Amino-pyrrolidine-2-carboxylic acid ^(D)4AmPyrr2 (2R,4R)-4-Amino-pyrrolidine-2-carboxylic acid 4PhePyrr1 (2S,4R)-4-Phenyl-pyrrolidine-2- carboxylic acid ^(D)4PhePyrr1 (2R,4R)-4-Phenyl-pyrrolidine-2- carboxylic acid 4PhePyrr2 (2S,4S)-4-Phenyl-pyrrolidine-2- carboxylic acid ^(D)4PhePyrr2 (2R,4S)-4-Phenyl-pyrrolidine-2- carboxylic acid 5PhePyrr1 (2S,5R)-5-Phenyl-pyrrolidine-2- carboxylic acid ^(D)5PhePyrr1 (2R,5R)-5-Phenyl-pyrrolidine-2- carboxylic acid 5PhePyrr2 (2S,5S)-5-Phenyl-pyrrolidine-2- carboxylic acid ^(D)5PhePyrr2 (2R,5S)-5-Phenyl-pyrrolidine-2- carboxylic acid 4Hyp1 (4S)-L-Hydroxyproline ^(D)4Hyp1 (4S)-D-Hydroxyproline 4Hyp2 (4R)-L-Hydroxyproline ^(D)4Hyp2 (4R)-D-Hydroxyproline 4Mp1 (4S)-L-Mercaptoproline ^(D)4Mp1 (4S)-D-Mercaptoproline 4Mp2 (4R)-L-Mercaptoproline ^(D)4Mp2 (4R)-D-Mercaptoproline Pip L-Pipecolic acid ^(D)Pip D-Pipecolic acid H-β³-HCit-OH (3S)-3-Amino-6-carbamidyl-hexanoic acid H-β³-HOrn-OH (3S)-3,6-Diamino-hexanoic acid H-β³-HtBuA-OH (3S)-3-Amino-5,5-dimethyl-hexanoic acid H-β³-HSar-OH N-Methyl-3-amino-propionic acid H-β³-HPen-OH (3R)-3-Amino-4-methyl-4-mercapto- pentanoic acid H-β³-HtBuG-OH (3R)-3-Amino-4,4-dimethyl-pentanoic acid H-β³-H4AmPhe-OH (3S)-3-Amino-4-(4′-aminophenyl)-butyric acid H-β³-H3AmPhe-OH (3S)-3-Amino-4-(3′-aminophenyl)-butyric acid H-β³-H2AmPhe-OH (3S)-3-Amino-4-(2′-aminophenyl)-butyric acid H-β³- (3S)-3-Amino-4-(3′-amidinophenyl)-butyric HPhe(mC(NH₂)═NH)—OH acid H-β³- (3S)-3-Amino-4-(4′-amidinophenyl)-butyric HPhe(pC(NH₂)═NH)—OH acid H-β³- (3S)-3-Amino-4-(3′-guanidinophenyl)- HPhe(mNHC(NH₂)═NH)—OH butyric acid H-β³- (3S)-3-Amino-4-(4′-guanidino-phenyl)- HPhe(pNHC(NH₂)═NH)—OH butyric acid H-β³-H2Pal-OH (3S)-3-Amino-4-(pyridine-2′-yl)-butyric acid H-β³-H4Pal-OH (3S)-3-Amino-4-(pyridine-4′-yl)-butyric acid H-β³-HPhg-OH (3R)-3-Amino-3-phenyl-propionic acid H-β³-HCha-OH (3S)-3-Amino-4-cyclohexyl-butyric acid H-β³-HC₄al-OH (3S)-3-Amino-4-cyclobutyl-butyric acid H-β³-HC₅al-OH (3S)-3-Amino-4-cyclopentyl-butyric acid H-β³-HNle-OH (3S)-3-Amino-heptanoic acid H-β³-H2Nal-OH (3S)-3-Amino-4-(2′-naphthyl)-butyric acid H-β³-H1Nal-OH (3S)-3-Amino-4-(1′-naphthyl)-butyric acid H-β³-H4ClPhe-OH (3S)-3-Amino-4-(4′-chlorophenyl)-butyric acid H-β³-H3ClPhe-OH (3S)-3-Amino-4-(3′-chlorophenyl)-butyric acid H-β³-H2ClPhe-OH (3S)-3-Amino-4-(2′-chlorophenyl)-butyric acid H-β³-H3,4Cl₂Phe-OH (3S)-3-Amino-4-(3′,4′-dichlorophenyl)- butyric acid H-β³-H4FPhe-OH (3S)-3-Amino-4-(4′-fluorophenyl)-butyric acid H-β³-H3FPhe-OH (3S)-3-Amino-4-(3′-fluorophenyl)-butyric acid H-β³-H2FPhe-OH (3S)-3-Amino-4-(2′-fluorophenyl)-butyric acid H-β³-HThi-OH (3R)-3-Amino-4-(2′-thienyl)-butyric acid H-β³-HTza-OH (3R)-3-Amino-4-(2′-thiazolyl)-butyric acid H-β³-HMso-OH (3R)-3-Amino-4-methylsulfoxyl-butyric acid Code Chemical Name H-β³-HAcLys-OH (3S)-7-Acetylamino-3-amino-heptanoic acid H-β³-HDpr-OH (3R)-3,4-diamino-butyric acid H-β³-HA₂Bu—OH (3S)-3,5-Diamino-pentanoic acid H-β³-HDbu-OH (3R)-3,4-Diamino-pentanoic acid H-β³-HAib-OH Amino-dimethyl acetic acid H-β³-HCyp-OH 1-Amino-cyclopentane-1-yl-acetic acid H-β³-HY(Bzl)-OH (3S)-3-Amino-4-(4′-benzyloxyphenyl)- butyric acid H-β³-HH(Bzl)-OH (3S)-3-Amino-4-(1′-benzylimidazole-4′- yl)-butyric acid H-β³-HBip-OH (3S)-3-Amino-4-biphenylyl-butyric acid H-β³-HS(Bzl)-OH (3S)-3-Amino-4-(benzyloxy)-butyric acid H-β³-HT(Bzl)-OH (3R,4R)-3-Amino-4-benzyloxy-pentanoic acid H-β³-HalloT-OH (3R,4S)-3-Amino-4-hydroxy-pentanoic acid H-β³-HLeu3OH—OH (3R,4R)-3-Amino-4-hydroxy-5-methyl- hexanoic acid H-β³-HhAla-OH (3S)-3-Amino-pentanoic acid H-β³-HhArg-OH (3S)-3-Amino-7-guanidino-heptanoic acid H-β³-HhCys-OH (3R)-Amino-5-mercapto-pentanoic acid H-β³-HhGlu-OH (3S)-3-Amino-heptanedioic acid H-β³-HhGln-OH (3S)-3-Amino-6-carbamoyl hexanoic acid H-β³-HhHis-OH (3S)-3-Amino-5-(imidazole-4′-yl)- pentanoic acid H-β³-HhIle-OH (3S,5S)-3-Amino-5-methyl-heptanoic acid H-β³-HhLeu-OH (3S)-3-Amino-6-methyl-heptanoic acid H-β³-HhNle-OH (3S)-3-Amino-octanoic acid H-β³-DiAoc-OH (3S)-3,8-Diamino-octanoic acid H-β³-HhMet-OH (3S)-3-Amino-6-methylthio-hexanoic acid H-β³-HhPe-OH (3S)-3-Amino-5-phenyl-pentanoic acid H-β³-HhSer-OH (3S)-3-Amino-5-hydroxy-pentanoic acid H-β³-HhThr-OH (3S,5R)-3-Amino-5-hydroxy-hexanoic acid H-β³-HhTrp-OH (3S)-3-Amino-5-(indol-3′-yl)-pentanoic acid H-β³-HhThr-OH (3S)-3-Amino-5-(4′-hydroxyphenyl)- pentanoic acid H-β³-HhCha-OH (3S)-3-Amino-5-cyclohexyl-pentanoic acid H-β³-HBpa-OH (3S)-3-Amino-4-(4′-benzoylphenyl)-butyric acid H-β³-HOctG-OH (3S)-3-Amino-undecanoic acid H-β³-HNle-OH (3S)-3-Amino-heptanoic acid H-β³-HTic-OH (3S)-1,2,3,4-Tetrahydroisoquinoline-3-yl- acetic acid H-β³-HTiq-OH (1S)-1,2,3,4-Tetrahydroisoquinoline-1- acetic acid H-β³-HOic-OH (2S,3aS,7aS)-1-Octahydro-1H-indole-2- yl-acetic acid H-β³-H4AmPyrr1-OH (2S,4S)-4-Amino-pyrrolidine-2-acetic acid H-β³-H4AmPyrr2-OH (2S,4R)-4-Amino-pyrrolidine-2-acetic acid H-β³-H4PhePyrr1-OH (2S,4R)-4-Phenyl-pyrrolidine-2-acetic acid H-β³-H4PhePyrr2-OH (2S,4S)-4-Phenyl-pyrrolidine-2-acetic acid H-β³-H5PhePyrr1-OH (2S,5R)-5-Phenyl-pyrrolidine-2-acetic acid H-β³-H5PhePyrr2-OH (2S,5S)-5-Phenyl-pyrrolidine-2-acetic acid H-β³-H4Hyp1-OH (2S,4S)-4-Hydroxy-pyrrolidine-2-acetic acid H-β³-H4Hyp2-OH (2S,4R)-4-Hydroxy-pyrrolidine-2-acetic acid H-β³-H4Mp1-OH (2R,4S)-4-Mercapto-pyrrolidine-2-acetic acid H-β³-H4Mp2-OH (2R,4R)-4-Mercapto-pyrrolidine-2-acetic acid H-β³-HPip-OH (2S)-piperidine-2-acetic acid H-β³-HPro-OH (2S)-pyrrolidine-2-acetic acid H-β³-H^(D)Pro-OH (2R)-pyrrolidine-2-acetic acid Ahb 4-Amino-2-hydroxy butyric acid H-γ⁴-DiHCit-OH (4S)-4-Amino-7-carbamidyl-heptanoic acid H-γ⁴-DiHOrn-OH (4S)-4,7-Diamino-heptanoic acid H-γ⁴-DiHtBuA-OH (4R)-4-Amino-6,6-dimethyl-heptanoic acid H-γ⁴-DiHSar-OH N-Methyl-4-amino-butyric acid H-γ⁴-DiHPen-OH (4R)-4-Amino-5-methyl-5-mercapto-hexanoic acid H-γ⁴-DiHtBuG-OH (4R)-4-Amino-5,5-dimethyl-hexanoic acid H-γ⁴-DiH4AmPhe-OH (4R)-4-Amino-5-(4′-aminophenyl)-pentanoic acid H-γ⁴-DiH3AmPhe-OH (4R)-4-Amino-5-(3′-aminophenyl)-pentanoic acid H-γ⁴-DiH2AmPhe-OH (4R)-4-Amino-5-(2′-aminophenyl)-pentanoic acid H-γ⁴- (4R)-4-Amino-5-(3′-amidinophenyl)- DiHPhe(mC(NH₂)═NH)—OH pentanoic acid H-γ⁴- (4R)-4-Amino-5-(4′-amidinophenyl)- DiHPhe(pC(NH₂)═NH)—OH pentanoic acid H-γ⁴- (4R)-4-Amino-5-(3′-guanidino-phenyl)- DiHPhe(mNHC(NH₂)═NH)—OH pentanoic acid H-γ⁴- (4R)-4-Amino-5-(4′-guanidino-phenyl)- DiHPhe(pNHC(NH₂)═NH)—OH pentanoic acid H-γ⁴-DiH2Pal-OH (4R)-4-Amino-5-(pyridine-4′-yl)-pentanoic acid H-γ⁴-DiH4Pal-OH (4R)-4-Amino-5-(pyridine-4′-yl)-pentanoic acid H-γ⁴-DiHPhg-OH (4R)-4-Amino-4-phenyl-butyric acid H-γ⁴-DiHCha-OH (4R)-4-Amino-5-cyclohexyl-pentanoic acid H-γ⁴-DiHC₄al-OH (4R)-4-Amino-5-cyclobutyl-pentanoic acid H-γ⁴-DiHC₅al-OH (4R)-4-Amino-5-cyclopentyl-pentanoic acid H-γ⁴-DiHNle-OH (4S)-4-Amino-octanoic acid H-γ⁴-DiH2Nal-OH (4S)-4-Amino-5-(2′-naphthyl)-pentanoic acid H-γ⁴-DiH1Nal-OH (4S)-4-Amino-5-(1′-naphthyl)-pentanoic acid H-γ⁴-DiH4ClPhe-OH (4R)-4-Amino-5-(4′-chlorophenyl)- pentanoic acid H-γ⁴-DiH3ClPhe-OH (4R)-4-Amino-5-(3′-chlorophenyl)- pentanoic acid H-γ⁴-DiH2ClPhe-OH (4R)-4-Amino-5-(2′-chlorophenyl)- pentanoic acid H-γ⁴-DiH3,4Cl₂Phe-OH (4R)-4-Amino-5-(3′,4′-dichloro-phenyl)- pentanoic acid H-γ⁴-DiH4FPhe-OH (4R)-4-Amino-5-(4′-fluorophenyl)- pentanoic acid H-γ⁴-DiH3FPhe-OH (4R)-4-Amino-5-(3′-fluorophenyl)- pentanoic acid H-γ⁴-DiH2FPhe-OH (4R)-4-Amino-5-(2′-fluorophenyl)- pentanoic acid H-γ⁴-DiHThi-OH (4R)-4-Amino-5-(2′-thienyl)-pentanoic acid H-γ⁴-DiHTza-OH (4R)-4-Amino-5-(2′-thiazolyl)-pentanoic acid H-γ⁴-DiHMso-OH (4R)-4-Amino-5-methylsulfoxyl-pentanoic acid H-γ⁴-DiHAcLys-OH (4S)-8-Acetylamino-4-amino-ocatanoic acid H-γ⁴-DiHDpr-OH (4R)-4,5-diamino-pentanoic acid H-γ⁴-DiHA₂Bu—OH (4R)-4,5-Diamino-hexanoic acid H-γ⁴-DiHDbu-OH (4R)-4,5-Diamion-hexanoic acid H-γ⁴-DiHAib-OH 3-Amino-3,3-dimethyl propionic acid H-γ⁴-DiHCyp-OH (1′-Amino-cyclopentane-1′-yl)-3-propionic acid H-γ⁴-DiHY(Bzl)-OH (4R)-4-Amino-5-(4′-benzyloxyphenyl)- pentanoic acid H-γ⁴-DiHH(Bzl)-OH (4R)-4-Amino-5-(1′-benzylimidazole-4′- yl)-pentanoic acid H-γ⁴-DiHBip-OH (4R)-4-Amino-5-biphenylyl-pentanoic acid H-γ⁴-DiHS(Bzl)-OH (4S)-4-Amino-5-(benzyloxy)-pentanoic acid H-γ⁴-DiHT(Bzl)-OH (4R,5R)-4-Amino-5-benzyloxy-hexanoic acid H-γ⁴-DiHalloT-OH (4R,5S)-4-Amino-5-hydroxy-hexanoic acid H-γ⁴-DiHLeu3OH—OH (4R,5R)-4-Amino-5-hydroxy-6-methyl- heptanoic acid H-γ⁴-DiHhAla-OH (4S)-4-Amino-hexanoic acid H-γ⁴-DiHhArg-OH (4S)-4-Amino-8-guanidino-octanoic acid H-γ⁴-DiHhCys-OH (4R)-Amino-6-mercapto-hexanoic acid H-γ⁴-DiHhGlu-OH (4S)-4-Amino-ocatanedioic acid H-γ⁴-DiHhGln-OH (4S)-4-Amino-7-carbamoyl-heptanoic acid H-γ⁴-DiHhHis-OH (4S)-4-Amino-6-(imidazole-4′-yl)-hexanoic acid H-γ⁴-DiHhIle-OH (4S,6S)-4-Amino-6-methyl-octanoic acid H-γ⁴-DiHhLeu-OH (4S)-4-Amino-7-methyl-ocatanoic acid H-γ⁴-DiHhNle-OH (4S)-4-Amino-nonanoic acid H-γ⁴-DiHhLys-OH (4S)-4,9-Diamino-nonanoic acid H-γ⁴-DiHhMet-OH (4R)-4-Amino-7-methylthioheptanoic acid H-γ⁴-DiHhPhe-OH (4S)-4-Amino-6-phenyl-hexanoic acid H-γ⁴-DiHhSer-OH (4R)-4-Amino-6-hydroxy-hexanoic acid H-γ⁴-DiHhThr-OH (4R,6R)-4-Amino-6-hydroxy-heptanoic acid H-γ⁴-DiHhTrp-OH (4S)-4-Amino-6-(indol-3′-yl)-hexanoicacid H-γ⁴-DiHhTyr-OH (4S)-4-Amino-6-(4′-hydroxyphenyl)- hexanoic acid H-γ⁴-DiHhCha-OH (4R)-4-Amino-5-cyclohexyl-pentanoic acid H-γ⁴-DihBpa-OH (4R)-4-Amino-5-(4′-benzoylphenyl)- pentanoic acid H-γ⁴-DiHOctG-OH (4S)-4-Amino-dodecanoic acid H-γ⁴-DiHNle-OH (4S)-4-Amino-octanoic acid H-γ⁴-DiHTic-OH (3R)-1′,2′,3′,4′-Tetrahydroisoquinoline- 3′-yl-3-propionic acid H-γ⁴-DiHTiq-OH (1′R)-1′,2′,3′,4′-Tetrahydroisoquinoline- 1′-yl-3-propionic acid H-γ⁴-DiHOic-OH (2′S,3′aS,7′aS)-1′-Octahydro-1H-indole- 2′-yl-3-propionic acid H-γ⁴-DiH4AmPyrr1-OH (2′R,4′S)-4′-Amino-pyrrolidine-2′-yl-3- propionic acid H-γ⁴-DiH4AmPyrr2-OH (2′R,4′R)-4′-Amino-pyrrolidine-2′-yl-3- propionic acid H-γ⁴-DiH4PhePyrr1-OH (2′R,4′R)-4′-Phenyl-pyrrolidine-2′-yl-3- propionic acid H-γ⁴-DiH4PhePyrr2-OH (2′R,4′S)-4′-Phenyl-pyrrolidine-2′-yl-3- propionic acid H-γ⁴-DiH5PhePyrr1-OH (2′S,5′R)-5′-Phenyl-pyrrolidine-2′-yl-3- propionic acid H-γ⁴-DiH5PhePyrr2-OH (2′S,5′S)-5′-Phenyl-pyrrolidine-2′-yl-3- propionic acid H-γ⁴-DiH4Hyp1-OH (2′R,4′S)-4′-Hydroxy-pyrrolidine-2′-yl- 2-propionic acid H-γ⁴-DiH4Hyp2-OH (2′R,4′R)-4′-Hydroxy-pyrrolidine-2′-yl- 3-propionic acid H-γ⁴-DiH4Mp1-OH (2′R,4′S)-4′-Mercapto-pyrrolidine-2′-yl- 3-propionic acid H-γ⁴-DiH4Mp2-OH (2′R,4′R)-4′-Mercapto-pyrrolidine-2′-yl- 3-propionic acid H-γ⁴-DiHPip-OH (2′S)-Piperidine-2′-yl-3-propionic acid H-γ⁴-DiHPro-OH (2′S)-Pyrrolidine-2′-yl-3-propionic acid (AEt)G N-(2-Aminoethyl)glycine (APr)G N-(3-Amino-n-propyl)glycine (ABu)G N-(4-Amino-n-butyl)glycine (APe)G N-(5-Amino-n-pentyl)glycine (GuEt)G N-(2-Guanidinoethyl)glycine (GuPr)G N-(3-Guanidino-n-propyl)glycine (GuBu)G N-(4-Guanidino-n-butyl)glycine (GuPe)G N-(5-Guanidino-n-pentyl)glycine (PEG₃-NH₂)G N—[H₂N—(CH₂)₃—(OCH₂—CH₂)₂—O(CH₂)₃]glycine (Me)G N-Methylglycine (Et)G N-Ethylglycine (Bu)G N-Butylglycine (Pe)G N-Pentylglycine (Ip)G N-Isopropylglycine (2MePr)G N-(2-Methylpropyl)glycine (3MeBu)G N-(3-Methylbutyl)glycine (1MePr)G (1S)-N-(1-Methylpropyl)glycine (2MeBu)G (2S)-N-(2-Methylbutyl)glycine (MthEt)G N-(Methylthioethyl)glycine (MthPr)G N-(Methylthiopropyl)glycine (Ben)G N-(Benzyl)glycine (PhEt)G N-(2-Phenylethyl)glycine (HphMe)G N-([4′-hydroxyphenyl]methyl)glycine (HphEt)G N-(2-[4′-hydroxyphenyl]ethyl)glycine (ImMe)G N-(Imidazol-5-yl-methyl)glycine (ImEt)G N-(2-(Imidazol-5′-yl)ethyl)glycine (InMe)G N-(Indol-2-yl-methyl)glycine (InEt)G N-(2-(Indol-2′-yl)ethyl)glycine (CboMe)G N-(Carboxymethyl)glycine (CboEt)G N-(2-Carboxyethyl)glycine (CboPr)G N-(3-Carboxypropyl)glycine (CbaMe)G N-(Carbamoylmethyl)glycine (CbaEt)G N-(2-Carbamoylethyl)glycine (CbaPr)G N-(3-Carbamoylpropyl)glycine (HyEt)G N-(2-Hydroxyethyl)glycine (HyPr)G (2R)-N-(2-Hydroxypropyl)glycine (Mcet)G N-(2-Mercaptoethyl)glycine NMeAla L-N-Methylalanine NMe^(D)Ala D-N-Methylalanine NMeVal L-N-Methylvaline NMe^(D)Val D-N-Methylvaline NMeIle L-N-Methylisoleucine NMe^(D)Ile D-N-Methylisoleucine NMeLeu L-N-Methylleucine NMe^(D)Leu D-N-Methylleucine NMeNle L-N-Methylnorleucine NMe^(D)Nle D-N-Methylnorleucine NMeMet L-N-Methylmethionine NMe^(D)Met D-N-Methylmethionine NMeTyr L-N-Methyltyrosine NMe^(D)Tyr D-N-Methyltyrosine NMeHis L-N-Methylhistidine NMe^(D)His D-N-Methylhistidine NMePhe L-N-Methylphenylalanine NMe^(D)Phe D-N-Methylphenylalanine NMeTrp L-N-Methyltryptophane NMe^(D)Trp D-N-Methyltryptophane NMeSer L-N-Methylserine NMe^(D)Ser D-N-Methylserine NMeAsp L-N-Methylaspartic acid NMe^(D)Asp D-N-Methylaspartic acid NMeGlu L-N-Methylglutamic acid NMe^(D)Glu D-N-Methylglutamic acid NMeLys L-N-Methyllysine NMe^(D)Lys D-N-Methyllysine NMeArg L-N-Methylarginine NMe^(D)Arg D-N-Methylarginine NMeDab L-N-Methyl-2,4-diamino butyric acid NMe^(D)Dab D-N-Methyl-2,4-diamino butyric acid NMeCys L-N-Methylcysteine NMe^(D)Cys D-N-Methylcysteine NMeAsn L-N-Methylasparagine NMe^(D)Asn D-N-Methylasparagine NMeGln L-N-Methylglutamine NMe^(D)Gln D-N-Methylglutamine NMeThr L-N-Methylthreonine NMe^(D)Thr D-N-Methylthreonine.


6. Compounds according to claim 1, selected from: (2S,11S,19aS)-2-(acetylamino)-15-fluoro-N-[2-(1H-indol-3-yl)ethyl]-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide, (2S,11S,19aS)—N-[2-(dimethylamino)ethyl]-15-fluoro-2-{[2-(1H-indol-3-yl)acetyl]amino}-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide; (2S,11S,19aS)-15-fluoro-2-{[2-(1H-indol-3-yl)acetyl]amino}-N-[2-(1H-indol-3-yl)ethyl]-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide; (2S,11S,19aS)-2-{[2-(dimethylamino)acetyl]amino}-15-fluoro-N-[2-(1H-indol-3-yl)ethyl]-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide; tert-butyl N-[(2S,11S,19aS)-15-fluoro-11-({[2-(1H-indol-3-yl)ethyl]amino}carbonyl)-7,12-dimethyl-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecin-2-yl]carbamate; (2S,11S,19aS)—N-[2-(dimethylamino)ethyl]-15-fluoro-7,12-dimethyl-2-{[2-(1-naphthyl)acetyl]amino}-5,8,13-trioxo-2,3,6,7,8,9,10,11,12,13,19,19a-dodecahydro-1H,5H-pyrrolo[2,1-c][1,4,7,12]benzoxatriazacyclopentadecine-11-carboxamide; benzyl N-[(4S,6S,10S)-14-methyl-6-{[2-(2-naphthyl)acetyl]amino}-9,15-dioxo-2-oxa-8,14-diazatricyclo[14.3.1.0˜4,8˜]icosa-1(20),16,18-trien-10-yl]carbamate; benzyl N-[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0˜4,8˜]henicosa-[(21),17,19-trien-13-yl]carbamat; N-[(4S,6S,13S)-6-{[2-(1H-indol-3-yl)acetyl]amino}-11,15-dimethyl-9,12,16-trioxo-2-oxa-8,11,15-triazatricyclo[15.3.1.0˜4,8˜]henicosa-[(21),17,19-trien-13-yl]decanamide.
 7. A composition having the compound according to any one of claims 2, 3, 5, 6 or 1 in a therapeutically active amount and having agonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT_(2B) (5-HT_(2B) receptor), and on the prostaglandin F2α receptor (FP receptor).
 8. A pharmaceutical composition containing a compound according to any one of claims 2, 3, 5, 6 or 1 and a therapeutically inert carrier.
 9. The composition according to claim 8 having agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT_(2B) (5-HT_(2B) receptor), and on the prostaglandin F2α receptor (FP receptor).
 10. The composition according to claim 9 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary or inhalation administration.
 11. The composition according to claim 10 in form of tablet, degree, capsule, solution, liquid, gel, plaster, scream, ointment, syrup, slurry, suspension, spray, nebuliser or suppository.
 12. A medicament comprising the compound according to claim 1 having agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT_(2B) (5-HT_(2B) receptor), and on the prostaglandin F2α receptor (FP receptor).
 13. A method of treating hypomotility disorders of the gastrointestinal tract selected from the group consisting of diabetic gastroparesis and constipation type irritable bowl syndrome; CNS diseases selected from the group consisting of migraine, schizophrenia, psychosis and depression; ocular hypertension associated with glaucoma or preterm labour; said method comprising: administering the compound of claim 1 to a patient in need thereof. 